<SEC-DOCUMENT>0001387131-16-004361.txt : 20160226
<SEC-HEADER>0001387131-16-004361.hdr.sgml : 20160226
<ACCEPTANCE-DATETIME>20160226163332
ACCESSION NUMBER:		0001387131-16-004361
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20151231
FILED AS OF DATE:		20160226
DATE AS OF CHANGE:		20160226

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		161462431

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>txmd-10k_123115.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 12pt;">
<div style="border-bottom: Black 1pt solid; border-top: Black 4pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-size: 14pt;"><b>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</b></font></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-size: 12pt;">&#xA0;<b>Washington, DC 20549</b></font></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<hr align="center" style="color: black; margin-bottom: 3pt; margin-top: 3pt; width: 20%;" noshade="noshade" size="1">
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-size: 18pt;"><b>Form 10-K</b></font></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0in;"></td>
<td style="width: 0.5in; text-align: left; font: bold 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 12pt;"><b>&#x2612;</b></font></td>
<td style="text-align: justify;"><font style="font-size: 12pt;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) <b>OF THE SECURITIES EXCHANGE ACT OF 1934</b></b></font></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><b>For the fiscal year ended December 31, 2015</b></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>Commission File Number 001-001000</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<hr align="center" style="color: black; margin-bottom: 3pt; margin-top: 3pt; width: 20%;" noshade="noshade" size="1">
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 24pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: center; font: 24pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 24pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left;">
<td style="width: 33%;"><font style="font-size: 10pt;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; width: 34%; text-align: center;" nowrap><font style="font-size: 24pt;"><b>TherapeuticsMD, Inc.</b></font></td>
<td style="width: 33%;"><font style="font-size: 10pt;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: top; text-align: left;">
<td><font style="font-size: 10pt;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font-size: 10pt;"><i>(Exact Name of Registrant as Specified in Its Charter)</i></font></td>
<td><font style="font-size: 10pt;">&#xA0;</font></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: center; font: 24pt Times New Roman, Times, Serif;"><font style="font-size: 8pt;">&#xA0;&#xA0;</font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 30%; text-align: center;"><b>Nevada</b></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 20%; text-align: justify;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 20%; text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 30%; text-align: center;"><b>87-0233535</b></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font-size: 10pt;"><i>(State or Other Jurisdiction of<br> Incorporation or Organization)</i></font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: justify;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font-size: 10pt;"><i>(I.R.S. Employer Identification No.)</i></font></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>6800 Broken Sound Parkway NW</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>Third Floor</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>Boca Raton, Florida 33487</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>(561) 961-1900</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><i>(Address, including zip code, and telephone number,&#xA0;</i></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><i>including area code, of Principal Executive Offices)</i></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>Securities registered pursuant to Section 12(b) of the Act:</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="border-bottom: Black 1pt solid; width: 50%;">
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>Title of Each Class</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
</td>
<td style="border-bottom: Black 1pt solid; width: 50%;">
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>Name of Each Exchange on Which Registered</b></p>
</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-top: 3pt; text-align: center;">Common Stock, par value $0.001 per share</td>
<td style="padding-top: 3pt; text-align: center;">NYSE MKT</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: center; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;"><b>Securities registered pursuant to Section 12(g) of the Act: </b>None.</p>
<p style="margin: 0pt 0; text-align: center; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: normal 10pt Times New Roman, Times, Serif;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#x2610;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;No <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal;">&#x2612;</font></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: normal 10pt Times New Roman, Times, Serif;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#x2610;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;No <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal;">&#x2612;</font></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: normal 10pt Times New Roman, Times, Serif;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal;">&#x2612;</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;No &#x2610;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: normal 10pt Times New Roman, Times, Serif;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#xA7; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal;">&#x2612;</font>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;No &#x2610;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant&#x2019;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. &#x2612;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#x201C;large accelerated filer,&#x201D; &#x201C;accelerated filer&#x201D; and &#x201C;smaller reporting company&#x201D; in Rule 12b-2 of the Exchange Act. (Check one):</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 49%; text-align: center;">Large accelerated filer &#x2612;</td>
<td style="padding-left: 5.4pt; padding-right: 45pt; width: 51%; text-align: right;">&#xA0;Accelerated filer &#x2610;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;">&#xA0;&#xA0;&#xA0;Non-accelerated filer &#x2610;</td>
<td style="padding-right: 45pt; text-align: right;">Smaller reporting company &#x2610;</td>
</tr>
<tr>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;">(Do not check if a smaller reporting company)</td>
<td style="padding-bottom: 12pt; text-align: justify;"></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: normal 10pt Times New Roman, Times, Serif;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes &#x2610;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;No <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal;">&#x2612;</font></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">The aggregate market value of common stock held by non-affiliates of the registrant (94,011,647 shares) based on the closing price of the registrant&#x2019;s common stock as reported on NYSE MKT on June 30, 2015, which was the last business day of the registrant&#x2019;s most recently completed second fiscal quarter, was $738,931,545. For purposes of this computation, all officers, directors, and 10% beneficial owners of the registrant are deemed to be affiliates. Such determination should not be deemed to be an admission that such officers, directors, or 10% beneficial owners are, in fact, affiliates of the registrant.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0 0pt 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">As of February 22, 2016, there were outstanding 196,150,311 shares of the registrant&#x2019;s common stock, par value $0.001 per share.</p>
<p style="margin: 0pt 0 0pt 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>Documents Incorporated by Reference</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">Portions of the registrant&#x2019;s definitive Proxy Statement for its 2016 Annual Meeting of Stockholders are incorporated by reference into Part III of this Annual Report on Form 10- K where indicated. Such Proxy Statement will be filed with the Securities and Exchange Commission no later than 120 days after the end of the registrant&#x2019;s fiscal year ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 12pt; margin-top: 3pt;">
<div style="border-bottom: Black 4pt solid; border-top: Black 1pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC.</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>ANNUAL REPORT ON FORM 10-K</b>&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>Fiscal Year Ended December 31, 2015</b>&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>TABLE OF CONTENTS&#xA0;</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 9%;">&#xA0;</td>
<td style="width: 84%;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 5%;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: center;"><a href="#txmda001_v1"><font style="font-size: 10pt;">PART I</font></a></td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda002_v1"><font style="font-size: 10pt;">Item 1.</font></a></td>
<td><a href="#txmda002_v1"><font style="font-size: 10pt;"><i>Business</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">1</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda003_v1"><font style="font-size: 10pt;">Item 1A.</font></a></td>
<td><a href="#txmda003_v1"><font style="font-size: 10pt;"><i>Risk Factors</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">26</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda004_v1"><font style="font-size: 10pt;">Item 1B.</font></a></td>
<td><a href="#txmda004_v1"><font style="font-size: 10pt;"><i>Unresolved Staff Comments</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">47</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda005_v1"><font style="font-size: 10pt;">Item 2.</font></a></td>
<td><a href="#txmda005_v1"><font style="font-size: 10pt;"><i>Properties</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">47</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda006_v1"><font style="font-size: 10pt;">Item 3.</font></a></td>
<td><a href="#txmda006_v1"><font style="font-size: 10pt;"><i>Legal Proceedings</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">48</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda007_v1"><font style="font-size: 10pt;">Item 4.</font></a></td>
<td><a href="#txmda007_v1"><font style="font-size: 10pt;"><i>Mine Safety Disclosures</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">48</font></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: center;"><a href="#txmda008_v1"><font style="font-size: 10pt;">PART II</font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda009_v1"><font style="font-size: 10pt;">Item 5.</font></a></td>
<td><a href="#txmda009_v1"><font style="font-size: 10pt;"><i>Market for the Registrant&#x2019;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">49</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda010_v1"><font style="font-size: 10pt;">Item 6.</font></a></td>
<td><a href="#txmda010_v1"><font style="font-size: 10pt;"><i>Selected Financial Data</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">51</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda011_v1"><font style="font-size: 10pt;">Item 7.</font></a></td>
<td><a href="#txmda011_v1"><font style="font-size: 10pt;"><i>Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">52</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda012_v1"><font style="font-size: 10pt;">Item 7A.</font></a></td>
<td><a href="#txmda012_v1"><font style="font-size: 10pt;"><i>Quantitative and Qualitative Disclosures about Market Risk</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">66</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda013_v1"><font style="font-size: 10pt;">Item 8.</font></a></td>
<td><a href="#txmda013_v1"><font style="font-size: 10pt;"><i>Financial Statements and Supplementary Data</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">66</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda014_v1"><font style="font-size: 10pt;">Item 9.</font></a></td>
<td><a href="#txmda014_v1"><font style="font-size: 10pt;"><i>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">66</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda015_v1"><font style="font-size: 10pt;">Item 9A.</font></a></td>
<td><a href="#txmda015_v1"><font style="font-size: 10pt;"><i>Controls and Procedures</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">67</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda016_v1"><font style="font-size: 10pt;">Item 9B.</font></a></td>
<td><a href="#txmda016_v1"><font style="font-size: 10pt;"><i>Other Information</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">70</font></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: center;"><a href="#txmda017_v1"><font style="font-size: 10pt;">PART III</font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda018_v1"><font style="font-size: 10pt;">Item 10.</font></a></td>
<td><a href="#txmda018_v1"><font style="font-size: 10pt;"><i>Directors, Executive Officers, and Corporate Governance</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">70</td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda019_v1"><font style="font-size: 10pt;">Item 11.</font></a></td>
<td><a href="#txmda019_v1"><font style="font-size: 10pt;"><i>Executive Compensation</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">70</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda020_v1"><font style="font-size: 10pt;">Item 12.</font></a></td>
<td><a href="#txmda020_v1"><font style="font-size: 10pt;"><i>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">70</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda021_v1"><font style="font-size: 10pt;">Item 13.</font></a></td>
<td><a href="#txmda021_v1"><font style="font-size: 10pt;"><i>Certain Relationships and Related Transactions, and Director Independence</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font-size: 10pt;">70</font></td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda022_v1"><font style="font-size: 10pt;">Item 14.</font></a></td>
<td><a href="#txmda022_v1"><font style="font-size: 10pt;"><i>Principal Accounting Fees and Services</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">70</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: center;"><a href="#txmda023_v1"><font style="font-size: 10pt;">PART IV</font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td><a href="#txmda024_v1"><font style="font-size: 10pt;">Item 15.</font></a></td>
<td><a href="#txmda024_v1"><font style="font-size: 10pt;"><i>Exhibits and Financial Statement Schedules</i></font></a></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;">71</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
<div style="border-top: Black 1pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">vitaMedMD<sup>&#xAE;</sup>, TherapeuticsMD<sup>&#xAE;</sup>, and BocaGreenMD<sup>&#xAE;</sup> are registered trademarks of our company. This Annual Report also contains trademarks and trade names of other companies.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">This Annual Report includes market and industry data that we obtained from periodic industry publications, third-party studies and surveys, government agency sources, filings of public companies in our industry, and internal company surveys. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Although we believe the foregoing industry and market data to be reliable at the date of the report, this information could prove to be inaccurate as a result of a variety of matters.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 2 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>Statement Regarding Forward-Looking Information</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. For example, statements regarding our operations, financial position, business strategy, product development, and other plans and objectives for future operations, and assumptions and predictions about future product development and demand, research and development, marketing, expenses and sales are all forward-looking statements. These statements may be found in the items of this Annual Report entitled &#x201C;Business&#x201D; and &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201D; as well as in this Annual Report generally. These statements are generally accompanied by words such as &#x201C;intend,&#x201D; &#x201C;anticipate,&#x201D; &#x201C;believe,&#x201D; &#x201C;estimate,&#x201D; &#x201C;potential(ly),&#x201D; &#x201C;continue,&#x201D; &#x201C;forecast,&#x201D; &#x201C;predict,&#x201D; &#x201C;plan,&#x201D; &#x201C;may,&#x201D; &#x201C;will,&#x201D; &#x201C;could,&#x201D; &#x201C;would,&#x201D; &#x201C;should,&#x201D; &#x201C;expect,&#x201D; or the negative of such terms or other comparable terminology.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have based these forward-looking statements on our current expectations and projections about future events. We believe that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to us on the date hereof, but we cannot assure you that these assumptions and expectations will prove to have been correct or that we will take any action that we may presently be planning. These forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, research and product development uncertainties, regulatory policies and approval requirements, competition from other similar businesses, market and general economic factors, and the other risks discussed in Item 1A of this Annual Report. This discussion should be read in conjunction with the consolidated financial statements and notes thereto included in this Annual Report.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have identified some of the important factors that could cause future events to differ from our current expectations and they are described in this Annual Report in the section entitled &#x201C;Risk Factors&#x201D; that you should review carefully. Please consider our forward-looking statements in light of those risks as you read this Annual Report. If one or more of these or other risks or uncertainties materialize, or if our underlying assumptions prove to be incorrect, actual results may vary materially from what we project. We do not undertake to update any forward-looking statements or to publicly announce the results of any revisions to any statements to reflect new information or future events or developments.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 3 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: center; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: bold 10pt Times New Roman, Times, Serif;"><a name="txmda001_v1"></a>PART I</p>
<p style="margin: 0pt 0; text-align: center; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap><a name="txmda002_v1"></a>Item 1.</td>
<td style="text-align: justify;"><i>Business</i></td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Overview</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Our Company</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 22pt; font: 10pt Times New Roman, Times, Serif;">We are a women&#x2019;s health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created using our SYMBODA<sup>TM</sup> hormone technology, which enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins.</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 22pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">We have obtained U.S. Food and Drug Administration, or FDA, acceptance of our Investigational New Drug, or IND, applications to conduct clinical trials for four of our hormone therapy drug candidates. In December 2015, we completed a Phase 3 clinical trial of TX-004HR, our applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse), a symptom of vulvar and vaginal atrophy, or VVA, in post-menopausal women with vaginal linings that do not receive enough estrogen, and we are currently conducting a Phase 3 clinical trial for TX-001HR, our oral combination of progesterone and estradiol.&#xA0; In July 2014, we temporarily suspended enrollment in the Phase 3 clinical trial for TX-002HR, our oral progesterone alone, and, in October 2014, we temporarily stopped the trial in order to update the Phase 3 protocol based on discussions with the FDA. We have no current plans to conduct clinical trials for TX-003HR, our oral estradiol alone.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Throughout this Annual Report, the terms &#x201C;we,&#x201D; &#x201C;us,&#x201D; &#x201C;our,&#x201D; &#x201C;TherapeuticsMD,&#x201D; or &#x201C;our company&#x201D; refer to TherapeuticsMD, Inc., a Nevada corporation, and unless specified otherwise, include our wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Hormone Therapy Market</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The menopause hormone therapy market includes two major components: an FDA-approved drug market and a non-FDA approved drug market supplied by compounding pharmacies. On November 27, 2013, the Drug Quality and Security Act of 2013, or the DQSA, became law and the FDA was given additional oversight over compounding pharmacies. We believe FDA-approved products are easily measured and monitored, while non-FDA approved hormone therapy drug products, typically referred to as bioidenticals when produced and sold by compounding pharmacies, are not easily measured or monitored. We estimate the non-FDA approved compounded bioidentical hormone therapy combination sales of estradiol and progesterone products by compounding pharmacies approximate $1.5 billion per year and according to Symphony Health Solutions PHAST Prescription Monthly by IVD, or Symphony Heath Solutions, the FDA-approved market for hormone therapies approximated $4.3 billion based on 2015 sales. Our Phase 3 clinical trials are intended to establish an indication of the safety and efficacy of our hormone therapy drug candidates at specific dosage levels. We intend our hormone therapy drug candidates, if approved, to provide hormone therapies with well characterized safety and efficacy profiles that can be consistently manufactured to target specifications. This would provide an alternative to the non-FDA approved compounded bioidentical market. This is based on our belief that our drug candidates will offer advantages in terms of demonstrated safety and efficacy consistency in the hormone dose, lower patient cost as a result of insurance coverage, and improved access as a result of availability from major retail pharmacy chains rather than custom order or formulation by individual compounders.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Pipeline of our Hormone Therapy Drug Candidates</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>TX-001HR</i></p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-001HR, our combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause, including hot flashes, night sweats, sleep disturbances, and vaginal discomfort for post-menopausal women with an intact uterus. The hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman&#x2019;s body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time a combination product of estradiol and progesterone bioidentical to &#x2013; or having the same chemical and molecular structure as - the estradiol and progesterone produced by the ovaries would be approved for use in a single combined product. According to Symphony Health Solutions, sales of FDA-approved estrogen and progestins combined were approximately $616 million and the sales of estradiol and progesterone on a stand-alone basis were $926 million and $322 million, respectively, in the United States for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>TX-002HR</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy drug candidate is bioidentical to &#x2013; or having the same chemical and molecular structure as - the hormones that naturally occur in a woman&#x2019;s body. If approved by the FDA, we believe TX-002HR would be similarly effective to traditional treatments, but may be effective at lower dosages. According to Symphony Health Solutions, the total FDA-approved market for oral progesterone and progestin was approximately $505 million in U.S. sales for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>TX-003HR</i></p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-003HR is a natural estradiol formulation. This hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman&#x2019;s body. We currently do not have plans to further develop this hormone therapy drug candidate. According to Symphony Health Solutions, the total FDA-approved market for oral estradiol and estrogen was approximately $868 million in U.S. sales for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>TX-004HR</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-004HR is an applicator-free vaginal estradiol softgel drug candidate for the treatment of VVA in post-menopausal women with vaginal linings that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments for VVA because of an early onset of action with less systemic exposure inferring a greater probability of dose administration to the target tissue, and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments. According to Symphony Health Solutions, the total FDA-approved market for VVA treatment was approximately $1.5 billion in U.S. sales for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Preclinical Development</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Based upon leveraging our SYMBODA<sup>TM</sup> hormone technology, we have five preclinical projects that include development of our proposed progesterone-alone and combination estradiol and progesterone products in a topical cream form, which we refer to as TX-005HR and TX-006HR, respectively, and transdermal patch form, which we refer to as TX-007HR and TX-008HR, respectively. We recently completed a preclinical study of TX-005HR in 32 rats. The study used four groups of 8 female overectomized rats each and applied subcutaneous estrogen with either placebo, subcutaneous progesterone or topical TX-005HR. The results, presented to the North American Menopause Society, or NAMS, in October, 2015, showed that TX-005HR penetrated the skin and opposed the subcutaneous estrogen effect on the endometrium. We intend to file an IND with respect to TX-005HR and TX-006HR as soon as the first half of 2016 and then commence phase 1 clinical trials, assuming that FDA has no objections. We may in the future engage with a financing partner to advance our topical cream and transdermal patch projects. We also plan to evaluate various other indications for our hormone technology, including oral contraception, treatment of preterm birth, and premature ovarian failure. According to Symphony Health Solutions, the total FDA-approved menopause-related market for estrogen alone and in combination was approximately $3.8 billion in U.S. sales for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 5; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Current Products</i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As we continue the clinical development of our hormone therapy drug candidates, we continue to manufacture and distribute our prescription and OTC product lines, consisting of prenatal vitamins, iron supplements, and natural menopause relief products under our vitaMedMD<sup>&#xAE;</sup> brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD<sup>&#xAE;</sup> Prena1 name. All of our prenatal vitamins are gluten-, sugar-, and lactose-free. We believe our product attributes result in greater consumer acceptance and satisfaction than competitive products while offering the highest quality and patented ingredients.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Industry and Market</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Health Care and Pharmaceutical Market</i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">According to the EvaluatePharma&#xAE; World Preview 2015, Outlook to 2020 report, continued confidence in the pharmaceutical industry is being driven by a number of positive fundamentals, including the industry&#x2019;s recent increase in research and development productivity and the emergence of breakout drugs. Although the global pharmaceutical industry faces pricing and market access concerns, worldwide prescription drug sales are expected to reach almost $1 trillion by 2020, which would represent a compound annual growth rate of approximately 4.8% between 2014 and 2020. A record number of new drugs were approved by the FDA in 2014, with 50 new drugs (consisting of new molecular entities and biologics) approved, compared to 35 in 2013. The quality of these drugs continues to be high, with eight of the top ten new drugs approved in 2014 being forecast to have sales of more than $1 billion within five years after launch.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-left: 0in; margin-top: 0; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><i>Women&#x2019;s Health Care Market</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">According to
the GBI Research (a provider of industry-leading business intelligence solutions on a global basis) report
&#x201C;Women&#x2019;s Health Therapeutic Market through 2018,&#x201D; the women&#x2019;s health therapeutics market is one
of the most attractive markets in the global pharmaceutical industry. Hormone therapy, gynecological disorders, and
musculoskeletal disorders in women are the prime areas of focus in the women&#x2019;s health therapeutics market. The
women&#x2019;s health therapeutics market in the United States was estimated to be valued at $18.8 billion in 2011. Revenues
are projected to increase to $22.7 billion in 2018 at a compound and growth rate of 2.7%. This can be attributed to the
launch of new drug molecules.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Hormone Therapy Market</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Menopause is the spontaneous and permanent cessation of menstruation, which naturally occurs in most women between the ages of 40 and 58. It is defined as the final menstrual period and is confirmed when a woman has not had her period for 12 consecutive months. Hormone therapy is the most effective treatment in the United States and Canada for relief of menopausal symptoms according to NAMS. These symptoms are caused by the reduced levels of circulating estrogen as ovarian production shuts down. The symptoms include hot flashes, night sweats, sleep disturbances, and vaginal dryness. According to Symphony Health Solutions, prescriptions for FDA-approved hormone therapy products for the treatment of menopause symptoms or prevention of osteoporosis generated total sales of over $4.3 billion on over 32 million prescriptions for the 12 months ended December 31, 2015. Oral hormone therapy accounted for $1.9 billion on 21.4 million prescriptions over the same time period.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Prescriptions for menopausal hormone therapy in the United States dropped significantly following the Women&#x2019;s Health Initiative, or WHI, study in 2002, which found that subjects using estrogen plus synthetic progestin had, among other things, a greater incidence of coronary heart disease, breast cancer, stroke, and pulmonary embolism. A number of additional studies regarding the benefits and risks of hormone therapy have been conducted over the last decade since the WHI results were first published. In general, recommendations for hormone therapy use are to be judged on an individual basis, and the FDA recommends that women with moderate to severe menopausal symptoms who want to try menopausal hormone therapy for relief use it for the shortest time needed and at the lowest effective dose.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">There were approximately 41.7 million women in the United States between the ages of 45 and 64 in 2010, projected to increase slightly (2.8%) to 42.9 million in 2015 and to approximately 44.3 million in 2040, according to the 2010 National Census population figures. These women are the target market for hormone therapy to treat menopausal related symptoms.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 6; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Hormone Therapy Products</i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Estrogen (with or without a progestin) is the most effective treatment of vasomotor symptoms and VVA due to menopause according to NAMS. According to Symphony Health Solutions, sales of total FDA-approved oral, transdermal, and suppository estrogen (with and without a progestin) hormone therapy products were approximately $3.7 billion for the 12 months ended December 31, 2015. The three primary hormone therapy products are estrogen, progestin, and combination of estrogen and progestin, which are produced in a variety of forms, including oral tablets or capsules, skin patches, gels, emulsion, or vaginal suppositories and creams.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Estrogen-Only Therapies</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Estrogen therapies are used to treat vasomotor symptoms due to menopause that are a direct result of the decline in estrogen levels associated with ovarian shutdown at menopause. Estrogen therapy has been used to manage these symptoms for more than 50 years. Estrogen is a generic term for any substance, natural or synthetic, that exerts biological effects characteristic of estrogenic hormones, such as estradiol, a natural ovarian produced estrogen. Based upon the age demographic for all women receiving prescriptions for estrogen therapy and the average age range during which women experience vasomotor symptoms, we believe that estrogen is primarily used for the treatment of vasomotor symptoms, but also prescribed for the prevention of osteoporosis.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Estrogen-only therapy, or ET, is used primarily in women who have had a hysterectomy and/or are undergoing a surgical menopause, as those women do not require a progestin to protect the uterine endometrium from proliferation. Approximately 433,000 women undergo a hysterectomy each year in the United States according to the United States Centers for Disease Control and Prevention.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">ET is also used for the treatment of VVA, which has a variety of indications, including vaginal dryness, vaginal itching and irritation, painful intercourse, painful urination, and other symptoms.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">ET is also approved for the prevention of osteoporosis. Multiple studies conducted on various estrogen compositions, including studies published in the Journal of the American Medical Association in 2002, Osteoporosis International in 2000, The Lancet in 2002, Maturitas in 2008, and Climacteric in 2005, suggested efficacy based on increases in bone mineral density. Epidemiological and some fracture prevention studies, such as the study published in the New England Journal of Medicine in 1980, also have suggested a decrease in bone fractures as a result of ET.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Total FDA-approved ET only sales amounted to $2.4 billion, of which $1.5 billion was specifically used for the treatment of VVA, for the 12 months ended December 31, 2015, according to Symphony Health Solutions.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Progestin-Only Therapies</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Progestins include the naturally occurring hormone progesterone and a number of synthetic progestin compounds that have progestational activity. These agents are used for a variety of indications and conditions, but most often, progestins are used either alone or in combination with an estrogen for hormonal contraception and to prevent endometrial hyperplasia from unopposed estrogen in hormone therapy. Progestins alone are also used to treat women with secondary amenorrhea in order to create withdrawal bleeding in these women who have not had regular menses. Progestins are also used to treat dysfunctional uterine bleeding and endometriosis. Progesterone has also been used to prevent threatened or recurrent pregnancy loss and for the prevention of preterm birth. Progestins have also been used in fertility treatments. Progestins have also been used as a palliative measure for metastatic endometrial carcinoma and in the treatment of renal and breast carcinoma.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Estrogen/Progestin Combination Products</i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Progestins are used in combination with estrogen in post-menopausal women with uteruses to avoid an increase in the incidence of endometrial hyperplasia, which is a condition caused by chronic use of estrogen alone by a woman with a uterus and is associated with an increased incidence of uterine, or endometrial, cancer. Studies have shown that, after one year, the incidence of endometrial hyperplasia is less than 1% in women taking estrogen/progestin combinations, in contrast to up to 20% in women taking estrogen alone. In accordance with FDA recommendations, doctors typically recommend that a menopausal or post-menopausal woman who has a uterus take estrogen plus a progestin, either as a combination drug or as two separate drugs. Symphony Health Solutions estimates that sales of FDA-approved estogen and progestins combined were approximately $616 million and the sales of estradiol and progesterone on the stand-alone basis were $926 million and $322 million, respectively, in the United States for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 7; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Limitations of Existing Estrogen/Progestin Therapies</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The most commonly prescribed progestin is a synthetic progestin (medroxyprogesterone acetate), which can cause some women to experience painful vaginal bleeding, breast tenderness, and bloating and may reduce cardio-protective benefits potentially associated with estrogen therapy by limiting the estrogen&#x2019;s ability to raise high-density lipoprotein cholesterol, or good cholesterol, and low-density lipoprotein, or bad cholesterol.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">A widely prescribed naturally occurring progesterone is known as Prometrium<sup>&#xAE;</sup> (progesterone USP). The brand is marketed by AbbVie Inc, and generic versions have been available since 2012. Natural progesterone is used in combination with estrogen for hormone therapy; however, we believe there are currently no FDA-approved hormone therapy combination products with natural progesterone.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Prenatal Vitamin Market</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">According to the Centers for Disease Control and Prevention, there are approximately four million births per year in the U.S. Of women giving birth in the U.S., the U.S. Department of Health and Human Services reports that approximately 74% received early prenatal care in the first trimester, while 6% began prenatal care in the third trimester or did not receive any prenatal care. Most doctors encourage taking a prenatal vitamin as the recommended standard of care. Prenatal vitamins are dietary supplements intended to be taken before and during pregnancy and during postnatal lactation that provide nutrients recognized by various health organizations as helpful for a healthy pregnancy outcome.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">There are hundreds of prenatal vitamins available, with both prescription and OTC choices. According to Symphony Health Solutions, during the 12 months ended December 31, 2015, approximately 7.3 million prescriptions for prenatal vitamins were issued in the United States resulting in total sales of approximately $386 million, with sales between branded and generic products split nearly evenly. According to the 2012 Gallup Target Market Report on Prenatal Vitamins, supplement use has been fairly constant overall between 2008 and 2011. However, shifts have occurred in terms of types used, with the trend toward OTC prenatal vitamins and away from prescription prenatal vitamins. During this same period, the use of OTC products surpassed the use of prescription products, largely driven by increased use among women currently pregnant.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>Our Business Model</b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We are a women&#x2019;s health care<i> </i>company focused on creating and commercializing products exclusively for women, including products specifically for pregnancy, childbirth, nursing, pre-menopause, menopause, and post-menopause. We intend to use our current prescription and OTC product lines, consisting of prenatal vitamins, iron supplements, and natural menopause relief products, as the foundation of our business platform. If approved and commercialized, our hormone therapy drug candidates will allow us to enter the $4.3 billion FDA-approved hormone therapy market, based on 2015 total sales of the hormone therapy market, according to Symphony Health Solutions.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our current product line is marketed and sold by a direct national sales force that calls on health care providers in the OB/GYN market space, as well as through our websites to consumers who have been referred to our websites by physicians or direct marketing efforts. We market our prescription and OTC prenatal vitamins and other products under our vitaMedMD brand name and authorized generic formulations of our prescription prenatal vitamin products under our BocaGreenMD Prena1 brand name. We believe that our vitaMedMD brand name has become a recognized name for high quality women&#x2019;s health care, while our BocaGreenMD products provide physicians, women, and payors with a lower Wholesale Acquisition Cost (WAC) alternative for prenatal vitamins. We intend to leverage our existing relationships and distribution system to introduce our hormone therapy drug candidates, if approved, which we believe will enable us to provide a comprehensive line of women&#x2019;s health care products all under one brand.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our sales model focuses on the &#x201C;4Ps&#x201D;: patient, provider, pharmacist, and payor. We market and sell our current products primarily through a direct national sales force of approximately 33 full-time professionals that calls on health care providers in the OB/GYN market space, as well as through our websites directly to consumers. In addition, our products allow health care providers to offer an alternative to patients to meet their individual nutritional and financial requirements related to co-payment and cost-of-care considerations and help patients realize cost savings over competing products. We also believe that our combination of branded, authorized generic, and OTC lines offers physicians, women, and payors cost-effective alternatives for top-quality care. We supply our prescription products to consumers through retail pharmacies nationwide. We market our OTC products either directly to consumers via our websites and phone sales followed by direct shipment to their homes or offices or through physicians who then re-sell them to their patients. Our fully staffed customer care center uses current customer relationship management software to respond to health care providers, pharmacies, and consumers via incoming and outgoing telephone calls, e-mails, and live-chat.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 8; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As health care becomes increasingly consumer driven, patients are seeking more information, control, and convenience, which places additional time and financial pressures on physicians, and as a result, physicians are looking for improved ways to provide better service to their patients. A recent study by IMS Health Inc. concluded that physicians desire fewer but more encompassing relationships with companies that can provide more valuable information, deliver more relevant services, and better respond to specific needs of their practice and patients. Our goal is to meet this challenge by focusing on the opportunities in women&#x2019;s health, specifically the OB/GYN market, to provide a better customer experience for physician, payor, pharmacist, and patient through the following means:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">We believe we will offer physicians a comprehensive product line of women&#x2019;s health care products, including our hormone therapy drug candidates, if approved.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">Our hormone therapy drug candidates are designed to use the lowest effective dose for the shortest duration.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">We believe the attributes of our dietary supplements will result in greater consumer acceptance and satisfaction than competitive products while offering the highest quality products incorporating patented ingredients, such as Quatrefolic<sup>&#xAE;</sup>, FOLMAX&#xAE;, FePlus&#xAE;, and pur-DHA&#x2122;. All of our prenatal vitamins are gluten-, sugar-, and lactose-free.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">We strive to improve our existing products and develop new products to generate additional revenue through our existing sales channels.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">We believe health care providers are able to offer alternatives to patients that meet the patient&#x2019;s individual nutritional and financial requirements and help patients realize cost savings over competing products.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">Health care provider practices that choose to dispense our OTC products directly to their patients through their offices could earn revenue from the sale of the products.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">Improved patient education, a high level of patient compliance, and reduced cost of products all result in lower cost of care for payors and improved outcomes for patients.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Our Growth Strategy</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We are a women&#x2019;s health care company with a corporate culture designed to foster innovation in the development and commercialization of products that address the needs of patients, payers and providers in the twenty-first century.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We believe that building a culture of innovation around patient needs and opportunities, rather than focusing on specific drugs, will enable us to effectively develop and commercialize our products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Exclusive Focus on Women&#x2019;s Health Issues</i>. For the last five years, we have steadily develop relationships with many of the largest OB/GYN practices in the country through the sales of our line of prenatal vitamins. Our singular focus on women&#x2019;s health issues will enable us to continue to build long-term relationships with women as they move through their life cycles of family planning through pre- and post- menopause.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Focus on Hormone Therapy Products</i>. We plan to continue our focus on the development, clinical trials, and commercialization of hormone therapy products designed to (1) alleviate the symptoms of, and reduce the health effects resulting from, menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness, and (2) demonstrate equivalent clinical efficacy at lower doses, enabling an enhanced side effect profile compared with competing products. We believe there is a large unmet need in this segment of the market.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 9; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Penetrate Compound Market with FDA-approved Products</i>. As we are not aware of any current FDA-approved hormone therapy combination products that are bioidentical to &#x2013; or having the same chemical and molecular structure as - the estradiol and progesterone produced by the ovaries, we believe that our hormone therapy drug candidate for combined estradiol and progesterone, if approved by the FDA, will provide a safer and more effective alternative to non-FDA approved compounded bioidentical hormone therapy products, at a lower price to patients since most insurance companies do not provide coverage for non-FDA approved compounded products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Multi-Channel Marketing Emphasis</i>. We plan to continue our emphasis on large group OB/GYN practices that provide opportunities to reach large patient bases and that are receptive to the data and savings we provide. We believe this will effectively position us for the launch of our hormone therapy products, if approved.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, proliferation of digital technology has dramatically increased the amount of information to available to patients and providers putting more power in their hands. We believe this makes patient/provider engagement and experience a more important lever for life sciences companies and that providing patients and providers with important information whenever and however they want it, on a real time basis, is a critical piece of serving this market.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Multiple Distribution Channels</i>. We plan to continue to pursue multiple distribution channels, including large chain pharmacies, independent community pharmacies, mail order and compounding and specialty pharmacies. We believe providing a higher level of customer care through unique programs targeted at each of these channels can produce better outcomes and value for the patient, provider and payer.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Geographical Expansion</i>. We plan to expand our geographic market and sales team to cover the entire country in 2016.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Introducing New Products</i>. We continue to develop our hormone therapy drug candidates consisting of a (1) oral combination of progesterone and estradiol product (TX-001HR), and (2) a vaginal estradiol softgel product (TX-004HR).</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Our Current Product Lines</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We offer a wide range of products targeted for women&#x2019;s health specifically associated with pregnancy, child birth, nursing, post-child birth, and menopause, including prescription and OTC prenatal vitamins, iron supplements, and a natural menopause relief product under our vitaMedMD brand name and authorized generic formulations of some of our prescription prenatal vitamin products under our BocaGreenMD Prena1 name.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">For the years ended December 31, 2015, 2014, and 2013, approximately 99.5%, 98%, and 98%, respectively, of our consolidated revenue was generated by our prenatal vitamin products. Our prenatal vitamin products are marketed as either OTC products or prescription products. Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary significant difference between our OTC and prescription prenatal vitamin products is the usual source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while most purchasers of our prescription prenatal vitamin products pay for the product primarily via a co-pay and third-party payers. For both our OTC and prescription prenatal vitamin products, we employ the same sales force and marketing team to sell and market our products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In March 2012, we launched our first prescription prenatal vitamin, vitaMedMD Plus Rx, with subsequent launches of our second prescription prenatal vitamin, vitaMedMD One Rx, in April 2012 and our third prescription prenatal vitamin, vitaMedMD RediChew&#x2122; Rx, in May 2012. In the fourth quarter of 2012, we launched our BocaGreenMD Prena1 line of prescription prenatal vitamins, which included three prescription prenatal vitamins that were authorized generic formulations of our vitaMedMD-branded prescription prenatal vitamins. In the first quarter of 2014, we introduced a new prescription prenatal vitamin product under our branded vitaMedMD name as vitaPearl and under our authorized generic Prena1 name as Prena1 Pearl, which features a unique, proprietary combination of FOLMAX&#x2122;, FePlus&#x2122;, and pur-DHA&#x2122;. In January, 2016 we launched vitaTrue. Our current product line is detailed below.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaTrue<sup>TM</sup></i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaTrue<sup>TM</sup></i> is our newest prenatal vitamin and is targeted at health conscious consumers. <i>vitaTrue<sup>TM</sup></i> is the first and only vegan and kosher prenatal vitamin with 40% more folic acid than the leading prescription prenatal vitamin. <i>vitaTrue<sup>TM</sup></i> contains a complete multivitamin with 16 essential vitamins and minerals and 300 mg of plant based docosahexaenoic acid, or DHA. vitaTrue is fish, gluten, lactose, and sugar free.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 10; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaPearl&#x2122;</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaPearl</i> is our leading product and is a complete prenatal vitamin in one tiny pearl. <i>vitaPearl</i> provides 40% more folic acid than the leading prescription prenatal vitamin. <i>vitaPearl</i> delivers 14 key vitamins and minerals plus 200 mg of DHA, providing comprehensive support for a woman and her body whether she is planning a pregnancy, pregnant, or nursing.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD Plus (Prenatal Women&#x2019;s Multivitamin + DHA&#x2122;) </i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD Plus Prenatal</i> is a once-daily, two pill combo pack that contains a complete multivitamin with 16 essential vitamins and minerals and 300 mg of plant based DHA.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD One Prenatal Multivitamin </i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD One</i> is a single-dose daily multivitamin that provides 14 vitamins and minerals and 200 mg of plant-based DHA. Each convenient, easy-to-swallow softgel also features 975 mcg of folic acid.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD Plus Rx Prenatal Multivitamin </i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD Plus Rx</i> is a once-daily, two pill combo prescription product containing one prenatal vitamin tablet with Quatrefolic<sup>&#xAE;</sup>, the fourth generation folate, and one plant-based DHA 300 mg capsule. Quatrefolic<sup>&#xAE;</sup> is a registered trademark of Gnosis S.P.A. All minerals, including iron, zinc, and copper, are chelated to improve absorption.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD One Rx Prenatal Multivitamin</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD</i> <i>One Rx</i> is a prescription product with a single-dose daily multivitamin that provides 14 vitamins and minerals, Quatrefolic<sup>&#xAE;</sup>, and 200 mg of plant-based DHA.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD RediChew&#xAE; Rx Prenatal Multivitamin </i></p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD</i> <i>RediChew&#xAE;</i> <i>Rx</i> is a prescription, easy-to-chew, small, vanilla-flavored chewable tablet containing Folmax<i>&#xAE;</i>, vitamin D3, vitamin B2, vitamin B6, and vitamin B12. We believe <i>vitaMedMD RediChew Rx</i> is an excellent option for women who have difficulty swallowing tablets or softgels, or are experiencing nausea and morning sickness.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD Iron 21/7</i></p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD Iron 21/7</i> is an iron replacement supplement with a three weeks-on/one week-off dosing schedule intended to maximize absorption and enhance tolerability. It is formulated with 150 mg of chelated iron to help improve tolerability and limit typical side effects associated with iron replacements. Each easy-to-swallow single tablet serving also includes 800 mcg of folic acid, plus vitamins C and B12, and succinic acid to aid in absorption.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD Menopause Relief with Lifenol<sup>&#xAE;</sup> Plus Bone Support</i></p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD Menopause Relief with Lifenol<sup>&#xAE;</sup> Plus Bone Support</i> offers a natural treatment for hot flashes, night sweats, and mood disturbances. Each single tablet dosage delivers 120 mg of Lifenol<sup>&#xAE;</sup>, a well-studied female hops extract recognized for its potency and support in alleviating hot flashes, plus plant phytoestrogens. It also includes calcium and vitamin D3 for added bone support.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD Vitamin D3 50,000 IU </i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>vitaMedMD Vitamin D3 50,000 IU </i>is a dietary supplement provided in a small, easy-to-swallow gel capsule that help replenish and maintain beneficial levels of vitamin D in the body. Sustaining adequate levels of vitamin D in the body is essential to bone health, enhancing the absorption of calcium and phosphorus. Vitamin D3, also known as cholecalciferol, is considered the most preferred form of vitamin D as it is the most active form of the nutrient. We believe <i>vitaMedMD</i> <i>Vitamin D3 50,000 IU</i> is ideal for pregnant, breastfeeding, and menopausal women to sustain adequate levels of vitamin D.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 11; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>BocaGreenMD Prena1 Pearl</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>BocaGreenMD Prena1 Pearl</i> is an authorized generic of <i>vitaPearl</i>, a complete prenatal vitamin in one tiny pearl.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>BocaGreenMD Prena1 Chew</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>BocaGreenMD Prena1 Chew</i> is an authorized generic of <i>vitaMedMD RediChew Rx</i>, a prescription, single daily easy-to-chew, vanilla-flavored, chewable tablet.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Our Hormone Therapy Drug Candidates</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have obtained FDA acceptance of our IND applications to conduct clinical trials for four of our proposed products: TX-001HR, our oral combination of progesterone and estradiol; TX-002HR, our oral progesterone alone; TX-003HR, our oral estradiol alone; and TX-004HR, our applicator-free vaginal estradiol softgel.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>TX-001HR</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-left: 0in; margin-top: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-001HR, our combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause, including hot flashes, night sweats, sleep disturbances, and vaginal discomfort for post-menopausal women with an intact uterus. The hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman&#x2019;s body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time a combination product of estradiol and progesterone bioidentical to &#x2013; or having the same chemical and molecular structure as - the estradiol and progesterone produced by the ovaries would be approved for use in a single combined product.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-left: 0in; margin-top: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On September 5, 2013, we began enrollment in the REPLENISH Trial, a multicenter, double-blind, placebo-controlled, Phase 3 study of TX-001HR in postmenopausal women with an intact uterus. The study is designed to evaluate the efficacy of TX-001HR for the treatment of moderate to severe vasomotor symptoms due to menopause and the endometrial safety of TX-001HR. Patients are assigned to one of five arms, four active and one placebo, and receive study medication for 12 months. The primary endpoint for the reduction of endometrial hyperplasia is an incidence of endometrial hyperplasia of less than 1% at 12 months, as determined by endometrial biopsy. The primary endpoint for the treatment of moderate to severe vasomotor symptoms is the mean change of frequency and severity of moderate to severe vasomotor symptoms at weeks four and 12 compared to placebo, as measured by the number and severity of hot flushes. Only subjects experiencing a minimum daily frequency of seven moderate to severe hot flushes at screening are included in the vasomotor symptoms analysis, while all subjects are included in the endometrial hyperplasia analysis. The secondary endpoints include reduction in sleep disturbances and improvement in quality of life measures, night sweats and vaginal dryness, measured at 12 weeks, six months and 12 months. The trial is designed to enroll approximately 1,750 patients at approximately 100 sites. We completed enrollment in the REPLENISH Trial in October 2015 and we currently anticipate that results of the trial will be reported late in the fourth quarter of 2016. Based on such timeline and assuming a successful trial, we would anticipate filing a New Drug Application, or NDA, for TX-001HR as soon as the first half of 2017 and assuming an FDA review period of ten months from the receipt date to the Prescription Drug User Fee Act, or PDUFA, date for a non-new molecular entity, the NDA for TX-001HR could be approved by the FDA as soon as the fourth quarter of 2017 or the first quarter of 2018. As of February 23, 2016, approximately 1,400 patients have exited the REPLENISH Trial and the incidence of endomentrial hyperplasia for these patients is less than 1%.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-left: 0in; margin-top: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We previously conducted a pharmacokinetics, or PK, study of TX-001HR to demonstrate that our drug candidate is bioequivalent to the reference listed drug based on the criterion that the 90% confidence interval on the test-to-reference ratio is contained entirely within the interval 80% to 125%. The study compared our combined capsule TX-001HR of 2 mg estradiol and 200 mg of progesterone to 2 mg of Estrace<sup>&#xAE;</sup> and 200 mg of Prometrium<sup>&#xAE;</sup>.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-left: 0in; margin-top: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The study compared the mean plasma concentrations for free estradiol between TX-001HR and Estrace<sup>&#xAE;</sup> in 62 female test subjects. When the results of a single dose-fed study were compared over 48 hours by the test drug versus reference drug, the ratio was 0.93 with the standard deviation within the subject being 0.409 for an upper 95% confidence bound of -0.089. The maximum plasma concentration levels of free estradiol showed that the drug -versus -reference drug ratio was 0.88 with the standard deviation within the subject being 0.344 for an upper 95% confidence bound of -0.040 over 48 hours.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 12; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The study also compared the mean plasma concentrations for progesterone between TX-001HR and Prometrium<sup>&#xAE;</sup> in 62 female test subjects. When the results were compared over 48 hours of the test that the drug-versus-reference drug, the ratio was 1.05 with the standard deviation within the subject being 0.956 for an upper 95% confidence bound of -0.542. The maximum plasma concentration levels of progesterone showed drug versus reference drug ratio as 1.16 with the standard deviation within the subject being 1.179 for an upper 95% confidence bound of -0.785 over 48 hours.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We believe these data are sufficient to demonstrate the bioequivalence of TX-001HR to Estrace<sup>&#xAE;</sup> and Prometrium<sup>&#xAE;</sup> based on the criteria for demonstrating bioequivalence established in connection with the study, which was published in the journal Menopause in December 2015. Symphony Health Solutions estimates that sales of FDA-approved estrogen and progestins combined were approximately $616 million and the sales of estradiol and progesterone on the stand-alone basis were $926 million and $322 million, respectively, in the United States for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>TX-002HR</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy drug candidate is bioidentical to &#x2013; or having the same chemical and molecular structure as - the hormones that naturally occur in a woman&#x2019;s body. We believe it will be similarly effective to traditional treatments, but may demonstrate efficacy at lower dosages. In January 2014, we began recruitment of patients in the SPRY Trial, a phase 3 clinical trial designed to measure the safety and effectiveness of TX-002HR in the treatment of secondary amenorrhea. During the first two quarters of 2014, the SPRY Trial encountered enrollment challenges because of Institutional Review Board approved clinical trial protocols and FDA inclusion and exclusion criteria. In July 2014, we temporarily suspended enrollment and in October 2014 we temporarily stopped the SPRY Trial in order to update the phase 3 protocol based on discussions with the FDA. We are considering updating the phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial. We believe that the updated phase 3 protocol, if proposed by us and approved by the FDA, would allow us to mitigate the enrollment challenges in, and shorten the duration of, the SPRY Trial. However, there can be no assurance that the FDA will approve the updated phase 3 protocol if we propose it. According to Symphony Health Solutions, the total FDA-approved market for oral progesterone and progestin was approximately $505 million in U.S. sales for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>TX-003HR</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-003HR is a natural estradiol formulation. This hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman&#x2019;s body. We currently do not have plans to further develop this hormone therapy drug candidate. According to Symphony Health Solutions, the total FDA-approved market for oral estradiol and estrogen was approximately $868 million in U.S. sales for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>TX-004HR</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-004HR is a vaginal estradiol softgel drug candidate for the treatment of VVA in post-menopausal women with vaginal linings that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments for VVA because of an early onset of action with less systemic exposure, inferring a greater probability of dose administration to the target tissue, and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments. TX-004HR features our SYMBODA<sup>TM</sup> technology, which enables partial and complete solubilization of estradiol into medium-chain fatty acid oils often derived from coconut oil. This allows for the production of cohesive, stable formulations and provides content uniformity and accuracy of dosing strengths for TX-004HR. We initiated the REJOICE Trial, a randomized, multicenter, double-blind, placebo-controlled Phase 3 clinical trial during the third quarter of 2014 to assess the safety and efficacy of three doses &#x2014; 25 mcg, 10 mcg and 4 mcg (compared to placebo) &#x2014; of TX-004HR for the treatment of moderate to severe dyspareunia, or painful intercourse, as a symptom of VVA due to menopause.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 13; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; On December 7, 2015, we announced positive top-line results from the REJOICE Trial. The pre-specified four co-primary efficacy endpoints were the changes from baseline to week 12 versus placebo in the percentage of vaginal superficial cells, percentage of vaginal parabasal cells, vaginal pH and severity of participants&#x2019; self-reported moderate to severe dyspareunia as the most bothersome symptom of VVA. The trial enrolled 764 postmenopausal women (40 to 75 years old) experiencing moderate to severe dyspareunia at approximately 89 sites across the United States and Canada. Trial participants were randomized to receive either TX-004HR at 25 mcg (n=190), 10 mcg (n=191), or 4 mcg (n=191) doses or placebo (n=192) for a total of 12 weeks, all administered once daily for two weeks and then twice weekly (approximately three to four days apart) for ten weeks. We recently received conditional approval for the brand name Yuvvexy related to TX-004HR.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 0 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">The following table sets forth the statistical significance of the REJOICE Trial results for the four pre-specified co-primary efficacy endpoints, based on mean changes from baseline to week 12 compared to placebo.&#xA0; Based on our ongoing analyses of the REJOICE Trial data, statistical significance of the results for the co-primary endpoint of severity of participants&#39; self-reported moderate to severe dyspareunia as the most bothersome symptom of VVA has improved for all three doses from the results originally reported.&#xA0;</p>
<p style="margin: 0 0 0 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>25 mcg</b></td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>10 mcg</b></td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>4 mcg</b></td>
<td style="text-align: justify;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff;">
<td style="padding-left: 8.8pt; width: 70%; vertical-align: top; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Superficial Cells</b></td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;&lt;&#xA0;0.0001</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;&lt;&#xA0;0.0001</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;&lt;&#xA0;0.0001</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
</tr>
<tr>
<td style="padding-left: 8.8pt; vertical-align: top; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Parabasal Cells</b></td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff;">
<td style="padding-left: 8.8pt; vertical-align: top; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Vaginal pH</b></td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
</tr>
<tr>
<td style="padding-left: 8.8pt; vertical-align: top; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Severity of Dyspareunia</b></td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P = 0.0149</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
</tr>
</table>
<p style="margin: 8pt 0 0 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">The 25 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 10 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 4 mcg dose of TX-004HR also demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoints of vaginal superficial cells, vaginal parabasal cells, and vaginal pH; the change from baseline compared to placebo in the severity of dyspareunia was statistically significant at the p = 0.0149 level. The FDA has previously indicated to us that in order to approve the drug based on a single trial, the trial would need to show statistical significance at the 0.01 level or lower for each endpoint, and that a trial that is merely statistically significant at a higher level may not provide sufficient evidence to support an NDA filing or approval of a drug candidate where the NDA relies on a single clinical trial.</p>
<p style="margin: 0 0 0 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">Statistical improvement over placebo was also observed for all three doses at the first assessment at week two and sustained through week 12 (see table below).</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="background-color: white;">
<td style="border-bottom: white 3pt solid; border-left: white 1pt solid; border-right: white 1pt solid; border-top: white 1pt solid; width: 25%;">&#xA0;</td>
<td style="border-bottom: white 3pt solid; border-right: white 1pt solid; border-top: white 1pt solid; padding-left: 8.8pt; width: 25%; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b><u>25 mcg</u><br></b></td>
<td style="border-bottom: white 3pt solid; border-right: white 1pt solid; border-top: white 1pt solid; padding-left: 8.8pt; width: 25%; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b><u>10 mcg</u><br></b></td>
<td style="border-bottom: white 3pt solid; border-right: white 1pt solid; border-top: white 1pt solid; padding-left: 8.8pt; width: 25%; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b><u>4 mcg</u><br></b></td>
</tr>
<tr style="background-color: #cceeff;">
<td style="border-bottom: white 1pt solid; border-left: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Week 2</b></td>
<td style="border-bottom: 1pt solid white; border-right: 1pt solid white; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt;"><b>P = 0.0105</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.0019</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.026</b></td>
</tr>
<tr style="background-color: white;">
<td style="border-bottom: white 1pt solid; border-left: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Week 6</b></td>
<td style="border-bottom: 1pt solid white; border-right: 1pt solid white; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt;"><b>P &lt; 0.0001</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.0009</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.0069</b></td>
</tr>
<tr style="background-color: #cceeff;">
<td style="border-bottom: white 1pt solid; border-left: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Week 8</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P &lt; 0.0001</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P &lt; 0.0001</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.0003</b></td>
</tr>
<tr style="background-color: white;">
<td style="border-bottom: white 1pt solid; border-left: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Week 12</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P &lt; 0.0001</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P &lt; 0.0001</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.0149</b></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 12pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Vaginal dryness was a prespecified key secondary endpoint. The 25 mcg and 10 mcg doses of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoint of vaginal dryness. The 4 mcg dose of TX-004HR demonstrated statistically significant results at the p = 0.0014 level compared to placebo (see table below).</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>25 mcg</b></td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>10 mcg</b></td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>4 mcg</b></td>
</tr>
<tr style="background-color: #cceeff;">
<td style="padding-left: 8.8pt; vertical-align: top; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Severity of Vaginal Dryness </b></td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;&lt;&#xA0;0.0001</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;&lt;&#xA0;0.0001</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;=&#xA0;0.0014</td>
</tr>
<tr>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
</table>
<p style="margin: 4.4pt 0 12pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">The pharmacokinetic data for all three doses demonstrated negligible to very low systemic absorption of 17 beta estradiol, estrone and estrone conjugated, supporting the previous Phase 1 trial data. TX-004HR was well tolerated, and there were no clinically significant differences compared to placebo-treated participants with respect to adverse events. There were no drug-related serious adverse events reported.</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">We currently intend to submit an NDA for the 25 mcg, 10 mcg and 4 mcg doses of TX-004HR to the FDA as early as the first half of 2016 and that such NDA could be approved by the FDA as soon as the first quarter of 2017, assuming an FDA review period of ten months from the receipt date to the PDUFA date for a non-new molecular entity. If approved, the 4 mcg formulation would represent a lower effective dose than the currently available VVA therapies approved by the FDA.</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">According to Symphony Health Solutions, the total FDA-approved market for VVA treatment was approximately $1.5 billion in U.S. sales for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">On November 10, 2015, FDA held a scientific workshop on labeling &#x201C;lower&#x201D; dose estrogen-alone products for symptoms of VVA to provide an opportunity for FDA to obtain input from experts on several topics related to the product label of lower dose estrogen-alone products approved solely for the treatment of moderate to severe symptoms of VVA due to menopause. According to the FDA, lower-dose estrogen products means products that contain less than the 0.625 milligrams (mg) of conjugated estrogens used in the WHI study and estradiol products containing 0.0375 mg and below. Discussion topics at the workshop were to include the relevance of the boxed warnings based on data from the WHI to the lower dose estrogen-alone products; certain members in the scientific/medical community have questioned whether the boxed warnings section in the labeling, which is currently required to be included on all estrogen products, is applicable in whole or in part to these lower-dose estrogen products. The boxed warnings include: (1) an increased risk of endometrial cancer in women with a uterus who uses unopposed estrogens, (2) estrogen therapy with or without progestins should not be used for the prevention of cardiovascular disease or dementia, (3) an increased risk of stroke and deep vein thrombosis (DVT) in women treated with estrogen-alone, (4) an increased risk of probable dementia in postmenopausal women 65 years of age and older treated with estrogen-alone, (5) an increased risk of invasive breast cancer in women treated with estrogen plus progestin, and (6) to use the lowest effective dose for the shortest duration. It is unknown at this time what, if any, changes the FDA may propose with respect to the boxed warnings on lower dose estrogen-alone products for symptoms of VVA or whether such label changes would be applicable to TX-004HR, if approved.</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 14; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As of December 31, 2015, we had fourteen issued patents, which included 12 utility patents that relate to our combination progesterone and estradiol formulations, one utility patent that relates to TX-004HR, which establishes an important intellectual property foundation for TX-004HR, and one utility patent that relates to our OPERA<sup>&#xAE;</sup> information technology platform.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Preclinical Development</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Based upon leveraging our SYMBODA<sup>TM</sup> hormone technology, we have five preclinical projects that include development of our proposed progesterone-alone and combination estradiol and progesterone products in a topical cream form, which we refer to as TX-005HR and TX-006HR, respectively, and in a transdermal patch form, which we refer to as TX-007HR and TX-008HR, respectively. We recently completed a preclinical study of TX-005HR in 32 rats. The study used four groups of eight female overectomized rats each and applied subcutaneous estrogen with either placebo, subcutaneous progesterone or topical TX-005HR. The results, presented a NAMS in October, 2015, showed that TX-005HR penetrated the skin and opposed the subcutaneous estrogen effect on the endometrium. We intend to file an IND with respect to TX-005HR and TX-006HR as soon as the first half of 2016 and then commence Phase 1 clinical trials. We may in the future engage with a financing partner to advance our topical cream and transdermal patch projects. We are also evaluating various other indications for our hormone technology, including oral contraception, treatment of preterm birth, and premature ovarian failure. According to Symphony Health Solutions, the total FDA-approved menopause-related market for estrogen alone and in combination was approximately $3.8 billion in U.S. sales for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Sales and Marketing </b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Although our direct national sales force is similar to that of a traditional pharmaceutical company in that sales representatives call on OB/GYN practices to provide education and sampling, we believe our sales representatives are more customer -centric in their sales approach by offering physicians more than just differences in our products from the competition; they are also able to offer physicians opportunities to assist their patients in obtaining products in a cost-efficient manner.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our national rollout strategy has been to focus first on the largest metropolitan areas in the United States. In order to accelerate the sales ramp-up in a new territory, we employ a national sales/large practice sales effort to identify key practices in new or expanding markets. Concurrent with our provider sales effort, we work with commercial insurance payors for partnerships in which the payor can support the prescription and/or recommendation of our products for the benefit of the patient, physician, and payor, with an end result of providing better outcomes for all three constituents.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">At the forefront of our sales approach is the philosophy that the physician should recommend or prescribe products based only on what is best for the patient. In general, a better outcome is achieved by providing patients with the best products and care at the best value. We believe having an assortment of high-quality product options that can be recommended or prescribed by both the physician and payor is the foundation of providing valuable options to the patient.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We believe our
sales force has developed strong relationships in the OB/GYN market to sell our current products. We have also established
relationships with some of the largest OB/GYN practices in their respective markets. By delivering additional products
through the same sales channel, we believe we can leverage our already deployed assets to increase our sales and achieve
profitability. We intend to leverage and grow our current marketing and sales organization to commercialize our drug
candidates in the United States assuming the successful completion of the FDA regulatory process. In addition, we may partner
with licensors or other strategic partners to commercialize our drug candidates outside of the OB/GYN market or in non-U.S.
markets.</p>



<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 15; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Online Commerce</i></p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">A vast majority of our OTC product sales are completed online. The Internet has continued to increase its influence over communication, content, and commerce. We believe several factors will contribute to this continuing increase, including convenience, expanded range of available products and services, improved security and electronic payment technology, increased access to broadband Internet connections and widespread consumer confidence and acceptance of the Internet as a means of commerce.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Retail Commerce</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The vast majority of our prescription product sales are completed through the traditional pharmacy distribution network. Although online and mail order pharmacy commerce continues to grow, the majority of products are still purchased directly by the consumer locally at traditional stores. As this division of our business expands, we will continue to employ strategies that help us reduce inefficiencies in this channel and develop relationships that allow our products to be differentiated from the competition.</p>

<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">&nbsp;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><em>Sales Concentration</em></p>

<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">&nbsp;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><em></em></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">See Note 13 to the consolidated financial statements included in this Annual Report for a discussion of the concentration of sales of our prescription prenatal vitamin products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>Competition</b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Pharmaceutical Industry</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The pharmaceutical industry is subject to intense competition and is characterized by extensive research efforts and rapid technological change. Competition in our industry occurs in a variety of areas, including developing and bringing new products to market before others, developing new technologies to improve existing products, developing new products to provide the same benefits as existing products at lower cost, and developing new products to provide benefits superior to those of existing products. Most major pharmaceutical companies, as well as numerous specialty pharmaceutical companies, sell products in the women&#x2019;s health sector of the pharmaceutical industry, which is comprised of products designed for post-pubescent females and is generally considered very fragmented. There are many companies focused on the women&#x2019;s health sector of the pharmaceutical industry that have significantly greater financial and other resources than we do, including generic manufacturers, drug compounding pharmacies, and large pharmaceutical companies. In addition, academic and other research institutions could be engaged in research and development efforts for the indications targeted by our products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Hormone Therapy Market</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The menopause hormone therapy market includes two major components: an FDA-approved drug market and a non-FDA approved drug market supplied by compounding pharmacies. On November 27, 2013, the DQSA became law and the FDA was given additional oversight over compounding pharmacies. We believe FDA-approved products are easily measured and monitored, while non-FDA approved hormone therapy drug products, typically referred to as &#x201C;bioidenticals&#x201D; when produced and sold by compounding pharmacies, are not easily measured or monitored. Our phase 3 clinical trials are intended to establish an indication of the safety and efficacy of our hormone therapy drug candidates at specific dosage levels. We intend our hormone therapy drug candidates, if approved by the FDA, to provide hormone therapies with well characterized safety and efficacy profiles that can be consistently manufactured to target specifications. This would provide an alternative to the non-FDA approved compounded bioidentical market. This aim is based on our belief that our drug candidates will offer advantages in terms of demonstrated safety and efficacy consistency in the hormone dose, lower patient cost due to the increased likelihood of insurance coverage and improved access as a result of availability from major retail pharmacy chains rather than custom order or formulation by individual compounders.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-001HR, our combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause. The combination of estradiol and progesterone for the treatment of moderate to severe vasomotor symptoms due to menopause for postmenopausal women with an intact uterus is comprised of two components: the FDA-approved drug market and the non-FDA-approved compounded drug market. Symphony Health Solutions estimates that sales of FDA-approved estrogen and progestins combined were approximately $616 million and the sales of estradiol and progesterone on the stand-alone basis were $926 million and $322 million, respectively, in the United States for the 12 months ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 16; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The largest competitors in the FDA-approved market are Pfizer (PREMARIN and PREMPRO), TEVA and BARR (generic estradiol and progestins) and Noven (Minivelle), with sales of PREMARIN cream constituting a majority of such sales. None of the current FDA-approved drugs for the treatment of moderate to severe vasomotor symptoms due to menopause is bioidentical to the estradiol and progesterone produced by the ovaries. Based on various reports, included data recently presented at NAMS, including Knowledge, Use, and Prescribing of Custom-Compounded Bioidentical Hormones for Menopausal Women: It&#x2019;s Not What You Think, by JoAnn V. Pinkerton, et al., we estimate that U.S. sales of non-FDA-approved compounded combination estradiol and progesterone products approximate $1.5 billion per year. The market for non-FDA-approved compounded hormone therapy products is generally considered very fragmented because the products are prepared and sold by individual compounding pharmacies. We believe that TX-001HR, if approved by the FDA, would represent the first time a combination product of estradiol and progesterone that is bioidentical to &#x2013; or having the same chemical and molecular structure as - the estradiol and progesterone produced by the ovaries would be approved for use in a single combined product.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-002HR,
our progesterone only drug candidate, is being developed for the treatment of secondary amenorrhea. According to Symphony
Health Solutions, the total FDA-approved market for oral progesterone and progestin was approximately $505 million in U.S.
sales for the 12 months ended December 31, 2015. The largest competitors in the progesterone and progestin market are
generics from Actavis, Teva and Akorn with the largest branded product being Prometrium (AbbVie). We believe that TX-002HR,
if approved by the FDA, would provide for treatment of secondary amenorrhea without the potentially allergenic component of
peanut oil found in existing products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-004HR, our vaginal estradiol softgel drug candidate, is undergoing clinical trials for the treatment of VVA in post-menopausal women with vaginal linings that do not receive enough estrogen. According to Symphony Health Solutions, the FDA-approved U.S. market for treatment of VVA in post-menopausal women was approximately $1.5 billion for the 12 months ended December 31, 2015. Approximately $1.4 billion of such sales were by three products currently on the market: Pfizer (PREMARIN cream), Actavis (ESTRACE cream) and Novo Nordisk (Vagifem tablets). We believe that TX-004HR, if approved by the FDA, will be at least as effective as the existing treatments for VVA because of an early onset of action with less systemic exposure inferring a greater probability of dose administration to the target tissue, and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Prenatal Vitamin Market</i></p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The prenatal vitamin market is highly fragmented, with dozens of companies selling hundreds of competitive products. Prenatal vitamin products are marketed as either OTC products or prescription products, with many companies marketing their products through both channels. According to Symphony Health Solutions, during the 12 months ended December 31, 2015, approximately 7.3 million prescriptions for prenatal vitamins were issued in the United States resulting in total sales of approximately $386 million.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Seasonality</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The specialty pharmaceutical industry is not subject to seasonal sales fluctuation.</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>Products in Development</b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We introduced our branded prescription products in the first and second quarters of 2012 and introduced our first prescription authorized generic product line in the fourth quarter of 2012. Our market objective is to develop an entire suite of products that are condition-specific and geared to the women&#x2019;s health sector. Our focus is to introduce products in which we use proprietary or patented molecules or ingredients that will differentiate our products from the competition. We currently have numerous products in development, including our hormone therapy drug candidates as described above.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Raw Materials for Our Products</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We acquire all raw materials and ingredients for our proprietary products from a group of third-party suppliers specializing in raw material manufacturing, processing, and specialty distribution. Our primary manufacturer maintains multiple supply and purchasing relationships throughout the raw materials marketplace to provide an uninterrupted supply of product to meet our manufacturing requirements.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 17; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>Availability of and Dependence Upon Suppliers</b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We currently obtain approximately 99% of our vitaMedMD and BocaGreen products from Lang Pharma Nutrition, or Lang, a full-service, private label and corporate brand manufacturer specializing in premium health benefit driven products, including medical foods, nutritional supplements, beverages, bars, and functional foods in the dietary supplement category. As a result, we are dependent on Lang and its subcontractors for the manufacture of most of our products. We believe the terms of our agreements with Lang are competitive with other suppliers and manufacturers. Although we anticipate continuing our relationship with Lang, we believe that we could obtain similar terms with other suppliers to provide the same services. We have experienced no difficulties in obtaining the products we need in the amounts we require and do not anticipate those issues in the future.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Manufacturing of Our Products</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our vitamin products are manufactured in accordance with the FDA&#x2019;s current Good Manufacturing Practice, or cGMPs, for dietary supplements. In addition, we employ an outside third party to enforce rigorous quality audits.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">All of our manufacturing is performed by third-party manufacturers. In addition to manufacturing substantially all of our products, Lang also provides a variety of additional services to us, including development processes, prototype development, raw materials sourcing, regulatory review, and packaging production. At present, we believe our relationship with Lang is excellent, and we intend to continue to use Lang as our third-party manufacturer for most of our products. In the event our relationship with Lang terminates for any reason, there are a number of other manufacturers available to us. Accordingly, we do not believe that such termination would have a material adverse effect on our business.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We use third-party manufacturers to source key raw materials and manufacture and package our products. The FDA must approve the manufacturing facility for compliance with the FDA&#x2019;s cGMP regulations before an NDA for a new drug is approved. Accordingly, we intend to engage only those third-party contract manufacturers that have consistently shown the ability to satisfy these requirements for our hormone therapy drug candidates.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Quality Control for our Products</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">A quality assurance team establishes process controls and documents and tests every stage of the manufacturing process to ensure we meet product specifications and that our finished products contain the correct ingredients, purity, strength, and composition in compliance with FDA regulations. We test incoming raw materials and finished goods to ensure they meet or exceed FDA and U.S. Pharmacopeia standards, including quantitative and qualitative assay and microbial and heavy metal contamination.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our manufacturers&#x2019; quality and production standards are designed to meet or exceed current FDA regulations. To ensure the highest quality, our manufacturing operations are audited by AIB International, Inc., or AIB, among others, for independent cGMP certification. AIB is an independent, not-for-profit organization that offers programs and services to augment and support the work of regulatory officials around the country, including standards development, product testing and certification, and onsite audits and inspections. The manufacturing facilities we primarily use are also ISO 9001 certified, which is a family of standards related to quality management systems and are designed to help organizations ensure they meet the needs of customers.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Distribution of our Products</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We use a variety of distribution channels dependent upon product type. We sell our prescription prenatal vitamins to patients through their pharmacies. Since the launch of our prescription products, in addition to third-party logistics providers, we use some of the same national and regional distributors as other pharmaceutical companies, including Cardinal, McKesson, AmerisourceBergen, H.D. Smith, and Smith Drug. Wholesaler product inventory is monitored daily and sales out is monitored weekly. National and regional retail chain pharmacies are also an area of focus to make sure our products are purchased and dispensed properly. We sell our OTC products directly to consumers via our website and phone sales and the products are shipped directly from us to the consumer&#x2019;s home or office. In a few instances, we sell OTC products to physicians who then sell the products directly to their patients.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Customer Service</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our goal is 100% customer satisfaction by consistently delivering superior customer experiences before, during, and after the sale. To achieve this goal, we maintain a fully -staffed customer care center that uses current customer relationship management software to respond to health care providers, pharmacies, and consumers and accept orders for non-prescription products via incoming and outgoing telephone calls, e-mails, and live-chat. We believe our customer service initiatives allow us to establish and maintain long-term customer relationships and facilitate repeat visits and purchases. We also facilitate repeat customer orders through our auto-ship feature.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 18; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our representatives receive regular training so that they can effectively and efficiently field questions from current and prospective customers and are also trained not to answer questions that should be directed to a customer&#x2019;s physician. Having a quality customer care center allows our representatives to provide an array of valuable data in the areas of sales, market research, quality assurance, lead generation, and customer retention.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Our Return Policy</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We sell our prescription products through third-party logistics providers, major distributors, and pharmacies, all of whom may return a product within six months prior to and twelve months after the expiration date of the product. Once customers buy a product from the pharmacy, the product may not be returned. Customers may return or exchange our non-prescription products for any reason by returning the product within 30 days of receipt. We will refund the entire purchase price, less shipping. The customer is responsible for the cost of returning the products to us, except in cases in which the product is being returned because of a defect or an error made in our order fulfillment. If the purchased product exceeded a 30-day supply, the unused product must be returned to receive the full refund. All unopened OTC products may be exchanged for different products; the customer will be responsible for the difference in price if the replacement product is more expensive or we will refund the difference if the replacement product is less expensive.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Our Quality Guarantee</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We proudly stand behind the quality of our products. We believe our guarantee makes it easy, convenient, and safe for customers to purchase our products. Under our quality guarantee, we:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">ensure the potency and quality of our vitamin products;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">help health care providers and payors by delivering information on patient compliance and satisfaction;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">provide a 30-day money back guarantee for all of our OTC products; and</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">ensure a safe, secure online shopping experience through our encrypted website.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We value frequent communication with and feedback from our customers in order to continue to improve our offerings and services.</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Research and Development</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our product development programs are concentrated in the area of advanced hormone therapy pharmaceutical products. We engage in programs to provide alternatives to the FDA and non-FDA-approved compounded bioidentical market for hormone therapy. Our programs seek to bring new products to market in unique delivery systems or formats that enhance the effectiveness, safety, and reliability of existing hormone therapy alternatives.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We intend for our hormone therapy drug candidates, if approved, to provide an alternative to the non-FDA -approved compounded bioidentical market based on our belief that our drug candidates will offer advantages in terms of proven safety, efficacy, and stability, lower patient cost as a result of insurance coverage, and improved access as a result of availability from major retail pharmacy chains rather than custom order or formulation by individual compounders.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 40.3pt; font: 10pt Times New Roman, Times, Serif;">Our research and development expenses were $72.0 million in 2015, $43.2 million in 2014, and $13.6 million in 2013.</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 40.3pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Intellectual Property</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our success depends, in part, on our ability to obtain patents, maintain trade secret protection, and operate without infringing the proprietary rights of others. Our intellectual property portfolio is one of the means by which we attempt to protect our competitive position. We rely primarily on a combination of know-how, trade secrets, patents, trademarks, and contractual restrictions to protect our products and to maintain our competitive position. We are diligently seeking ways to protect our intellectual property through various legal mechanisms in relevant jurisdictions.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 19; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have developed hormone products using our SYMBODA<sup>&#xAE;</sup> technology, which is our advanced hormone therapy technology that enables us to deliver bioidentical hormones through a variety of dosage forms and administrative routes.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition to numerous pending patent applications, as of December 31, 2015, we had 14 issued patents, including:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Symbol;">&#xB7;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font>12 utility patents that relate to our combination progesterone and estradiol product candidates, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa and South Korea.&#xA0;</p>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Symbol;">&#xB7;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font>one utility patent that relates to TX-004HR, our applicator-free vaginal estradiol softgel product candidate, which establishes an important intellectual property foundation for TX-004HR, is owned by us and is a U.S. jurisdiction patent with an expiration date in 2033. We have pending patent applications with respect to this patent in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea.&#xA0;</p>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Symbol;">&#xB7;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;</font>one utility patent that relates to our OPERA<sup>&#xAE;</sup> information technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029; and</p>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As of December 31, 2015, we had filed 34 non-provisional and 16 provisional patent applications with the U.S. Patent and Trademark Office, or the USPTO, with respect to our hormone therapy drug candidates, including issued patents, and 72 international patent applications with respect to our hormone therapy drug candidates, including Patent Cooperation Treaty (PCT) and national stage filings.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We hold multiple U.S. trademark registrations and have numerous pending trademark applications. Issuance of a federally registered trademark creates a rebuttable presumption of ownership of the mark; however, it is subject to challenge by others claiming first use in the mark in some or all of the areas in which it is used. Federally registered trademarks have a perpetual life as long as they are maintained and renewed on a timely basis and used properly as trademarks, subject to the rights of third parties to seek cancellation of the trademarks if they claim priority or confusion of usage. We believe our patents and trademarks are valuable and provide us certain benefits in marketing our products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We intend to actively protect our intellectual property with patents, trademarks, trade secrets, or other legal avenues for the protection of intellectual property and to aggressively prosecute, enforce, and defend our patents, trademarks, and proprietary technology. The loss, by expiration or otherwise, of any one patent may have a material effect on our business. Defense and enforcement of our intellectual property rights can be expensive and time consuming, even if the outcome is favorable to us. It is possible that the patents issued or licensed to us will be successfully challenged, that a court may find that we are infringing on validly issued patents of third parties, or that we may have to alter or discontinue the development of our products or pay licensing fees to take into account patent rights of third parties.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">OPERA is our patented information technology platform used in our business. We believe the deployment of OPERA and the further development and deployment of related technology creates a sustainable competitive advantage in clinical development and product improvement.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As we continue to develop proprietary intellectual property, we will expand our protection by applying for patents on future technologies. As we examine our current product offerings and new product pipeline, we are in the process of modifying and developing new formulations that will enable us to gain patent protection for these products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">While we seek broad coverage under our patent applications, there is always a risk that an alteration to the process may provide sufficient basis for a competitor to avoid infringement claims. In addition, patents expire and we cannot provide any assurance that any patents will be issued from our pending application or that any potentially issued patents will adequately protect our intellectual property.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>Government Regulation</b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In the United States, the FDA regulates pharmaceuticals, dietary supplements, and cosmetics under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. These products are also subject to other federal, state, and local statutes and regulations, including federal and state consumer protection laws, laws protecting the privacy of health-related information, and laws prohibiting unfair and deceptive acts and trade practices.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 20; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Pharmaceutical Regulation</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The process required by the FDA before a new drug product may be marketed in the United States generally involves the following:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">completion or reference of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the FDA&#x2019;s Good Laboratory Practice, or GLP, regulations;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">submission to the FDA of an IND, which the FDA must allow to become effective before human clinical trials may begin and must be updated annually;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the drug candidate for each proposed indication; and</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">submission to the FDA of an NDA after completion of all pivotal clinical trials.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">An IND is a request for authorization from the FDA to administer an investigational drug product to humans. We currently have effective INDs for all of our hormone therapy drug candidates, although we have no current plans to conduct clinical trials for TX-003HR.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Clinical trials involve the administration of the investigational drug to human subjects under the supervision of qualified investigators in accordance with current Good Clinical Practices, or cGCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical trial site&#x2019;s IRB before the trials may be initiated, and the IRB must monitor the study until completed. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Clinical trials are usually conducted in three phases. Phase 1 clinical trials are normally conducted in small groups of healthy volunteers to assess safety and find the potential dosing range. After a potentially safe dose has been established, the drug is administered to small populations of patients (phase 2) to look for initial signs of efficacy in treating the targeted disease or condition and to continue to assess safety. Phase 3 clinical trials are usually multi-center, double-blind controlled trials in hundreds or even thousands of subjects at various sites to assess as fully as possible both the safety and effectiveness of the drug.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, or DSMB. This group reviews unblinded data from clinical trials and provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the study. We may also suspend or terminate a clinical trial based on evolving business objectives or competitive climates.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational drug product information is submitted to the FDA in the form of an NDA requesting approval to market the product for one or more indications. The application includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#x2019;s chemistry, manufacturing, controls and proposed labeling, among other things.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Once the NDA submission has been accepted for filing, the FDA&#x2019;s goal is to review applications within ten months of filing or 12 months of filing for a new molecular entity. However, the review process is often significantly extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it typically follows such recommendations.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 21; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">After the FDA evaluates the NDA and conducts inspections of manufacturing facilities in which the drug product will be formulated and its active pharmaceutical ingredient, or API, will be produced, it may issue an approval letter or, instead, a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter may require additional clinical data and/or an additional pivotal phase 3 clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. The FDA could also approve the NDA with a Risk Evaluation and Mitigation Strategies, or REMS, plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include phase 4 clinical trials and surveillance to further assess and monitor the product&#x2019;s safety and effectiveness after commercialization.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">After regulatory approval of a drug product is obtained, we would be required to comply with a number of post-approval requirements. As a holder of an approved NDA, we would be required to report, among other things, certain adverse reactions and production problems to the FDA, to provide updated safety and efficacy information, and to comply with requirements concerning advertising and promotional labeling for any of our products. Also, quality control and manufacturing procedures must continue to conform to cGMP after approval to ensure and preserve the long-term stability of the drug product. The FDA periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural, substantive, and record keeping requirements. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our drug candidates. Future FDA and state inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a product, manufacturer, or holder of an approved NDA, including withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further marketing. Newly discovered or developed safety or effectiveness data may require changes to a product&#x2019;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#x2019;s policies may change, which could delay or prevent regulatory approval of our products under development.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our hormone therapy drug candidates may compete with unapproved hormone therapy products supplied by compounding pharmacies. Pharmacy compounding is a practice in which a licensed pharmacist combines, mixes, or alters ingredients in response to a prescription to create a medication tailored to the medical needs of an individual patient. The medications created by the compounding pharmacy are theoretically &#x201C;new drugs&#x201D; that would otherwise be subject to the new drug approval requirements of the FDCA.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">However, for approximately 50 years, FDA left regulation of compounding pharmacies to the states. In 1992, in response to various safety concerns, FDA issued a Compliance Policy Guide, which announced that the &#x201C;FDA may, in the exercise of its enforcement discretion, initiate federal enforcement actions...when the scope and nature of a pharmacy&#x2019;s activities raises the kinds of concerns normally associated with a manufacturer and...results in significant violations of the new drug, adulteration, or misbranding provisions of the Act.&#x201D; Thereafter, Congress enacted the Food and Drug Administration Modernization Act of 1997, or FDAMA, which sought to clarify FDA&#x2019;s regulatory authority over compounding pharmacies. FDAMA exempted &#x201C;compounded drugs&#x201D; from FDA&#x2019;s standard drug approval requirements as long as the providers of those drugs abide by several restrictions, including that they refrain from advertising or promoting particular compounded drugs. In 2002, though, the Supreme Court declared this provision of FDAMA to be unconstitutional under the First Amendment, effectively re-instating the pre-FDAMA regime. Shortly thereafter, FDA issued its 2002 Compliance Policy Guide 460.200, which states that FDA will exercise enforcement discretion to exclude compounded drugs from the new drug approval requirements except where compounding pharmacies act more akin to traditional drug manufacturers.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 22; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">To further clarify FDA&#x2019;s jurisdiction, Congress enacted and the President signed into law the DQSA, which among other things, formalized the relationship between the FDA and compounding pharmacies by exempting compounding pharmacy products from the FDA approval requirements and the requirement to label products with adequate directions for use, but not the exemption from cGMP requirements. To qualify for this exemption, a compounding pharmacy must register with FDA as an &#x201C;outsourcing facility,&#x201D; subject to FDA inspection and other requirements. The FDA does not exercise the same authority to regulate compounding pharmacies as pharmaceutical manufacturers. For example, compounding pharmacies are not required to report adverse events associated with compounded drugs, while commercial drug manufacturers are subject to stringent regulatory reporting requirements.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i>505(b)(2) Applications</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We intend to submit NDAs for our hormone therapy drug candidates, assuming that the clinical data justify submission, under section 505(b)(2) of the FDCA, or Section 505(b)(2). Section 505(b)(2) permits the filing of an NDA when at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. The applicant may rely upon published literature and the FDA&#x2019;s findings of safety and effectiveness based on certain pre-clinical or clinical studies conducted for an approved product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) applicant. In regards to TX-001HR, we are required to conduct phase 3 studies for vasomotor symptoms versus placebo and an endometrial protection study.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Phase 3 clinical trials for secondary amenorrhea versus placebo will be required for TX-002HR. TX-003HR would be required to undergo phase 3 studies of vasomotor symptoms compared to placebo, though we currently do not have plans to continue development of this drug candidate.</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As part of our NDA submission, we intend to certify that all of the patents for approved products referenced in the NDA for each of the hormone therapy drug candidates as listed in the FDA&#x2019;s Orange Book have expired and that we will not be compelled to certify that any patent is invalid, unenforceable, or will not be infringed by the new product. If, in fact, this assessment is incorrect, it can have a serious and significant adverse effect on our ability to obtain FDA approval or market our new product. If we are compelled to certify that a patent is invalid, unenforceable, or not infringed, then the holder of that patent can initiate a patent infringement suit against us and the FDA is precluded from approving our product for 30 months or until a court decision or settlement finding that the patent is invalid, unenforceable or not infringed, whichever is earlier.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-indent: 0.5in; font: italic 10pt Times New Roman, Times, Serif;">Marketing Exclusivity</p>
<p style="margin: 0pt 0; text-indent: 0.5in; font: italic 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">A 505(b)(2) NDA applicant may be eligible for its own regulatory exclusivity period, such as a three-year exclusivity. The first approved 505(b)(2) NDA applicant for a particular condition, or change to a marketed product, such as a new extended release formulation for a previously approved product, may be granted three-year Hatch-Waxman exclusivity if one or more clinical studies, other than bioavailability or bioequivalence studies, was essential to the approval of the application and was conducted or sponsored by the applicant. Should this occur, the FDA would be precluded from making effective any other application for the same condition of use or for a change to the marketing product that was granted exclusivity until after that three-year exclusivity period has run. Additional exclusivities may also apply.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Additionally, the 505(b)(2) NDA applicant may have relevant patents in the Orange Book, and if it does, it can initiate patent infringement litigation against those applicants that challenge such patents, which could result in a 30-month stay delaying those applicants.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Dietary Supplement Regulation</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our currently marketed products are regulated as dietary supplements. The processing, formulation, safety, manufacturing, packaging, labeling, advertising, and distribution of these products are subject to regulation by one or more federal agencies, including the FDA and the Federal Trade Commission, or the FTC, and by various agencies of the states and localities in which our products are sold.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Generally, our nutritional product formulations are proprietary in that in designing them, we attempt to blend an optimal combination of nutrients that appear to have beneficial impact based upon scientific literature and input from physicians; however, we are generally prohibited from making disease treatment and prevention claims in the promotion of our products that use these formulations.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 23; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The Dietary Supplement Health and Education Act of 1994, or DSHEA, amended the FDCA to establish a new framework governing the composition, safety, labeling, manufacturing, and marketing of dietary supplements. Generally, under the FDCA, dietary ingredients that were marketed in the United States prior to October 15, 1994 may be used in dietary supplements without notifying the FDA. &#x201C;New&#x201D; dietary ingredients (<i>i.e.</i>, dietary ingredients that were &#x201C;not marketed in the United States before October 15, 1994&#x201D;) must be the subject of a new dietary ingredient notification submitted to the FDA unless the ingredient has been &#x201C;present in the food supply as an article used for food&#x201D; without being &#x201C;chemically altered.&#x201D; A new dietary ingredient notification must provide the FDA evidence of a &#x201C;history of use or other evidence of safety&#x201D; establishing that use of the dietary ingredient &#x201C;will reasonably be expected to be safe.&#x201D; A new dietary ingredient notification must be submitted to the FDA at least 75 days before the initial marketing of the new dietary ingredient. The FDA may determine that a new dietary ingredient notification does not provide an adequate basis to conclude that a dietary ingredient is reasonably expected to be safe. Such a determination could prevent the marketing of such dietary ingredient. The FDA recently issued draft guidance governing the notification of new dietary ingredients. FDA guidance is not mandatory and companies are free to use an alternative approach if the approach satisfies the requirements of applicable laws and regulations. However, FDA guidance is a strong indication of the FDA&#x2019;s &#x201C;current thinking&#x201D; on the topic discussed in the guidance, including its position on enforcement. The draft guidance on new dietary ingredients is expected to be significantly revised when published in final form. Moreover, Congress can amend the dietary supplement provisions of the FDCA to impose additional restrictions on labeling and marketing of dietary supplements. Such action would have material adverse impact on our business and growth prospects.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The FDA or other agencies could take actions against products or product ingredients that in its determination present an unreasonable health risk to consumers that would make it illegal for us to sell such products. In addition, the FDA could issue consumer warnings with respect to the products or ingredients in such products. Such actions or warnings could be based on information received through FDCA-mandated reporting of serious adverse events. The FDCA requires that reports of serious adverse events be submitted to the FDA, and based in part on such reports, the FDA has issued public warnings to consumers to stop using certain third party dietary supplement products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The FDCA permits &#x201C;statements of nutritional support&#x201D; to be included in labeling for dietary supplements without premarket approval. Such statements must be submitted to the FDA within 30 days of marketing. Such statements may describe how a particular dietary ingredient affects the structure, function, or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect body structure, function, or well-being, but may not expressly or implicitly represent that a dietary supplement will diagnose, cure, mitigate, treat, or prevent a disease. A company that uses a statement of nutritional support in labeling must possess scientific evidence substantiating that the statement is truthful and not misleading. If the FDA determines that a particular statement of nutritional support is an unacceptable drug claim, conventional food claim, or an unauthorized version of a &#x201C;health claim,&#x201D; or, if the FDA determines that a particular claim is not adequately supported by existing scientific data or is false or misleading, we would be prevented from using the claim.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, DSHEA provides that so-called &#x201C;third-party literature,&#x201D; such as a reprint of a peer-reviewed scientific publication linking a particular dietary ingredient with health benefits, may be used &#x201C;in connection with the sale of a dietary supplement to consumers&#x201D; without the literature being subject to regulation as labeling. The literature: (1) must not be false or misleading; (2) may not &#x201C;promote&#x201D; a particular manufacturer or brand dietary supplement; (3) must present a balanced view of the available scientific information on the subject matter; (4) if displayed in establishment, must be physically separate from the dietary supplements; and (5) should not have appended to it any information by sticker or another method. If the literature fails to satisfy each of these requirements, we may be prevented from disseminating such literature with our products, and any dissemination could subject our product to regulatory action as an illegal drug.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In June 2007, pursuant to the authority granted by the FDCA as amended by DSHEA, the FDA published detailed cGMP regulations that govern the manufacturing, packaging, labeling, and holding operations of dietary supplement manufacturers. The cGMP regulations, among other things, impose significant recordkeeping requirements on manufacturers. The cGMP requirements are in effect for all manufacturers, and the FDA is conducting inspections of dietary supplement manufacturers pursuant to these requirements. There remains considerable uncertainty with respect to the FDA&#x2019;s interpretation of the regulations and their actual implementation in manufacturing facilities. In addition, the FDA&#x2019;s interpretation of the regulations will likely change over time as the agency becomes more familiar with the industry and the regulations. The failure of a manufacturing facility to comply with the cGMP regulations renders products manufactured in such facility &#x201C;adulterated,&#x201D; and subjects such products and the manufacturer to a variety of potential FDA enforcement actions. In addition, under the Food Safety Modernization Act, or FSMA, which was enacted on January 2, 2011, the manufacturing of dietary ingredients contained in dietary supplements will be subject to similar or even more burdensome manufacturing requirements, which will likely increase the costs of dietary ingredients and will subject suppliers of such ingredients to more rigorous inspections and enforcement. The FSMA will also require importers of food, including dietary supplements and dietary ingredients, to conduct verification activities to ensure that the food they might import meets applicable domestic requirements.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 24; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The FDA has broad authority to enforce the provisions of federal law applicable to dietary supplements, including powers to issue public Warning Letters or Untitled Letters to a company, publicize information about illegal products, detain products intended for import, require the reporting of serious adverse events, request a recall of illegal or unsafe products from the market, and request that the Department of Justice initiate a seizure action, an injunction action, or a criminal prosecution in the U.S. courts. The FSMA expands the reach and regulatory powers of the FDA with respect to the production and importation of food, including dietary supplements. The expanded reach and regulatory powers include the FDA&#x2019;s ability to order mandatory recalls, administratively detain domestic products, require certification of compliance with domestic requirements for imported foods associated with safety issues and administratively revoke manufacturing facility registrations, effectively enjoining manufacturing of dietary ingredients and dietary supplements without judicial process. The regulation of dietary supplements may increase or become more restrictive in the future.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The FTC exercises jurisdiction over the advertising of dietary supplements and cosmetics. In recent years, the FTC has instituted numerous enforcement actions against companies for failure to have adequate substantiation for claims made in advertising or for the use of false or misleading advertising claims.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In recent years, the FTC has instituted numerous enforcement actions against dietary supplement companies for making false or misleading advertising claims and for failing to adequately substantiate claims made in advertising. These enforcement actions have often resulted in consent decrees and the payment of civil penalties and/or restitution by the companies involved. The FTC also regulates other aspects of consumer purchases, including promotional offers of savings compared policies, telemarketing, continuity plans, and &#x201C;free&#x201D; offers.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We are also subject to regulation under various state, local, and international laws that include provisions governing, among other things, the formulation, manufacturing, packaging, labeling, advertising, and distribution of dietary supplements and drugs. For example, Proposition 65 in the state of California is a list of substances deemed to pose a risk of carcinogenicity or birth defects at or above certain levels. If any such ingredient exceeds the permissible levels in a dietary supplement, cosmetic, or drug, the product may be lawfully sold in California only if accompanied by a prominent warning label alerting consumers that the product contains an ingredient linked to cancer or birth defect risk. Private attorney general actions as well as California attorney general actions may be brought against non-compliant parties and can result in substantial costs and fines.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-indent: 0.5in; font: italic 10pt Times New Roman, Times, Serif;">Other U.S. Health Care Laws and Compliance Requirements</p>
<p style="margin: 0pt 0; text-indent: 0.5in; font: italic 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We are also subject to additional health care regulation and enforcement by the federal government and the states in which we conduct our business. Applicable federal and state health care laws and regulations include the following:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">The federal health care anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment may be made under federal health care programs, such as Medicare and Medicaid.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">The Ethics in Patient Referrals Act of 1989, commonly referred to as the Stark Law, and its corresponding regulations, prohibit physicians from referring patients for designated health services, including outpatient drugs, reimbursed under the Medicare or Medicaid programs to entities with which the physicians or their immediate family members have a financial relationship or an ownership interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting claims to Medicare or Medicaid for payment of items or services provided to a referred beneficiary.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">The federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 25; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any health care benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">The federal false statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for health care benefits, items, or services.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving health care items or services reimbursed by non-governmental third-party payors, including private insurers, and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Efforts to ensure that our business arrangements with third parties comply with applicable health care laws and regulations could be costly. Although we believe that our business practices are structured to be compliant with applicable laws, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other health care laws and regulations. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, exclusion from third party payor programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians, providers, or entities with whom we do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusion from government funded health care programs.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Many aspects of these laws have not been definitively interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations are subject to change. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#x2019;s attention from the operation of our business, and damage our reputation.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, from time to time in the future, we may become subject to additional laws or regulations administered by the FDA, the FTC, or by other federal, state, local, or foreign regulatory authorities, to the repeal of laws or regulations that we generally consider favorable, such as DSHEA, or to more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals, or interpretations, and we cannot predict what effect additional governmental regulation, if and when it occurs, would have on our business in the future. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have a material adverse effect on our business.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The growth and demand for eCommerce could result in more stringent consumer protection laws that impose additional compliance burdens on online retailers. These consumer protection laws could result in substantial compliance costs and could interfere with the conduct of our business.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">There is currently great uncertainty in many states whether or how existing laws governing issues such as property ownership, sales and other taxes, and libel and personal privacy apply to the Internet and commercial online retailers. These issues may take years to resolve. For example, tax authorities in a number of states, as well as a Congressional advisory commission, are currently reviewing the appropriate tax treatment of companies engaged in online commerce and new state tax regulations may subject us to additional state sales and income taxes. New legislation or regulation, the application of laws and regulations from jurisdictions whose laws do not currently apply to our business, or a change in application of existing laws and regulations to the Internet and commercial online services could result in significant additional taxes on our business. These taxes could have an adverse effect on our results of operations.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 26; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Employees</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As of December 31, 2015, we had 122 full-time employees, six of whom are executive officers. Additionally, from time to time, we hire temporary contract employees. None of our employees are covered by a collective bargaining agreement, and we are unaware of any union organizing efforts. We have never experienced a major work stoppage, strike, or dispute. We consider our relationship with our employees to be good.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 27; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Our History</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On October 3, 2011, we changed our name to TherapeuticsMD, Inc. On October 4, 2011, we closed a reverse merger with VitaMedMD pursuant to which (1) all outstanding membership units of VitaMed were exchanged for shares of our common stock, (2) all outstanding VitaMed options and warrants were exchanged and converted into options and warrants to purchase shares of our common stock, and (3) VitaMed became our wholly owned subsidiary. As of December 31, 2011, we determined that VitaMed would become the sole focus of our company and services previously performed relative to the licensing agreement discussed in the following paragraph were discontinued.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; We were incorporated in Utah in 1907 under the name Croff Mining Company, or Croff. Prior to 2008, Croff&#x2019;s operations consisted entirely of oil and natural gas leases. Due to a spin-off of its operations in December 2007, Croff had no business operations or revenue source and had reduced its operations to a minimal level although it continued to file reports required under the Securities Exchange Act of 1934, or the Exchange Act. As a result of the spin-off, Croff was a &#x201C;shell company&#x201D; under the rules of the Securities and Exchange Commission, or the SEC. In July 2009, Croff (i) closed a transaction to acquire America&#x2019;s Minority Health Network, Inc. as a wholly owned subsidiary, (ii) ceased being a shell company, and (iii) experienced a change in control in which the former stockholders of America&#x2019;s Minority Health Network, Inc. acquired control of our company. On June 11, 2010, we closed a transaction to acquire Spectrum Health Network, Inc. as a wholly owned subsidiary. On July 20, 2010, we filed Articles of Conversion and Articles of Incorporation to redomicile in the state of Nevada. On July 31, 2010, we transferred the assets of America&#x2019;s Minority Health Network, Inc. to a secured noteholder in exchange for the satisfaction of certain associated debt. On February 15, 2011, we transferred the assets of Spectrum Health Network, Inc. to a secured noteholder in exchange for the satisfaction of associated debt and in exchange for a licensing agreement under which we subsequently sold subscription services and advertising on the Spectrum Health Network for commissions.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Available Information</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We are a Nevada corporation. We maintain our principal executive offices at 6800 Broken Sound Parkway NW, Third Floor, Boca Raton, Florida 33487. Our telephone number is (561) 961-1900. We maintain websites at <i>www.therapeuticsmd.com</i>, <i>www.vitamedmd.com</i>, <i>www.vitamedmdrx.com</i>, and <i>www.bocagreenmd.com</i>. The information contained on our websites or that can be accessed through our websites is not incorporated by reference into this Annual Report or in any other report or document we file with the SEC.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We file reports with the SEC, including Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any other filings required by the SEC. Through our website, we make available free of charge our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and all amendments to those reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The public may read and copy any materials we file with, or furnish to, the SEC at the SEC&#x2019;s Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains an Internet site (<i>www.sec.gov</i>) that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 28; Options: NewSection; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: center; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>Risk Factors</b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 1A.<a name="txmda003_v1"></a></td>
<td style="text-align: justify;"><i>Risk Factors</i></td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Investing in our common stock involves a high degree of risk. You should carefully consider the following risk factors, together with all of the information included in this Annual Report before you decide to purchase shares of our common stock. We believe the risks and uncertainties described below are the most significant we face. Additional risks and uncertainties of which we are unaware, or that we currently deem immaterial, also may become important factors that affect us. If any of the following risks occur, our business, financial condition, or results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><i>Risks Related to Our Business</i></b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have incurred recurring net losses, including net losses of $85 million, $54 million, and $28 million for the years ended December 31, 2015, 2014, and 2013, respectively. As of December 31, 2015, we had an accumulated deficit of approximately $220 million. We have generated limited revenue and have funded our operations to date primarily from public and private sales of equity and private sales of debt securities. We expect to incur substantial additional losses over the next several years as our research, development, clinical trial and commercialization activities increase, especially those related to our hormone therapy drug candidates. As a result, we may never achieve or maintain profitability unless we successfully commercialize our products, in particular, our hormone therapy drug candidates. If we continue to incur substantial losses and are unable to secure additional financing, we could be forced to discontinue or curtail our business operations, sell assets at unfavorable prices, refinance then-existing debt obligations on terms unfavorable to us, or merge, consolidate, or combine with a company with greater financial resources in a transaction that might be unfavorable to us.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>We currently derive all of our revenue from sales of our women&#x2019;s health care products, and our failure to maintain or increase sales of these products could have a material adverse effect on our business, financial condition, results of operations, and growth prospects.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We currently derive all of our revenue from sales of women&#x2019;s health care products, including prenatal and women&#x2019;s multi-vitamins, iron supplements, vitamin D supplements, and natural menopause relief. While sales of our vitamin products grew from 2010 through 2015, we cannot assure you that such sales will continue to grow. In addition to other risks described herein, our ability to maintain or increase existing product sales is subject to a number of risks and uncertainties, including the following:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">the presence of new or existing competing products, including generic copies of our prescription prenatal vitamin products that are not our authorized generic products ;</td>
</tr>
</table>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">any supply or distribution problems arising with any of our manufacturing and distribution strategic partners;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">changed or increased regulatory restrictions or regulatory actions by the FDA;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">changes in health care laws and policy, including changes in requirements for rebates, reimbursement, and coverage by federal health care programs;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">the impact or efficacy of any price increases we may implement in the future;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">changes to our labels and labeling, including new safety warnings or changes to our boxed warning, that further restrict how we market and sell our products; and</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">acceptance of our products as safe and effective by physicians and patients.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 29; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">If revenue from sales of our existing prescription and OTC prenatal vitamins does not continue or increase, we may be required to reduce our operating expenses or to seek to raise additional funds, which could have a material adverse effect on our business, financial condition, results of operations, and growth prospects, or we may not be able to commence or continue clinical trials to seek approval for and commercialize our hormone therapy drug candidates or any other products we may choose to develop in the future.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">If our products do not have the effects intended or cause undesirable side effects, our business may suffer.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Although many of the ingredients in our current dietary supplement products are vitamins, minerals, and other substances for which there is a long history of human consumption, they also contain innovative ingredients or combinations of ingredients. Although we believe all of these products and the combinations of ingredients in them are safe when taken as directed, the products could have certain undesirable side effects if not taken as directed or if taken by a consumer who has certain medical conditions, such as the potential effect of high doses of folic acid masking pernicious anemia. In addition, these products may not have the effect intended if they are not taken in accordance with certain instructions, which include certain dietary restrictions. Furthermore, there can be no assurance that any of the products, even when used as directed, will have the effects intended or will not have harmful side effects in an unforeseen way or on an unforeseen cohort. If any of our products or products we develop or commercialize in the future are shown to be harmful or generate negative publicity from perceived harmful effects, our business, financial condition, results of operations, and prospects could be harmed significantly.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">Our future success will depend in large part on our ability to commercialize our hormone therapy drug candidates designed to alleviate the symptoms of and reduce the health risks resulting from menopause, including hot flashes, osteoporosis, and vaginal dryness.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our future success will depend in large part on our ability to successfully develop and commercialize our hormone therapy drug candidates designed to alleviate the symptoms of and reduce the health risks resulting from menopause, including hot flashes, osteoporosis, and vaginal dryness. We have submitted IND applications for four hormone therapy drug candidates, which the FDA has made effective and which permit us to conduct clinical testing on these proposed products. We recently announced positive top-line results from the REJOICE Trial, a pivotal phase 3 clinical trial of our TX-004HR drug candidate, and have completed enrollment in the REPLENISH Trial, a pivotal phase 3 clinical trial for our TX-001HR drug candidate. In July 2014, we temporarily suspended enrollment in the phase 3 clinical trial for our TX-002HR drug candidate, and in October 2014, we temporarily stopped the trial in order to update the phase 3 protocol based on discussions with the FDA. We have no current plans to conduct clinical trials for our TX-003HR drug candidate. However, we may not be able to complete the development of these drug candidates, the results of the clinical trials may not be sufficient to support an NDA for any of them, and even if we believe the results of our clinical trials are sufficient to support any NDA that we submit, the FDA may disagree and may not approve our NDA. In addition, even if the FDA approves one or more of our NDAs, it may do so with restrictions on the intended uses that may make commercialization of the product or products financially untenable. The failure to commercialize or obtain necessary approval for any one or more of these products could substantially harm our prospects and our business.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">We may not be able to complete the development and commercialization of our hormone therapy drug candidates if we fail to obtain additional financing.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We need substantial amounts of cash to complete the clinical development and commercialization of our hormone therapy drug candidates. Our existing cash may not be sufficient to fund these requirements. In addition, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected on these programs because of circumstances beyond our control. We do not currently have any committed external source of funds. We will attempt to raise additional capital from the issuance of equity or debt securities, collaborations with third parties, licensing of rights to these products, or other means, or a combination of any of the foregoing. Securing additional financing will require a substantial amount of time and attention from our management and may divert a disproportionate amount of their attention away from our day-to-day activities, which may adversely affect our ability to conduct our day-to-day operations. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to take one or more of the following actions:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">significantly delay, scale back, or discontinue our product development and commercialization efforts;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">seek collaborators for our hormone therapy drug candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be the case; and</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 30; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">license, potentially on unfavorable terms, our rights to our hormone therapy drug candidates that we otherwise would seek to develop or commercialize ourselves.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing stockholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products or grant licenses on terms that may not be favorable to us.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing discovery, development, and commercialization efforts, and our ability to generate revenue and achieve or sustain profitability will be substantially harmed.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">We have no experience as a company in bringing a drug to regulatory approval.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have never obtained regulatory approval for, or commercialized, a drug. It is possible that the FDA may refuse to accept any or all of our planned NDAs for substantive review or may conclude, after review of our data, that our applications are insufficient to obtain regulatory approval of any of our hormone therapy drug candidates. We have recently begun to conduct validation and scale up of the manufacturing processes for TX-001HR, our proposed combination estradiol and progesterone drug candidate, and TX-004HR, our proposed applicator-free vaginal estradiol softgel drug candidate. The FDA may also require that we conduct additional clinical or manufacturing validation studies, which may be costly and time-consuming, and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA required studies, approval of any NDA that we submit may be significantly delayed, possibly for years, or may require us to expend more resources than we have available or can secure. Any delay or inability in obtaining regulatory approvals would delay or prevent us from commercializing our hormone therapy drug candidates, generating revenue from these proposed products, and achieving and sustaining profitability. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve any NDA we submit. If any of these outcomes occur, we may be forced to abandon our planned NDAs for one or more of our hormone therapy drug candidates, which would materially adversely affect our business and could potentially cause us to cease operations.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>We have recently completed our Phase 3 clinical trial of TX-004HR for the treatment of moderate to severe dyspareunia in postmenopausal women with VVA. Although we have discussed our clinical development plans with the FDA, the agency may ultimately determine that our Phase 3 clinical trial is not sufficient for regulatory approval. If we are required to conduct additional clinical trials or non-clinical studies, our development of TX-004HR will be more time-consuming and costly than we presently anticipate, which could have a material adverse effect on our business, results of operations and financial condition.&#xA0;</i></b></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On December 7, 2015 we announced positive top-line results from the REJOICE Trial, our Phase 3 clinical trial to evaluate the safety and efficacy of three doses&#x2014;25 mcg, 10 mcg and 4 mcg (compared to placebo)&#x2014;of TX-004HR for the treatment of moderate to severe dyspareunia in postmenopausal women with VVA. Both the 25 mcg dose and the 10 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary efficacy endpoints. The 4 mcg dose of TX-004HR also demonstrated highly statistically significant results at the p&#xA0;&lt; 0.0001 level compared to placebo for the endpoints of vaginal superficial cells, vaginal parabasal cells, and vaginal pH; the change from baseline compared to placebo in the severity of dyspareunia was statistically significant at the p = 0.0149 level.&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Based on the results of this clinical trial, we currently intend to seek regulatory approval for the 25 mcg, 10 mcg and 4 mcg doses of TX-004HR for the treatment of moderate to severe dyspareunia in postmenopausal women with VVA in the U.S. We cannot assure you that the FDA will approve all or any doses of TX-004HR for commercialization. The FDA may not agree with one or more aspects of our clinical trial designs, including the duration of the trials, clinical endpoints, controls, dose ranges, collection of safety data, or adequacy of our non-clinical studies. In addition, to date we have only analyzed the top line data of the REJOICE Trial; further safety and efficacy analyses of the trial data are ongoing. If the further analyses suggest the data is not as positive as we currently believe it to be, we may need to conduct additional clinical or non-clinical trials or studies, which could result in delays in approval or could prevent approval of TX-004HR.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 31; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">If we submit an NDA and the FDA does not agree with our clinical and non-clinical designs or does not agree that our NDA is otherwise complete, the FDA may not accept our NDA for review and our development of TX-004HR may be delayed and we may incur additional costs and be required to devote additional resources to address the FDA&#x2019;s concerns. In addition, we may be required to conduct additional clinical trials or studies, which could result in additional delays and costs. There is no assurance that we will complete the other clinical and non-clinical studies, if required, within the timeframes and the costs that we currently expect, or at all, or in a manner that is acceptable to the FDA. Any delays or unplanned costs resulting from our Phase 3 clinical trials of TX-004HR may have a material adverse effect on our business, results of operations and financial condition. Even if we eventually submit an NDA and receive approval of TX-004HR, the FDA may grant approval contingent on the performance of costly additional post-approval clinical trials. The FDA may also approve TX-004HR for a more limited indication or a narrower patient population than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of TX-004HR or our other product candidates. Any delay in obtaining, or inability to obtain, applicable regulatory approval for TX-004HR would delay or prevent commercialization of TX-004HR and could materially adversely impact our business, results of operations and financial condition.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, prior to approval of an NDA for TX-004HR, the FDA may audit one or more of the sites where the Phase 3 clinical trial was conducted to ensure the integrity of the data and will inspect the facilities of our third party contract manufacturers where TX-004HR is manufactured. If one or more site audits reveals anomalies, or if the manufacturing facilities do not pass inspection, full consideration of the NDA by FDA could be delayed, or the FDA may require us to undertake further clinical or non-clinical trials or could require our contract manufacturers to improve or change their processes, any of which would delay or prevent commercialization of TX-004HR and could materially adversely impact our business, results of operations and financial condition.&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>Clinical trials are lengthy and expensive with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results</i>.&#xA0;</b></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Clinical trials are expensive, can take many years to complete and have highly uncertain outcomes. For example, we temporarily suspended enrollment in and subsequently temporarily stopped the SPRY trial for our progesterone alone drug candidate in order to update the phase 3 protocol based on discussions with the FDA. Failure can occur at any time during the clinical trial process as a result of inadequate performance of a drug, inadequate adherence by patients or investigators to clinical trial protocols, or other factors. New drugs in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through earlier clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials as a result of a lack of efficacy or adverse safety profiles, despite promising results in earlier trials. Our future clinical trials may not be successful or may be more expensive or time-consuming than we currently expect. Prior to approving a new drug, the FDA generally requires that the safety and efficacy of the drug be demonstrated in two adequate and well-controlled clinical trials. In some situations the FDA approves drugs on the basis of a single well-controlled clinical trial. We believe we may be required to conduct only a single phase 3 clinical trial of each of TX-001HR, our proposed combination estradiol and progesterone drug candidate, TX-002HR, our progesterone alone drug candidate, and TX-004HR, our applicator-free vaginal estradiol softgel drug candidate. However, in connection with our TX-004HR drug candidate, the FDA has previously indicated to us that in order to approve the drug based on a single trial, the trial would need to show statistical significance at the 0.01 level or lower for each endpoint, and that a trial that is merely statistically significant at a higher numerical level may not provide sufficient evidence to support an NDA filing or approval of a drug candidate where the NDA relies on a single clinical trial. If clinical trials for any of our hormone therapy drug candidates fail to demonstrate safety or efficacy to the satisfaction of the FDA, the FDA will not approve that drug and we would not be able to commercialize it, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">Delays in clinical trials are common for many reasons, and any such delays could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales as currently contemplated.</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 32; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We may experience delays in clinical trials for our hormone therapy drug candidates. Our planned clinical trials might not begin on time; may be interrupted, delayed, suspended, or terminated once commenced; might need to be redesigned; might not enroll a sufficient number of patients; or might not be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including the following:</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">delays in obtaining regulatory approval to commence a trial;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">imposition of a clinical hold following an inspection of our clinical trial operations or trial sites by the FDA or other regulatory authorities;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">imposition of a clinical hold because of safety or efficacy concerns by the DSMB, FDA, or IRB, or us;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">delays in obtaining required IRB approval at each site;</td>
</tr>
</table>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Symbol;"></font></p>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">delays in identifying, recruiting, and training suitable clinical investigators;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">delays in recruiting suitable patients to participate in a trial;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">clinical sites dropping out of a trial to the detriment of enrollment;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">time required to add new sites;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">delays in obtaining sufficient supplies of clinical trial materials, including suitable API; or</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">delays resulting from negative or equivocal findings of DSMB for a trial.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Patient enrollment, a significant factor in the timing of clinical trials, is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical trials, and clinicians&#x2019; and patients&#x2019; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. Any of these delays in completing our clinical trials could increase our costs, slow down our product development and approval process, and jeopardize our ability to commence product sales and generate revenue from our hormone therapy drug candidates.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">We may be required to suspend or discontinue clinical trials because of adverse side effects or other safety risks that could preclude approval of our hormone therapy drug candidates.</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our clinical trials may be suspended or terminated at any time for a number of reasons. A clinical trial may be suspended or terminated by us, our collaborators, the FDA, or other regulatory authorities because of a failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, presentation of unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using the investigational drug, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or negative or equivocal findings of the DSMB or the IRB for a clinical trial. An IRB may also suspend or terminate our clinical trials for failure to protect patient safety or patient rights. We may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to participants. In addition, regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe the clinical trials are not being conducted in accordance with applicable regulatory requirements or present an unacceptable safety risk to participants. If we elect or are forced to suspend or terminate any clinical trial of any proposed product that we develop, the commercial prospects of such proposed product will be harmed and our ability to generate product revenue from any of these proposed products will be delayed or eliminated. Any of these occurrences may harm our business, financial condition, results of operations, and prospects significantly.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 33; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>We rely on third parties to conduct our research and development activities, including our clinical trials, and we may experience delays in obtaining or may be unsuccessful in obtaining regulatory approval for, or in commercializing, our hormone therapy drug candidates if these third parties do not successfully carry out their contractual duties or meet expected deadlines.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We do not have the resources to independently conduct research and development activities. Therefore, we have relied, and plan to continue to rely, on various third-party CROs to conduct our research and development activities and to recruit patients and monitor and manage data for our on-going clinical programs for our hormone therapy drug candidates, as well as for the execution of our clinical studies. Although we control only certain aspects of our CROs&#x2019; activities, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities. We cannot assure you that the CROs will conduct the research properly or in a timely manner, or that the results will be reproducible. We and our CROs are required to comply with the FDA&#x2019;s cGCPs, which are regulations and guidelines enforced by the FDA for all of our products in clinical development. The FDA enforces these cGCPs through periodic inspections of trial sponsors, principal investigators, and clinical trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable or invalid, and the FDA may require us to perform additional clinical trials before approving our proposed products. We cannot assure you that, upon inspection, the FDA will determine that any of our clinical trials comply with cGCPs. In addition, to evaluate the safety and effectiveness compared to placebo of our hormone therapy drug candidates to a statistically significant degree, our clinical trials will require an adequately large number of test subjects. Any clinical trial that a CRO conducts abroad on our behalf is subject to similar regulation. Accordingly, if our CROs fail to comply with these regulations or recruit a sufficient number of patients, we may be required to repeat clinical trials, which would delay the regulatory approval process.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, we do not employ the personnel of our CROs, and, except for remedies available to us under our agreements with such organizations, we cannot control whether or not they will devote sufficient time and resources to our on-going clinical and pre-clinical programs. Our CROs may also have relationships with other commercial entities, including one or more of our competitors, for which they may also be conducting clinical studies or other drug development activities, which could impede their ability to devote appropriate time to our clinical programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised because of the failure to adhere to our clinical protocols or regulatory requirements, or for other reasons, our clinical trials may be extended, delayed, or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our hormone therapy drug candidates that we seek to develop. As a result, our financial results and the commercial prospects for our hormone therapy drug candidates that we seek to develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed or ended.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We typically engage one or more CROs on a project-by-project basis for each study or trial. While we have developed and plan to maintain our relationships with CROs that we have previously engaged, we also expect to enter into agreements with other CROs to obtain additional resources and expertise in an attempt to accelerate our progress with regard to on-going clinical programs and, specifically, the compilation of clinical trial data for submission with an NDA for each of our hormone therapy drug candidates. If any of our relationships with these third parties terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or entering into new relationships with CROs involves substantial cost and requires extensive management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially affect our ability to meet our desired clinical development timelines and can increase our costs significantly. Although we try to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition, results of operations, or prospects.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 34; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">Future legislation, regulations, and policies adopted by the FDA or other regulatory authorities may increase the time and cost required for us to conduct and complete clinical trials for our hormone therapy drug candidates.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The FDA has established regulations, guidelines, and policies to govern the drug development and approval process, as have foreign regulatory authorities. Any change in regulatory requirements resulting from the adoption of new legislation, regulations, or policies may require us to amend existing clinical trial protocols or add new clinical trials to comply with these changes. Such amendments to existing protocols or clinical trial applications or the need for new ones, may significantly and adversely affect the cost, timing, and completion of the clinical trials for our hormone therapy drug candidates.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, the FDA&#x2019;s policies may change and additional government regulations may be issued that could prevent, limit, or delay regulatory approval of our drug candidates, or impose more stringent product labeling and post-marketing testing and other requirements. For example, in the past the FDA has indicated it would regulate prenatal vitamins containing greater than 0.8 mg of folic acid as a drug under the FDCA. More recently the FDA indicated that there is no specified upper limit on the amount of folic acid permitted in a dietary supplement. If the FDA were to seek to regulate products with higher amounts of folic acid as drugs, it may require us to stop selling certain of our dietary supplement products and otherwise adversely affect our business. If we are slow or unable to adapt to any such changes, our business, prospects, and ability to achieve or sustain profitability would be adversely affected.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">Even if we obtain regulatory approval for our hormone therapy drug candidates, we will still face extensive, ongoing regulatory requirements and review, and our products may face future development and regulatory difficulties.</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Even if we obtain regulatory approval for one or more of our hormone therapy drug candidates in the United States, the FDA may still impose significant restrictions on a product&#x2019;s indicated uses or marketing or to the conditions for approval, or impose ongoing requirements for potentially costly post-approval studies, including phase 4 clinical trials or post-market surveillance. As a condition to granting marketing approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in these post-approval clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased concerns about side effects or efficacy of a product. For example, the labeling for our hormone therapy drug candidates, if approved, may include restrictions on use or warnings. The Food and Drug Administration Amendments Act of 2007, or FDAAA, gives the FDA enhanced post-market authority, including the explicit authority to require post-market studies and clinical trials, labeling changes based on new safety information, and compliance with FDA-approved REMS programs. If approved, our hormone therapy drug candidates will also be subject to ongoing FDA requirements governing the manufacturing, labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record keeping, and reporting of safety and other post-market information. The FDA&#x2019;s exercise of its authority could result in delays or increased costs during product development, clinical trials and regulatory review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of approved products. Foreign regulatory agencies often have similar authority and may impose comparable costs. Post-marketing studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely affect sales of our hormone therapy drug candidates once approved, and potentially our other marketed products. Further, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products could have an adverse effect on sales of our approved products. Accordingly, new data about our products could negatively affect demand because of real or perceived side effects or uncertainty regarding efficacy and, in some cases, could result in product withdrawal or recall. Furthermore, new data and information, including information about product misuse, may lead government agencies, professional societies, and practice management groups or organizations involved with various diseases to publish guidelines or recommendations related to the use of our products or the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of our products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 35; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The holder of an approved NDA also is subject to obligations to monitor and report adverse events and instances of the failure of a product to meet the specifications in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials. Legal requirements have also been enacted to require disclosure of clinical trial results on publicly available databases.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with the FDA&#x2019;s cGMPs regulations. If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility, or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing, requiring new warnings or other labeling changes to limit use of the drug, requiring that we conduct additional clinical trials, imposing new monitoring requirements, or requiring that we establish a REMS program. Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable federal and state laws. The distribution of product samples to physicians must comply with the requirements of the Prescription Drug Marketing Act. Sales, marketing, and scientific/educational grant programs must comply with the anti-fraud and abuse provisions of the Social Security Act, the False Claims Act, and similar state laws. We would also be required under the Sunshine provision of the Affordable Care Act to report annually to the Centers for Medicare and Medicaid Services on payments that we make to physicians and teaching hospitals and ownerships interests in the company held by physicians. Pricing and rebate programs must comply with the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 and the Veterans Healthcare Act of 1992. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration and to low income patients of certain hospitals, additional laws and requirements apply. Our activities are also potentially subject to federal and state consumer protection and unfair competition laws. If we or our third-party collaborators fail to comply with applicable regulatory requirements, a regulatory agency may take any of the following actions:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">conduct an investigation into our practices and any alleged violation of law;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">issue warning letters or untitled letters asserting that we are in violation of the law;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">seek an injunction or impose civil or criminal penalties or monetary fines;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">suspend or withdraw regulatory approval;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">require that we suspend or terminate any ongoing clinical trials;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">refuse to approve pending applications or supplements to applications filed by us;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">suspend or impose restrictions on operations, including costly new manufacturing requirements;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall; or</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">exclude us from providing our products to those participating in government health care programs, such as Medicare and Medicaid, and refuse to allow us to enter into supply contracts, including government contracts.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The occurrence of any of the foregoing events or penalties may force us to expend significant amounts of time and money and may significantly inhibit our ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign jurisdictions.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">Our dependence upon third parties for the manufacture and supply of our existing women&#x2019;s health care products and our hormone therapy drug candidates may cause delays in, or prevent us from, successfully developing, commercializing, and marketing our products.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We do not currently have nor do we plan to build the infrastructure or capability internally to manufacture our existing women&#x2019;s health care products. For example, we depend on Lang, a full-service, private label and corporate brand manufacturer, to supply approximately 99% of our vitaMedMD and BocaGreen products. In certain circumstances, including our failure to satisfy our production forecasts to Lang, we may be obligated to reimburse Lang for the costs of excess raw materials purchased by Lang that it cannot use in another product category that it then sells. We also rely on third-party contract manufacturing organizations, or CMOs to supply our hormone therapy drug candidates for use in the conduct of our clinical trials. We rely on these third parties to manufacture these products in accordance with our specifications and in compliance with applicable regulatory requirements. We do not have long-term contracts for the commercial supply of our products or our hormone therapy drug candidates. We intend to pursue long-term manufacturing agreements, but we may not be able to negotiate such agreements on acceptable terms, if at all.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 36; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, regulatory requirements could pose barriers to the manufacture of our products, including our hormone therapy drug candidates. Our third-party manufacturers are required to comply with cGMP regulations. As a result, the facilities used by any of our current or future manufacturers must be approved by the FDA. Holders of NDAs, or other forms of FDA approvals or clearances, or those distributing a regulated product under their own name, are responsible for manufacturing even though that manufacturing is conducted by a third-party CMO. All of our existing products are, and our hormone therapy drug candidates, if approved, will be, manufactured by CMOs. These CMOs are required by the terms of our contracts to manufacture our products in compliance with the applicable regulatory requirements. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, they will not be able to secure the applicable approval for their manufacturing facilities. If these facilities are not approved for the commercial manufacture of our existing products or our hormone therapy drug candidates, we may need to find alternative manufacturing facilities, which would result in disruptions of our sales and significant delays of up to several years in obtaining approval for our hormone therapy drug candidates. In addition, our manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign agencies for compliance with cGMPs and similar regulatory requirements. Failure by any of our manufacturers to comply with applicable cGMP regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply, recalls, withdrawals, issuance of safety alerts, and criminal prosecutions, any of which could have a material adverse impact on our business, financial condition, results of operations, and prospects. Finally, we also could experience manufacturing delays if our CMOs give greater priority to the supply of other products over our products and proposed products or otherwise do not satisfactorily perform according to the terms of their agreements with us.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">If any supplier of the product for our hormone therapy drug candidates experiences any significant difficulties in its respective manufacturing processes, does not comply with the terms of the agreement between us, or does not devote sufficient time, energy, and care to providing our manufacturing needs, we could experience significant interruptions in the supply of our hormone therapy drug candidates, which could impair our ability to supply our hormone therapy drug candidates at the levels required for our clinical trials and commercialization and prevent or delay their successful development and commercialization.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">The commercial success of our existing products and our hormone therapy drug candidates that we develop, if approved in the future, will depend upon gaining and retaining significant market acceptance of these products among physicians and payors.</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Physicians may not prescribe our products, including any of our hormone therapy drug candidates, if approved by the appropriate regulatory authorities for marketing and sale, which would prevent us from generating revenue or becoming profitable. Market acceptance of our products, including our hormone therapy drug candidates, by physicians, patients, and payors, will depend on a number of factors, many of which are beyond our control, including the following:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">the clinical indications for which our hormone therapy drug candidates are approved, if at all;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">acceptance by physicians and payors of each product as safe and effective treatment;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the cost of treatment in relation to alternative treatments, including numerous generic drug products;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the relative convenience and ease of administration of our products in the treatment of the symptoms for which they are intended;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the availability and efficacy of competitive drugs;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the effectiveness of our sales force and marketing efforts;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the extent to which the product is approved for inclusion on formularies of hospitals and managed care organizations;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 37; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">the availability of coverage and adequate reimbursement by third parties, such as insurance companies and other health care payors, or by government health care programs, including Medicare and Medicaid;</td>
</tr>
</table>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Symbol;"></font></p>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">limitations or warnings contained in a product&#x2019;s FDA-approved labeling; and</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">prevalence and severity of adverse side effects.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Even if the medical community accepts that our products are safe and efficacious for their approved indications, physicians may not immediately be receptive to the use or may be slow to adopt our products as an accepted treatment for the symptoms for which they are intended. We cannot assure you that any labeling approved by the FDA will permit us to promote our products as being superior to competing products. If our products, including, in particular our hormone therapy drug candidates, if approved, do not achieve an adequate level of acceptance by physicians and payors, we may not generate sufficient or any revenue from these products and we may not become profitable. In addition, our efforts to educate the medical community and third-party payors on the benefits of our products may require significant resources and may never be successful.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">Our products, including our hormone therapy drug candidates if approved, face significant competition from branded and generic products, and our operating results will suffer if we fail to compete effectively.</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Development and awareness of our brand will depend largely upon our success in increasing our customer base. The dietary supplement and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our products, including any hormone therapy drug candidates that are approved, face intense competition, including from major multinational pharmaceutical and dietary supplement companies, established biotechnology companies, specialty pharmaceutical, and generic drug companies. A new non-hormonal product, Brisdelle, produced by Noven Pharmaceuticals, was approved by the FDA for treatment of vasomotor symptoms in June 2013. Many of these companies have greater financial and other resources, such as larger research and development staffs and more experienced marketing and manufacturing organizations. As a result, these companies may obtain regulatory approval more rapidly and may be more effective in selling and marketing their products. They also may invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the products that we sell or develop obsolete. As a result, our competitors may succeed in commercializing products before we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. If we are unable to economically promote or maintain our brand, our business, results of operations and financial condition could be severely harmed. In addition, our efforts to provide an alternative to the non-FDA-approved compound bioidentical market for estradiol and progesterone products sold by compounding pharmacies may not be successful.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>Coverage and reimbursement may not be available for our products, which could make it difficult for us to sell our products profitably, or if available, government mandated rebates may be too high and may adversely affect our profitability</i></b><i>.</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Market acceptance and sales of our products, including any hormone therapy drug candidates, will depend on coverage and reimbursement policies and may be affected by health care reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which products they will pay for and establish reimbursement levels. Third-party payors generally do not cover OTC products, and coverage for vitamins and dietary supplements varies. We cannot be sure that coverage and reimbursement will be available for our products, including any hormone therapy drug candidates, if approved, or whether the amount of such coverage and reimbursement, if any, will be sufficient to enable us to successfully compete with other products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Specifically, in both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the health care system in ways that could affect our ability to sell our products profitably. In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and certain others by establishing a new Part D to the Medicare program. However, unlike traditional Medicare&#x2014;which provides coverage for outpatient drugs&#x2014;coverage under Part D is provided by private insurers operating under contract with CMS. In addition, this legislation provided authority for limiting the number of certain outpatient drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These and future cost-reduction initiatives could decrease the coverage and price that we receive for our products from Medicare, if any, including our hormone therapy drug candidates, if approved, and could seriously harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policies and payment limitations in setting their own reimbursement rates, and any reduction in reimbursement under Medicare may result in a similar reduction in payments from private payors.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 38; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Affordable Care Act or ACA, became law in the United States. The goal of ACA is to reduce the cost of health care and substantially change the way health care is financed by both governmental and private insurers. Among other measures, ACA increased rebates on manufacturers for certain covered drug products reimbursed by state Medicaid programs. While we cannot predict the full effect that the Affordable Care Act will have on federal reimbursement policies in general or on our business specifically, the Act may result in downward pressure on drug reimbursement, which could negatively affect market acceptance of our products. In addition, we cannot predict whether new proposals will be made or adopted, when they may be adopted, or what impact they may have on us if they are adopted.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The availability of generic products at lower prices than branded products may also substantially reduce the likelihood of reimbursement for branded products, such as our hormone therapy drug candidates, if approved. We expect to experience pricing pressures in connection with the sale of our products generally due to the trend toward managed health care, the increasing influence of health maintenance organizations, and additional legislative proposals. If we fail to successfully secure and maintain adequate coverage and reimbursement for our products or are significantly delayed in doing so, we could have difficulty achieving market acceptance of our products and our business will be harmed.</p>

<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">&nbsp;</p>

<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"></p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0"><b><i>Failure to obtain regulatory approval outside the U.S.
will prevent us from marketing our product candidates in non- U.S. markets.</i></b></p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We may attempt to market certain of our
product candidates in non-U.S. markets. In order to market our product candidates in the European Union and many other non-U.S.
jurisdictions, we must obtain separate regulatory approvals. We have had limited interactions with non-U.S. regulatory authorities,
the approval procedures vary among countries and can involve additional testing, and the time required to obtain approval may differ
from that required to obtain FDA approval or clearance. Approval or clearance by the FDA does not ensure approval by regulatory
authorities in other countries, and approval by one or more non-U.S. regulatory authorities does not ensure approval by other regulatory
authorities in other countries or by the FDA. The non-U.S. regulatory approval process may include all of the risks associated
with obtaining FDA approval or clearance. If we pursue non-U.S. regulatory approvals, we may not obtain them on a timely basis,
if at all. If we pursue non-U.S. regulatory approvals, our failure to receive necessary approvals to commercialize our product
candidates in a given market could have a material adverse effect on our business, financial condition, results of operations,
and prospects.</p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</p>

<p style="font: 10pt/12pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In addition, if we seek and obtain approval
to market our product candidates in one or more non-U.S. markets, we will be subject to rules and regulations in those markets
relating to our product. In some countries, particularly countries of the European Union, each of which has developed its own rules
and regulations, pricing is subject to governmental control. In these countries, pricing negotiations with governmental authorities
can take considerable time after the receipt of regulatory approval for a drug. To obtain reimbursement or pricing approval in
some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidates to
other available products. If reimbursement of our product candidates is unavailable or limited in scope or amount, or if pricing
is set at unsatisfactory levels, we may be unable to generate revenues and achieve or sustain profitability with respect to any
given market, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.</p>



<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>Future legislation or regulations may adversely affect reimbursement from government programs</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. More recently, in August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reductions, triggering the legislation&#x2019;s automatic reduction of several government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, starting in 2013. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. The Bipartisan Budget Act of 2015, signed into law on November 2, 2015, increased the rebates that generic drug manufacturers are obligated to pay under the Medicaid program by applying an inflation-based rebate formula to generic drugs that previously only applied to brand name drugs. If we ever obtain regulatory approval and commercialization of any of our drug candidates, these new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly, our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our drug candidates may be.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>Product liability lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We face an inherent risk of product liability claims as a result of the marketing of our current products and the clinical testing of our hormone therapy drug candidates despite obtaining appropriate informed consents from our clinical trial participants, and, in light of the history of product liability claims related to other hormone replacement therapy products, we will face an even greater risk if we obtain FDA approval and commercialize our hormone therapy drug candidates in the United States or other additional jurisdictions or if we engage in the clinical testing of proposed new products or commercialize any additional products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during clinical testing, manufacturing, marketing, or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, failures to warn of dangers inherent in the product, negligence, strict liability, or breaches of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our existing products or hormone therapy drug candidates, if approved. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, product liability claims may result in any of the following:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 39; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the inability to commercialize our products or hormone therapy drug candidates;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">difficulty recruiting subjects for clinical trials or withdrawal of these subjects before a trial is completed;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">labeling, marketing, or promotional restrictions;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">product recalls or withdrawals;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">decreased demand for our products or products that we may develop in the future;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">loss of revenue;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">injury to our reputation;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">initiation of investigations by regulators;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">costs to defend the related litigation;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">a diversion of management&#x2019;s time and our resources;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">substantial monetary awards to trial participants or patients;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">exhaustion of any available insurance and our capital resources; and</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">a decline in our stock price.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Although we maintain general liability insurance of up to $10 million in the aggregate and clinical trial liability insurance of $10 million in the aggregate for our hormone therapy drug candidates, this insurance may not fully cover potential liabilities. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. In addition, our inability to obtain or maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product liability claims could prevent or inhibit the development and commercial production and sale of our products, which could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">Our business may be affected by unfavorable publicity or lack of consumer acceptance.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We are highly dependent upon consumer acceptance of the safety and quality of our products, as well as similar products distributed by other companies. Consumer acceptance of a product can be significantly influenced by scientific research or findings, national media attention, and other publicity about product use. A product may be received favorably, resulting in high sales associated with that product that may not be sustainable as consumer preferences change. Future scientific research or publicity could be unfavorable to our industry or any of our particular products and may not be consistent with earlier favorable research or publicity. A future research report or publicity that is perceived by our consumers as less than favorable or that may question earlier favorable research or publicity could have a material adverse effect on our ability to generate revenue. Adverse publicity in the form of published scientific research, statements by regulatory authorities or otherwise, whether or not accurate, that associates consumption of our product or any other similar product with illness or other adverse effects, or that questions the benefits of our product or a similar product, or that claims that such products do not have the effect intended could have a material adverse effect on our business, reputation, financial condition, or results of operations.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>If we use hazardous materials in a manner that causes injury or violates applicable law, we may be liable for damages.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;<b><i>&#xA0;</i></b>&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical, biological, and radioactive materials. In addition, our operations produce hazardous waste products. Federal, state, and local laws and regulations in the United States govern the use, manufacture, storage, handling, and disposal of hazardous materials. Although we believe that our procedures for use, handling, storing, and disposing of these materials (all of which only occur at third-party sites operated by our contractors) comply with legally prescribed standards, we may incur significant additional costs to comply with applicable laws in the future. We also cannot predict the impact on our business of new or amended environmental laws or regulations or any changes in the way existing and future laws and regulations are interpreted or enforced. Also, even if we are in compliance with applicable laws, we cannot completely eliminate the risk of contamination or injury resulting from hazardous materials, and we may incur liability as a result of any such contamination or injury. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources, and we do not carry liability insurance covering the use of hazardous materials. If we fail to comply with applicable requirements, we could incur substantial costs, including civil or criminal fines and penalties, clean-up costs, or capital expenditures for control equipment or operational changes necessary to achieve or maintain compliance. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, and adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 40; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">We are subject to extensive and costly government regulation.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The products we currently market, including the vitamins, and the pharmaceutical products we are developing and planning to develop in the future, are subject to extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers for Medicare &#38; Medicaid Services, or CMS, other divisions of the U.S. Department of Health and Human Services, including its Office of Inspector General, the U.S. Department of Justice, the Departments of Defense and Veterans Affairs, to the extent our products are paid for directly or indirectly by those departments, state and local governments, and their respective foreign equivalents. The FDA regulates dietary supplements, cosmetics, and drugs under different regulatory schemes. For example, the FDA regulates the processing, formulation, safety, manufacturing, packaging, labeling, and distribution of dietary supplements and cosmetics under its dietary supplement and cosmetic authority, respectively. The FDA also regulates the research, development, pre-clinical and clinical testing, manufacture, safety, effectiveness, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical products under various regulatory provisions. If any drug products we develop are tested or marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not we have obtained FDA approval for a given product and its uses. Such foreign regulation may be equally or more demanding than corresponding U.S. regulation.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Government regulation substantially increases the cost and risk of researching, developing, manufacturing, and selling products. Our failure to comply with these regulations could result in, by way of example, significant fines, criminal and civil liability, product seizures, recalls, withdrawals, withdrawals of approvals, and exclusion and debarment from government programs. Any of these actions, including the inability of our hormone therapy drug candidates to obtain and maintain regulatory approval, could have a materially adverse effect on our business, financial condition, results of operations, and prospects.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">We are subject to additional federal and state laws and regulations relating to our business, and our failure to comply with those laws could have a material adverse effect on our results of operations and financial conditions.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We are subject to additional health care regulation and enforcement by the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include the following:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">the federal health care program Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order, or recommendation of, any good or service for which payment may be made under government health care programs such as the Medicare and Medicaid programs;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">federal false claims laws that prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or other government health care programs that are false or fraudulent;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">federal criminal laws that prohibit executing a scheme to defraud any health care benefit program or making false statements relating to health care matters; and</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including commercial insurers.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Further, the recently enacted ACA, among other things, amends the intent requirement of the federal anti-kickback and criminal health care fraud statutes. A person or entity can now be found guilty of fraud or false claims under ACA without actual knowledge of the statute or specific intent to violate it. In addition, ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes. Possible sanctions for violation of these anti-kickback laws include monetary fines, civil and criminal penalties, exclusion from Medicare, Medicaid and other government programs and forfeiture of amounts collected in violation of such prohibitions. Any violations of these laws, or any action against us for violation of these laws, even if we successfully defend against it, could result in a material adverse effect on our reputation, business, results of operations, and financial condition.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 41; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">ACA also imposes new reporting requirements on device and pharmaceutical manufacturers to make annual public disclosures of payments to certain health care providers and physician ownership of their stock by health care providers. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year (or up to an aggregate of $1 million per year for &#x201C;knowing failures&#x201D;), for all payments, transfers of value, or ownership or investment interests that are not reported. Manufacturers were required to begin data collection on August 1, 2013 and were required to report such data to CMS by March 31, 2014.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians for marketing. Some states, such as California, Massachusetts and Vermont, mandate implementation of corporate compliance programs, along with the tracking and reporting of gifts, compensation, and other remuneration to physicians.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The scope and enforcement of these laws is uncertain and subject to change in the current environment of health care reform, especially in light of the lack of applicable precedent and regulations. We cannot predict the impact on our business of any changes in these laws. Federal or state regulatory authorities may challenge our current or future activities under these laws. Any such challenge could have a material adverse effect on our reputation, business, results of operations, and financial condition. Any state or federal regulatory review of us, regardless of the outcome, would be costly and time-consuming.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b><i>If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</i></b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our ability to compete in the highly competitive pharmaceutical industry depends in large part on our ability to attract and retain highly qualified managerial, scientific, and medical personnel. In order to induce valuable employees to remain with us, we have, among other things, provided stock-based compensation that vests over time. The value to employees of stock-based compensation will be significantly affected by movements in our stock price that we cannot control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific, and medical teams may terminate their employment with us on short notice. We do not have employment agreements with a number of our key employees. As a result, most employees are employed on an at-will basis, which means that any of these employees could leave our employment at any time, with or without notice, and may go to work for a competitor. The loss of the services of any of our executive officers or other key employees could potentially harm our business, operating results, and financial condition. Our success also depends on our ability to continue to attract, retain, and motivate highly skilled scientific and medical personnel.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b><i>Any failure to adequately expand a direct sales force will impede our growth.</i></b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We expect to be substantially dependent on a direct sales force to attract new business and to manage customer relationships. We plan to expand our direct sales force and believe that there is significant competition for qualified, productive direct sales personnel with advanced sales skills and technical knowledge. Our ability to achieve significant growth in revenue in the future will depend, in large part, on our success in recruiting, training, and retaining sufficient direct sales personnel. New and future hires may not become as productive as expected, and we may be unable to hire sufficient numbers of qualified individuals in the future in the markets in which we do business. While there presently exists a high rate of unemployment, if we are unable to hire and develop sufficient numbers of productive sales personnel our business prospects could suffer.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Other pharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and longer histories than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we offer. If we are unable to continue to attract and retain high-quality personnel, our ability to commercialize drug candidates may be limited.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 42; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b><i>Our success is tied to our distribution channels.</i></b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the year ended December 31, 2015, two customers each generated more than 10% of our total revenues; revenue generated from these two customers combined accounted for approximately 67% of our total revenue during the year ended December 31, 2015. Our business would be harmed if any of these customers refused to distribute our products or refused to purchase our products on commercially favorable terms to us.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>A failure to maintain optimal inventory levels to meet commercial demand for our products could harm our reputation and subject us to financial losses.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our ability to maintain optimal inventory levels to meet commercial demand depends on the performance of third-party contract manufacturers. In some instances, our products have unique ingredients used under license arrangements. If our manufacturers are unsuccessful in obtaining raw materials, if we are unable to manufacture and release inventory on a timely and consistent basis, if we fail to maintain an adequate level of product inventory, if inventory is destroyed or damaged, or if our inventory reaches its expiration date, patients might not have access to our products, our reputation and brands could be harmed, and physicians may be less likely to recommend our products in the future, each of which could have a material adverse effect on our business, financial condition, results of operations, and cash flows.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>Our ability to utilize net operating loss carryforwards may be limited.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As of December 31, 2015, we had net operating loss carryforwards, or NOLs, of approximately $192.6 million available to offset future taxable income through 2035. These NOLs may be used to offset future taxable income, to the extent we generate any taxable income, and thereby reduce or eliminate our future federal income taxes otherwise payable. Section 382 of the Internal Revenue Code of 1986, as amended, imposes limitations on a corporation&#x2019;s ability to utilize NOLs if it experiences an ownership change as defined in Section 382. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 percent over a three-year period. In the event that an ownership change has occurred, or were to occur, utilization of our NOLs would be subject to an annual limitation under Section 382 determined by multiplying the value of our stock at the time of the ownership change by the applicable long-term tax-exempt rate. Any unused annual limitation may be carried over to later years. We may be found to have experienced an ownership change under Section 382 as a result of events in the past or the issuance of shares of our common stock in the future. If so, the use of our NOLs, or a portion thereof, against our future taxable income may be subject to an annual limitation under Section 382, which may result in expiration of a portion of our NOLs before utilization.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-left: 0in; margin-top: 0; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><b><i>Our success depends on how efficiently we respond to changing consumer preferences and demand.</i></b></p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our success depends, in part, on our ability to anticipate and respond to changing consumer trends and preferences. We may not be able to respond in a timely or commercially appropriate manner to these changes. Our failure to accurately predict these trends could negatively impact our inventory levels, sales, and consumer opinion of us as a source for the latest product. The success of our new product offerings depends upon a number of factors, including our ability to achieve the following:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">accurately anticipate customer needs;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">innovate and develop new products;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">successfully commercialize new products in a timely manner;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">competitively price our products in the market;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">procure and maintain products in sufficient volumes and in a timely manner; and</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">differentiate our product offerings from those of our competitors.</td>
</tr>
</table>
<p style="margin: 0pt 0 0pt 0.5in; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Symbol;"> </font>&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">If we do not introduce new products, make enhancements to existing products, or maintain the appropriate inventory levels to meet customers&#x2019; demand in a timely manner, our business, results of operations, and financial condition could be materially and adversely affected.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 43; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b><i>We may initiate product recalls or withdrawals, or may be subject to regulatory enforcement actions that could negatively affect our business.</i></b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We may be subject to product recalls, withdrawals, or seizures if any of the products we formulate, manufacture, or sell are believed to cause injury or illness or if we are alleged to have violated governmental regulations in the manufacture, labeling, promotion, sale, or distribution of any of our products. A recall, withdrawal, or seizure of any of our products could materially and adversely affect consumer confidence in our brands and lead to decreased demand for our products. In addition, a recall, withdrawal, or seizure of any of our products would require significant management attention, would likely result in substantial and unexpected expenditures, and could materially and adversely affect our business, financial condition, and results of operations.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b><i>We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</i></b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As of December 31, 2015, we had 122 employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, financial, and other resources and, depending on our commercialization strategy, we may further expand our employee base for sales and marketing resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate, and integrate additional employees. Also, our management may need to divert a disproportionate amount of its attention away from their day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional drug candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to increase revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our hormone therapy drug candidates, if approved, and compete effectively will depend, in part, on our ability to effectively manage any future growth in our organization.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b><i>Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</i></b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately, or to disclose unauthorized activities to us. In particular, sales, marketing, and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs, and other business arrangements. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Conduct and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><i>Risks Related to our Intellectual Property</i></b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>Another party could develop hormone therapy products and obtain FDA regulatory exclusivity in the United States before we do, potentially preventing our ability to commercialize our hormone therapy drug candidates and other products in development.&#xA0;</i></b></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We plan to seek to obtain market exclusivity for our hormone therapy drug candidates and any other drug candidates we develop in the future. To the extent that patent protection is not available or has expired, FDA marketing exclusivity may be the only available form of exclusivity available for these proposed products. Marketing exclusivity can delay the submission or the approval of certain marketing applications. Potentially competitive products may also be seeking marketing exclusivity and may be in various stages of development, including some more advanced than us. We cannot predict with certainty the timing of FDA approval or whether FDA approval will be granted, nor can we predict with certainty the timing of FDA approval for competing products or whether such approval will be granted. It is possible that competing products may obtain FDA approval with marketing exclusivity before we do, which could delay our ability to submit a marketing application or obtain necessary regulatory approvals, result in lost market opportunities with respect to our hormone therapy drug candidates, and materially adversely affect our business, financial condition, and results of operations.</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 44; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>If our efforts to protect the proprietary nature of the intellectual property covering our hormone therapy drug candidates and other products are not adequate, we may not be able to compete effectively in our market.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our commercial success will depend in part on our ability to obtain additional patents and protect our existing patent positions as well as our ability to maintain adequate protection of other intellectual property for our hormone therapy drug candidates and other products. If we do not adequately protect our intellectual property, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could harm our business and ability to achieve profitability. The patent positions of pharmaceutical companies are highly uncertain. The legal principles applicable to patents are in transition due to changing court precedent and legislative action, and we cannot be certain that the historical legal standards surrounding questions of validity will continue to be applied or that current defenses relating to issued patents in these fields will be sufficient in the future. Changes in patent laws in the United States, such as the America Invents Act of 2011, may affect the scope, strength, and enforceability of our patent rights or the nature of proceedings that may be brought by us related to our patent rights. In addition, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and we may encounter significant problems in protecting our proprietary rights in these countries. We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our proprietary technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">These risks include the possibility of the following:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">the patent applications that we have filed may fail to result in issued patents in the United States or in foreign countries;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">patents issued or licensed to us or our partners may be challenged or discovered to have been issued on the basis of insufficient, incomplete, or incorrect information, and thus held to be invalid or unenforceable;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">the scope of any patent protection may be too narrow to exclude competitors from developing or designing around these patents;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">we or our licensors were not the first to make the inventions covered by each of our issued patents and pending patent applications;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">we or our licensors were not the first inventors to file patent applications for these technologies in the United States or were not the first to file patent applications directed to these technologies abroad;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">we may fail to comply with procedural, documentary, fee payment, and other similar provisions during the patent application process, which can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">future drug candidates may not be patentable;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">others will claim rights or ownership with regard to patents and other proprietary rights that we hold or license;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">delays in development, testing, clinical trials, and regulatory review may reduce the period of time during which we could market our drug candidates under patent protection; and</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">we may fail to timely apply for patents on our technologies or products.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">While we apply for patents covering our technologies and products, as we deem appropriate, many third parties may already have filed patent applications or have received patents in our areas of product development. These entities&#x2019; applications, patents, and other intellectual property rights may conflict with patent applications to which we have rights and could prevent us from obtaining patents or could call into question the validity of any of our patents, if issued, or could otherwise adversely affect our ability to develop, manufacture, or commercialize our hormone therapy drug candidates. In addition, if third parties file patent applications in the technologies that also claim technology to which we have rights, we may have to participate in interference, derivation, or other proceedings with the USPTO or foreign patent regulatory authorities to determine our rights in the technologies, which may be time-consuming and expensive. Moreover, issued patents may be challenged in the courts or in post-grant proceedings at the USPTO, or in similar proceedings in foreign countries. These proceedings may result in loss of patent claims or adverse changes to the scope of the claims.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 45; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">If we, our licensors, or our strategic partners fail to obtain and maintain patent protection for our products, or our proprietary technologies and their uses, companies may be dissuaded from collaborating with us. In such event, our ability to commercialize our hormone therapy drug candidates or future drug candidates, if approved, may be threatened, we could lose our competitive advantage, and the competition we face could increase, all of which could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, mechanisms exist in much of the world permitting some form of challenge by generic drug marketers to our patents prior to, or immediately following, the expiration of any regulatory exclusivity, and generic companies are increasingly employing aggressive strategies, such as &#x201C;at risk&#x201D; launches to challenge relevant patent rights.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our business also may rely on unpatented proprietary technology, know-how, and trade secrets. If the confidentiality of this intellectual property is breached, it could adversely impact our business.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>If we are sued for infringing intellectual property rights of third parties, litigation will be costly and time consuming and could prevent or delay us from developing or commercializing our drug candidates.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our commercial success depends, in part, on our not infringing the patents and proprietary rights of other parties and not breaching any collaboration or other agreements we have entered into with regard to our technologies and products. We are aware of numerous third-party U.S. and non-U.S. issued patents and pending applications that exist in the areas of hormone therapy, including compounds, formulations, treatment methods, and synthetic processes, which may be applied towards the synthesis of hormones. Patent applications are confidential when filed and remain confidential until publication, approximately 18 months after initial filing, while some patent applications remain unpublished until issuance. As such, there may be other third-party patents and pending applications of which we are currently unaware with claims directed towards composition of matter, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our products or drug candidates. Therefore, we cannot ever know with certainty the nature or existence of every third-party patent filing. We cannot provide assurances that we or our partners will be free to manufacture or market our drug candidates as planned or that we or our licensors&#x2019; and partners&#x2019; patents will not be opposed or litigated by third parties. If any third-party patent was held by a court of competent jurisdiction to cover aspects of our materials, formulations, methods of manufacture, or methods of treatment related to the use or manufacture of any of our drug candidates, the holders of any such patent may be able to block our ability to develop and commercialize the applicable drug candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. There can be no assurances that we will be able to obtain a license to such patent on favorable terms or at all. Failure to obtain such license may have a material adverse effect on our business.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">There is a substantial amount of litigation involving intellectual property in the pharmaceutical industry generally. If a third party asserts that we infringe its patents or other proprietary rights, we could face a number of risks that could adversely affect our business, financial condition, results of operations, and prospects, including the following:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">infringement and other intellectual property claims, which would be costly and time-consuming to defend, whether or not we are ultimately successful, which in turn could delay the regulatory approval process, consume our capital, and divert management&#x2019;s attention from our business;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">substantial damages for past infringement, which we may have to pay if a court determines that our products or technologies infringe a competitor&#x2019;s patent or other proprietary rights;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">a court prohibiting us from selling or licensing our technologies or future products unless the third party licenses its patents or other proprietary rights to us on commercially reasonable terms, which it is not required to do;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">if a license is available from a third party, we may have to pay substantial royalties or lump sum payments or grant cross licenses to our patents or other proprietary rights to obtain that license; or</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">redesigning our products so they do not infringe, which may not be possible or may require substantial monetary expenditures and time.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<!-- Field: Page; Sequence: 46; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We are party from time to time to legal proceedings relating to our intellectual property, and third parties in the future may file claims asserting that our technologies, processes, or products infringe on their intellectual property. We cannot predict whether third parties will assert these claims against us or our strategic partners or against the licensors of technology licensed to us, or whether those claims will harm our business. In addition, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance. If we or our partners were to face infringement claims or challenges by third parties relating to our drug candidates, an adverse outcome could subject us to significant liabilities to such third parties, and force us or our partners to curtail or cease the development of some or all of our drug candidates, which could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We intend to submit NDAs for our hormone therapy drug candidates, assuming that the clinical data justify submission, under Section 505(b)(2), which was enacted as part of the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act. Section 505(b)(2) permits the filing of an NDA when at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference. To the extent that a Section 505(b)(2) NDA relies on clinical trials conducted for a previously approved drug product or the FDA&#x2019;s prior findings of safety and effectiveness for a previously approved drug product, the Section 505(b)(2) applicant must submit patent certifications in its Section 505(b)(2) NDA with respect to any patents for the approved product on which the application relies that are listed in the FDA&#x2019;s publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the Orange Book. Specifically, the applicant must certify for each listed patent that (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the listed patent has not expired, but will expire on a particular date and approval is not sought until after patent expiration; or (iv) the listed patent is invalid, unenforceable or will not be infringed by the proposed new product. A certification that the new product will not infringe the previously approved product&#x2019;s listed patent or that such patent is invalid or unenforceable is known as a Paragraph IV certification.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">If the Section 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the owner of the referenced NDA for the previously approved product and relevant patent holders within 20 days after the Section 505(b)(2) NDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement suit against the Section 505(b)(2) applicant. Under the FDCA, the filing of a patent infringement lawsuit within 45 days of receipt of the notification regarding a Paragraph IV certification automatically prevents the FDA from approving the Section 505(b)(2) NDA for 30 months beginning on the date the patent holder receives notice, or until a court deems the patent unenforceable, invalid or not infringed, whichever is earlier. The court also has the ability to shorten or lengthen the 30 month period if either party is found not to be reasonably cooperating in expediting the litigation. Thus, the Section 505(b)(2) applicant may invest a significant amount of time and expense in the development of its product only to be subject to significant delay and patent litigation before its product may be commercialized. Alternatively, if the NDA or relevant patent holder does not file a patent infringement lawsuit within the specified 45 day period, the FDA may approve the Section 505(b)(2) application at any time.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">If we cannot certify that all of the patents listed in the Orange Book for the approved products referenced in the NDAs for each of our hormone therapy drug candidates have expired, we will be compelled to include a Paragraph IV certification in the NDA for such drug candidate. Our inability to certify that all of the patents listed in the FDA&#x2019;s Orange Book for approved products referenced in the NDAs for each of our hormone therapy drug candidates could have a serious and significant adverse effect on the timing for obtaining approval of our hormone therapy drug candidates. For example, at least one approved product that may be referenced in our 505(b)(2) application as a reference product for our applicator-free vaginal estradiol softgel product currently lists unexpired patents in the Orange Book.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>We may be required to file lawsuits or take other actions to protect or enforce our patents or the patents of our licensors, which could be expensive and time-consuming.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. Moreover, there can be no assurance that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 47; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents, or those of our licensors, do not cover the technology in question or on other grounds. An adverse result in any litigation or defense proceedings could put one or more of our patents, or those of our licensors, at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications, or those of our licensors, at risk of not issuing. Moreover, we may not be able to prevent, alone or with our licensors, misappropriation of our proprietary rights, particularly in countries in which the laws may not protect those rights as fully as in the United States or in those countries in which we do not file national phase patent applications. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, if securities analysts or investors perceive public announcements of the results of hearings, motions, or other interim proceedings or developments to be negative, the price of our common stock could be adversely affected. The occurrence of any of the above could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>If we are unable to protect the confidentiality of certain information, the value of our products and technology could be materially adversely affected.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We also rely on trade secrets, know-how, and continuing technological advancement to develop and maintain our competitive position. To protect this competitive position, we regularly enter into confidentiality and proprietary information agreements with third parties, including employees, independent contractors, suppliers, and collaborators. We cannot, however, ensure that these protective arrangements will be honored by third parties, and we may not have adequate remedies if these arrangements are breached. In addition, enforcement of claims that a third party has illegally obtained and is using trade secrets, know-how, or technological advancements is expensive, time-consuming, and uncertain. Non-U.S. courts are sometimes less willing than U.S. courts to protect this information. Moreover, our trade secrets, know-how, and technological advancements may otherwise become known or be independently developed by competitors in a manner providing us with no practical recourse against the competing parties. If any such events were to occur, they could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>We may be subject to claims that our employees have wrongfully used or disclosed alleged trade secrets of their former employers or of other third parties with whom we have obligations of confidentiality.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As is common in the pharmaceutical industry, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. Such claims may lead to material costs for us, or an inability to protect or use valuable intellectual property rights, which could adversely affect our business, financial condition, results of operations, and prospects.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><i>Risks Related to Ownership of Our Common Stock</i></b></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">The market price of our common stock may be highly volatile, and you could lose all or part of your investment.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The trading price of our common stock on NYSE MKT is likely to be volatile. This volatility may prevent you from being able to sell your shares at or above the price you paid for your shares. Our stock price could be subject to wide fluctuations in response to a variety of factors, which include the following:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">any delay of our phase 3 clinical trials for our hormone therapy drug candidates;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">adverse results or delays in clinical trials;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">any delay in filing our NDAs for our hormone therapy drug candidates and any adverse development or perceived adverse development with respect to the FDA&#x2019;s review of the NDAs, including the FDA&#x2019;s issuance of a &#x201C;refusal to file&#x201D; letter or a request for additional information;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">changes in laws or regulations applicable to our products or proposed products, including clinical trial requirements for approvals;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">unanticipated serious safety concerns related to the use of our hormone therapy drug candidates;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">a decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 48; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the inability to obtain adequate clinical supply for our hormone therapy drug candidates or the inability to do so at acceptable prices;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">adverse regulatory decisions;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the introduction of new products or technologies offered by us or our competitors;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the effectiveness of our or our potential strategic partners&#x2019; commercialization efforts;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">developments concerning our sources of manufacturing supply and any commercialization strategic partners;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the inability to effectively manage our growth;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">actual or anticipated variations in quarterly operating results;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the failure to meet or exceed the estimates and projections of the investment community;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the overall performance of the U.S. equity markets and general political and economic conditions;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our competitors;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">additions or departures of key scientific or management personnel;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">adverse market reaction to any indebtedness we may incur or securities we may issue in the future;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">sales of our common stock by us or our stockholders in the future;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">significant lawsuits, including patent or stockholder litigation;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">changes in the market valuations of similar companies;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">the trading volume of our common stock;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">increases in our common stock available for sale upon expiration of lock-up agreements;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">effects of natural or man-made catastrophic events or other business interruptions; and</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: left;">other events or factors, many of which are beyond our control.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, the stock market in general and the stock of biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">At December 31, 2015, our executive officers, directors, holders of 5% or more of our stock, and their affiliates beneficially owned approximately 65% of our common stock on an as converted basis. These stockholders may be able to determine the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">If we fail to maintain proper internal controls, our ability to produce accurate financial statements or comply with applicable regulations could be impaired.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Pursuant to Section 404 of the Sarbanes-Oxley Act, our management is required annually to deliver a report that assesses the effectiveness of our internal control over financial reporting and our independent registered public accounting firm is required annually to deliver an attestation report on the effectiveness of our internal control over financial reporting. If we are unable to maintain effective internal control over financial reporting or if our independent auditors are unwilling or unable to provide us with an attestation report on the effectiveness of internal control over financial reporting for future periods as required by Section 404 of the Sarbanes-Oxley Act, we may not be able to produce accurate financial statements, and investors may therefore lose confidence in our operating results, our stock price could decline and we may be subject to litigation or regulatory enforcement actions.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 49; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which might cause our stock price and trading volume to decline.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain any future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will be limited to the value of their stock.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><i>Some provisions of our charter documents and Nevada law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management.</i></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Provisions in our articles of incorporation and bylaws, as well as certain provisions of Nevada law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if an acquisition would benefit our stockholders, and could also make it more difficult to remove our current management. These provisions in our articles of incorporation and bylaws include the following:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">authorizing the issuance of &#x201C;blank check&#x201D; preferred stock that could be issued by our board of directors to increase the number of outstanding shares and thwart a takeover attempt;</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">prohibiting cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates; and</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">advance notice provisions in connection with stockholder proposals that may prevent or hinder any attempt by our stockholders to bring business to be considered by our stockholders at a meeting or replace our board of directors.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In addition, we are subject to Nevada&#x2019;s Combination with Interested Stockholders statute (Nevada Revised Statute Sections 78.411 - 78.444), which prohibits an &#x201C;interested stockholder&#x201D; from entering into a &#x201C;combination&#x201D; with a company, unless certain conditions are met. An &#x201C;interested stockholder&#x201D; is a person who, together with affiliates and associates, beneficially owns (or within the prior two years, did beneficially own) 10% or more of the corporation&#x2019;s capital stock entitled to vote.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 1B.<a name="txmda004_v1"></a></td>
<td style="text-align: justify;">Unresolved Staff Comments</td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">None.</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 2.<a name="txmda005_v1"></a></td>
<td style="text-align: justify;">Properties</td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our corporate headquarters is located in Boca Raton, Florida, where we lease 21,219 square feet of office space pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013, was amended on February 18, 2015, and expires on September 30, 2018. The primary functions performed at this location are executive, administrative, accounting, treasury, marketing, and human resources. We believe that our current facility is in good working order and is capable of supporting our operations for the foreseeable future.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 50; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 3.<a name="txmda006_v1"></a></td>
<td style="text-align: justify;">Legal Proceedings</td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">From time to time, we are involved in litigation and proceedings in the ordinary course of our business. We are not currently involved in any legal proceeding that we believe would have a material effect on our business or financial condition.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 4.<a name="txmda007_v1"></a></td>
<td style="text-align: left;">Mine Safety Disclosures</td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Not applicable.</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 51; Value: 25 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: bold 10pt Times New Roman, Times, Serif;"><a name="txmda008_v1"></a>PART II</p>
<p style="margin: 0pt 0; text-align: center; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 5.</td>
<td style="text-align: justify;"><a name="txmda009_v1"></a>Market for the Registrant&#x2019;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</td>
</tr>
</table>
<p style="margin: 0pt 0 0pt 45pt; text-indent: -45pt; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>Market Information on Common Stock</b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Since April 23, 2013, our common stock has been listed on the NYSE MKT under the symbol &#x201C;TXMD.&#x201D; Prior to that time, our common stock was quoted on the OTCQB. The following table sets forth for the periods indicated the high and low sales prices of our common stock on the NYSE MKT.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 88%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: center;">&#xA0;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;"><b>High</b></td>
<td style="padding-bottom: 1pt; text-align: left; font-weight: bold;">&#xA0;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;"><b>Low</b></td>
<td style="padding-bottom: 1pt; text-align: left; font-weight: bold;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; font-weight: bold;">2015</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 68%; text-align: justify;">Fourth Quarter</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 7%; text-align: right;">11.26</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 7%; text-align: right;">5.18</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Third Quarter</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">8.83</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">5.29</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Second Quarter</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">8.60</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">5.63</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">First Quarter</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">6.75</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">4.00</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify; font-weight: bold;">2014</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Fourth Quarter</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">4.95</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3.44</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Third Quarter</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">6.29</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3.88</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Second Quarter</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">6.35</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3.42</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">First quarter</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">9.01</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">4.86</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On February 17, 2016, there were approximately 249 record holders and approximately 10,436 beneficial owners of our common stock.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>Dividends</b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Historically, we have not paid dividends on our common stock, and we currently do not intend to pay any dividends on our common stock in the foreseeable future. We currently plan to retain any earnings to finance the growth of our business rather than to pay cash dividends. Payments of any cash dividends in the future will depend on our financial condition, results of operations, and capital requirements as well as other factors deemed relevant by our board of directors.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>Performance Graph </b></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The following line graph compares cumulative total shareholder return for the five years ended December 31, 2015 for (i) our common stock; (ii) NASDAQ Pharmaceutical Index; and (iii) NASDAQ Stock Market. The graph assumes $100 invested on December 31, 2010 and includes reinvestment of dividends. Measurement points are at the last trading day of the fiscal years ended December 31, 2010, 2011, 2012, 2013, 2014 and 2015. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 52; Options: NewSection; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;<img alt="(LINE GRAPH)" src="txmd001_v1.jpg"></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The following line graph compares cumulative total shareholder return for the period beginning when our common stock became listed on the NYSE MKT exchange (April 23, 2013) and ended December 31, 2015 for (i) our common stock; (ii) NASDAQ Pharmaceutical Index; and (iii) NASDAQ Stock Market. The graph assumes $100 invested on April 23, 2013 and includes reinvestment of dividends. Measurement points are April 23, 2013 and the last trading day of the fiscal years ended December 31, 2015, 2014 and 2013 and each of the following quarters ended therein beginning with the quarter ended June 30, 2013. The stock price performance on the following graph is not necessarily indicative of future stock price performance.</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><img style="height: 319px; width: 600px;" alt="" src="txmd002_v2.jpg">&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 53; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The performance graphs shall not be deemed &#x201C;filed&#x201D; for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. The performance graphs will not be deemed incorporated by reference into any filing of our company under the Exchange Act or the Securities Act.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>I<a name="txmda010_v1"></a>tem 6.</td>
<td style="text-align: justify;">Selected Financial Data</td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The following table sets forth selected consolidated financial and other data as of and for the periods indicated. You should read the following information together with the more detailed information contained in &#x201C;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201D; and our consolidated financial statements and the related notes included elsewhere in this Annual Report. The consolidated statements of operations for the years ended December 31, 2015, 2014, and 2013, and the consolidated balance sheet data as of December 31, 2015, and 2014 are derived from our audited consolidated financial statements included in this Annual Report. The consolidated statements of operations for the years ended December 31, 2012 and 2011, and the consolidated balance sheet data as of December 31, 2013, 2012, and 2011, are derived from our audited consolidated financial statements not included in this Annual Report.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Arial, Helvetica, Sans-Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></font></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>(in thousands, except per share data)</b></font></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="18"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Year Ended December 31,</b></font></td>
<td>&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;"><b>2015</b></font></td>
<td style="text-align: center;">&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;"><b>2014</b></font></td>
<td style="text-align: center;">&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;"><b>2013</b></font></td>
<td style="text-align: center;">&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;"><b>2012</b></font></td>
<td style="text-align: center;">&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;"><b>2011</b></font></td>
<td>&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td colspan="3">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Consolidated Statements of Operations Data:</b></font></td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 35%; text-align: left;">Revenue, net</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;">20,143</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;">15,026</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;">8,776</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;">3,818</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 9%; text-align: right;">2,088</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Cost of goods sold</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">4,506</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">3,672</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">1,960</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">1,348</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">947</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Gross profit</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">15,637</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">11,354</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">6,816</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">2,470</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">1,141</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Operating expenses:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Sales, general, and administration</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">28,721</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">22,124</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">19,015</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">14,070</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">6,406</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Research and development</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">72,043</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">43,219</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">13,551</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4,492</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">107</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Depreciation and amortization</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">63</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">52</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">58</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">56</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">55</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.12in; text-align: left;">Total operating expense</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">100,827</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">65,395</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">32,624</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">18,618</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">6,568</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Operating loss</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(85,190</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(54,041</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(25,808</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(16,148</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(5,427</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Other income (expense), net</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">113</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(176</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(2,611</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(18,972</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(7,486</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Net loss</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(85,077</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(54,217</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(28,419</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(35,120</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(12,913</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Net loss per share, basic and diluted</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.49</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.36</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.22</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.38</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.21</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.12in; text-align: left; text-indent: -0.12in;">Weighted average number of common&#xA0;&#xA0;shares outstanding, basic and diluted</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">173,174</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">149,727</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">127,570</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">91,630</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">62,516</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Consolidated Balance Sheet Data (at end of period)</b></font></td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.24in; text-align: left;">Total assets</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">73,729</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">59,079</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">62,016</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">5,926</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1,439</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.24in; text-align: left;">Total liabilities</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">10,666</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">10,690</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">7,318</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">7,359</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3,151</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.12in; text-align: left;">Total stockholders&#x2019; equity (deficit)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">63,063</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">48,389</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">54,698</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(1,433</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(1,712</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Other Data:</b></font></td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Capital expenditures (for the period)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">584</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">617</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">480</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">273</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">38</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Working capital (deficit)(at the end of period)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">60,014</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">45,545</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">52,085</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1,015</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(1,914</td>
<td style="text-align: left;">)</td>
</tr>
</table>
<p style="margin: 0pt 0; text-indent: 0.5in; font: 10pt Arial, Helvetica, Sans-Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 54; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-indent: 0.5in; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>I<a name="txmda011_v1"></a>tem 7.</td>
<td style="text-align: justify;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>You should read the following discussion and analysis in conjunction with the information set forth under &#x201C;Selected Consolidated Financial and Other Data&#x201D; and our consolidated financial statements and the notes to those financial statements included elsewhere in this Annual Report. This discussion contains forward-looking statements based upon current expectations that involve risks and uncertainties. See &#x201C;Special Note Regarding Forward-Looking Statements.&#x201D; Our actual results may differ materially from those contained in or implied by any forward-looking statements as a result of various factors, including, but not limited to, the risks and uncertainties described under &#x201C;Risk Factors&#x201D; elsewhere in this Annual Report.</i></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Company Overview</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">We are a women&#x2019;s health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created using our SYMBODA<sup>TM</sup> hormone technology, which enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and authorized generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins. We recently completed a Phase 3 clinical trial of TX-004HR, our applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vuvlar and vaginal atrophy, or VVA, in post-menopausal women with vaginal linings that do not receive enough estrogen.</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Research and Development &#x2013; Overview</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-left: 0in; margin-top: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have obtained U.S. Food and Drug Administration, or FDA, acceptance of our Investigational New Drug, or IND, applications to conduct clinical trials for four of our hormone therapy drug candidates. In December 2015, we completed a Phase 3 clinical trial of TX-004HR, our applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia (vaginal pain during sexual intercourse), a symptom of VVA in post-menopausal women with vaginal linings that do not receive enough estrogen, and we are currently conducting a Phase 3 clinical trial for TX-001HR, our oral combination of progesterone and estradiol. In July 2014, we temporarily suspended enrollment in the Phase 3 clinical trial for TX-002HR, our oral progesterone alone, and, in October 2014, we temporarily stopped the trial in order to update the Phase 3 protocol based on discussions with the FDA. We have no current plans to conduct clinical trials for TX-003HR, our oral estradiol alone.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-left: 0in; margin-top: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-001HR, our combination estradiol and progesterone drug candidate, is undergoing clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause, including hot flashes, night sweats, sleep disturbances, and vaginal discomfort for post-menopausal women with an intact uterus. The hormone therapy drug candidate is chemically identical to the hormones that naturally occur in a woman&#x2019;s body, namely estradiol and progesterone, and is being studied as a continuous-combined regimen, in which the combination of estrogen and progesterone are taken together in one product daily. If approved by the FDA, we believe this would represent the first time a combination product of estradiol and progesterone bioidentical to &#x2013; or having the same chemical and molecular structure as - the estradiol and progesterone produced by the ovaries would be approved for use in a single combined product.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On September 5, 2013, we began enrollment in the REPLENISH Trial, a multicenter, double-blind, placebo-controlled, Phase 3 study of TX-001HR in postmenopausal women with an intact uterus. The study is designed to evaluate the efficacy of TX-001HR for the treatment of moderate to severe vasomotor symptoms due to menopause and the endometrial safety of TX-001HR. Patients are assigned to one of five arms, four active and one placebo, and receive study medication for 12 months. The primary endpoint for the reduction of endometrial hyperplasia is an incidence of endometrial hyperplasia of less than 1% at 12 months, as determined by endometrial biopsy. The primary endpoint for the treatment of moderate to severe vasomotor symptoms is the mean change of frequency and severity of moderate to severe vasomotor symptoms at weeks four and 12 compared to placebo, as measured by the number and severity of hot flushes. Only subjects experiencing a minimum daily frequency of seven moderate to severe hot flushes at screening are included in the vasomotor symptoms analysis, while all subjects are included in the endometrial hyperplasia analysis. The secondary endpoints include reduction in sleep disturbances and improvement in quality of life measures, night sweats and vaginal dryness, measured at 12 weeks, six months and 12 months. The trial is designed to enroll approximately 1,750 patients at approximately 100 sites. We completed enrollment in the REPLENISH Trial in October 2015 and we currently anticipate that results of the trial will be reported late in the fourth quarter of 2016. Based on such timeline and assuming a successful trial, we would anticipate filing a New Drug Application, or NDA, for TX-001HR as soon as the first half of 2017 and assuming an FDA review period of ten months from the receipt date to the Prescription Drug User Fee Act, or PDUFA, date for a non-new molecular entity, the NDA for TX-001HR could be approved by the FDA as soon as the fourth quarter of 2017 or the first quarter of 2018.&#xA0; As of February 23, 2016, approximately 1,400 patients have exited the REPLENISH Trial and the incidence of endometrial hyperplasia for these patients is less than 1%.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 55; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-002HR is a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. The hormone therapy drug candidate is bioidentical to &#x2013; or having the same chemical and molecular structure as - the hormones that naturally occur in a woman&#x2019;s body. We believe it will be similarly effective to traditional treatments, but may demonstrate efficacy at lower dosages. In January 2014, we began recruitment of patients in the SPRY Trial, a phase 3 clinical trial designed to measure the safety and effectiveness of TX-002HR in the treatment of secondary amenorrhea. During the first two quarters of 2014, the SPRY Trial encountered enrollment challenges because of Institutional Review Board approved clinical trial protocols and FDA inclusion and exclusion criteria. In July 2014, we temporarily suspended enrollment and in October 2014 we temporarily stopped the SPRY Trial in order to update the phase 3 protocol based on discussions with the FDA. We are considering updating the phase 3 protocol to, among other things, target only those women with secondary amenorrhea due to polycystic ovarian syndrome and to amend the primary endpoint of the trial. We believe that the updated phase 3 protocol, if proposed by us and approved by the FDA, would allow us to mitigate the enrollment challenges in, and shorten the duration of, the SPRY Trial. However, there can be no assurance that the FDA will approve the updated phase 3 protocol if we propose it.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">TX-004HR is a vaginal estradiol softgel drug candidate for the treatment of VVA in post-menopausal women with vaginal linings that do not receive enough estrogen. We believe that our drug candidate will be at least as effective as the traditional treatments for VVA because of an early onset of action with less systemic exposure, inferring a greater probability of dose administration to the target tissue, and it will have an added advantage of being a simple, easier to use dosage form versus traditional VVA treatments. TX-004HR features our SYMBODA<sup>TM</sup> technology, which enables partial and complete solubilization of estradiol into medium-chain fatty acid oils often derived from coconut oil. This allows for the production of cohesive, stable formulations and provides content uniformity and accuracy of dosing strengths for TX-004HR. We initiated the REJOICE Trial, a randomized, multicenter, double-blind, placebo-controlled Phase 3 clinical trial during the third quarter of 2014 to assess the safety and efficacy of three doses &#x2014; 25 mcg, 10 mcg and 4 mcg (compared to placebo) &#x2014; of TX-004HR for the treatment of moderate to severe dyspareunia, or painful intercourse, as a symptom of VVA due to menopause.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">On December&#xA0;7, 2015, we announced positive top-line results from the REJOICE Trial. The pre-specified four co-primary efficacy endpoints were the changes from baseline to week 12 versus placebo in the percentage of vaginal superficial cells, percentage of vaginal parabasal cells, vaginal pH and severity of participants&#x2019; self-reported moderate to severe dyspareunia as the most bothersome symptom of VVA. The trial enrolled 764 postmenopausal women (40 to 75 years old) experiencing moderate to severe dyspareunia at approximately 89 sites across the United States and Canada. Trial participants were randomized to receive either TX-004HR at 25 mcg (n=190), 10 mcg (n=191), or 4 mcg (n=191) doses or placebo (n=192) for a total of 12 weeks, all administered once daily for two weeks and then twice weekly (approximately three to four days apart) for ten weeks.&#xA0; We recently received conditional approval for the brad name Yuvvexy related to TX-004HR.</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 0 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">The following table sets forth the statistical significance of the REJOICE Trial results for the four pre-specified co-primary efficacy endpoints, based on mean changes from baseline to week 12 compared to placebo.&#xA0; Based on our ongoing analyses of the REJOICE Trial data, statistical significance of the results for the co-primary endpoint of severity of participants&#39; self-reported moderate to severe dyspareunia as the most bothersome symptom of VVA has improved for all three doses from the results originally reported.</p>
<p style="margin: 0 0 0 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>25 mcg</b></td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>10 mcg</b></td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>4 mcg</b></td>
<td style="text-align: justify;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff;">
<td style="padding-left: 8.8pt; width: 70%; vertical-align: top; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Superficial Cells</b></td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;&lt;&#xA0;0.0001</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;&lt;&#xA0;0.0001</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;&lt;&#xA0;0.0001</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
</tr>
<tr>
<td style="padding-left: 8.8pt; vertical-align: top; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Parabasal Cells</b></td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff;">
<td style="padding-left: 8.8pt; vertical-align: top; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Vaginal pH</b></td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
</tr>
<tr>
<td style="padding-left: 8.8pt; vertical-align: top; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Severity of Dyspareunia</b></td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P &lt; 0.0001</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: right;">P = 0.0149</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
</tr>
</table>
<p style="margin: 8pt 0 0 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">The 25 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 10 mcg dose of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo across all four co-primary endpoints. The 4 mcg dose of TX-004HR also demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoints of vaginal superficial cells, vaginal parabasal cells, and vaginal pH; the change from baseline compared to placebo in the severity of dyspareunia was statistically significant at the p = 0.0149 level. The FDA has previously indicated to us that in order to approve the drug based on a single trial, the trial would need to show statistical significance at the 0.01 level or lower for each endpoint, and that a trial that is merely statistically significant at a higher level may not provide sufficient evidence to support an NDA filing or approval of a drug candidate where the NDA relies on a single clinical trial.</p>
<p style="margin: 0 0 0 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 56; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">Statistical improvement over placebo was also observed for all three doses at the first assessment at week two and sustained through week 12 (see table below).</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="background-color: white;">
<td style="border-bottom: white 3pt solid; border-left: white 1pt solid; border-right: white 1pt solid; border-top: white 1pt solid; width: 25%;">&#xA0;</td>
<td style="border-bottom: white 3pt solid; border-right: white 1pt solid; border-top: white 1pt solid; padding-left: 8.8pt; width: 25%; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b><u>25 mcg</u><br></b></td>
<td style="border-bottom: white 3pt solid; border-right: white 1pt solid; border-top: white 1pt solid; padding-left: 8.8pt; width: 25%; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b><u>10 mcg</u><br></b></td>
<td style="border-bottom: white 3pt solid; border-right: white 1pt solid; border-top: white 1pt solid; padding-left: 8.8pt; width: 25%; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b><u>4 mcg</u><br></b></td>
</tr>
<tr style="background-color: #cceeff;">
<td style="border-bottom: white 1pt solid; border-left: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Week 2</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;">P = 0.0105</td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.0019</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.026</b></td>
</tr>
<tr style="background-color: white;">
<td style="border-bottom: white 1pt solid; border-left: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Week 6</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;">P &lt; 0.0001</td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.0009</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.0069</b></td>
</tr>
<tr style="background-color: #cceeff;">
<td style="border-bottom: white 1pt solid; border-left: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Week 8</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;">P &lt; 0.0001</td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P &lt; 0.0001</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.0003</b></td>
</tr>
<tr style="background-color: white;">
<td style="border-bottom: white 1pt solid; border-left: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Week 12</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;">P &lt; 0.0001</td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P &lt; 0.0001</b></td>
<td style="border-bottom: white 1pt solid; border-right: white 1pt solid; padding-left: 8.8pt; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>P = 0.0149</b></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 12pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Vaginal dryness was a prespecified key secondary endpoint. The 25 mcg and 10 mcg doses of TX-004HR demonstrated highly statistically significant results at the p &lt; 0.0001 level compared to placebo for the endpoint of vaginal dryness. The 4 mcg dose of TX-004HR demonstrated statistically significant results at the p = 0.0014 level compared to placebo (see table below).</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>25 mcg</b></td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>10 mcg</b></td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: black 1pt solid; text-align: center; font-weight: bold;" colspan="2"><b>4 mcg</b></td>
</tr>
<tr style="background-color: #cceeff;">
<td style="padding-left: 8.8pt; vertical-align: top; text-align: justify; text-indent: -8.8pt; font-weight: bold;"><b>Severity of Vaginal Dryness </b></td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;&lt;&#xA0;0.0001</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;&lt;&#xA0;0.0001</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 1%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="width: 7%; vertical-align: bottom; text-align: right;">P&#xA0;=&#xA0;0.0014</td>
</tr>
<tr>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
</table>
<p style="margin: 4.4pt 0 12pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">The pharmacokinetic data for all three doses demonstrated negligible to very low systemic absorption of 17 beta estradiol, estrone and estrone conjugated, supporting the previous Phase 1 trial data. TX-004HR was well tolerated, and there were no clinically significant differences compared to placebo-treated participants with respect to adverse events. There were no drug-related serious adverse events reported.</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">We currently intend to submit an NDA for the 25 mcg, 10 mcg and 4 mcg doses of TX-004HR to the FDA as early as the first half of 2016 and that such NDA could be approved by the FDA as soon as the first quarter of 2017, assuming an FDA review period of ten months from the receipt date to the PDUFA date for a new non-molecular entity. If approved, the 4 mcg formulation would represent a lower effective dose than the currently available VVA therapies approved by the FDA.</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">As of December 31, 2015, we had 14 issued patents, which included 12 utility patents that relate to our combination progesterone and estradiol formulations, one utility patent that relates to TX-004HR, which establishes an important intellectual property foundation for TX-004HR, and one utility patent that relates to our OPERA&#xAE; information technology platform.</p>
<p style="margin: 0pt 0 0pt 1.1pt; text-align: justify; text-indent: 34.9pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Research and Development Expenses</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">A significant portion of our operating expenses to date have been incurred in research and development activities. Research and development expenses relate primarily to the discovery and development of our drug products. Our business model is dependent upon our company continuing to conduct a significant amount of research and development. Until one of our drug products receives IND approval from the FDA, products costs are listed as &#x201C;Other research and development&#x201D; costs in the accompanying consolidated financial statements. Our research and development expenses consist primarily of expenses incurred under agreements with CROs, investigative sites, and consultants that conduct our clinical trials and a substantial portion of our preclinical studies; employee-related expenses, which include salaries and benefits, and non-cash share-based compensation; the cost of developing our chemistry, manufacturing and controls capabilities, and acquiring clinical trial materials; and costs associated with other research activities and regulatory approvals.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We make payments to the CROs based on agreed upon terms that may include payments in advance of a study starting date. Nonrefundable advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been received rather than when the payment is made. Advance payments to be expensed in future research and development activities were $1,138,073 and $1,175,082, at December 31, 2015 and December 31, 2014, respectively.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The following table indicates our research and development expense by project for the periods indicated (in thousands):</p>
<p style="margin: 0;">&#xA0;</p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">Year Ended December 31,</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2013</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="9">(000s)</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 50%; text-align: justify;">TX-001HR</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">33,227</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">26,123</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">4,809</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">TX-002HR</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">23</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1,443</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1,059</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">TX-004HR</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">19,574</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">3,984</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: justify;">Other research and development</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">19,219</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">11,669</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">7,683</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2pt; text-align: justify;">Total research and development</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">72,043</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">43,219</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">13,551</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 57; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Research and development expenditures will continue to be significant as we continue development of our drug candidates and advance the development of our proprietary pipeline of novel drug candidates. We expect to incur significant research and development costs as we develop our drug pipeline, complete the ongoing clinical trials of our drug candidates, conduct our planned phase 3 clinical trials, subject to receiving input from regulatory authorities, and prepare regulatory submissions.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2015 and since the project&#x2019;s inception in February 2013, we have incurred approximately $33,227,000 and $64,159,000, respectively, in research and development costs with respect to TX-001HR, our combination estradiol and progesterone drug candidate.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2015 and since the project&#x2019;s inception in April 2013, we have incurred approximately $23,000 and $2,525,000, respectively, in research and development costs with respect to TX-002HR, our progesterone only drug candidate.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2015 and since the project&#x2019;s inception in August 2014, we have incurred approximately $19,574,000 and $23,558,000, respectively, in research and development costs with respect to TX-004HR, our vaginal estradiol softgel drug candidate.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The costs of clinical trials may vary significantly over the life of a project owing to factors that include, but are not limited to, the following: per patient trial costs; the number of patients that participate in the trials; the number of sites included in the trials; the length of time each patient is enrolled in the trial; the number of doses that patients receive; the drop-out or discontinuation rates of patients; the amount of time required to recruit patients for the trial; the duration of patient follow-up; and the efficacy and safety profile of the drug candidate. We base our expenses related to clinical trials on estimates that are based on our experience and estimates from CROs and other third parties.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Results of Operations</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">Comparison of Years Ended December 31, 2015, 2014, and 2013:</p>
<p style="margin: 0pt 0; font: italic bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Year ended December 31, 2015 compared with year ended December 31, 2014</u></i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 88%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Year Ended December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
<td style="text-align: center;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td style="text-align: center;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Change</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">(000s)</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 50%; text-align: justify;">Revenue</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">20,143</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">15,026</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">5,117</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Cost of goods sold</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4,506</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">3,672</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">834</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: justify;">Operating expenses</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">100,827</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">65,395</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">35,432</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Operating loss</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(85,190</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(54,041</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(31,149</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Financing Costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(260</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">260</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: justify;">Other income, net</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">113</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">84</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">29</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2pt; text-align: justify;">Net loss</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(85,077</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(54,217</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(30,860</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Revenue</i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Revenue for year ended December 31, 2015 increased by approximately $5,117,000, or 34%, to approximately $20,143,000, compared with approximately $15,026,000 for the year ended December 31, 2014. Of this $5,117,000 increase, approximately $2,437,000, or 48%, was attributable to an increase in the average sales price of our existing products, and approximately $2,680,000, or 52%, was attributable to the number of units sold during the year ended December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Cost of Goods Sold</i></p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Cost of goods sold increased by approximately $834,000, or 23%, to approximately $4,506,000 for the year ended December 31, 2015, compared with approximately $3,672,000 for the year ended December 31, 2014. Our gross margins increased to approximately 78% for the year ended December 31, 2015, compared to approximately 76% for the year ended December 31, 2014. The gross margin change was primarily attributable to favorable change in product mix partially offset by increased distribution costs.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 58; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Operating Expenses</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our principal operating costs included the following items as a percentage of total operating expenses.</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 88%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Year Ended<br>December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;" colspan="2">2015</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;" colspan="2">2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 66%; text-align: justify;">Human resource related costs</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 8%; text-align: right;">15</td>
<td style="width: 1%; text-align: left;">%</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 8%; text-align: right;">16</td>
<td style="width: 1%; text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Sales and marketing costs, excluding human resource costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">6</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">9</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Product research and development costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">71</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">66</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Professional fees and consulting costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Other operating expenses</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">5</td>
<td style="text-align: left;">%</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Operating expenses increased by approximately $35,432,000, or 54%, to approximately $100,827,000 for the year ended December 31, 2015, compared with approximately $65,395,000 for year ended December 31, 2014, as a result of the following items:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 88%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt; width: 80%; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt; width: 2%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 10%; text-align: center;">(000s)</td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Increase in product research and development costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">28,824</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Increase in human resource related costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4,096</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Increase in sales and marketing, excluding human resource costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">203</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Increase in professional and consulting costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1,281</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: justify;">Increase in all other operating expenses</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">1,028</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2pt; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">35,432</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Research and development costs for the year ended December 31, 2015 increased by approximately $28,824,000, or 67%, to approximately $72,043,000, primarily as a result of an increase in scale-up and manufacturing activities for our Phase 3 clinical trials of TX-001HR and TX-004HR. Research and developments costs during the year ended December 31, 2015 included the following research and development projects:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2015 and since the project&#x2019;s inception in February 2013, we have incurred approximately $33,227,000 and $64,159,000, respectively, in research and development costs with respect to TX-001HR, our combination estradiol and progesterone drug candidate.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2015 and since the project&#x2019;s inception in April 2013, we have incurred approximately $23,000 and $2,525,000, respectively, in research and development costs with respect to TX-002HR, our progesterone only drug candidate.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2015 and since the project&#x2019;s inception in August 2014, we have incurred approximately $19,574,000 and $23,558,000, respectively, in research and development costs with respect to TX-004HR, our vaginal estradiol softgel drug candidate.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">For a discussion of the nature of efforts and steps necessary to complete these projects, see &#x201C;Item 1. Business &#x2014; Research and Development.&#x201D; For a discussion of the risks and uncertainties associated with completing development of our products, see &#x201C;Item 1A. Risk Factors &#x2014; Risks Related to Our Business.&#x201D; For a discussion of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see &#x201C;&#x2014; Liquidity and Capital Resources.&#x201D; For a discussion as to whether a future milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see &#x201C;Item 1. Business &#x2014; Our Hormone Therapy Drug Candidates,&#x201D; &#x201C;Item 1. Business &#x2014; Products in Development&#x201D; and &#x201C;Item 1. Business &#x2014; Pharmaceutical Regulation.&#x201D; Future milestones, including NDA submission dates, are not easily determinable as such milestones are dependent on various factors related to our clinical trials, including the timing of ongoing patient recruitment efforts to find eligible subjects for the applicable trials.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Human resource related costs, including salaries and benefits, increased by approximately $4,096,000, or 38%, to approximately $14,966,000, compared with approximately $10,870,000 for the year ended December 31, 2014, primarily as a result of an increase in salary and wages and related cost of $2,617,000 associated with additional employees required for our clinical trials and by an increase in amortization of non-cash compensation totaling approximately $1,479,000 related to employee stock options issued during 2015 as compared to 2014.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 59; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Sales and marketing costs increased approximately $203,000, or 4%, to approximately $5,920,000, compared with approximately $5,717,000 for the year ended December 31, 2014, primarily as a result of increased employee incentives partially offset by decreased marketing expenses.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Professional and consulting costs increased approximately $1,281,000, or 54%, to approximately $3,649,000 compared with approximately $2,368,000 for the year December 31, 2014, as a result of additional costs incurred for legal, consulting, accounting and board of director fees.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">All other costs increased approximately $1,028,000, or 32%, to approximately $4,249,000, compared with approximately $3,221,000 for the year ended December 31, 2014, primarily as a result of increased insurance, rent and office expenses.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Operating Loss</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the foregoing, our operating loss increased approximately $31,149,000, or 58%, to approximately $85,190,000 for the year ended December 31, 2015, compared with approximately $54,041,000 for the year ended December 31, 2014, primarily as a result of increased research and development costs associated with our continued development of our hormone therapy drug candidates, partially offset by increased revenue from sales of our prenatal vitamin products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the continued development of our hormone therapy drug candidates, we anticipate that we will continue to have operating losses for the near future until our hormone therapy drug candidates are approved by the FDA and brought to market, although there is no assurance that we will attain such approvals or that any marketing of our hormone therapy drug candidates, if approved, will be successful.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Financing Costs</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Financing costs decreased approximately $260,000, or 100%, during the year ended December 31, 2015, from approximately $260,000 for the year ended December 31, 2014, primarily as a result of a decrease in amortization costs associated with warrants.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Net Loss</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the net effects of the foregoing, net loss increased approximately $30,860,000, or 57%, to approximately $85,077,000 for the year ended December 31, 2015, compared with approximately $54,217,000 for the year ended December 31, 2014. Net loss per share of common stock, basic and diluted, was ($0.49) for the year ended December 31, 2015, compared with ($0.36) per share of common stock for the year ended December 31, 2014.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Year ended December 31, 2014 compared with year ended December 31, 2013</u></i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Year Ended December 31,</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2013</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Change</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">(000s)</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 50%; text-align: justify;">Revenue</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">15,026</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">8,776</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">6,250</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Cost of goods sold</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">3,672</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1,960</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1,712</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: justify;">Operating expenses</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">65,395</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">32,624</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">32,771</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Operating loss</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(54,041</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(25,808</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(28,233</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Financing Costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(260</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(1,504</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1,244</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Interest expense</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(1,166</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1,166</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: justify;">Other income, net</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">84</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">59</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">25</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2pt; text-align: justify;">Net loss</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(54,217</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(28,419</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(25,798</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Revenue</i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Revenue for year ended December 31, 2014 increased by approximately $6,250,000, or 71%, to approximately $15,026,000, compared with approximately $8,776,000 for the year ended December 31, 2013. Of this $6,250,000, approximately $2,003,494, or 32%, was attributable to an increase in the average sales price of our existing products, and approximately $4,247,127, or 68%, was attributable to sales of new products introduced during the year ended December 31, 2014.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 60; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Cost of Goods Sold</i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Cost of goods sold increased by approximately $1,712,000, or 87%, to approximately $3,672,000 for the year ended December 31, 2014, compared with approximately $1,960,000 for the year ended December 31, 2013. Our gross margins decreased to approximately 76% for the year ended December 31, 2014, compared to approximately 78% for the year ended December 31, 2013. The gross margin change was primarily attributable to increases in distribution related costs.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Operating Expenses</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our principal operating costs included the following items as a percentage of total operating expenses.</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 89%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">Year Ended <br>December 31,</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;" colspan="2">2014</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;" colspan="2">2013</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 68%; text-align: justify;">Human resource related costs</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 8%; text-align: right;">16</td>
<td style="width: 1%; text-align: left;">%</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 8%; text-align: right;">33</td>
<td style="width: 1%; text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Sales and marketing costs, excluding human resource costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">9</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">15</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Product research and development costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">66</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">41</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Professional fees and consulting costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Other operating expenses</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">5</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">7</td>
<td style="text-align: left;">%</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Operating expenses increased by approximately $32,771,000, or 100%, to approximately $65,395,000 for the year ended December 31, 2014, compared with approximately $32,624,000 for year ended December 31, 2013, as a result of the following items:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 89%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt; width: 79%; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt; width: 1%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 8%; text-align: center;">(000s)</td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Increase in product research and development costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">29,668</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Increase in human resource related costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">509</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Increase in sales and marketing, excluding human resource costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">702</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Increase in professional and consulting costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">852</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; text-align: justify;">Increase in all other operating expenses</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">1,040</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2pt; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">32,771</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Research and development costs for the year ended December 31, 2014 increased by approximately $29,668,000, or 219%, to approximately $43,219,000, primarily as a result of the continuing phase 3 clinical trial of TX-001HR, the partial year phase 3 clinical trial for TX-002HR, and phase 1 and partial year phase 3 clinical trial for TX-004HR. Research and developments costs during the year ended December 31, 2014 included the following research and development projects:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2014 and since the project&#x2019;s inception in February 2013, we have incurred approximately $26,123,000 and $30,932,000, respectively, in research and development costs with respect to TX-001HR, our combination estradiol and progesterone drug candidate.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2014 and since the project&#x2019;s inception in April 2013, we have incurred approximately $1,443,000 and $2,502,000, respectively, in research and development costs with respect to TX-002HR, our progesterone only drug candidate.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2014 and since the project&#x2019;s inception in August 2014 , we have incurred approximately $3,984,000 in research and development costs with respect to TX-004HR, our vaginal estradiol softgel drug candidate.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 61; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">For a discussion of the nature of efforts and steps necessary to complete these projects, see &#x201C;Item 1. Business &#x2014; Research and Development.&#x201D; For a discussion of the risks and uncertainties associated with completing development of our products, see &#x201C;Item 1A. Risk Factors &#x2014; Risks Related to Our Business.&#x201D; For a discussion of the extent and nature of additional resources that we may need to obtain if our current liquidity is not expected to be sufficient to complete these projects, see &#x201C;&#x2014; Liquidity and Capital Resources.&#x201D; For a discussion as to whether a future milestone such as completion of a development phase, date of filing an NDA with a regulatory agency or approval from a regulatory agency can be reliably determined, see &#x201C;Item 1. Business &#x2014; Our Hormone Therapy Drug Candidates,&#x201D; &#x201C;Item 1. Business &#x2014; Products in Development&#x201D; and &#x201C;Item 1. Business &#x2014; Pharmaceutical Regulation.&#x201D; Future milestones, including NDA submission dates, are not easily determinable as such milestones are dependent on various factors related to our clinical trials, including the timing of ongoing patient recruitment efforts to find eligible subjects for the applicable trials.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Human resource related costs, including salaries and benefits, increased by approximately $509,000, or 5%, to approximately $10,870,000, primarily as a result of an increase in salary and wages and related cost of $1,060,000 associated with additional employees required for our clinical trials, partially offset by a decrease in amortization of non-cash compensation totaling approximately $551,000 related to employee stock options issued during 2014 as compared to 2013.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Sales and marketing costs increased approximately $702,000, or 14%, to approximately $5,717,000, primarily as a result of expanded marketing, advertising, education, and training. Many of these incurred added costs were associated with our new prenatal products introduced in 2014.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Professional and consulting costs increased approximately $852,000, or 67%, to approximately $2,368,000 as a result of additional costs incurred for legal, consulting, and regulatory compliance.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">All other costs increased approximately $1,040,000, or 48%, to approximately $3,221,000 as a result of additional costs incurred for rent, travel, corporate communications, insurance, and contract labor.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Operating Loss</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the foregoing, our operating loss increased approximately $28,233,000, or 109%, to approximately $54,041,000 for the year ended December 31, 2014, compared with approximately $25,808,000 for the year ended December 31, 2013, primarily as a result increased research and development costs associated with our continued development of our hormone therapy drug candidates, partially offset by increased revenue from sales of our prenatal vitamin products.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the continued development of our hormone therapy drug candidates, we anticipate that we will continue to have operating losses for the near future until our hormone therapy drug candidates are approved by the FDA and brought to market, although there is no assurance that we will attain such approvals or that any marketing of our hormone therapy drug candidates, if approved, will be successful.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Financing Costs</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Financing costs decreased approximately $1,244,000, or 83%, to approximately $260,000 for the year ended December 31, 2014, compared with approximately $1,504,000 for the year ended December 31, 2013, primarily as a result of the amortization of the costs associated with warrants granted in 2013 in connection with a $10,000,000 revolving line of credit.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Interest Expense</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We did not incur interest expense for the year ended December 31, 2014, compared with approximately $1,166,000 in interest expense incurred for the year ended December 31, 2013, as a result of the retirement of our debt during 2013.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Net Loss</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As a result of the net effects of the foregoing, net loss increased approximately $25,798,000, or 91%, to approximately $54,217,000 for the year ended December 31, 2014, compared with approximately $28,419,000 for the year ended December 31, 2013. Net loss per share of common stock, basic and diluted, was ($0.36) for the year ended December 31, 2014, compared with ($0.22) per share of common stock for the year ended December 31, 2013. Net loss per share of common stock was positively affected by our issuance of shares of common stock in an underwritten public offering in August 2014.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 62; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Liquidity and Capital Resources</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have funded our operations primarily through public offerings of our common stock and private placements of equity and debt securities. For the three year period ending December 31, 2015, we received approximately $212.8 million in net proceeds from the issuance of shares of our common stock. As of December 31, 2015, we had a cash balance of approximately $64.7 million, however, changing circumstances may cause us to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On January&#xA0;6, 2016, we entered into an underwriting agreement with Goldman, Sachs&#xA0;&#38; Co. and Cowen and Company, LLC, as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of our common stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of our common stock, which option was exercised in full. The net proceeds to us from the offering were approximately $134.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on January&#xA0;12, 2016.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In January 2016, certain individuals exercised stock options to purchase 281,657 shares of our common stock for approximately $758,000 in cash and warrants to purchase 500,000 shares of our common stock were exercised for $1,285,000 in cash.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; We believe that our existing cash will allow us to fund our operating plan through at least the next 12 months. If our available cash is insufficient to satisfy our liquidity requirements, we may seek to sell additional equity or debt securities or obtain a credit facility. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our existing shareholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing shareholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or proposed products. Additionally, we may have to grant licenses on terms that may not be favorable to us.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We need substantial amounts of cash to complete the clinical development of our hormone therapy drug candidates. The following table sets forth the primary sources and uses of cash for each of the periods set forth below:</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Summary of (Uses) and Sources of Cash</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">Year Ended December 31,</td>
<td>&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2013</td>
<td>&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: justify;" colspan="11">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 50%; text-align: justify;">Net cash flows used in operating activities</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">(79,044,119</td>
<td style="width: 1%; text-align: left;">)</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">(45,520,996</td>
<td style="width: 1%; text-align: left;">)</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">(20,768,069</td>
<td style="width: 1%; text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: justify;">Net cash flows used in investing activities</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(584,361</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(606,756</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(583,561</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: justify;">Net cash flows provided by financing activities</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">92,973,228</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">43,298,099</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">73,989,416</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Operating Activities</i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The use of cash in all periods resulted primarily from our net loss adjusted for non-cash charges and changes in components of working capital.</p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The increase of approximately $33.5 million in cash used in operating activities for the year ended December 31, 2015 in comparison to the year ended December 31, 2014 was due primarily to research and development, sales, general and administrative costs. These were partially offset by an approximately $5.1 million increase in sales.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 63; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The increase of approximately $25 million in cash used in operating activities for the year ended December 31, 2014 in comparison to the year ended December 31, 2013 was due primarily to research and development, sales, general and administrative costs. These were partially offset by an approximately $6 million increase in sales.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Investing Activities</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The decrease of approximately $22,000 in cash used in investing activities for the year ended December 31, 2015 compared with the prior year was due to a decrease in patent costs partially offset by the increase in costs relating to purchase of fixed assets.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The increase of approximately $23,000 in cash used in investing activities for the year ended December 31, 2014 compared with the prior year was due to patent development costs and purchase of property and equipment.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Financing Activities</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Financing activities represent the principal source of our cash flow.</p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our financing activities for the year ended December 31, 2015 provided net cash of approximately $92,973,000. The cash provided by financing activities included approximately $91,375,000 proceeds from sale of our common stock and approximately $1,598,000 proceeds from the exercise of options and warrants.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus &#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of our common stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of our common stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting underwriting discounts and commissions and other estimated offering expense payable by us. The offering closed on July 15, 2015 and we issued 4,423,077 shares of our common stock.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of our common stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of our common stock, which option was exercised in full. The net proceeds to us from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expense payable by us. The offering closed February 17, 2015 and we issued 15,617,282 shares of our common stock.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our financing activities for the year ended December 31, 2014 provided net cash of approximately $43,298,000.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On July 29, 2014, we entered into an underwriting agreement relating to the issuance and sale by us of 8,565,310 shares of our common stock. Under the terms of the underwriting agreement, we granted the underwriters a 30-day option to purchase up to an additional 1,284,796 shares of our common stock, which was exercised in full on July 30, 2014. The offering closed on August 4, 2014. The net proceeds to us from this offering were approximately $42.8 million, after deducting underwriting discounts and commissions and other offering expenses payable by us.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our financing activities for the year ended December 31, 2013 provided net cash of approximately $73,989,000.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On March 14, 2013, we entered into an underwriting agreement relating to the issuance and sale by us of 29,411,765 shares of our common stock. Under the terms of the underwriting agreement, we granted the underwriters a 30-day option to purchase up to an additional 4,411,765 shares of our common stock. On April 12, 2013, the underwriters exercised their option to purchase 1,954,587 shares of our common stock. The net proceeds to us from this offering were approximately $48 million, after deducting underwriting discounts and commissions and other offering expenses.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 64; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">On September 25, 2013, we entered into an underwriting agreement relating to the issuance and sale by us of 13,750,000 shares of our common stock. The net proceeds to us from this offering were approximately $30 million, after deducting underwriting discounts and commissions and other offering expenses payable by us.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In March 2013, we repaid approximately $5 million in notes and credit lines.</p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Critical Accounting Policies and New Accounting Pronouncements</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Critical Accounting Policies<br></i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The preparation of financial statements in accordance with accounting principles generally accepted in the United States, or GAAP, requires us to make estimates and assumptions that affect reported amounts and related disclosures in the financial statements. We consider an accounting estimate to be critical if</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.5in; text-align: left;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">it requires assumptions to be made that were uncertain at the time the estimate was made, and</td>
</tr>
</table>
<p style="margin: 0pt 0 0pt 39pt; text-align: left; text-indent: -3pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.5in; text-align: left;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">changes in the estimate or different estimates that could have been selected could have a material impact on our results of operations or financial condition.</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We base our estimates and judgments on our experience, our current knowledge, our beliefs of what could occur in the future, our observation of trends in the industry, information provided by our customers, and information available from other sources. Actual results may differ from these estimates under different assumptions or conditions. We have identified the following accounting policies and estimates as those that we believe are most critical to our financial condition and results of operations and that require our most subjective and complex judgments in estimating the effect of inherent uncertainties: share-based compensation expense and income taxes.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Revenue Recognition</i>. We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;Our OTC and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 27.5pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i><u>OTC Products</u></i></p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees</p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i><u>Prescription Products</u></i></p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of estimated returns, sales discounts, chargebacks, and customer rebates.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We accept returns of unsalable product from prescription products customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015, we deferred the recognition of revenue on certain arrangements until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 65; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Research and Development Expense.</i> Research and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&#38;D expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Share-Based Compensation.</i> We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718 to value options. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; Equity instruments (&#x201C;instruments&#x201D;) issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, Equity - Based Payments to Non-Employees, or ASC 505. ASC 505 defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We believe that these assumptions are &#x201C;critical accounting estimates&#x201D; because significant changes in the assumptions used to develop the estimates materially affect key financial measures including net income/(loss).</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 66; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Income Taxes.</i> As part of the process of preparing our consolidated financial statements, we are required to estimate income taxes in each of the jurisdictions in which we operate. We determine provision for income taxes using the asset and liability approach to account for income taxes. We record current liability for the estimated taxes payable for the current year. We record deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using the enacted tax rates in effect for the years in which the timing differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of changes in tax rates or tax laws is recognized in the provision for income taxes in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount more-likely-than-not to be realized. Changes in valuation allowances will flow through the statement of operations unless related to deferred tax assets that expire unutilized or are modified through translation, in which case both the deferred tax asset and related valuation allowance are similarly adjusted.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The determination of our provision for income taxes requires significant judgment, the use of estimates, and the interpretation and application of complex tax laws. In the ordinary course of our business, there are transactions and calculations for which the ultimate tax determination is uncertain. In spite of our belief that we have appropriate support for all the positions taken on our tax returns, we acknowledge that certain positions may be successfully challenged by the taxing authorities. We determine the tax benefits more likely than not to be recognized with respect to uncertain tax positions. Although we believe our recorded tax assets and liabilities are reasonable, tax laws and regulations are subject to interpretation and inherent uncertainty; therefore, our assessments can involve both a series of complex judgments about future events and rely on estimates and assumptions. Although we believe these estimates and assumptions are reasonable, the final determination could be materially different than that which is reflected in our provision for income taxes and recorded tax assets and liabilities.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Segment Reporting. </i>We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to our president. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>New Accounting Pronouncements</i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In November 2015, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes. This guidance requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet instead of separating deferred taxes into current and noncurrent amounts. Also, companies will no longer allocate valuation allowances between current and noncurrent deferred tax assets because those allowances also will be classified as noncurrent. For public business entities, the guidance is effective for financial statements issued for annual periods beginning December 15, 2016, and interim periods within those annual periods. Companies can adopt the guidance either prospectively or retrospectively. We adopted&#xA0;this guidance in the fourth quarter of 2015. The adoption of this guidance did not have a material impact on our consolidated financial statements or disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), simplifying the Measurement of Inventory. This guidance requires entities to measure inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM). The guidance applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does not change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM guidance. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Under the new guidance, however, entities will no longer need to calculate other measures of &#x201C;market.&#x201D; The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact of this guidance, if any, on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In June 2015, the FASB issued ASU No. 2015-10, Technical Corrections and Improvements, to correct differences between original guidance and the Accounting Standards Codification, or ASC, clarify the guidance, correct references and make minor improvements affecting a variety of topics. Amendments that the FASB deemed more substantive are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-10 did not have a material effect on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 67; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#x2019;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. We are currently evaluating the impact of ASU 2014-09 on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Off-Balance Sheet Arrangements</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">As of December 31, 2015, 2014, and 2013, we had no off-balance sheet arrangements that have had or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In the ordinary course of business, we enter into agreements with third parties that include indemnification provisions, which, in our judgment, are normal and customary for companies in our industry sector. These agreements are typically with business partners, clinical sites, and suppliers. Pursuant to these agreements, we generally agree to indemnify, hold harmless, and reimburse indemnified parties for losses suffered or incurred by the indemnified parties with respect to our drug candidates, use of such drug candidates, or other actions taken or omitted by us. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. As a result, the estimated fair value of liabilities relating to these provisions is minimal. Accordingly, we have no liabilities recorded for these provisions as of December 31, 2015, 2014, or 2013.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In the normal course of business, we may be confronted with issues or events that may result in a contingent liability. These generally relate to lawsuits, claims, environmental actions or the actions of various regulatory agencies. We consult with counsel and other appropriate experts to assess the claim. If, in our opinion, we have incurred a probable loss as set forth by GAAP, an estimate is made of the loss and the appropriate accounting entries are reflected in our financial statements.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">Effects of Inflation</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-weight: normal;">For each of the fiscal years ended December 31, 2015, 2014, and 2013, our business and operations have not been materially affected by inflation.</font></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 68; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Contractual Obligations</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">A summary of contractual obligations as of December 31, 2015 is as follows:</p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
<td style="padding-bottom: 1pt; font-weight: bold;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center; font-weight: bold;" colspan="10">Payments Due By Period</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: center;" colspan="10">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; width: 39%; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt; width: 1%; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 10%; text-align: center; font-weight: bold;"><b>Total</b></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: center; font-weight: bold;">&#xA0;</td>
<td style="padding-bottom: 1pt; width: 1%; text-align: center; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 1pt; padding-left: 5.4pt; width: 10%; text-align: center; font-weight: bold;">Less than <br> 1 Year</td>
<td style="padding-bottom: 1pt; width: 1%; text-align: center; font-weight: bold;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: center; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 10%; text-align: center; font-weight: bold;"><b>1-3 Years</b></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: center; font-weight: bold;">&#xA0;</td>
<td style="padding-bottom: 1pt; width: 1%; text-align: center; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: center; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 10%; text-align: center; font-weight: bold;"><b>4-5 Years</b></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left; font-weight: bold;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2pt; text-align: left;">Operating Lease Obligations</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">1,389,853</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double;">$</td>
<td style="border-bottom: Black 2pt double; padding-bottom: 2pt; padding-left: 5.4pt; text-align: right;">493,790</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">896,063</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Legal Proceedings</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">From time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations, or cash flows.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><strong>Employment Agreements</strong></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We have entered into&#xA0;employment&#xA0;agreements&#xA0;with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>Seasonality</b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The specialty pharmaceutical industry component of women&#x2019;s health is not subject to seasonal sales fluctuation.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap><b>Item 7A.</b></td>
<td style="text-align: justify;"><b><a name="txmda012_v1"></a>Quantitative and Qualitative Disclosures about Market Risk</b></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We had a cash balance of $64.7 million as of December 31, 2015<font style="color: #252525;">. </font>We hold certain portions of our cash balances in overnight money market placements all of which are fully availale to us to support our cash flow requirements. The primary objective of our investment policy is to preserve principal and maintain proper liquidity to meet operating needs<font style="color: #252525;">. </font>Our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure to any single issue, issuer or type of investment<font style="color: #252525;">. </font>Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates<font style="color: #252525;">. </font>To minimize this risk, we intend to maintain a portfolio that may include cash, cash equivalents and investment securities available-for-sale in a variety of securities which may include money market funds, government and non-government debt securities and commercial paper, all with various maturity dates<font style="color: #252525;">. </font> Due to the low risk profile of our investments, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our portfolio.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 8.</td>
<td style="text-align: justify;"><i><a name="txmda013_v1"></a>Financial Statements and Supplementary Data</i></td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Reference is made to the financial statements, the notes thereto, and the reports thereon, commencing on page F-1 of this Annual Report, which financial statements, notes, and reports are incorporated herein by reference.</p>
<p style="background-color: white; margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 9.</td>
<td style="text-align: justify;"><i><a name="txmda014_v1"></a>Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</i></td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">None.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 69; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 9A.</td>
<td style="text-align: justify;"><i><a name="txmda015_v1"></a>Controls and Procedures</i></td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Evaluation of Disclosure Controls and Procedures</i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">We maintain disclosure controls and procedures designed to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the specified time periods, and that such information is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(f) or 15d-15(f)) as of the end of the period covered by this Annual Report on Form 10-K. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December 31, 2015, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is (i) recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Changes in Internal Control over Financial Reporting</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">There was no change in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Inherent Limitations on Effectiveness of Controls</i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all error and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefit of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, misstatements, errors, and instances of fraud, if any, within our company have been or will be prevented or detected. Further, internal controls may become inadequate as a result of changes in conditions, or through the deterioration of the degree of compliance with policies or procedures.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><i>Management&#x2019;s Annual Report on Internal Control over Financial Reporting</i></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined under Exchange Act Rules 13a-15(f) and 15d-15(f). Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. Internal control over financial reporting includes those policies and procedures that:</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; text-align: left;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;</td>
</tr>
</table>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; text-align: left;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and</td>
</tr>
</table>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in; text-align: left;"><font style="font-family: Symbol;">&#xB7;</font></td>
<td style="text-align: justify;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.</td>
</tr>
</table>
<p style="margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 70 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<p style="margin: 0pt;"></p>
<table style="width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: left;">
<td style="width: 100%; vertical-align: bottom; text-align: center; font-size: 10pt;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt;"></p>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2015. In making this assessment, our management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control&#x2014;Integrated Framework (2013). Management&#x2019;s assessment included an evaluation of the design of our internal control over financial reporting and testing of the operational effectiveness of its internal control over financial reporting. Based on management&#x2019;s assessment, we believe that our internal controls over financial reporting were effective as of December 31, 2015.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The effectiveness of our internal control over financial reporting as of December 31, 2015 has been audited by Grant Thornton LLP, an independent registered public accounting firm, as stated in their Report of Independent Registered Certified Public Accounting Firm on Internal Control Over Financial Reporting as of December 31, 2015, which appears below.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 71 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Board of Directors and Stockholders</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;">TherapeuticsMD, Inc.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We have audited the internal control over financial reporting of TherapeuticsMD, Inc. and subsidiaries (the &#x201C;Company&#x201D;) as of December 31, 2015, based on criteria established in the 2013 <i>Internal Control&#x2014;Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company&#x2019;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#x2019;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#x2019;s internal control over financial reporting based on our audit.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">A company&#x2019;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#x2019;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#x2019;s assets that could have a material effect on the financial statements.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2015, based on criteria established in the 2013 <i>Internal Control&#x2014;Integrated Framework</i> issued by COSO.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated financial statements of the Company as of and for the year ended December 31, 2015, and our report dated February 26, 2016 expressed an unqualified opinion on those financial statements.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">/s/ GRANT THORNTON LLP</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Ft. Lauderdale, Florida</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">February 26, 2016&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 72; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 9B.</td>
<td style="text-align: justify;"><i><a name="txmda016_v1"></a>Other Information</i></td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">None.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: bold 10pt Times New Roman, Times, Serif;"><a name="txmda017_v1"></a>PART III</p>
<p style="margin: 0pt 0; text-align: center; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 10.</td>
<td style="text-align: justify;"><i><a name="txmda018_v1"></a>Directors, Executive Officers, and Corporate Governance</i></td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The information required by this Item relating to our directors and corporate governance is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for our 2016 Annual Meeting of Stockholders.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left; font: bold 10pt Times New Roman, Times, Serif;" nowrap><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Item 11.</b></font></td>
<td style="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif;"><a name="txmda019_v1"></a><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b><i>Executive Compensation</i></b></font></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The information required by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regulation 14A of the Exchange Act for our 2016 Annual Meeting of Stockholders.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 12.</td>
<td style="text-align: justify;"><i><a name="txmda020_v1"></a>Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</i></td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The information required by this Item is incorporated by reference to the definitive Proxy Statement to be filed pursuant to Regulations 14A of the Exchange Act for our 2016 Annual Meeting of Stockholders.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 13.</td>
<td style="text-align: justify;"><i><a name="txmda021_v1"></a>Certain Relationships and Related Transactions, and Director Independence</i></td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The information required by this Item is incorporated herein by reference to the definitive Proxy Statements to be filed pursuant to Regulation 14A of the Exchange Act for our 2016 Annual Meeting of Stockholders.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap>Item 14.</td>
<td style="text-align: justify;"><i><a name="txmda022_v1"></a>Principal Accounting Fees and Services</i></td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The information required by this Item is incorporated herein by reference to the definitive Proxy Statement to be filed pursuant to Regular 14A of the Exchange Act for our 2016 Annual Meeting of Stockholders.</p>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 73; Value: 49 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence -->&#xA0;</p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: center; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: bold 10pt Times New Roman, Times, Serif;"><a name="txmda023_v1"></a>PART IV</p>
<p style="margin: 0pt 0; text-align: center; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 6pt; margin-top: 0; font: bold 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 1in; text-align: left;" nowrap><a name="txmda024_v1"></a>Item 15.</td>
<td style="text-align: justify;"><i>Exhibits and Financial Statement Schedules</i></td>
</tr>
</table>
<p style="margin: 0pt 0; font: bold 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0in;"></td>
<td style="width: 0.5in; text-align: left;">(a)</td>
<td style="text-align: justify;"><b>Financial Statements and Financial Statements Schedules</b></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.5in;">(1)</td>
<td style="text-align: justify;">Financial Statements are listed in the Index to Consolidated Financial Statements on page F-1 of this Annual Report.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.5in;">(2)</td>
<td style="text-align: justify;">No financial statement schedules are included because such schedules are not applicable, are not required, or because required information is included in the consolidated financial statements or notes thereto.</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0in;"></td>
<td style="width: 0.5in; text-align: left;">(b)</td>
<td style="text-align: justify;"><b>Exhibits</b></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="border-bottom: Black 1pt solid; width: 7%; text-align: left; font-weight: bold;"><b>Exhibit</b></td>
<td style="width: 2%; text-align: left; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 14%; text-align: left; font-weight: bold;"><b>Date</b></td>
<td style="width: 2%; text-align: left; font-weight: bold;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 69%; text-align: left; font-weight: bold;"><b>Description</b></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left; font-weight: bold;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">2.1</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">July 6, 2009</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Agreement and Plan of Reorganization among Croff Enterprises, Inc., AMHN Acquisition Corp., America&#x2019;s Minority Health Network, Inc., and the Major Shareholders<sup>(1)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">2.2</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">June 11, 2010</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Agreement and Plan of Reorganization among AMHN, Inc., SHN Acquisition Corp., Spectrum Health Network, Inc., and the Sole Shareholder of Spectrum Health Network, Inc.<sup>(2)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">2.3</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">October 25, 2007</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Croff Enterprises, Inc. Plan of Corporate Division and Reorganization<sup>(3)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">2.4</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">July 18, 2011</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Agreement and Plan of Merger among VitaMedMD, LLC, AMHN, Inc., and VitaMed Acquisition, LLC<sup>(4)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">3.1</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">July 20, 2010</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Articles of Conversion of AMHN, Inc. filed in the State of Nevada<sup>(5)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">3.2</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">July 20, 2010</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Articles of Incorporation of AMHN, Inc. filed in the State of Nevada<sup>(5)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">3.3</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Composite Amended and Restated Articles of Incorporation of the Company, as amended<sup>(6)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">3.4</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Bylaws of AMHN, Inc.<sup>(7)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">3.5</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">December 17, 2015</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">First Amendment to Bylaws of the Company<sup>(8)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">4.1</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Form of Certificate of Common Stock<sup>(9)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.1</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Form of Common Stock Purchase Warrant<sup> (10)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.2*</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Form of Non-Qualified Stock Option Agreement<sup> (10)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: justify;">10.3*</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">n/a</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">Amended and Restated 2012 Stock Incentive Plan<sup>(11)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: justify;">10.4*</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">n/a</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">2009 Long Term Incentive Compensation Plan, as amended<sup>(12)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.5</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">October 23, 2011</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Common Stock Purchase Warrant to Lang Naturals, Inc.<sup>(13)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.6</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">November 3, 2011</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Software License Agreement between vitaMedMD, LLC and Pernix Therapeutics, LLC<sup>(14)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.7</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">February 24, 2012</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Form of Common Stock Purchase Warrant<sup>(15)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.8</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">April 17, 2012</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Master Services Agreement between the Company and Sancilio and Company, Inc.<sup>(16)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.9&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">May 17, 2012</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;"><a href="ex10-9.htm">Consulting Agreement between the Company and Sancilio and Company, Inc.</a></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.10</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">September 26, 2012</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Form of Securities Purchase Agreement<sup> (17)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.11*</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">November 8, 2012</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Form of Employment Agreement<sup>(18) </sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.12</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">January 31, 2013</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Multiple Advance Revolving Credit Note, issued to Plato &#38; Associates, LLC<sup>(19)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.13</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">January 31, 2013</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Common Stock Purchase Warrant, issued to Plato &#38; Associates, LLC<sup>(19)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.14</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">May 7, 2013</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Consulting Agreement between the Company and Sancilio and Company, Inc.<sup> (20)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.15*</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">May 8, 2013</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Agreement to Forfeit Non-Qualified Stock Options between the Company and Robert G. Finizio<sup>(20)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="text-align: left;">10.16</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">May 16, 2013</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">Lease between the Company and 6800 Broken Sound LLC<sup>(21)</sup></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<!-- Field: Page; Sequence: 74 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 0; text-align: left;"><b>Exhibit</b></td>
<td style="text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 0; text-align: left;"><b>Date</b></td>
<td style="text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 0; text-align: left;"><b>Description</b></td>
</tr>
<tr style="vertical-align: top;">
<td style="width: 0.5in;">&#xA0;</td>
<td style="padding-bottom: 0; width: 7%; text-align: left;">10.17</td>
<td style="width: 2%; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; width: 14%; text-align: left;">February 18, 2015</td>
<td style="width: 2%; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; width: 69%; text-align: left;">First Amendment to Lease between the Company and 6800 Broken Sound, LLC<sup>(22) </sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">10.18*</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">December 17, 2015</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">Employment Agreement between the Company and Brian Bernick<sup>(8)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">10.19*</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">December 17, 2015</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">Employment Agreement between the Company and Michael Donegan<sup>(8)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">10.20*</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">December 17, 2015</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">Employment Agreement between the Company and Mitchel Krassan<sup>(8)</sup></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">21.1&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">December 31, 2012</td>
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;"><a href="ex21-1.htm">Subsidiaries of the Company</a></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">23.1&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">February 26, 2016</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;"><a href="ex23-1.htm">Consent of Grant Thornton, LLP</a></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">23.2&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">February 26, 2016</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;"><a href="ex23-2.htm">Consent of Rosenberg Rich Baker Berman &#38; Company</a></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">31.1&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">February 26, 2016</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;"><a href="ex31-1.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended</a></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">31.2&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">February 26, 2016</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;"><a href="ex31-2.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended</a></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">32.1&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">February 26, 2016</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;"><a href="ex32-1.htm">Certification pursuant to U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: justify;">32.2&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">February 26, 2016</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;"><a href="ex32-2.htm">Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">101.INS&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">XBRL Instance Document</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">101.SCH&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">XBRL Taxonomy Extension Schema Document</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">101.CAL&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">XBRL Taxonomy Extension Calculation Linkbase Document</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">101.DEF&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">XBRL Taxonomy Extension Definition Linkbase Instance Document</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">101.LAB&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">XBRL Taxonomy Extension Label Linkbase Instance Document</td>
</tr>
<tr style="vertical-align: top;">
<td>&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">101.PRE&#x2020;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">n/a</td>
<td style="text-align: left;">&#xA0;</td>
<td style="padding-bottom: 0; text-align: left;">XBRL Taxonomy Extension Presentation Linkbase Instance Document</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 3pt; margin-top: 3pt;">
<div style="border-top: Black 1pt solid; width: 20%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 3%; text-align: justify;">*</td>
<td style="width: 97%; text-align: justify;">Indicates a contract with management or compensatory plan or arrangement.</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;">&#x2020;</td>
<td style="text-align: justify;">Filed herewith.</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(1)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 8-K filed with the Commission on July 10, 2009 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(2)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 8-K filed with the Commission on June 14, 2010 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(3)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 10-K for the year ended December 31, 2007 filed with the Commission on May 1, 2008 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(4)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 8-K filed with the Commission on July 21, 2011 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(5)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2010 filed with the Commission on August 3, 2010 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(6)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2015 filed with the Commission on August 7, 2015 and incorporated herein by reference (SEC File No. 001-00100).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(7)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Definitive 14C Information Statement filed with the Commission on June 29, 2010 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(8)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 8-K filed with the Commission on December 22, 2015 and incorporated herein by reference (SEC File No. 001-00100).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(9)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form S-3 filed with the Commission on January 25, 2013 and incorporated hereby by reference (SEC File No. 333-186189).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(10)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 8-K filed with the Commission on October 11, 2011 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(11)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 8-K filed with the Commission on August 22, 2013 and incorporated herein by reference (SEC File No. 001-00100).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(12)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Registration Statement on Form S-8 filed with the Commission on October 15, 2013 and incorporated herein by reference (SEC File No. 333-191730).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(13)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 8-K filed with the Commission on October 24, 2011 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(14)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 10-Q for quarter ended September 30, 2011 filed with the Commission on November 7, 2011 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(15)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 8-K filed with the Commission on February 24, 2012 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(16)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2012 filed with the Commission on August 9, 2012 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(17)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 8-K filed with the Commission on October 2, 2012 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(18)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 10-Q for quarter ended September 30, 2012 filed with the Commission on November 13, 2012 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(19)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 8-K filed with the Commission on February 6, 2013 and incorporated herein by reference (SEC File No. 000-16731).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(20)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 10-Q for quarter ended March 31, 2013 filed with the Commission on May 10, 2013 and incorporated herein by reference (SEC File No. 001-00100).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(21)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 10-Q for quarter ended June 30, 2013 filed with the Commission on August 7, 2013 and incorporated herein by reference (SEC File No. 001-00100).</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><sup>(22)</sup></td>
<td style="text-align: justify;">Filed as an exhibit to Form 10-K for the year ended December 31, 2014 filed with the Commission on March 12, 2015 and incorporated herein by reference (SEC File No. 001-00100).</td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 75; Value: 69 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;"><b>SIGNATURES</b></p>
<p style="margin: 0pt 0 0pt 0.5in; text-align: center; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 55%; text-align: justify;">Date: February 26, 2016</td>
<td style="width: 45%; text-align: justify;"><b>THERAPEUTICSMD, INC.</b></td>
</tr>
<tr style="vertical-align: top; text-align: justify;">
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">&#xA0;</td>
</tr>
<tr style="vertical-align: top; text-align: justify;">
<td style="text-align: justify;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: justify;"><i>/s/ Robert G. Finizio</i></td>
</tr>
<tr style="vertical-align: top; text-align: justify;">
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">Robert G. Finizio</td>
</tr>
<tr style="vertical-align: top; text-align: justify;">
<td style="text-align: justify;">&#xA0;</td>
<td style="text-align: justify;">Chief Executive Officer</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: left; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the date indicated.</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 13%; text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 7%; text-align: center;"><font style="font-size: 10pt;"><b>Signature</b></font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 13%; text-align: center;">&#xA0;</td>
<td style="width: 3%;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 15%; text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 7%; text-align: center;"><font style="font-size: 10pt;"><b>Capacity</b></font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 15%; text-align: center;">&#xA0;</td>
<td style="width: 3%;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 10%; text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 3%; text-align: center;"><font style="font-size: 10pt;"><b>Date</b></font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 10%; text-align: center;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="2">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr>
<td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3"><font style="font-size: 10pt;"><i>/s/ Robert G. Finizio</i></font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">Chief Executive Officer, Director</font><br> <font style="font-size: 10pt;">(Principal Executive Officer)</font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">February 26, 2016</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;">Robert G. Finizio</font></td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr>
<td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3"><font style="font-size: 10pt;"><i>/s/ John C.K. Milligan, IV</i></font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">President, Secretary, Director</font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">February 26, 2016</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;">John C.K. Milligan, IV</font></td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;"><i>/s/ Daniel A. Cartwright</i></font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt;" colspan="3" rowspan="2">
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">Chief Financial Officer, Treasurer</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">(Principal Financial and Accounting Officer)</p>
</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">February 26, 2016</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;">Daniel A. Cartwright</font></td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr>
<td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3"><font style="font-size: 10pt;"><i>/s/ Tommy G. Thompson</i></font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">Chairman</font></td>
<td>&#xA0;</td>
<td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">February 26, 2016</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;">Tommy G. Thompson </font></td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr>
<td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3"><font style="font-size: 10pt;"><i>/s/ Brian Bernick </i></font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">Director</font></td>
<td>&#xA0;</td>
<td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">February 26, 2016</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;">Brian Bernick </font></td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;"><i>/s/ J. Martin Carroll</i></font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">Director</font></td>
<td>&#xA0;</td>
<td style="text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">February 26, 2016</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;">&#xA0;J. Martin Carroll</font></td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="background-color: white;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr style="background-color: white;">
<td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3"><font style="font-size: 10pt;"><i>/s/ Cooper C. Collins</i></font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">Director</font></td>
<td>&#xA0;</td>
<td style="padding-bottom: 12pt; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">February 26, 2016</font></td>
</tr>
<tr style="background-color: white; vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;">Cooper C. Collins</font></td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr style="background-color: white;">
<td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3"><font style="font-size: 10pt;"><i>/s/ Robert V. LaPenta, Jr.</i></font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">Director</font></td>
<td>&#xA0;</td>
<td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">February 26, 2016</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;">Robert V. LaPenta, Jr </font></td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="background-color: white;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr style="background-color: white;">
<td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3"><font style="font-size: 10pt;"><i>/s/ Jules Musing</i></font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">Director</font></td>
<td>&#xA0;</td>
<td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">February 26, 2016</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;">Jules Musing</font></td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="background-color: white;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr>
<td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3"><font style="font-size: 10pt;"><i>/s/ Angus C. Russell</i></font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3"><font style="font-size: 10pt;">Director</font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3"><font style="font-size: 10pt;">February 26, 2016</font></td>
</tr>
<tr>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3"><font style="font-size: 10pt;">Angus C. Russell</font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3">&#xA0;</td>
</tr>
<tr>
<td style="border-bottom: black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: bottom; text-align: center;" colspan="3"><font style="font-size: 10pt;"><i>/s/ Nicholas Segal </i></font></td>
<td>&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">Director</font></td>
<td>&#xA0;</td>
<td style="vertical-align: top; text-align: center;" colspan="3" rowspan="2"><font style="font-size: 10pt;">February 26, 2016</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;" colspan="3"><font style="font-size: 10pt;">Nicholas Segal</font></td>
<td>&#xA0;</td>
<td>&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: left; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 76; Value: 69 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>INDEX TO FINANCIAL STATEMENTS</b></font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 89%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 8%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">Page</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;">Reports of Independent Registered Public Accounting Firms</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">F-2</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;"><a href="#txmdb001_v1">Consolidated Balance Sheets as of December 31, 2015 and 2014</a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">F-4</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;"><a href="#txmdb002_v1">Consolidated Statements of Operations for the years ended December 31, 2015, 2014 and 2013</a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">F-5</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;"><a href="#txmdb003_v1">Consolidated Statements of Stockholders&#x2019; Equity for the years ended December 31, 2015, 2014 and 2013</a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">F-6</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;"><a href="#txmdb004_v1">Consolidated Statements of Cash Flows for the years ended December 31, 2015, 2014 and 2013</a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">F-7</font></td>
</tr>
<tr style="vertical-align: top;">
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: justify;"><font style="font: 10pt Times New Roman, Times, Serif;"><a href="#txmdb005_v1">Notes to Consolidated Financial Statements</a></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">F-8</font></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></font></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 77; Options: NewSection; Value: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;<font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>&#xA0;</b></font></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 72%;">
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
</td>
<td style="width: 3%; line-height: 9pt; font-size: 10pt; font-weight: bold;">&#xA0;</td>
<td style="width: 25%;">
<p style="margin: 0; font: bold 10pt/9pt Times New Roman, Times, Serif;"></p>
</td>
</tr>
</table>
<p style="margin: 0; font: 10pt/14pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">Board of Directors and Stockholders</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;">TherapeuticsMD, Inc.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We have audited the accompanying consolidated balance sheet of TherapeuticsMD, Inc. and subsidiaries (the &#x201C;Company&#x201D;) as of December 31, 2015, and the related consolidated statements of operations, stockholders&#x2019; equity, and cash flows for the year ended December 31, 2015. These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on these financial statements based on our audit.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of TherapeuticsMD, Inc. and subsidiaries as of December 31, 2015, and the results of their operations and their cash flows for the year ended December 31, 2015 in conformity with accounting principles generally accepted in the United States of America.</p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the Company&#x2019;s internal control over financial reporting as of December 31, 2015, based on criteria established in the 2013 <i>Internal Control&#x2014;Integrated Framework</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated February 26, 2016 expressed an unqualified opinion thereon<font style="color: blue;">.</font></p>
<p style="margin: 0 0 8pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">/s/ GRANT THORNTON LLP</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Fort Lauderdale, Florida</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">February 26, 2016</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b></b></font></p>
<!-- Field: Page; Sequence: 78 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></font></p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></p>
<p style="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">&#xA0;</font></p>
<p style="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">&#xA0;</font></p>
<p style="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">To the Board of Directors and</font></p>
<p style="margin: 0; text-align: left; text-indent: 0; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">Stockholders of TherapeuticsMD, Inc.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">We have audited the accompanying consolidated balance sheets of TherapeuticsMD, Inc. as of December 31, 2014, and the related consolidated statements of operations, stockholders&#x2019; equity, and cash flows for each of the years in the two year period ended December 31, 2014. These financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on these financial statements based on our audits.</font></p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of TherapeuticsMD, Inc. as of December 31, 2014, and the results of its operations and its cash flows for each of the years in the two year period ended December 31, 2014, in conformity with accounting principles generally accepted in the United States of America. </font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">/s/Rosenberg Rich Baker Berman &#38; Company</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">Somerset, New Jersey</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">March 12, 2015</font></p>
<p style="margin: 0; font: 10pt/normal Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 79 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></font></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></font><br> <font style="font: 10pt Times New Roman, Times, Serif;"><b><a name="txmdb001_v1"></a>CONSOLIDATED BALANCE SHEETS</b></font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; width: 75%; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 8%; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 8%; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="5"><font style="font: 10pt Times New Roman, Times, Serif;">December 31,</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">2015</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">2014</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-align: center;" colspan="7"><font style="font: 10pt Times New Roman, Times, Serif;">ASSETS</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Current Assets:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Cash</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">64,706,355</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">51,361,607</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Accounts receivable, net of allowance for doubtful accounts of $81,910 and $59,753, respectively</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">3,049,715</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">2,154,217</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Inventory</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">690,153</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,182,113</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Other current assets</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">2,233,897</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,537,407</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Total current assets</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">70,680,120</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">56,235,344</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Fixed assets, net</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">198,592</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">63,293</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Other Assets:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Intangible assets, net</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,615,251</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,228,588</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Prepaid expense</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,109,883</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,427,263</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Security deposit</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">125,000</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">125,000</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Total other assets</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">2,850,134</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">2,780,851</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 34.55pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Total assets</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">73,728,846</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">59,079,488</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt;" colspan="7"><font style="font: 10pt Times New Roman, Times, Serif;">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Current Liabilities:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Accounts payable</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">3,126,174</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">6,327,129</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Other current liabilities</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">7,539,526</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">3,840,639</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Deferred revenue</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">522,613</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Total current liabilities</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">10,665,700</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">10,690,381</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Commitments and Contingencies - See Note 14</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Stockholders&#x2019; Equity:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Common stock - par value $0.001; 350,000,000 and 250,000,000 shares authorized; 177,928,041 and 156,097,019 issued and outstanding, respectively</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">177,928</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">156,097</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Additional paid-in capital</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">282,712,078</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">182,982,846</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Accumulated deficit</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(219,826,860</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(134,749,836</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Total stockholders&#x2019; equity</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">63,063,146</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">48,389,107</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 34.55pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Total liabilities and stockholders&#x2019; equity</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">73,728,846</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">59,079,488</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">The accompanying footnotes are an integral part of these consolidated financial statements.</font></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 80 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></font><br> <font style="font: 10pt Times New Roman, Times, Serif;"><b><a name="txmdb002_v1"></a>CONSOLIDATED STATEMENTS OF OPERATIONS</b></font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; width: 63%; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 8%; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 8%; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 8%; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="8"><font style="font: 10pt Times New Roman, Times, Serif;">Year Ended December 31,</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">2015</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">2014</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">2013</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Revenues, net</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">20,142,898</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">15,026,219</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">8,775,598</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Cost of goods sold</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">4,506,673</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">3,671,803</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,959,597</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Gross profit</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">15,636,225</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">11,354,416</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">6,816,001</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Operating expenses:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Sales, general, and administrative</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">28,721,236</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">22,124,072</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">19,014,837</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Research and development</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">72,042,774</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">43,218,938</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">13,551,263</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Depreciation and amortization</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">62,400</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">52,467</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">58,145</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Total operating expenses</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">100,826,410</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">65,395,477</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">32,624,245</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Operating loss</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(85,190,185</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(54,041,061</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(25,808,244</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Other income and (expenses)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Miscellaneous income, net</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">95,719</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">46,569</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">34,544</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Interest income</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">17,442</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">37,309</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">27,234</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Financing costs</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(260,027</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(1,503,922</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Interest expense</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(1,165,981</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Loan guaranty costs</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(2,944</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Total other income (expense)<br></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">113,161</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(176,149</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(2,611,069</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Loss before income taxes</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(85,077,024</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(54,217,210</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(28,419,313</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Provision for income taxes</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Net loss</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(85,077,024</font></td>
<td style="padding-bottom: 2pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(54,217,210</font></td>
<td style="padding-bottom: 2pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(28,419,313</font></td>
<td style="padding-bottom: 2pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Loss per share, basic and diluted:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Net loss per share, basic and diluted</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(0.49</font></td>
<td style="padding-bottom: 2pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(0.36</font></td>
<td style="padding-bottom: 2pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(0.22</font></td>
<td style="padding-bottom: 2pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Weighted average number of common shares outstanding, basic and diluted</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">173,174,229</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">149,727,228</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">127,569,731</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">The accompanying footnotes are an integral part of these consolidated financial statements.</font></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 81; Value: 4 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></font><br> <font style="font: 10pt Times New Roman, Times, Serif;"><b><a name="txmdb003_v1"></a>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#x2019; EQUITY</b></font><br> <font style="font: 10pt Times New Roman, Times, Serif;"><b>FOR THE YEARS ENDED DECEMBER 31, 2015, 2014 AND 2013</b></font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; width: 39%; text-align: center; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 8%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 8%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 8%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 8%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 8%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">Additional</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="5"><font style="font: 10pt Times New Roman, Times, Serif;">Common Stock</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">Paid in</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">Accumulated</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">Shares</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">Amount</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">Capital</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">Deficit</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">Total</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Balance, January 1, 2013</b></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">99,784,982</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">99,785</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">50,580,400</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(52,113,313</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(1,433,128</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Shares issued in offerings, net of cost</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">45,116,352</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">45,117</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">78,605,236</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">78,650,353</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Shares issued for exercise of options, net</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">75,423</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">75</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">30,835</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">30,910</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Share-based compensation</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">3,254,083</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">3,254,083</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Warrants issued for financing costs</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,711,956</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,711,956</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Warrants issued for services</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">867,262</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">867,262</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Warrants issued as compensation-related party</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">36,284</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">36,284</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Net loss</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(28,419,313</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(28,419,313</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Balance, December 31, 2013</b></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">144,976,757</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">144,977</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">135,086,056</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(80,532,626</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">54,698,407</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Shares issued in offerings, net of cost</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">9,850,106</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">9,850</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">42,761,503</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">42,771,353</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Shares issued for exercise of options, net</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">854,573</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">855</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">344,891</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">345,746</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Shares issued for exercise of warrants, net</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">365,583</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">365</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">180,635</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">181,000</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Shares issued for exercise of restricted stock units</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">50,000</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">50</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(50</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Share-based compensation</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">4,609,811</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">4,609,811</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Net loss</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(54,217,210</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(54,217,210</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Balance, December 31, 2014</b></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">156,097,019</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">156,097</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">182,982,846</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(134,749,836</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">48,389,107</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Shares issued in offerings, net of cost</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">20,040,359</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">20,040</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">91,354,609</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">91,374,649</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Shares issued for exercise of options, net</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">612,981</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">613</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,231,966</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,232,579</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Shares issued for exercise of warrants, net</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,177,682</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,178</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">364,822</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">366,000</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Share-based compensation</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">6,777,835</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">6,777,835</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Net loss</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(85,077,024</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(85,077,024</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>Balance, December 31, 2015</b></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">177,928,041</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">177,928</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">282,712,078</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(219,826,860</font></td>
<td style="padding-bottom: 2pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">63,063,146</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">The accompanying footnotes are an integral part of these consolidated financial statements.</font></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 82; Value: 4 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></font><br> <font style="font: 10pt Times New Roman, Times, Serif;"><b><a name="txmdb004_v1"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></font></p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; width: 57%; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 10%; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 10%; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 3%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 10%; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="width: 1%;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="8"><font style="font: 10pt Times New Roman, Times, Serif;">Year Ended December, 31,</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-align: center; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">2015</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">2014</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2"><font style="font: 10pt Times New Roman, Times, Serif;">2013</font></td>
<td style="text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>CASH FLOWS FROM OPERATING ACTIVITIES</b></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Net loss</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(85,077,024</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(54,217,210</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(28,419,313</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 34.55pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Adjustments to reconcile net loss to net cash used in operating activities:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.6in; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Depreciation</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">29,959</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">28,987</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">47,883</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.6in; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Amortization of intangible assets</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">32,441</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">23,480</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">10,262</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.6in; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Provision for (recovery of) doubtful accounts</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">22,157</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(5,436</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(15,493</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.6in; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Amortization of debt discount</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,102,680</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.6in; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Share-based compensation</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">7,189,699</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">4,970,312</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">3,844,155</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.6in; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Amortization of deferred financing costs</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">260,027</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,451,934</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.6in; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Loan guaranty costs</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">2,944</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.6in; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Changes in operating assets and liabilities:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 51.85pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Accounts receivable</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(917,656</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(458,028</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(1,068,619</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 51.85pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Inventory</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">491,960</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(138,495</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">571,592</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 51.85pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Other current assets</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(773,532</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">680,281</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(1,386,319</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 51.85pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Other assets</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(17,442</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(37,309</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(565,706</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 51.85pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Accounts payable</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(3,200,955</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">4,212,912</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">472,851</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 51.85pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Deferred revenue</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(522,613</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(1,079,967</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">457,828</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 51.85pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Other current liabilities</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">3,698,887</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">239,450</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">2,875,320</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 51.85pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Other liabilities</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(150,068</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Net cash used in operating activities</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(79,044,119</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(45,520,996</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(20,768,069</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>CASH FLOWS FROM INVESTING ACTIVITIES</b></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Patent costs</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(419,104</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(586,480</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(439,034</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Purchase of fixed assets</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(165,257</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(30,962</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(40,790</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Refund (payment) of security deposit</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">10,686</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(103,737</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Net cash used in investing activities</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(584,361</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(606,756</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(583,561</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;"><b>CASH FLOWS FROM FINANCING ACTIVITIES</b></font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Proceeds from sale of common stock, net of costs</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">91,374,649</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">42,771,353</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">78,650,353</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Proceeds from exercise of options</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,232,579</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">345,746</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">30,910</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Proceeds from exercise of warrants</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">366,000</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">181,000</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Proceeds bank line of credit</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">500,000</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Repayment of bank line of credit</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(500,000</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 25.9pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Repayment of notes payable</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(4,691,847</font></td>
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Net cash provided by financing activities</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">92,973,228</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">43,298,099</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">73,989,416</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Increase (decrease) in cash</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">13,344,748</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">(2,829,653</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">)</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">52,637,786</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Cash, beginning of period</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">51,361,607</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">54,191,260</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 1pt solid; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,553,474</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Cash, end of period</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">64,706,355</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">51,361,607</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">54,191,260</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 8.65pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center;" colspan="10"><font style="font: 10pt Times New Roman, Times, Serif;">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;" colspan="10">&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Cash paid for interest</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">212,853</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Cash paid for income taxes</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center;" colspan="10">&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: center;" colspan="10"><font style="font: 10pt Times New Roman, Times, Serif;">SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: center;" colspan="10">&#xA0;</td>
<td>&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Warrants issued for financing</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1,711,956</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 17.3pt; text-indent: -8.65pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Warrants issued for services</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
<td style="border-bottom: Black 2pt double;"><font style="font: 10pt Times New Roman, Times, Serif;">$</font></td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">462,196</font></td>
<td><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">The accompanying footnotes are an integral part of these consolidated financial statements.</font></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p>
<!-- Field: Page; Sequence: 83; Value: 4 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-bottom: 12pt; margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b> <br><b><a name="txmdb005_v1"></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 1 &#x2013; THE COMPANY</u></b></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as &#x201C;our company,&#x201D; &#x201C;we,&#x201D; &#x201C;our,&#x201D; or &#x201C;us.&#x201D;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Nature of Business</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We are a women&#x2019;s health care product company focused on creating and commercializing products targeted exclusively for women. As of the date of these consolidated financial statements, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of our advanced hormone therapy pharmaceutical products. The drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: bold 11pt Times New Roman,serif;"><font style="letter-spacing: -0.15pt;"><u>NOTE 2 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></font></p>
<p style="margin: 0pt 0; text-align: justify; font: bold 11pt Times New Roman,serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><u>Principles of Consolidation</u></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed, BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-weight: normal;"><u>Cash</u></font></p>
<p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-weight: normal;">We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation (the &#x201C;FDIC&#x201D;) insured limits of $250,000 per bank. We have never experienced any losses related to these funds.</font></p>
<p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Trade Accounts Receivable and Allowance for Doubtful Accounts</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. <font style="color: #252525;">To the extent data we use to calculate these estimates does not accurately reflect bad debts; adjustments to these reserves may be </font>required.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 84 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b><br> <b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: -0.15pt;"><u>Inventories</u></font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: -0.15pt;">Inventories represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or market using the average-cost method. Any costs of manufacturing the prescription products associated with the deferred revenue (as discussed in Revenue Recognition) prior to January 1 , 2015, were recorded as deferred costs and included in inventory, until such time as the related deferred revenue was recognized. </font>We review our inventory for excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product improvements rendering previous versions obsolete.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: -0.15pt;"><i><u>Pre-Launch Inventory</u></i></font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: -0.15pt;">Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research and development expenses during the period the costs are incurred. We have not capitalized any pre-launch inventory to date.</font></p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Fixed Assets</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expenses as incurred. <font style="letter-spacing: -0.15pt;">We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years.</font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We capitalize software and&#xA0;software&#xA0;development&#xA0;costs&#xA0;incurred to create and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize&#xA0;software development&#xA0;costs&#xA0;when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally five to seven years.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: -0.15pt;"><u>Intangible </u></font><u>Assets</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: -0.15pt;"><i><u>Patents and Trademarks</u></i></font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: -0.15pt;">We have adopted the provisions of </font>Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, <font style="letter-spacing: -0.15pt;">350, <i>Intangibles - Goodwill and Other</i>,<i> </i>or </font>ASC 350<font style="letter-spacing: -0.15pt;">. Capitalized patent costs, net of accumulated amortization, include legal costs incurred for patent applications. </font>In accordance with ASC 350, <font style="letter-spacing: -0.15pt;">once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, 2015, we had 14 issued patents (See Note 7). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.</font></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 85; Value: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b><br> <b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Impairment of Long-Lived Assets</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol; font-size: 10pt;">&#xB7;</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">significant declines in an asset&#x2019;s market price;</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;"></p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol; font-size: 10pt;">&#xB7;</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">significant deterioration in an asset&#x2019;s physical condition;</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;"></p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol; font-size: 10pt;">&#xB7;</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">significant changes in the nature or extent of an asset&#x2019;s use or operation;</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;"></p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol; font-size: 10pt;">&#xB7;</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">significant adverse changes in the business climate that could impact an asset&#x2019;s value, including adverse actions or assessments by regulators; </font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;"></p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol; font-size: 10pt;">&#xB7;</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;"></p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol; font-size: 10pt;">&#xB7;</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset&#x2019;s use; and</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;"></p>
<table style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.25in;"></td>
<td style="width: 0.25in;"><font style="font-family: Symbol; font-size: 10pt;">&#xB7;</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 12pt Times New Roman,serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#x2019;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#x2019; fair value and respective carrying values. We determine the fair value of the assets using an &#x201C;income approach&#x201D; based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of long-lived assets to be held and used during the years ended December 31, 2015, 2014 and 2013.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We perform impairment tests for intangible&#xA0;assets&#xA0;with&#xA0;indefinite&#xA0;useful&#xA0;lives&#xA0;annually, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. There was no impairment of indefinite lived intangible assets during the years ended December 31, 2015, 2014 and 2013.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 86; Value: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b><br> <b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Fair Value of Financial Instruments</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Our financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <i>Fair Value Measurements. </i> The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<table style="margin-bottom: 0pt; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.75in; text-align: left;"><b>Level 1</b></td>
<td style="text-align: justify;">unadjusted quoted prices in active markets for identical assets or liabilities;</td>
</tr>
</table>
<table style="margin-bottom: 0pt; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.75in; text-align: left;"><b>Level 2</b></td>
<td style="text-align: justify;">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td>
</tr>
</table>
<p style="margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="margin-bottom: 0pt; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top; text-align: justify;">
<td style="width: 0.5in;"></td>
<td style="width: 0.75in; text-align: left;"><b>Level 3</b></td>
<td style="text-align: justify;">unobservable inputs for the asset or liability.</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">At December 31, 2015 and 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. There was no impairment of intangible assets during the years ended December 31, 2015, 2014 and 2013.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Income Taxes</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In accordance with ASC 740, <i>Income Taxes</i>, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2015 and 2014, we had no tax positions relating to open tax returns that were considered to be uncertain.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Our tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after 2012 are subject to review.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 87; Value: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b><br> <b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><u>Share-Based Compensation</u></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 12pt Times New Roman,serif;"><font style="font-size: 10pt;">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718 to value options. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.</font><font style="font-size: 10pt;"> </font><font style="font-size: 10pt;"> </font></p>
<p style="margin: 0pt 0; text-align: justify; font: 12pt Times New Roman,serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Equity instruments (&#x201C;instruments&#x201D;) issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, <i>Equity - Based Payments to Non-Employees</i>,<i> </i>or ASC 505<i>. </i>ASC 505<i> </i>defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Debt Discounts</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Costs incurred from parties that are providing long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based on the relative fair value of the debt and warrants to the total proceeds. We amortize discounts over the life of the related debt using the effective interest rate method.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Revenue Recognition</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 88; Value: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b><br> <b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Our over-the-counter (OTC) and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note 13. There are no major external customers for our OTC prenatal vitamin or other products.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>OTC Products</u></i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Prescription Products</u></i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and customer rebates.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We accept returns of unsalable prescription products from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015, we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Segment Reporting</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 89; Value: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b><br> <b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Shipping and Handling Costs</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: -0.15pt;"><u>Advertising Costs</u></font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We expense advertising costs when incurred. Advertising costs were $792,574, $698,871 and $11,739 during the years ended December 31, 2015, 2014 and 2013, respectively.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Research and Development Expenses</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Research and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities are capitalized, and were $1,138,073 at December 31, 2015, of which $1,009,175 was included in other current assets and $128,898 was included in long term prepaid expense on the accompanying consolidated balance sheets. Advance payments to be expensed in future R&#38;D activities were $1,175,082 at December 31, 2014, of which $711,362 was included in other current assets and $463,720 was included in long term prepaid expense on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&#38;D expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Earnings Per Share</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We calculate earnings per share, or EPS, in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 90; Value: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b><br> <b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="10">As of December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2013</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 35%; text-align: justify;">Stock options</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 12%; text-align: right;">20,725,325</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 12%; text-align: right;">16,792,443</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 12%; text-align: right;">15,632,742</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;">Warrants</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">12,722,431</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">13,927,916</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">14,293,499</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: right;">33,447,756</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: right;">30,720,359</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: right;">29,926,241</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Subsequent to December 31, 2015, we issued 17,424,242 shares of our Common Stock at a public offering price of $8.25 per share. In January 2016, certain individuals exercised stock options to purchase 281,657 shares of our Common Stock for approximately $758,000 in cash. In addition, warrants to purchase 500,000 shares of our Common Stock were exercised for approximately $1,285,000 in cash. See Note 16 - Subsequent Events for more details.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><u>Concentration of Credit Risk and other Risks and Uncertainties </u></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Financial instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. The Company has not experienced any historical losses on its deposits of cash.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Concentration of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacies. Credit is extended to our customers based on an evaluation of a customer&#x2019;s financial condition, and collateral is not required.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Use of Estimates</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Reclassifications</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u></u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Certain 2014 and 2013 amounts have been reclassified to conform to current year presentation.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Recently Issued Accounting Pronouncements</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 12pt Times New Roman,serif;"><font style="font-size: 10pt;">In November 2015, the FASB issued Accounting Standards Update, or ASU, No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred Taxes. This guidance requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet instead of separating deferred taxes into current and noncurrent amounts. Also, companies will no longer allocate valuation allowances between current and noncurrent deferred tax assets because those allowances also will be classified as noncurrent. For public business entities, the guidance is effective for financial statements issued for annual periods beginning December 15, 2016, and interim periods within those annual periods. Companies can adopt the guidance either prospectively or retrospectively. We adopted</font>&#xA0;<font style="font-size: 10pt;">this guidance in the fourth quarter of 2015. The adoption of this guidance did not have a material impact on our consolidated financial statements or disclosures.</font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 12pt Times New Roman,serif;"></p>
<!-- Field: Page; Sequence: 91; Value: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b><br> <b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman,serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), simplifying the Measurement of Inventory. This guidance requires entities to measure inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM). The guidance applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does not change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM guidance. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Under the new guidance, however, entities will no longer need to calculate other measures of &#x201C;market.&#x201D; The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact of this guidance, if any, on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In June 2015, the FASB issued ASU No. 2015-10, Technical Corrections and Improvements, to correct differences between original guidance and the ASC clarify the guidance, correct references and make minor improvements affecting a variety of topics. Amendments that the FASB deemed more substantive are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-10 did not have a material effect on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#x2019;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. We are currently evaluating the impact of ASU 2014-09 on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 92; Value: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b><br> <b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b>&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 3 &#x2013; INVENTORY</u></b></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">Inventory consists of the following:</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 70%; text-align: justify;">Finished product</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">661,167</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">874,294</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Raw material</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">28,986</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">155,341</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;">Deferred costs</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">152,478</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left;">TOTAL INVENTORY</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">690,153</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">1,182,113</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 4 &#x2013; OTHER CURRENT ASSETS</u></b></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Other current assets consist of the following:</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify; font-size: 12pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify; font-size: 12pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 70%; text-align: justify;">Prepaid insurance</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">695,421</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">394,878</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Prepaid research and development costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">674,353</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">299,498</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Other prepaid costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">369,812</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">181,186</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Prepaid consulting</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">334,822</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">411,864</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Prepaid vendor deposits</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">159,489</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left;">Other receivables-related party (Note 12)</td>
<td style="padding-bottom: 1pt; font-size: 12pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left; font-size: 12pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right; font-size: 12pt;">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font-size: 12pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">249,981</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left;">TOTAL OTHER CURRENT ASSETS</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">2,233,897</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">1,537,407</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 5 &#x2013; FIXED ASSETS, NET</u></b></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Fixed assets, net consist of the following:</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify; font-size: 12pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify; font-size: 12pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 70%; text-align: justify;">Equipment</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">132,150</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 12%; text-align: right;">132,150</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Accounting system in process</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">149,699</td>
<td style="text-align: left;">&#xA0;</td>
<td style="font-size: 12pt;">&#xA0;</td>
<td style="text-align: left; font-size: 12pt;">&#xA0;</td>
<td style="text-align: right; font-size: 12pt;">&#x2014;</td>
<td style="text-align: left; font-size: 12pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;">Furniture and fixtures</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">69,454</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">53,895</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify; font-size: 12pt;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">351,303</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">186,045</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;">Accumulated depreciation</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(152,711</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(122,752</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left;">TOTAL FIXED ASSETS, NET</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">198,592</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">63,293</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Depreciation expense for the years ended December 31, 2015, 2014, and 2013 was $29,959, $28,987 and $47,883, respectively.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 93; Value: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin-bottom: 0pt; margin-top: 0pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p>
</div>
<div style="margin-bottom: 6pt; margin-top: 6pt; page-break-before: always;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 6 &#x2013;PREPAID EXPENSE</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Prepaid expense (long-term) consists of the following:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 95%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 74%; text-align: justify;">Prepaid manufacturing costs</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">980,985</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">963,543</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;">Prepaid research and development&#xA0;&#xA0;costs</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">128,898</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">463,720</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;TOTAL PREPAID EXPENSE</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">1,109,883</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">1,427,263</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;&#xA0;</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 7 &#x2013; INTANGIBLE ASSETS, NET</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2015 and 2014:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="14">December 31, 2015</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Gross <br> Carrying <br> Amount</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Accumulated Amortization</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Net <br>Amount</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted- <br> Average Remaining Amortization <br> Period (yrs.)</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">Amortizable intangible assets:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.125in; width: 48%; text-align: left;">OPERA<sup>&#xAE;</sup> software patent</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">31,951</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">(4,493</td>
<td style="width: 1%; text-align: left;">)</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">27,458</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">13.75</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.125in; text-align: left;">Development costs of corporate website</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">91,743</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(91,743</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.125in; text-align: left;">Approved hormone therapy drug candidate patents</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">705,752</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(49,845</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">655,907</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">17</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.125in; text-align: left;">Hormone therapy drug candidate patents (in process)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">774,165</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">774,165</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td>Non-amortizable intangible assets:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.125in;">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">157,721</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">157,721</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.25in;">Total</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">1,761,332</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(146,081</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">1,615,251</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<!-- Field: Page; Sequence: 94 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="14">December 31, 2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Gross <br> Carrying <br> Amount</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Accumulated Amortization</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Net <br>Amount</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted- <br> Average Remaining Amortization <br> Period (yrs.)</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="text-align: left;">Amortizable intangible assets:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.125in; width: 48%; text-align: left;">OPERA<sup>&#xAE;</sup> software patent</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">31,951</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">(2,496</td>
<td style="width: 1%; text-align: left;">)</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">29,455</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">14.75</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.125in; text-align: left;">Development costs of corporate website</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">91,743</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(91,743</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.125in; text-align: left;">Approved hormone therapy drug candidate patents</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">439,184</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(19,401</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">419,783</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">18</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.125in; text-align: left;">Hormone therapy drug candidate patents (in process)</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">675,982</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">675,982</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Non-amortizable intangible assets:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 0.125in; text-align: left;">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">103,368</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">103,368</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 0.25in;">Total</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">1,342,228</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">(113,640</td>
<td style="padding-bottom: 2pt; text-align: left;">)</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">1,228,588</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">We amortize the approved hormone therapy drug candidate patents using straight-line method over the estimated useful life of approximately 20 years, which is the life of intellectual property patents.. As of December 31, 2015, the remaining life related to OPERA&#xAE; patent was approximately 14 years and the remaining life related to the approved hormone therapy drug candidate patents was approximately 17 years. During the years ended December 31, 2015 and 2014, there was no impairment recognized related to intangible assets.</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">&#xA0;</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">In addition to numerous pending patent applications, as of December 31, 2015, we had fourteen issued patents, including:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;"></font></p>
<p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Symbol;">&#xB7;</font><font style="font-family: Times New Roman, Times, Serif;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; <font style="background-color: white;">12 utility patents that relate to our combination progesterone and estradiol product candidates, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa and South Korea.</font></font></p>
<p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Symbol;">&#xB7;</font><font style="font-family: Times New Roman, Times, Serif;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; <font style="background-color: white;">one utility patent that relates to TX-004HR, our applicator-free vaginal estradiol softgel product candidate, which establishes an important intellectual property foundation for TX-004HR, is owned by us and is a U.S. jurisdiction patent with an expiration date in 2033. We have pending patent applications with respect to this patent in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea.</font></font></p>
<p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Symbol;">&#xB7;</font><font style="font-family: Times New Roman, Times, Serif;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; <font style="background-color: white;">one utility patent that relates to our OPERA&#xAE; information technology platform, which is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029.</font>&#xA0;&#xA0;&#xA0;&#xA0;</font></p>
<p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif;"></font></p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<!-- Field: Page; Sequence: 95; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif;">&#xA0; <font style="background-color: white;">&#xA0;</font></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">Amortization expense was $32,441, $23,480, and $10,262 for the years ended December 31, 2015, 2014, and 2013, respectively. Estimated amortization expense for the next five years is as follows:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<table align="CENTER" style="width: 30%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Year Ending <br> December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Estimated <br> Amortization</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 15%; text-align: right;">2016</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">40,580</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">2017</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">40,580</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">2018</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">40,580</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">2019</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">40,580</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">2020</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">40,580</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 8 &#x2013; OTHER CURRENT LIABILITIES</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">Other current liabilities consist of the following:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="6">December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 74%; text-align: justify;">Accrued clinical trial costs</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">3,725,377</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">1,706,542</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Accrued payroll, bonuses and commission costs</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">2,108,143</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">814,205</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Accrued compensated absences</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">562,096</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">442,430</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Other accrued expenses</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">546,264</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">185,965</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Allowance for coupons and returns</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">224,300</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">90,446</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Accrued legal and accounting expense</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">210,309</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">276,470</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Accrued rent</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">83,527</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">91,368</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: justify;">Accrued royalties</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">46,851</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">72,710</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify;">Allowance for wholesale distributor fees</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">32,659</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">160,503</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left;">TOTAL OTHER CURRENT LIABILITIES</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">7,539,526</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">3,840,639</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 9 &#x2013; NOTES PAYABLE</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Issuance and Payment of Multiple Advance Revolving Credit Note</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">On January 31, 2013, we entered into a business loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the Revolving Credit Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal amount, at a stated interest rate of 6% per annum. Plato was able to make advances to us from time to time under the Revolving Credit Note at our request, which advances were of a revolving nature and were able to be made, repaid, and made from time to time. Interest payments were due and payable on the tenth day following the end of each calendar quarter in which any interest was accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the Revolving Credit Note, together with all accrued interest and other amounts payable under the Revolving Credit Note, if any, was due and payable on February 24, 2014. The Revolving Credit Note was secured by substantially all of our assets. On each of February 25 and March 13, 2013, $200,000 was drawn against the Revolving Credit Note. On March 21, 2013, we repaid $401,085, which included accrued interest, and there was no balance outstanding under the Revolving Credit Note as of December 31, 2013 and February 24, 2014 when it expired. As additional consideration for the Revolving Credit Note, we granted to Plato a warrant to purchase 1,250,000 shares of our Common Stock at an exercise price of $3.20 per share (See Note 10).</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<!-- Field: Page; Sequence: 96; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 10 &#x2013; STOCKHOLDERS&#x2019; EQUITY</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Preferred Stock</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">At December 31, 2015, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred stock were issued or outstanding.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Common Stock</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">At December 31, 2015, we had 350,000,000 shares of Common Stock authorized for issuance, of which 177,928,041 shares of our Common Stock were issued and outstanding. During the year ended December 31, 2015, our stockholders&#x2019; approved an amendment to our articles of incorporation to increase the number of authorized shares of Common Stock from 250,000,000 to 350,000,000.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><i><u>Issuances During 2015</u></i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">On July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus&#xA0;&#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July&#xA0;15, 2015 and we issued 4,423,077 shares of our Common Stock.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our Common Stock.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2015, certain individuals exercised stock options to purchase 612,867 shares of Common Stock for $1,232,579 in cash. Also during the same period, stock options to purchase 417 shares of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein 114 shares of Common Stock were issued.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Subsequent to December 31, 2015, we issued 17,424,242 shares of our Common Stock in an underwritten public offering at a public offering price of $8.25 per share. In January 2016, certain individuals exercised stock options to purchase 281,657 shares of our Common Stock for approximately $758,000 in cash. In addition, warrants to purchase 500,000 shares of our Common Stock were exercised for approximately $1,285,000 in cash. See Note 16 - Subsequent Events for more details.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<!-- Field: Page; Sequence: 97; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Issuances During 2014</u></i></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">On July 29, 2014, we entered into an underwriting agreement with Goldman Sachs &#38; Co, or Goldman Sachs, as the representative of the underwriters named therein, or the Goldman Sachs Underwriters, relating to an underwritten public offering of 8,565,310 shares of Common Stock. The price to the public in the offering was $4.67 per share. Under the terms of the underwriting agreement, we granted the Goldman Sachs Underwriters a 30-day option to purchase up to an additional 1,284,796 shares of Common Stock. On July 30, 2014, the Goldman Sachs Underwriters exercised their option to purchase the additional 1,284,796 shares of Common Stock. Net proceeds from this offering were approximately $42.8 million, after deducting underwriting discounts and commissions and other offering expenses. The offering closed on August 4, 2014 and we issued 9,850,106 shares of our Common Stock.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2014, certain individuals exercised stock options to purchase 860,800 shares of our Common Stock. Stock options to purchase shares of our Common Stock were exercised as follows: (i) 724,193 options for $345,746 in cash and (ii) 136,607 options, pursuant to the stock options&#x2019; cashless provision, wherein 130,380 shares of Common Stock were issued. In addition, during 2014, we issued 50,000 shares of Common Stock to an employee upon the vesting of restricted stock units that were granted in December 2013.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i><u>Issuances During 2013</u></i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">On March 14, 2013, we entered into an underwriting agreement with Jefferies LLC as the representative of the underwriters named therein, or the Jefferies Underwriters, relating to the issuance and sale of 29,411,765 shares of our Common Stock. The price to the public in the offering was $1.70 per share. In addition, under the terms of the underwriting agreement, we granted the Jefferies Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of our Common Stock. The offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters exercised their option to purchase an additional 1,954,587 shares of our Common Stock, which were issued on April 18, 2013. The net proceeds to us from this offering were approximately $48.5 million, after deducting underwriting discounts and commissions and other offering expenses payable by us.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">On September 25, 2013, we entered into an underwriting agreement with Stifel, Nicolaus &#38; Company, Incorporated, as the representative of the underwriters named therein, relating to the issuance and sale of 13,750,000 shares of our Common Stock. The price to the public in the offering was $2.40 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2013, certain individuals exercised options to purchase an aggregate of 75,423 shares of our Common Stock for approximately $31,000.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<!-- Field: Page; Sequence: 98; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><u>Warrants to Purchase Common Stock</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">As of December 31, 2015, we had warrants outstanding to purchase an aggregate of 12,722,431 shares of our Common Stock with a weighted-average contractual remaining life of 1.7 years, and exercise prices ranging from $0.24 to $6.35 per share, resulting in a weighted average exercise price of $1.93 per share.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2015, we granted warrants to purchase 50,000 shares of Common Stock to an outside consultant at an exercise price of $6.35, vesting ratably over a 12 month period, with an expiration date of April 6, 2020. The grant date fair value of this warrant was $3.27. During the year ended December 31, 2015, we recorded $139,142 as non-cash compensation in the accompanying consolidated financial statements related to this warrant.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In January 2013, we issued warrants to purchase 1,250,000 shares of our Common Stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant (see NOTE 9 above for more details). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. During the years ended December 31, 2015, 2014 and 2013, $0, $260,027 and $1,451,934, respectively, was recorded as financing costs in connection with the issuance of the Plato Warrant on the accompanying consolidated financial statements.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In May 2013, we entered into a consulting agreement with SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to issue to SCI a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;">1.</td>
<td style="text-align: justify;">283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;</td>
</tr>
</table>
<p style="margin: 0 0 0 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;">2.</td>
<td style="text-align: justify;">283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During the years ended December 31 2015, 2014 and 2013, we recorded $154,068, $154,068 and $77,034, respectively, as non-cash compensation in the accompanying consolidated financial statements related to this warrant. As of December 31, 2015, there was a remaining balance of $77,026 related to this warrant which was included in other current assets in the accompanying consolidated financial statements; and</td>
</tr>
</table>
<p style="margin: 0 0 0 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<!-- Field: Page; Sequence: 99; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<table style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0" width="100%">
<tr style="vertical-align: top;">
<td style="width: 0.5in;"></td>
<td style="width: 0.25in;">3.</td>
<td style="text-align: justify;">283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that this event will not occur before December 2016.</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In May 2012, we issued warrants to purchase an aggregate of 1,300,000 shares of Common Stock to an unaffiliated entity for services to be rendered over approximately five years beginning in May 2012. Services provided are to include (a) services in support of our drug development efforts, including services in support our ongoing and future drug development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at $1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. At December 31, 2015, we had $257,796 reported as prepaid expense-short term and $128,898 recorded as prepaid expense-long term associated with these warrants. During the years ended December 31, 2015, 2014 and 2013, we recorded $257,796, $309,165 and $360,528, respectively as non-cash compensation with respect to these warrants in the accompanying consolidated financial statements. The contract will expire upon the commercial manufacture of a drug product. We have determined that the process will take approximately five years.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">As of December 31, 2015, unamortized costs associated with the SCI warrants issued in 2013 and 2012 totaled approximately $464,000 and will be recognized over a period of eighteen months.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><i><u>Warrant exercises</u></i></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2015, certain individuals and an entity exercised warrants to purchase 1,255,485 shares of Common Stock as follows: (i) 945,485 shares of Common Stock were issued for $366,000 in cash and (ii) warrants to purchase 310,000 shares of Common Stock were exercised pursuant to the warrants&#x2019; cashless exercise provisions, wherein 232,197 shares of Common Stock were issued.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">During the year ended December 31, 2014, certain individuals exercised warrants to purchase 365,583 shares of Common Stock for $181,000 in cash.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><i>Summary of our Warrant activity during the year ended December 31, 2015:</i></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Number of <br> Shares <br> Under <br> Warrants</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted <br> Average <br> Exercise <br> Price</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted <br>Average <br>Remaining <br>Contractual <br>Life in Years</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Aggregate <br>Intrinsic <br> Value</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 48%;">Balance at December 31, 2014</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">13,927,916</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">1.82</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">3.0</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">36,623,875</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt;">&#xA0;&#xA0;&#xA0;Granted</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">50,000</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">6.35</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt;">&#xA0;&#xA0;&#xA0;Exercised</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(1,255,485</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">0.79</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">7,282,404</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt;">&#xA0;&#xA0;&#xA0;Expired</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#x2014;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt;">&#xA0;&#xA0;&#xA0;Cancelled/Forfeited</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2pt; padding-left: 5.4pt;">Balance at December 31, 2015</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">12,722,431</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.93</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1.7</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">107,344,752</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;">Vested and Exercisable at December 31, 2015</td>
<td>&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2.5pt double; text-align: right;">12,422,432</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.92</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">1.6</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">104,909,091</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<!-- Field: Page; Sequence: 100; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2015, 2014 and 2013 are set forth in the table below.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 39%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">2015</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 2%; text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">2014</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 3%; text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">2013</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Weighted average fair value</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">$6.35</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">$2.83</font></td>
</tr>
<tr style="background-color: white; vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Risk-free interest rate</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">1.02%</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a </font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">0.88-1.12%</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Volatility</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">60.59%</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a </font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">44.29-45.89%</font></td>
</tr>
<tr style="background-color: white; vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Term (in years)</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">5</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a </font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">5-6</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Dividend yield</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">0.00%</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">n/a </font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right;">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">0.00%</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We have used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2011-2015.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Options to Purchase Common Stock of the Company</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. Prior to the merger with VitaMed, no Awards had been issued under the 2009 Plan. As of December 31, 2015, there were non-qualified stock options to purchase 17,856,851 shares of Common Stock outstanding under the 2009 Plan. As of December 31, 2015, there were 3,607,852 shares available to be issued under 2009 Plan.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In 2012, we adopted the 2012 Stock Incentive Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company. The Awards available under the 2012 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2012 Plan. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of December 31, 2015, there were non-qualified stock options to purchase 2,868,474 shares of Common Stock outstanding under the 2012 Plan. As of December 31, 2015, there were 7,050,000 shares available to be issued under 2012 Plan.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<!-- Field: Page; Sequence: 101; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2015, 2014 and 2013 are set forth in the table below.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 39%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">2015</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 2%; text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">2014</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 3%; text-align: center;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center;"><font style="font: 10pt Times New Roman, Times, Serif;">2013</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Risk-free interest rate</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">1.47-1.67%</font></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">0.07-1.77%</font></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">0.65-1.71%</font></td>
</tr>
<tr style="background-color: white; vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Volatility</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">58.78-62.94%</font></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">68.05-82.29%</font></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">33.35-45.76%</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Term (in years)</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">5.27-6.25</font></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">5-6.25</font></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">5-6.25</font></td>
</tr>
<tr style="background-color: white; vertical-align: top;">
<td style="padding-left: 5.4pt; padding-right: 5.4pt;"><font style="font: 10pt Times New Roman, Times, Serif;">Dividend yield</font></td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">0.00%</font></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">0.00%</font></td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">0.00%</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual terms of the stock option using the simplified method.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">A summary of activity under the 2009 and 2012 Plans and related information during the year ended December 31, 2015 is as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Number of <br> Shares <br> Under <br> Options</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted <br> Average <br> Exercise <br> Price</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Weighted <br>Average <br>Remaining <br>Contractual <br>Life in Years</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Aggregate <br>Intrinsic <br> Value</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 48%;">Balance at December 31, 2014</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">16,792,443</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">1.88</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">6.9</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">43,996,311</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt;">&#xA0;&#xA0;&#xA0;Granted</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4,685,000</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">8.14</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt;">&#xA0;&#xA0;&#xA0;Exercised</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(613,284</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">2.01</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt;">&#xA0;&#xA0;&#xA0;Expired</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(102,500</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">2.68</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt;">&#xA0;&#xA0;&#xA0;Cancelled/Forfeited</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(36,334</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">4.02</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2pt; padding-left: 5.4pt;">Balance at December 31, 2015</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: right;">20,725,325</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3.28</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">6.5</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">146,864,184</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left;">Vested and Exercisable at December 31, 2015</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: right;">15,461,986</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">1.86</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">5.5</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">131,523,505</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 2pt; padding-left: 5.4pt;">Unvested at December 31, 2015</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: right;">5,263,339</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">7.46</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">9.4</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">15,340,679</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">At December 31, 2015, our outstanding options had exercise prices ranging from $0.10 to $8.92 per share.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<!-- Field: Page; Sequence: 102; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The weighted average grant date fair value per share of options granted during the year ended December 31, 2015 was $4.45. The total intrinsic value of options exercised during the year ended December 31, 2015 was $3,186,371.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="font-size: 10pt;">Share-based compensation expense related to options recognized in our results of operations for the years ended December 31, 2015, 2014 and 2013 was $6,621,658, $4,393,455 and $3,200,655, respectively, and it is based on awards vested. We estimate forfeitures at the time of grant and revise the forfeiture rate in subsequent periods if actual forfeitures differ from the estimates. At December 31, 2015, total unrecognized estimated compensation expense related to unvested options was approximately $19.8 million, </font>which may be adjusted for future changes in forfeitures<font style="font-size: 10pt;">. This cost is expected to be recognized over a weighted-average period of 1.7 years. No tax benefit was realized due to a continued pattern of operating losses. </font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In December 2013, we granted a restricted stock unit, or the RSU, under our 2012 Plan to an employee for 50,000 shares of our Common Stock having a fair value of $233,500. During the years ended December 31, 2014 and 2013, we recorded $53,428 and $180,072, respectively, of non-cash compensation related to the RSU on the accompanying consolidated financial statements. The RSU was issued in June 2014.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 11 &#x2013; INCOME TAXES </u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><font style="background-color: white;">For the years ended December 31, 2015, 2014 and 2013, there was no provision for income taxes, current or deferred.&#xA0; All product sales are derived from sales in the United States.<br></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">At December 31, 2015, we had a federal net operating loss carry forward of $192,601,415 available to offset future taxable income through 2035. The federal carryforwards will begin to expire in 2021.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2013</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 58%; text-align: left;">Federal statutory tax rate</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">34.0</td>
<td style="width: 1%; text-align: left;">%</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">34.0</td>
<td style="width: 1%; text-align: left;">%</td>
<td style="width: 2%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 10%; text-align: right;">35.0</td>
<td style="width: 1%; text-align: left;">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;">State tax rate, net of federal tax benefit</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">4.73</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">5.8</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">5.8</td>
<td style="text-align: left;">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;">Adjustment in valuation allowances</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(38.97</td>
<td style="text-align: left;">)%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(50.9)</td>
<td style="text-align: left;">%</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">(32.4</td>
<td style="text-align: left;">)%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left;">Permanent and other differences</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">0.24</td>
<td style="padding-bottom: 1pt; text-align: left;">%</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">11.1</td>
<td style="padding-bottom: 1pt; text-align: left;">%</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(8.4</td>
<td style="padding-bottom: 1pt; text-align: left;">)%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left;">Provision (benefit) for income taxes</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td style="padding-bottom: 2pt; text-align: left;">%</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td style="padding-bottom: 2pt; text-align: left;">%</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: right;"><font style="font: 10pt Times New Roman, Times, Serif;">&#x2014;</font></td>
<td style="padding-bottom: 2pt; text-align: left;">%</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred income tax asset as of December 31, 2015, 2014, and 2013 are as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2015</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2014</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">2013</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;">Deferred Income Tax Assets:</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; width: 61%; text-align: left;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Net operating losses</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">79,499,633</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">43,091,437</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">14,773,537</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;R&#38;D Credit</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">186,347</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">547,511</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-left: 5.4pt; text-align: left;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Total deferred income tax asset</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">79,685,980</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">43,091,437</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">15,321,048</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left;">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Valuation allowance</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(79,685,980</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(43,091,437</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">(15,321,048</td>
<td style="padding-bottom: 1pt; text-align: left;">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left;">Deferred income tax assets, net</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 103; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We believe that it is more likely than not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on our balance sheet and as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2015.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><i>Unrecognized Tax Benefits</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">As of the period ended December 31, 2015, we have no unrecognized tax benefits.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 12 &#x2013; RELATED PARTIES</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Agreements with Pernix Therapeutics, LLC</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">On February 29, 2012, Cooper C. Collins, who was then president and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors. From time to time, we have entered into agreements with Pernix in the normal course of business. All such agreements are reviewed by independent directors of our company or a committee consisting of independent directors of our company.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">During the years ended December 31, 2015, 2014 and 2013, we did not engage in any transactions with Pernix. As of December 31, 2014 and 2013, there were amounts due to Pernix of approximately $46,000. Additionally, there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation matter stemming from a license and supply agreement in the amounts of approximately $250,000 as of the years ended December 31, 2014 and 2013. During the year ended December 31, 2015, we entered into a settlement agreement with Pernix according to which Pernix paid us $175,000 in cash, resulting in the elimination of the approximately $46,000 outstanding payable and $250,000 outstanding receivable disclosed above and the recording of approximately $29,000 in settlement fees on the accompanying consolidated financial statements.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 13 - BUSINESS CONCENTRATIONS</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We purchase our products from several suppliers with approximately 60%, 82% and 98% of our purchases supplied by one vendor for the years ended December 31, 2015, 2014 and 2013, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the year ended December 31, 2015, two customers each generated more than 10% of our total revenues and during the years ended December 31, 2014 and 2013, four customers each generated more than 10% of our total revenues. Revenue generated from two major customers combined accounted for approximately 67% of total revenue during the year ended December 31, 2015. Revenue generated from four major customers combined accounted for approximately 75% and 79% of our recognized revenue during the years ended December 31, 2014 and 2013, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Customers that generated more than 10% of our sales are designated as customers &#x201C;A&#x201D;, &#x201C;B&#x201D;, &#x201C;C&#x201D; and &#x201C;D&#x201D;. During the year ended December 31, 2015, customer A generated $8,848,243 in revenues and customer B generated approximately $4,843,463 in revenues. During the year ended December 31, 2014 customers A, B, C and D generated $1,609,950, $1,586,903, $1,804,018 and $4,053,838 in sales, respectively. During the year ended December 31, 2013, customers A, B, C and D generated $1,221,212, $1,711,417, $2,588,626 and $1,312,192 in sales, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 104; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">Prior to January 1, 2015, we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns. Revenue generated by major customers accounted for approximately 97% of deferred revenue for both periods ended December 31, 2014 and 2013. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. As a result no deferred revenue was recorded for the year ended December 31, 2015.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 14 &#x2013; COMMITMENTS AND CONTINGENCIES</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Operating Lease</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013. The lease expires on September 30, 2018 and we have an option to extend the lease term for a period of five years. On February 18, 2015, we entered into an agreement with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease. This addendum was effective beginning April 1, 2015 and will expire with the original lease term on September 30, 2018.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">The rental expense related to our current lease during the years ended December 31, 2015 and 2014 was $446,099 and $361,793, respectively. The rental expense during the year ended December 31, 2013 consisted of $180,894 expense related to our current lease and $60,168 expense related to our prior lease which expired June 30, 2013. The rental expense during the years ended December 31, 2014 and 2013 was partially offset by the rent income of $41,613 and $32,963, respectively. We did not sublet any space during the year ended December 31, 2015.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">As of December 31, 2015, future minimum rental payments on non-cancelable operating leases are as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table align="CENTER" style="width: 50%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="2">Years Ending December 31,</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td colspan="2">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 35%; text-align: left;">2016</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">493,790</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">2017</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">507,087</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">2018</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">388,976</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;">2019</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: right;">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: left;"><font style="font: 10pt Times New Roman, Times, Serif;">Total minimum lease payments</font></td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
<td style="padding-bottom: 2pt;">&#xA0;</td>
<td style="border-bottom: Black 2pt double; text-align: left;">$</td>
<td style="border-bottom: Black 2pt double; text-align: right;">1,389,853</td>
<td style="padding-bottom: 2pt; text-align: left;">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Legal Proceedings</u></p>
<p style="margin: 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">From time to time, we are involved in litigation and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would have a material effect on our consolidated financial condition, results of operations, or cash flows.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Off-Balance Sheet Arrangements</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">As of December 31, 2015, 2014 and 2013, we had no off-balance sheet arrangements that have had or are reasonably likely to have current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 105; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><u>Employment Agreements</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We have entered into&#xA0;employment&#xA0;agreements&#xA0;with certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the employment agreement.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;<b>&#xA0;</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 15 &#x2013; SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">Summarized quarterly financial data for fiscal years 2015 and 2014 is as follows:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-left: 3%; width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="14">2015 Quarters</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt;"><font style="font: 10pt Times New Roman, Times, Serif;"><i>(In thousands, except per share)</i></font></td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;">1<sup>st</sup></td>
<td style="padding-bottom: 1pt; text-align: left;"></td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;">2<sup>nd</sup></td>
<td style="padding-bottom: 1pt; text-align: left;"></td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;">3<sup>rd</sup></td>
<td style="padding-bottom: 1pt; text-align: left;"></td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;">4<sup>th</sup></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="width: 48%;">Revenues</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">4,475</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">4,848</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">5,190</td>
<td style="width: 1%; text-align: left;">&#xA0;</td>
<td style="width: 1%;">&#xA0;</td>
<td style="width: 1%; text-align: left;">$</td>
<td style="width: 10%; text-align: right;">5,630</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Gross profit</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3,431</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3,815</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3,996</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">4,395</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Net loss</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(20,895</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(27,227</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(19,472</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(17,483</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Loss per common share, basic and diluted</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.13</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.16</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.11</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.10</td>
<td style="text-align: left;">)</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="margin-left: 3%; width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td>&#xA0;</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; text-align: center;" colspan="14">2014 Quarters</td>
<td style="padding-bottom: 1pt;">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom;">
<td style="padding-bottom: 1pt; width: 48%;"><font style="font: 10pt Times New Roman, Times, Serif;"><i>(In thousands, except per share)</i></font></td>
<td style="padding-bottom: 1pt; width: 1%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 10%; text-align: center;">1<sup>st</sup></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"></td>
<td style="padding-bottom: 1pt; width: 1%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 10%; text-align: center;">2<sup>nd</sup></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"></td>
<td style="padding-bottom: 1pt; width: 1%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 10%; text-align: center;">3<sup>rd</sup></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"></td>
<td style="padding-bottom: 1pt; width: 1%;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 1%; text-align: left;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 10%; text-align: center;">4<sup>th</sup></td>
<td style="padding-bottom: 1pt; width: 1%; text-align: left;"></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td>Revenues</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">2,831</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3,752</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">4,186</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">4,257</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td style="text-align: left;">Gross profit</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">2,000</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">2,859</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3,118</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">3,377</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Net loss</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(9,183</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(10,899</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(17,832</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(16,303</td>
<td style="text-align: left;">)</td>
</tr>
<tr style="background-color: white; vertical-align: bottom;">
<td>&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td>&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
<td style="text-align: right;">&#xA0;</td>
<td style="text-align: left;">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom;">
<td style="text-align: left;">Loss per common share, basic and diluted</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.06</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.07</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.12</td>
<td style="text-align: left;">)</td>
<td>&#xA0;</td>
<td style="text-align: left;">$</td>
<td style="text-align: right;">(0.10</td>
<td style="text-align: left;">)</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b><u>NOTE 16 &#x2013; SUBSEQUENT EVENTS</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">On January&#xA0;6, 2016, we entered into an underwriting agreement with Goldman Sachs and Cowen and Company, LLC, as the representatives of the several underwriters, or the Underwriters, relating to an underwritten public offering of 15,151,515 shares of our Common Stock at a public offering price of $8.25 per share. Under the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $134.9 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on January&#xA0;12, 2016.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 106; Value: 18 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;"></p>
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>THERAPEUTICSMD, INC. AND SUBSIDIARIES</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
<p style="margin: 0;"></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">In January 2016, certain individuals exercised stock options to purchase 281,657 shares of our Common Stock for approximately $758,000 in cash and warrants to purchase 500,000 shares of our Common Stock were exercised for approximately $1,285,000 in cash.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 107; Options: Last -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 12pt;">
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>2
<FILENAME>ex10-9.htm
<DESCRIPTION>CONSULTING AGREEMENT BETWEEN THE COMPANY AND SANCILIO AND COMPANY, INC.
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 0; margin-top: 0;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;"><a href="txmd-10k_123115.htm">TherapeuticsMD, Inc. 10-K</a></p>
<p style="margin: 0; text-align: right;"><b>Exhibit 10.9</b></p>
<p style="margin: 0; text-align: left;"></p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 8pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><u>Consulting Agreement</u></b></p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">This Consulting Agreement (&#x201C;Agreement&#x201D;) by and between <font style="letter-spacing: 0.15pt;">Sancilio and Company, Inc.</font>, a Florida corporation (&#x201C;SCI&#x201D;), and TherapeuticsMD, Inc., a Nevada corporation (&#x201C;Therapeutics&#x201D;), is entered into as of May 17, 2012 (the &#x201C;Effective Date&#x201D;). Each of SCI and Therapeutics are referred to hereinafter as a &#x201C;Party&#x201D; and collectively as the &#x201C;Parties.&#x201D;</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">WHEREAS, Therapeutics has requested SCI to provide certain consulting services (the &#x201C;Consulting Services&#x201D;) as provided herein, and SCI is willing to provide the Consulting Services on the terms and subject to the conditions set forth in this Agreement,</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">NOW THEREFORE, in consideration of the mutual covenants contained herein and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties hereby agree as follows:</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">1.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Consulting Services</i>. SCI shall provide the following Consulting Services to Therapeutics:</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">(a)</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;">services provided in support of Therapeutics&#x2019; drug development efforts specifically pertaining to individual and combined hormone replacement drug products (&#x201C;Drug Products &#x201C;) including, but not limited to, services in support of Therapeutics&#x2019; ongoing and future drug development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and controls (&#x201C;CMC&#x201D;) efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated therewith;</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">(b)</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;">services in support of Therapeutics&#x2019; efforts to successfully obtain FDA Approval for the Drug Product described in Schedule I hereto; and</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">(c)</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">other consulting services as mutually agreed upon from time to time by SCI and Therapeutics in relation to new drug development opportunities.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">The term &#x201C;FDA Approval,&#x201D; as used herein, shall mean a marketing approval for commercial distribution in the United States pursuant to Section 505 of the Food, Drug and Cosmetic Act, as amended. For clarity, an &#x201C;FDA Approval&#x201D; as used herein shall not include any &#x201C;approvable&#x201D; determinations by the U.S. Food &#38; Drug Administration (&#x201C;FDA&#x201D;), including as set forth in any approvable letter under 21 CFR &#xA7; 314.110.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">2.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Expense Reimbursement</i>. Therapeutics agrees to reimburse SCI for all out-of-pocket expenses for reasonable business-related travel and engagement of experts required in the performance of the Consulting Services, provided however, that all such expenses shall be submitted in writing and pre-approved by Therapeutics prior to SCI incurring any such expense. All approved expenses shall be paid within 15 days of presentation of invoices and appropriate documentation therefore.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">3.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Consulting Fee</i>. No cash remuneration shall be paid hereunder.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">(a)</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;">In consideration for the Consulting Services to be provided pursuant to Section 1(a) hereof, Therapeutics agrees to issue and deliver to SCI contemporaneously with the execution and delivery hereof, a five-year Common Stock Purchase Warrant (&#x201C;Warrant&#x201D;), in the form attached hereto as <i><u>Exhibit A</u></i>, granting SCI the right to purchase up to One million three hundred thousand (1,300,000) shares of the Common Stock of Therapeutics (the &#x201C;First Warrant&#x201D;). The exercise price of the First Warrant shall be set at the five-day average closing bid price immediately preceding the execution of this Agreement and all shares thereunder shall vest immediately upon issuance of the First Warrant.</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 1 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center; font: normal 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">(b)</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;">Upon the receipt by Therapeutics of any final FDA Approval of a Drug Product, Therapeutics agrees to issue and deliver to SCI within five (5) business days after receipt of Approval, an additional five-year Warrant granting SCI the right to purchase Four hundred thirty-three thousand (433,000) shares of the Common Stock of Therapeutics (the &#x201C;Second Warrant&#x201D;). The Exercise Price of the Second Warrant shall be set at the same price as the First Warrant outlined in Section 3(a) above and all shares thereunder shall vest immediately upon issuance of the Second Warrant.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">(c)</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;">As incentive for SCI to specifically assist Therapeutics in obtaining FDA Approval of the Drug Product described in Section 1(b), Therapeutics hereby agrees to issue and deliver to SCI a five-year Warrant granting SCI the right to purchase Four hundred thousand (400,000) shares of the Common Stock of Therapeutics (the &#x201C;Third Warrant&#x201D;) upon the submission to FDA of the NDA pertaining to the Drug Product described in Schedule I. The Exercise Price of the Third Warrant shall be set at the five-day average closing bid price immediately preceding the submission of the NDA to FDA and all shares thereunder shall vest immediately upon issuance of the Third Warrant.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">(d)</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;">SCI expressly acknowledges that the issuance of the aforementioned Warrants shall constitute full and adequate compensation for all Consulting Services to be performed pursuant to this Agreement and that SCI shall not be entitled to any additional compensation in any form. For clarity, SCI shall not be entitled to seek additional consideration relative to any internal costs or other obligations incurred by SCI relating to its Consulting Services (so called &#x201C;soft costs&#x201D;), including consulting, legal, engineering and infrastructure-related costs and obligations incurred by SCI in the performance of its duties hereunder.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">(e)</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;">If (i)&#xA0;the shares of the Common Stock of Therapeutics shall be subdivided or combined into a greater or smaller number of shares or if Therapeutics shall issue any shares of Common Stock as a stock dividend on its outstanding Common Stock, or (ii)&#xA0;additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Common Stock, the number of shares of Common Stock that may be purchased pursuant to each of the Warrants described in this Section 3 shall be appropriately increased or decreased proportionately, and appropriate adjustments shall be made, including to the exercise price per share, to reflect such events.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">4.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Intellectual Property</i>. Any invention, trade secret or know-how and any materials, documents, programs or information belonging to Therapeutics and supplied to SCI by Therapeutics pursuant to this Agreement shall remain the property of Therapeutics. Any invention, trade secret or know-how and any materials, documents, programs or synthesis information belonging to SCI prior to the date of this Agreement, or developed by SCI independently of this Agreement (i.e. not falling within Section 4.1 below), shall remain the property of SCI.</p>
<p style="margin: 0 0 8pt; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">4.1</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">Any inventions (whether or not patentable), processes, techniques, improvements, discoveries, designs, formulae, copyright, trademark, trade secrets, know-how, developments, confidential information, computer software, data and documentation, and all other intellectual property rights created, discovered or reduced to practice by SCI solely or jointly in the course of performing the Consulting Services are collectively &#x201C;Project IP.&#x201D; SCI shall promptly notify Therapeutics in writing when it has made, created, or otherwise invented any Project IP. SCI agrees to assign and hereby does assign to Therapeutics all Project IP (including any patent and all other intellectual property rights therein) and Project IP shall be deemed the Confidential Information of Therapeutics for purposes of Section 5 below. SCI will take all reasonable steps and execute all documents that Therapeutics may reasonably request to transfer to and vest in Therapeutics the ownership and registration of all intellectual property rights that may exist in such Project IP.</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 2 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center; font: normal 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 31.5pt; font: 10pt Times New Roman, Times, Serif;">4.2</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 68pt; font: 10pt Times New Roman, Times, Serif;">With respect to Project IP, SCI will not knowingly or negligently incorporate or use therein any invention, discovery, process, technology or information that (a)&#xA0;is subject in whole or in part to a claim of any patent application or issued patent that is owned or controlled by SCI, but not assigned to Therapeutics pursuant to Section 4 (&#x201C;SCI Background Patent Rights&#x201D;), (b)&#xA0;is subject in whole or in part to a claim of any patent or patent application of a third party, or (c) incorporates any SCI processes, inventions, techniques, know-how, or trade secrets that are owned or controlled by SCI, but not assigned to Therapeutics pursuant to Section 4 (&#x201C;SCI Background Know-How&#x201D;). In the event any Project IP incorporates or requires the use of SCI Background Patent Rights or SCI Background Know-How (collectively, &#x201C;SCI Proprietary Technology&#x201D;), SCI shall grant and hereby grants to Therapeutics a non-exclusive, non-transferable, worldwide, royalty-free, fully paid license to use such SCI Proprietary Technology in connection with the procurement, use, sale and marketing of any Drug Product or other products or processes deriving from this Agreement.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">4.3</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">Therapeutics acknowledges that SCI is in the business of providing other services for a variety of organizations other than Therapeutics. Accordingly, nothing in this Agreement shall preclude or limit SCI from providing other services or developing materials for itself or other clients, or from utilizing the general knowledge gained during the course of its performance hereunder to perform similar services for other clients, provided that such provision of services or development of materials do not constitute a breach under Section 5 herein.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">5.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Confidentiality</i>. During the performance of the Consulting Services, SCI may receive from Therapeutics confidential or proprietary information, including information concerning Therapeutics&#x2019; regulatory submissions, pre-clinical and clinical trials; other data, testing and research techniques, inventions, materials, processes, practices, product research, development and acquisition plans; acquisitions, mergers, divestitures and the like; other business and marketing plans; and other proprietary and trade secrets and like information (collectively &#x201C;Confidential Information&#x201D;). Therapeutics agrees that it will only provide such Confidential Information to the extent that it is required by SCI to perform the Consulting Services.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">5.1</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">Notwithstanding the foregoing, the obligations of this Section 5 shall not apply in the case of:</p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">(i)</p>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">information of Therapeutics that is now in the public domain or which subsequently enters the public domain without fault on the part of SCI; or</p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">(ii)</p>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">information of Therapeutics that is presently known by SCI from its own sources, where said present knowledge can be demonstrated by written records; or</p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">(iii)</p>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">information of Therapeutics that SCI receives in good faith from a third party, where said third party is independent of Therapeutics and is under no obligation of confidentiality with respect to such information; or</p>
<p style="margin: 0 0 -11pt 1in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">(iv)</p>
<p style="margin: 0 0 8pt 1in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">information developed by or for SCI independent of the Consulting Services, or any other agreements with Therapeutics, and without the use of any Confidential Information of Therapeutics, as evidenced by SCI&#x2019;s written records.</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 3 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center; font: normal 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 0 0.75pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">5.1.1</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;">SCI may disclose Therapeutics&#x2019; Confidential Information to the extent required by law or order of a court or governmental agency or to enforce this Agreement; however, SCI must give Therapeutics prompt notice of such intended disclosure and SCI shall make a commercially reasonable effort to obtain a protective order or otherwise protect the confidentiality of such Confidential Information.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">5.2</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">SCI agrees that without the express written consent of Therapeutics, it will not itself use, or provide to, disclose to, or permit any third party to use said Confidential Information. SCI agrees to take commercially reasonable and appropriate measures to safeguard Confidential Information from theft, loss or negligent disclosure to others and to limit internal access to Confidential Information to those of its employees, consultants, agents or subcontractors who reasonably require such access in order to accomplish performance of the Consulting Services. All SCI employees, consultants, agents or subcontractors who have or will have access to Confidential Information have signed or, prior to disclosure of Confidential Information, will sign a confidentiality agreement with provisions no less protective than this Section 5. However, SCI assumes full responsibility for the acts or omissions of such third-parties, no less than if the acts or omissions were those of SCI.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">5.3</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">Unless otherwise consented to by Therapeutics in writing, SCI agrees not to analyze for chemical composition any samples or materials provided by Therapeutics, nor to allow or cause any such samples or materials to be released to third parties for analysis.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">5.4</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">SCI shall not use or disclose to Therapeutics any information it knows to be Confidential Information of a third party except as approved in advance in writing by Therapeutics.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">5.5</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">SCI agrees to notify Therapeutics promptly of the date of, and the circumstances involved in, the loss or unauthorized disclosure of any Confidential Information of Therapeutics.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">5.6</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">Upon termination of this Agreement, and at the written direction of Therapeutics, SCI will promptly return all of Therapeutics&#x2019; Confidential Information, including any documents prepared by SCI that contain such information. SCI may retain a single archival copy of the Confidential Information for the sole purpose of determining the scope of obligations incurred under this Agreement.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">5.7</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">Except for disclosure as may be required by regulatory authorities, the Parties agree that they shall not use the other Party&#x2019;s name, or disclose the existence of this Agreement or any matters relating to the Services provided hereunder in any advertising, promotion, written articles or communications without the prior written consent of the other Party, which consent shall not to be unreasonably withheld.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">5.8</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">The obligations of this Section 5 shall apply to all Confidential Information, whether such Confidential Information was disclosed before or after the Effective Date, and shall survive indefinitely unless specifically excluded under Section 5.1 (i)-(iv).</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">6.</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><i>Indemnification </i></p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">6.1.</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Indemnification by Therapeutics</i>. Subject to Section 6.3 below, Therapeutics shall indemnify and hold harmless SCI, its agents, employees, directors and Affiliates from any loss, expense and liability, including reasonable attorney&#x2019;s fees arising out of Therapeutics&#x2019; negligence or willful misconduct under this Agreement, except to the extent the claim, suit or proceeding is subject to SCI&#x2019;s indemnification obligations in Section 6.2 below.</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 4 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center; font: normal 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 8pt 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">6.2</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Indemnification by SCI</i>. Subject to Section 6.3 below, SCI shall indemnify and hold harmless Therapeutics, its agents, employees, directors and Affiliates from any loss, expense and liability, including reasonable attorney fees arising out of SCI&#x2019;s negligence or willful misconduct in the course of providing Consulting Services pursuant to this Agreement.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">6.3</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">A Party that intends to claim indemnification (the &#x201C;Indemnitee&#x201D;) under Section 6.1 or 6.2 shall promptly notify the other party (the &#x201C;lndemnitor&#x201D;) in writing of any claim, complaint, suit, proceeding or cause of action with respect to which the Indemnitee intends to claim such indemnification (for purposes of this Section 6, each a &#x201C;Claim&#x201D;), and the Indemnitor shall have sole control of the defense and/or settlement thereof; provided that the Indemnitee shall have the right to participate, at its own expense, with counsel of its own choosing in the defense and/or settlement of such Claim. The Indemnitor shall not settle any Claim without the consent of the Indemnitee, which consent shall not be unreasonably withheld or delayed. The Indemnitee, and its employees, at the Indemnitor&#x2019;s request and expense, shall provide full information and reasonable assistance to Indemnitor and its legal representatives with respect to such Claims covered by this indemnification.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">6.4</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">SCI shall be responsible for the safety of its own employees and agents with respect to the handling or use of materials involved in the performance of this Agreement.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">7.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: 0pt; font: normal 10pt Times New Roman, Times, Serif;">SCI</font> represents and warrants to Therapeutics as of the Effective Date that:</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: 0pt;">(a) </font></p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: 0pt;">the execution and delivery of this Agreement and the performance of the transactions, rights and licenses contemplated hereby have been duly authorized by all appropriate SCI corporate action;</font></p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">(b)</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;">SCI has the full right and authority to enter into this Agreement, <font style="letter-spacing: 0pt;">and is a legal and valid obligation binding upon SCI and enforceable in accordance with its terms, and the execution, delivery and performance of this Agreement by the terms set forth herein, and does not conflict with any agreement, instrument or understanding to which SCI is a party or by which it is bound;</font></p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: 0pt;">(c) </font></p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: 0pt;">SCI has the full right and legal capacity to grant the rights granted to Therapeutics hereunder without violating the rights of any third party; and</font></p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: 0pt;">(d) </font></p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;"><font style="letter-spacing: 0pt;">SCI is the owner of any SCI technology and Project IP, SCI Background Patent Rights, and SCI Proprietary Technology conveyed and that it is aware of no actual or threatened third party claims of ownership of the same</font>.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">8.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Term</i>. The term of this Agreement (&#x201C;Term&#x201D;) shall commence as of the Effective Date and continue until the time of the commercial manufacture of a Drug Product. The Term may be extended by mutual, written agreement between the Parties.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">9.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Assignment</i>. Neither party hereto may assign this Agreement, in whole or in part, without the prior written consent of the other party hereto.</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 5 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center; font: normal 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">10.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Notices</i>.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">(a)</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;">All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (i)&#xA0;upon personal delivery to the party to be notified, (ii)&#xA0;when sent by facsimile, upon written confirmation of receipt by addressee, (iii)&#xA0;five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (iv)&#xA0;one day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">(b)</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1.5in; font: 10pt Times New Roman, Times, Serif;">Notices shall be sent to each party at its respective address listed below (if a party desires to change its address for notice, it shall notify the other party according to these terms):</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; width: 1in; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; width: 15%; text-align: justify;"><font style="font-size: 10pt;">If to SCI:</font></td>
<td style="padding-bottom: 0; padding-top: 0; width: 5%; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">Sancilio and Company, Inc.</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">Attn:&#xA0;&#xA0;Fred Sancilio, President &#38; CEO</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">3874 Fiscal Court, Suite 200</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">Riviera Beach, Florida 33404</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">Facsimile No: (561) 847-2312</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">If to Therapeutics:</font></td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">TherapeuticsMD, Inc.</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">Attn:&#xA0;&#xA0;Robert Finizio, CEO</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">951 Broken Sound Parkway NW, Suite 320</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">Boca Raton, FL 33487</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">Facsimile No: (561) 431-3389 </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 31.5pt; font: 10pt Times New Roman, Times, Serif;">11.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 68pt; font: 10pt Times New Roman, Times, Serif;"><i>Records &#38; Audits</i>. SCI agrees to maintain records of all Consulting Services performed under this Agreement in accordance with the FDA&#x2019;s archival guidelines. Therapeutics may review the records of SCI relating to the Consulting Services performed and expenses incurred to assure compliance with all provisions of this Agreement, provided that such inspection may take place (i)&#xA0;only upon reasonable prior written notice (not less than ten (10) business days) and during SCI&#x2019;s regular business hours.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 31.5pt; font: 10pt Times New Roman, Times, Serif;">11.1</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 68pt; font: 10pt Times New Roman, Times, Serif;">Upon reasonable prior written notice (not less than fifteen (15)&#xA0;business days) and during regular business hours, Therapeutics may, at its own cost and expense, review SCI&#x2019;s quality control procedures and records, with a representative of SCI present.</p>
<p style="margin: 0 0 -11pt 0.5in; text-align: justify; text-indent: 31.5pt; font: 10pt Times New Roman, Times, Serif;">11.2</p>
<p style="margin: 0 0 8pt 0.5in; text-align: justify; text-indent: 68pt; font: 10pt Times New Roman, Times, Serif;">In the event of an inspection by any governmental or regulatory authority concerning the Consulting Services performed hereunder, SCI shall notify Therapeutics promptly upon learning of such an inspection, shall supply Therapeutics with copies of any correspondence or portions or correspondence relating to the Consulting Services and shall inform Therapeutics of the general findings and outcomes of such inspections.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 31.5pt; font: 10pt Times New Roman, Times, Serif;">12.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 68pt; font: 10pt Times New Roman, Times, Serif;"><i>Certification</i>. SCI represents, warrants and certifies that neither it, nor its Affiliates, nor any of their respective directors, officers, principals, employees and agents was or is debarred, suspended, proposed for debarment or otherwise determined to be ineligible to participate in the drug industry, federal health care programs under or convicted of a criminal offense related to the provision of health care items or services the United States Food, Drug and Cosmetic Act (21 U.S.C. 301 et seq.), and that it has not and will not use in any capacity the services of any entity or person debarred under such law with respect to Consulting Services to be performed under this Agreement. In the event that SCI, or any of its affiliates, directors, officers, principals, employees, or agents becomes or is debarred, suspended, proposed for debarment or otherwise determined to be ineligible to participate in the drug industry under such law or convicted of a criminal offense related to the provision of health care items or services, SCI shall notify Therapeutics in writing immediately.</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 6 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center; font: normal 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">13.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Waiver.</i> The failure of either Party hereto at any time or times to require performance of any provision of this Agreement shall in no manner affect the right of such Party at a later time to enforce the same. No waiver by any Party hereto of any condition, or of the breach of any provision, term, covenant, representation, or warranty contained in this Agreement, whether by conduct or otherwise, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such condition or of the breach of any other provision, term, covenant, representation or warranty of this Agreement.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">14.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Entire Understanding.</i> This Agreement contains the entire agreement between the Parties with respect to the subject matter thereof as of the Effective Date.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">15.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Severability.</i> If a court or other tribunal of competent jurisdiction holds any term or provision, or portion thereof, of this Agreement to be invalid, void or unenforceable, the remaining provisions of the Agreement shall remain in full force and effect. It is the Parties&#x2019; intention that if a court or other tribunal holds any term or provision of this Agreement to be excessive in scope, such term or provision shall be adjusted rather than voided, if possible.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">16. <i></i></p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Modification</i>. This Agreement may not be amended or modified except by written instrument signed by an authorized representative of the Parties.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">17.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Cooperation. </i>Each Party shall execute and deliver all such instruments and perform all such other acts as the other Party may reasonably request to carry out the transactions contemplated by this Agreement.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">18.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Governing Law</i>. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida without regard to any conflict of law provisions. In the event that an unresolved dispute arises over the enforcement, interpretation, construction, or breach of this Agreement, it shall be litigated in the State of Florida, within the U.S. District Court, Southern District of Florida, or the Florida State Court, Broward County, 17th Judicial Circuit, and both Parties irrevocably submit to the exclusive jurisdiction of such courts for all purposes with respect to any legal action or proceeding in connection with this Agreement.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">19.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;">&#x201C;<i>Affiliate</i>&#x201D; as used herein shall mean any corporation, company, partnership, joint venture and/or firm, which controls, is controlled by or is under common control with a Party. For purposes of this Section 19, &#x201C;control&#x201D; shall mean (a) in the case of corporate entities, direct or indirect ownership of at least fifty percent (50%) of the stock or shares entitled to vote for the election of directors; and (b) in the case of non-corporate entities, direct or indirect ownership of at least fifty percent (50%) of the equity interest or the power to substantially direct the management and policies of such non-corporate entities.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">20.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Counterparts; Signatures</i>. This Agreement may be signed in one or more counterparts, each of which shall be one and the same agreement. If a counterpart of this Agreement is signed and transmitted via facsimile, or via PDF transmitted by e-mail, such signatures shall bind the signing party to this Agreement in full. Original documents may also be signed by the parties and will have the same binding power.</p>
<p style="margin: 0 0 -11pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">21.</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 1in; font: 10pt Times New Roman, Times, Serif;"><i>Independent Parties</i>. This Agreement shall not be construed as constituting a joint venture or partnership between SCI and Therapeutics. No party shall have any right to obligate any other party in any manner whatsoever, and nothing herein is intended to confer any right of any kind to any third person.</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 7 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center; font: normal 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">IN WITNESS WHEREOF, the parties have each caused this Agreement to be signed and delivered by their duly authorized representatives as of the Effective Date.</p>
<p style="margin: 0 0 8pt 3in; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;" colspan="2"><font style="font-size: 10pt;">Sancilio and Company, Inc.</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;" colspan="2">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;" colspan="2">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;" colspan="2">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; width: 55%; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; width: 5%; text-align: justify;"><font style="font-size: 10pt;">By:</font></td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 0; padding-top: 0; width: 40%; text-align: justify;"><font style="font-size: 10pt;">/s/ Fred Sancilio </font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">Fred Sancilio</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">President &#38; CEO</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;" colspan="2"><font style="font-size: 10pt;">TherapeuticsMD, Inc.</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">By:</font></td>
<td style="border-bottom: Black 1pt solid; padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">/s/ Robert Finizio</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">Robert Finizio</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;">&#xA0;</td>
<td style="padding-bottom: 0; padding-top: 0; text-align: justify;"><font style="font-size: 10pt;">Chief Executive Officer</font></td>
</tr>
</table>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 8 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center; font: normal 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><i><u>Exhibit A</u></i></p>
<p style="margin: 0 0 8pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><i>&#xA0;</i></p>
<p style="margin: 0 0 8pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">Form of Warrant</p>
<p style="margin: 0 0 8pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 9 -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center; font: normal 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<div style="margin-top: 6pt; page-break-before: always;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;">&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt; text-align: center; font: 10pt Times New Roman, Times, Serif;"><u>SCHEDULE I</u></p>
<p style="margin: 0 0 8pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 8pt; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 45pt 8pt 67.5pt; text-align: justify; font: 10pt Times New Roman, Times, Serif;">An estradiol-based Drug Product with a dosage equal to or lower than one-half (1/2) of the lowest effective dose of the product currently known as Estrace, while achieving substantially identical bioequivalence.</p>
<p style="margin: 0 0 8pt; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: left;"></p>
<!-- Field: Page; Sequence: 10; Options: Last -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center; font: normal 10pt Times New Roman, Times, Serif;"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: left;">&#xA0;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>ex21-1.htm
<DESCRIPTION>SUBSIDIARIES OF THE COMPANY
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 0; margin-top: 0;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;"><a href="txmd-10k_123115.htm">TherapeuticsMD, Inc. 10-K</a></p>
<p style="margin: 0;"></p>
<p style="background-color: white; margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 21.1</b></p>
<p style="background-color: white; margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b></p>
<p style="background-color: white; margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><b><u>Subsidiaries of the Company</u></b></p>
<p style="background-color: white; margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 10pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: bottom;">
<td style="width: 58%; text-align: left; font-weight: bold;"><b>Name</b></td>
<td style="width: 42%; text-align: center; font-weight: bold;"><b>State or Jurisdiction of Incorporation or Organization</b></td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: left;">VitaMedMD, LLC</td>
<td style="text-align: center;">Delaware</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: left;">BocagreenMD, Inc.</td>
<td style="text-align: center;">Nevada</td>
</tr>
<tr style="vertical-align: top;">
<td style="text-align: left;">VitaCare Prescription Services, Inc.</td>
<td style="text-align: center;">Florida</td>
</tr>
</table>
<p style="margin: 0 0 6pt; text-align: left; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0;"></p>
<!-- Field: Page; Sequence: 1; Options: Last -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex23-1.htm
<DESCRIPTION>CONSENT OF GRANT THORNTON, LLP
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 0; margin-top: 0;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;"><a href="txmd-10k_123115.htm">TherapeuticsMD, Inc. 10-K</a></p>
<p style="margin: 0; text-align: right;"><b>Exhibit 23.1</b></p>
<p style="margin: 0; text-align: left;"></p>
<p style="margin: 0; font: 10pt/14pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt/14pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt/14pt Times New Roman, Times, Serif;"><b>Consent of Independent Registered Public Accounting Firm</b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">We have issued our reports dated
February 26, 2016, with respect to the consolidated financial statements and internal control over financial reporting
included in the Annual Report of TherapeuticsMD, Inc. on Form 10-K for the year ended December 31, 2015. We consent to the
incorporation by reference of said reports in the Registration Statements of TherapeuticsMD, Inc. on Forms S-3 (File No.
333-207837, File No. 333-185156, File No. 333-193558 and  File No. 333-201171) and on Form S-8 (File No. 333-191730).</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">/s/ GRANT THORNTON LLP</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">Fort Lauderdale, Florida</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">February 26, 2016</p>
<p style="margin: 0; font: 10pt/14pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: left;"></p>
<!-- Field: Page; Sequence: 1; Options: Last -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%; font-size: 10pt;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"><!-- Field: Sequence; Type: Arabic; Name: PageNo --><!-- Field: /Sequence -->&#xA0;</td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: left;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>ex23-2.htm
<DESCRIPTION>CONSENT OF ROSENBERG RICH BAKER BERMAN & COMPANY
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;"><a href="txmd-10k_123115.htm">TherapeuticsMD, Inc. 10-K</a></p>
<p style="margin: 0;">&#xA0;</p>
<p style="margin: 0; text-align: right; font: bold 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Exhibit 23.2</b></font></p>
<p style="margin: 0; text-align: right; font: bold 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;">&#xA0;</font></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>Consent of Independent Registered Public Accounting Firm</b></font></p>
<p style="margin: 0; text-align: center; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We consent to the incorporation by reference in the Registration Statements (Nos. 333-185156, 333-207837, 333-193558, 333-201171) on Form S-3 and (No. 333-191730) on Form S-8 of TherapeuticsMD, Inc. of our report dated March 12, 2015, with respect to the consolidated financial statements of TherapeuticsMD, Inc., included in this annual report (Form 10-K) for the year ended December 31, 2014.</font></p>
<p style="margin: 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>/s/ Rosenberg Rich Baker Berman &#38; Company</i></font></p>
<p style="margin: 0; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Somerset, NJ</font></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">February 26, 2016</font></p>
<p style="margin: 0 0 10pt; font: 11pt/115% Calibri, Helvetica, Sans-Serif;">&#xA0;</p>
<!-- Field: Page; Sequence: 1; Options: Last -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt; margin-top: 6pt;">
<p style="margin: 0pt;">&#xA0;</p>
</div>
<!-- Field: /Page -->
<p style="margin: 0 0 10pt; font: 11pt/115% Calibri, Helvetica, Sans-Serif;">&#xA0;</p>
<p style="margin: 0; text-align: left; font: bold 10pt Times New Roman, Times, Serif;"><font style="font: 10pt Times New Roman, Times, Serif;"></font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex31-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 0; margin-top: 0;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b><a href="txmd-10k_123115.htm">TherapeuticsMD, Inc. 10-K</a></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 31.1</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">I, Robert G. Finizio, certify that:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 4%; text-align: justify; font: 12pt Times New Roman, Times, Serif;"><font style="font-size: 10pt;">(1)</font></td>
<td style="text-align: justify; font: 12pt Times New Roman, Times, Serif;"><font style="font-size: 10pt;">I have reviewed this annual report on Form 10-K of TherapeuticsMD, Inc.; </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 4%; text-align: justify; font: 12pt Times New Roman, Times, Serif;"><font style="font-size: 10pt;">(2)</font></td>
<td style="text-align: justify; font: 12pt Times New Roman, Times, Serif;"><font style="font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 4%; text-align: justify; font: 12pt Times New Roman, Times, Serif;"><font style="font-size: 10pt;">(3)</font></td>
<td style="text-align: justify; font: 12pt Times New Roman, Times, Serif;"><font style="font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 4%; text-align: justify; font: 12pt Times New Roman, Times, Serif;"><font style="font-size: 10pt;">(4)</font></td>
<td style="text-align: justify; font: 12pt Times New Roman, Times, Serif;"><font style="font-size: 10pt;">The registrant&#39;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 4%; text-align: justify;">&#xA0;</td>
<td style="width: 4%; vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(a)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></td>
</tr>
<tr>
<td style="text-align: justify;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(b)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td>
</tr>
<tr>
<td style="text-align: justify;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(c)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td>
</tr>
<tr>
<td style="text-align: justify;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(d)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 4%; text-align: justify;"><font style="font-size: 10pt;">(5)</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">The registrant&#39;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 4%; text-align: justify;">&#xA0;</td>
<td style="width: 4%; vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(a)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></td>
</tr>
<tr>
<td style="text-align: justify;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(b)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-left: 12pt; width: 45%; vertical-align: top; text-align: justify; text-indent: -12pt;"><font style="font-size: 10pt;">February 26, 2016</font></td>
<td style="width: 5%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 50%; vertical-align: bottom; text-align: justify; text-decoration: underline;"><font style="font-size: 10pt;"><i><u style="text-decoration: none;">/s/ Robert G. Finizio</u></i></font></td>
</tr>
<tr>
<td style="vertical-align: top; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt;"><font style="font-size: 10pt;">Robert G. Finizio</font></td>
</tr>
<tr>
<td style="vertical-align: top; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom;">
<p style="margin: 0 0 0 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">Chief Executive Officer</p>
<p style="margin: 0 0 0 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">(Principal Executive Officer)</p>
</td>
</tr>
</table>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 1; Options: Last -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"></td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex31-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b></b></p>
<p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 0; margin-top: 0;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b><a href="txmd-10k_123115.htm">TherapeuticsMD, Inc. 10-K</a></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 31.2</b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">CERTIFICATION OF CHIEF FINANCIAL OFFICER</p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">I, Daniel A. Cartwright, certify that:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 4%; text-align: justify;"><font style="font-size: 10pt;">(1)</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">I have reviewed this annual report on Form 10-K of TherapeuticsMD, Inc.; </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 4%; text-align: justify;"><font style="font-size: 10pt;">(2)</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 4%; text-align: justify;"><font style="font-size: 10pt;">(3)</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 4%; text-align: justify;"><font style="font-size: 10pt;">(4)</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">The registrant&#39;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 4%; text-align: justify;">&#xA0;</td>
<td style="width: 4%; vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(a)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </font></td>
</tr>
<tr>
<td style="text-align: justify;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(b)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td>
</tr>
<tr>
<td style="text-align: justify;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(c)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </font></td>
</tr>
<tr>
<td style="text-align: justify;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(d)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="width: 4%; text-align: justify;"><font style="font-size: 10pt;">(5)</font></td>
<td style="text-align: justify;"><font style="font-size: 10pt;">The registrant&#39;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions): </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 4%; text-align: justify;">&#xA0;</td>
<td style="width: 4%; vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(a)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></td>
</tr>
<tr>
<td style="text-align: justify;">&#xA0;</td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">(b)</font></td>
<td style="vertical-align: top; text-align: justify;"><font style="font-size: 10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting. </font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; font: 12pt Times New Roman, Times, Serif;" cellpadding="0" cellspacing="0">
<tr>
<td style="padding-left: 12pt; width: 45%; vertical-align: top; text-align: justify; text-indent: -12pt;"><font style="font-size: 10pt;">February 26, 2016</font></td>
<td style="width: 5%; vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; width: 50%; vertical-align: bottom; text-align: justify; text-decoration: underline;"><font style="font-size: 10pt;"><i><u style="text-decoration: none;">/s/ Daniel A. Cartwright</u></i></font></td>
</tr>
<tr>
<td style="vertical-align: top; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="padding-left: 12pt; vertical-align: bottom; text-align: justify; text-indent: -12pt;"><font style="font-size: 10pt;">Daniel A. Cartwright</font></td>
</tr>
<tr>
<td style="vertical-align: top; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom; text-align: justify;">&#xA0;</td>
<td style="vertical-align: bottom;">
<p style="margin: 0 0 0 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">Chief Financial Officer</p>
<p style="margin: 0 0 0 12.25pt; text-align: justify; text-indent: -12.25pt; font: 10pt Times New Roman, Times, Serif;">(Principal Financial and Accounting Officer)</p>
</td>
</tr>
</table>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 1; Options: Last -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"></td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"></p>
<p style="margin: 0;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex32-1.htm
<DESCRIPTION>CERTIFICATION OF CHIEF EXECUTIVE OFFICER
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b></b></p>
<p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 0; margin-top: 0;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b><a href="txmd-10k_123115.htm">TherapeuticsMD, Inc. 10-K</a></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 32.1</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In connection with the annual report of TherapeuticsMD, Inc. (the &#34;Company&#34;) on Form 10-K for the year ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), I, Robert G. Finizio, Chief Executive Officer of the Company, certify, to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 0 91.5pt; text-align: justify; text-indent: -55.5pt; font: 10pt Times New Roman, Times, Serif;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</p>
<p style="margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 0 91.5pt; text-align: justify; text-indent: -55.5pt; font: 10pt Times New Roman, Times, Serif;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p>
<p style="margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;"></p>
<table style="width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="padding: 0; width: 50%; text-align: justify; text-indent: 0; font: 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">February 26, 2016</font></td>
<td style="border-bottom: Black 1pt solid; padding: 0; width: 50%; text-align: justify; text-indent: 0; font: 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>/s/ Robert G. Finizio</i></font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Robert G. Finizio</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Chief Executive Officer </font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Principal Executive Officer)</font></td>
</tr>
</table>
<p style="margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 1; Options: Last -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"></td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>9
<FILENAME>ex32-2.htm
<DESCRIPTION>CERTIFICATION OF CHIEF FINANCIAL OFFICER
<TEXT>
<html>
<head>
     <title></title>
</head>
<body style="font: 10pt Times New Roman, Times, Serif; font-family: Times New Roman, Times, serif;"><p style="margin: 0;"></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b></b></p>
<p style="margin: 0;"></p>
<!-- Field: Rule-Page -->
<div align="LEFT" style="margin-bottom: 0; margin-top: 0;">
<div style="border-bottom: Black 1pt solid; border-top: Black 2pt solid; width: 100%; font-size: 1pt;">&#xA0;</div>
</div>
<!-- Field: /Rule-Page -->
<p style="margin: 0;"></p>
<p style="margin: 0; text-align: left; font: 10pt Times New Roman, Times, Serif;"><b>&#xA0;</b><a href="txmd-10k_123115.htm">TherapeuticsMD, Inc. 10-K</a></p>
<p style="margin: 0; text-align: right; font: 10pt Times New Roman, Times, Serif;"><b>Exhibit 32.2</b></p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: center; font: 10pt Times New Roman, Times, Serif;">SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif;">In connection with the annual report of TherapeuticsMD, Inc. (the &#34;Company&#34;) on Form 10-K for the year ended December 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), I, Daniel A. Cartwright, Chief Financial Officer of the Company, certify to my best knowledge and belief, pursuant to 18 U.S.C. &#xA7; 1350, as adopted pursuant to &#xA7; 906 of the Sarbanes-Oxley Act of 2002, that:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 0 91.5pt; text-align: justify; text-indent: -55.5pt; font: 10pt Times New Roman, Times, Serif;">(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and</p>
<p style="margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0 0 0 91.5pt; text-align: justify; text-indent: -55.5pt; font: 10pt Times New Roman, Times, Serif;">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</p>
<p style="margin: 0 0 0 1in; text-align: justify; text-indent: -0.5in; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<table style="width: 100%; border-collapse: collapse;" cellpadding="0" cellspacing="0">
<tr style="vertical-align: top;">
<td style="padding: 0; width: 50%; text-align: justify; text-indent: 0; font: 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">February 26, 2016</font></td>
<td style="border-bottom: Black 1pt solid; padding: 0; width: 50%; text-align: justify; text-indent: 0; font: 12pt Times New Roman, Times, Serif;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>/s/ Daniel A. Cartwright</i></font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Daniel A. Cartwright</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Chief Financial Officer</font></td>
</tr>
<tr style="vertical-align: top;">
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">&#xA0;</font></td>
<td style="padding: 0; text-align: justify; text-indent: 0; font: 10pt Arial Unicode MS;"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">(Principal Financial and Accounting Officer)</font></td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">A signed original of this certification has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;"></p>
<!-- Field: Page; Sequence: 1; Options: Last -->
<div style="border-bottom: Black 1pt solid; margin-bottom: 6pt;">
<table style="width: 100%;" cellpadding="0" cellspacing="0">
<tr>
<td style="width: 100%; text-align: center;"></td>
</tr>
</table>
</div>
<!-- Field: /Page -->
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif;">&#xA0;</p>
<p style="margin: 0;"></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>txmd-20151231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.11b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20151231\txmd_123115.xfr; Date: 2016%2D02%2D25T23:12:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x801D0006 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:txmd="http://therapeuticsmd.com/20151231">
    <link:schemaRef xlink:href="txmd-20151231.xsd" xlink:type="simple" />
    <xbrli:context id="AsOf2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_EquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_FurnitureAndFixturesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_EmployeeStockOptionMember_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_StockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_StockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-01</xbrli:startDate>
        <xbrli:endDate>2013-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-05-08</xbrli:startDate>
        <xbrli:endDate>2013-05-11</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-06-29</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_LongTermIncentiveCompensationPlan2009Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:LongTermIncentiveCompensationPlan2009Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InternetDomainNamesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:HormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">txmd:MultipleTrademarksForVitaminsSupplementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-02-10_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-02-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-09</xbrli:startDate>
        <xbrli:endDate>2015-02-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:ApprovedHormoneTherapyDrugCandidatePatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-10-01to2015-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-10-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-10-01to2014-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-10-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-07-09_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-07-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-08</xbrli:startDate>
        <xbrli:endDate>2015-07-09</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-08to2015-07-15_custom_StifelUnderwritersMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelUnderwritersMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-08</xbrli:startDate>
        <xbrli:endDate>2015-07-15</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-02-09to2015-02-17_custom_CowenAndCompanyLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:CowenAndCompanyLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-02-09</xbrli:startDate>
        <xbrli:endDate>2015-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-28to2014-07-29_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-28</xbrli:startDate>
        <xbrli:endDate>2014-07-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-07-29_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-07-29</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-28to2014-08-04_custom_GoldmanSachsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:GoldmanSachsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-28</xbrli:startDate>
        <xbrli:endDate>2014-08-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_Option1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">txmd:Option1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_OutsideConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_OutsideConsultantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:OutsideConsultantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-02-24to2013-02-25_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-02-24</xbrli:startDate>
        <xbrli:endDate>2013-02-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-12to2013-03-13_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-12</xbrli:startDate>
        <xbrli:endDate>2013-03-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-19to2013-03-21_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-19</xbrli:startDate>
        <xbrli:endDate>2013-03-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-07-01to2014-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-07-01</xbrli:startDate>
        <xbrli:endDate>2014-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-01to2015-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-01</xbrli:startDate>
        <xbrli:endDate>2015-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-07-01to2015-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-07-01</xbrli:startDate>
        <xbrli:endDate>2015-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_InternalRevenueServiceIRSMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">txmd:CustomerConcentrationRisk4Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SupplierConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:SupplierConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-01to2013-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-03-14_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-03-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-11to2013-03-14_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-11</xbrli:startDate>
        <xbrli:endDate>2013-03-14</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-03-19to2013-03-20_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-03-19</xbrli:startDate>
        <xbrli:endDate>2013-03-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-04-12to2013-04-18_custom_JefferiesLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:JefferiesLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-04-12</xbrli:startDate>
        <xbrli:endDate>2013-04-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-09-25_custom_StifelNicolausAndCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelNicolausAndCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-09-25</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-09-24to2013-09-25_custom_StifelNicolausAndCompanyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">txmd:StifelNicolausAndCompanyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-09-24</xbrli:startDate>
        <xbrli:endDate>2013-09-25</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_OptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_SancilioAndCompanyWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:SancilioAndCompanyWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-02-17_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-02-17</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_Patents1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">txmd:Patents1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeByNatureAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">txmd:MultipleAdvanceRevolvingCreditNoteMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2012-05-01to2012-05-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2012-05-01</xbrli:startDate>
        <xbrli:endDate>2012-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2012-05-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2012-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_custom_Warrant1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_custom_Warrant2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">txmd:Warrant2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_DirectorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:DirectorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-01-01to2014-12-31_custom_DeferredSalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">txmd:DeferredSalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-01-01</xbrli:startDate>
        <xbrli:endDate>2014-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-01-01to2013-12-31_custom_DeferredSalesRevenueNetMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">txmd:DeferredSalesRevenueNetMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-01-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-06to2016-01-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-06</xbrli:startDate>
        <xbrli:endDate>2016-01-12</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-01-12_us-gaap_SubsequentEventMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-01-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-01-31_custom_SubsequentEvent1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">txmd:SubsequentEvent1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-01-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-02-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-02-22</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-12-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0000025743</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">txmd:NonQualified2012StockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-12-01</xbrli:startDate>
        <xbrli:endDate>2013-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <dei:EntityRegistrantName contextRef="From2015-01-01to2015-12-31">TherapeuticsMD, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2015-01-01to2015-12-31">0000025743</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2015-01-01to2015-12-31">10-K</dei:DocumentType>
    <dei:AmendmentFlag contextRef="From2015-01-01to2015-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2015-01-01to2015-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2015-01-01to2015-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2015-01-01to2015-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2015-01-01to2015-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityFilerCategory contextRef="From2015-01-01to2015-12-31">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:DocumentFiscalPeriodFocus contextRef="From2015-01-01to2015-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="From2015-01-01to2015-12-31">2015</dei:DocumentFiscalYearFocus>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2015-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">350000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">177928041</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">156097019</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">177928041</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">156097019</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-12-31" unitRef="Shares" decimals="INF">144976757</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">144976757</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">156097019</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">177928041</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2012-12-31_CommonStockMember" unitRef="Shares" decimals="INF">99784982</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">13580246</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">3846154</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-07-08to2015-07-15_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">4423077</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-02-09to2015-02-17_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">15617282</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2014-07-28to2014-07-29_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">8565310</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2014-07-28to2014-08-04_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">9850106</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">9850106</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2015-01-01to2015-12-31_CommonStockMember" unitRef="Shares" decimals="INF">20040359</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">45116352</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-03-11to2013-03-14_custom_JefferiesLLCMember" unitRef="Shares" decimals="INF">29411765</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2013-09-24to2013-09-25_custom_StifelNicolausAndCompanyMember" unitRef="Shares" decimals="INF">13750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-01to2016-02-17_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">17424242</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2016-01-06to2016-01-12_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">15151515</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="AsOf2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="USDPShares" decimals="INF">4.05</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2015-07-09_custom_StifelUnderwritersMember" unitRef="USDPShares" decimals="INF">7.80</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2014-07-29_custom_GoldmanSachsMember" unitRef="USDPShares" decimals="INF">4.67</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2013-03-14_custom_JefferiesLLCMember" unitRef="USDPShares" decimals="INF">1.70</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2013-09-25_custom_StifelNicolausAndCompanyMember" unitRef="USDPShares" decimals="INF">2.40</us-gaap:SharePrice>
    <us-gaap:SharePrice contextRef="AsOf2016-01-12_us-gaap_SubsequentEventMember" unitRef="USDPShares" decimals="INF">8.25</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">613284</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">612867</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">860800</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-12-31_custom_Option1Member" unitRef="Shares" decimals="INF">724193</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">75423</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">854573</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2015-01-01to2015-12-31_CommonStockMember" unitRef="Shares" decimals="INF">612981</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">75423</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">75423</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2016-01-01to2016-01-31_custom_SubsequentEvent1Member" unitRef="Shares" decimals="INF">281657</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">91374649</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">42771353</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="USD" decimals="0">59100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="USD" decimals="0">32000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-07-28to2014-07-29_custom_GoldmanSachsMember" unitRef="USD" decimals="0">42800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">78650353</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">9850</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-01-01to2015-12-31_CommonStockMember" unitRef="USD" decimals="0">20040</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">42761503</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2015-01-01to2015-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">91354609</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">45117</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">78605236</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-04-12to2013-04-18_custom_JefferiesLLCMember" unitRef="USD" decimals="0">48500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2013-09-24to2013-09-25_custom_StifelNicolausAndCompanyMember" unitRef="USD" decimals="0">30200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2016-01-06to2016-01-12_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0">134900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1232579</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">345746</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_OptionMember" unitRef="USD" decimals="0">1232579</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-12-31_custom_Option1Member" unitRef="USD" decimals="0">345746</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">30910</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">855</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31_CommonStockMember" unitRef="USD" decimals="0">613</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">344891</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2015-01-01to2015-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1231966</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">75</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">30835</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2013-01-01to2013-12-31_us-gaap_OptionMember" unitRef="USD" decimals="0">31000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2016-01-01to2016-01-31_custom_SubsequentEvent1Member" unitRef="USD" decimals="0">758000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">12772431</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="USDPShares" decimals="INF">2.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USDPShares" decimals="INF">3.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2015-12-31_custom_OutsideConsultantMember" unitRef="USDPShares" decimals="INF">6.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2015-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">.24</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2015-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">6.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2012-05-31_custom_Warrant1Member" unitRef="USDPShares" decimals="INF">2.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">2019-01-31</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights contextRef="From2015-01-01to2015-12-31_custom_OutsideConsultantMember">2020-04-06</txmd:ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrantsMember">2013-06-30</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">2013-10-31</txmd:ClassOfWarrantOrRightVestingDateOfWarrantsOrRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MinimumMember">P5M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y3M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2015-01-01to2015-12-31_EmployeeStockOptionMember_MaximumMember">P6Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.6805</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">.5878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.8229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">.6294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.3335</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.4576</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MinimumMember" unitRef="Pure" decimals="INF">0.0007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2014-01-01to2014-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">0.0177</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-12-31_EmployeeStockOptionMember_MaximumMember" unitRef="Pure" decimals="INF">.0167</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0065</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Pure" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights contextRef="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">833000</txmd:ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2015-12-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">25000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="AsOf2015-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">10000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-12-31_us-gaap_StockOptionMember_us-gaap_MinimumMember" unitRef="USDPShares" decimals="INF">0.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-12-31_us-gaap_StockOptionMember_us-gaap_MaximumMember" unitRef="USDPShares" decimals="INF">8.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">3.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">6621658</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4393455</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3200655</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">4685000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2016-01-06to2016-01-12_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF">2272727</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-36334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">661167</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">874294</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">28986</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">155341</us-gaap:InventoryRawMaterials>
    <us-gaap:DeferredCostsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">152478</us-gaap:DeferredCostsCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">690153</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1182113</us-gaap:InventoryNet>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">334822</txmd:PrepaidConsultingCurrent>
    <txmd:PrepaidConsultingCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">411864</txmd:PrepaidConsultingCurrent>
    <us-gaap:PrepaidInsurance contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">695421</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">394878</us-gaap:PrepaidInsurance>
    <us-gaap:DueFromRelatedPartiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">249981</us-gaap:DueFromRelatedPartiesCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">369812</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">181186</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2015-12-31_custom_Warrant1Member" unitRef="USD" decimals="0">257796</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">2233897</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1537407</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">351303</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31_EquipmentMember" unitRef="USD" decimals="0">132150</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31_EquipmentMember" unitRef="USD" decimals="0">132150</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31_FurnitureAndFixturesMember" unitRef="USD" decimals="0">53895</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31_FurnitureAndFixturesMember" unitRef="USD" decimals="0">69454</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">186045</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-31_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0">149699</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">152711</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">122752</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">198592</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">63293</us-gaap:PropertyPlantAndEquipmentNet>
    <txmd:PrepaidResearchDevelopmentCostsNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">128898</txmd:PrepaidResearchDevelopmentCostsNoncurrent>
    <txmd:PrepaidResearchDevelopmentCostsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">463720</txmd:PrepaidResearchDevelopmentCostsNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">31951</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">439184</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">705752</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">27957</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">29455</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">419783</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">655907</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">7539526</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">3840639</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">83527</us-gaap:AccruedRentCurrent>
    <us-gaap:AccruedRentCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">91368</us-gaap:AccruedRentCurrent>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">224300</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <txmd:SalesDiscountsReturnsAndAllowancesGoods1 contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">90446</txmd:SalesDiscountsReturnsAndAllowancesGoods1>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">46851</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">72710</us-gaap:AccruedRoyaltiesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">32659</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <txmd:AllowanceForWholesaleDistributorFeesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">160503</txmd:AllowanceForWholesaleDistributorFeesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">546264</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">185965</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">210309</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">276470</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">562096</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">442430</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">2108143</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">814205</us-gaap:AccruedSalariesCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">3725377</txmd:AccruedClinicalTrialCostsCurrent>
    <txmd:AccruedClinicalTrialCostsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1706542</txmd:AccruedClinicalTrialCostsCurrent>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">73728846</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">59079488</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">63063146</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">48389107</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">54698407</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">144977</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">156097</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">177928</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_CommonStockMember" unitRef="USD" decimals="0">99785</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">135086056</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">182982846</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">282712078</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">50580400</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-80532626</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-134749836</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2015-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-219826860</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-52113313</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">-1433128</us-gaap:StockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">-219826860</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">-134749836</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">282712078</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">182982846</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:CommonStockValue contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">177928</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">156097</us-gaap:CommonStockValue>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">10665700</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">10690381</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenue contextRef="AsOf2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredRevenue contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">522613</us-gaap:DeferredRevenue>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">3126174</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">6327129</us-gaap:AccountsPayableCurrent>
    <us-gaap:Assets contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">73728846</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">59079488</us-gaap:Assets>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">2850134</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2780851</us-gaap:AssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">125000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">125000</us-gaap:DepositsAssetsNoncurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">70680120</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">56235344</us-gaap:AssetsCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">3049715</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">2154217</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:Cash contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">64706355</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">51361607</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">54191260</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2012-12-31" unitRef="USD" decimals="0">1553474</us-gaap:Cash>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">81910</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">96916</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2015-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2014-12-31" unitRef="USDPShares" decimals="INF">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2015-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2014-12-31" unitRef="Shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">20142898</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">15026219</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member" unitRef="USD" decimals="0">8848243</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member" unitRef="USD" decimals="0">1609950</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member" unitRef="USD" decimals="0">4843463</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member" unitRef="USD" decimals="0">1586903</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member" unitRef="USD" decimals="0">1804018</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member" unitRef="USD" decimals="0">4053838</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-10-01to2015-12-31" unitRef="USD" decimals="-3">5630000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="-3">4257000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">8775598</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="-3">2831000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="-3">3752000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="-3">4186000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="-3">4475000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="-3">4848000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="-3">5190000</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk1Member" unitRef="USD" decimals="0">1221212</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk2Member" unitRef="USD" decimals="0">1711417</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk3Member" unitRef="USD" decimals="0">2588626</us-gaap:SalesRevenueNet>
    <us-gaap:SalesRevenueNet contextRef="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_custom_CustomerConcentrationRisk4Member" unitRef="USD" decimals="0">1312192</us-gaap:SalesRevenueNet>
    <us-gaap:PreferredStockValue contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <txmd:CapitalLeaseObligationsTerm contextRef="From2015-01-01to2015-12-31">P63M</txmd:CapitalLeaseObligationsTerm>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">41613</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1 contextRef="From2013-07-01to2013-12-31" unitRef="USD" decimals="0">32963</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:DueFromRelatedParties contextRef="AsOf2014-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">250000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties contextRef="AsOf2013-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">250000</us-gaap:DueFromRelatedParties>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2014-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">46000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="AsOf2013-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">46000</us-gaap:AccountsPayableRelatedPartiesCurrent>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2015-01-01to2015-12-31_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">.60</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-12-31_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">.82</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-12-31_us-gaap_SupplierConcentrationRiskMember" unitRef="Pure" decimals="INF">.98</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2015-01-01to2015-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">.67</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-12-31_us-gaap_SalesRevenueNetMember_us-gaap_CustomerConcentrationRiskMember" unitRef="Pure" decimals="INF">.79</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2014-01-01to2014-12-31_custom_DeferredSalesRevenueNetMember" unitRef="Pure" decimals="INF">.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="From2013-01-01to2013-12-31_custom_DeferredSalesRevenueNetMember" unitRef="Pure" decimals="INF">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-12-31" unitRef="Shares" decimals="INF">33447756</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">20725325</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">16792443</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">12722431</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">30720359</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">29926241</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-12-31_us-gaap_StockOptionMember" unitRef="Shares" decimals="INF">15632742</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">13927916</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Shares" decimals="INF">14293499</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">774165</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">157721</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">675982</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">103368</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">774165</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2015-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">157721</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">675982</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet contextRef="AsOf2014-12-31_custom_HormoneTherapyDrugCandidatePatentsMember_custom_MultipleTrademarksForVitaminsSupplementsMember" unitRef="USD" decimals="0">103368</txmd:IndefiniteLivedIntangibleAssetsExcludingGoodwillNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">1761332</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1342228</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">32441</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">23480</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">10262</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:Depreciation contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">29959</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">28987</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">47883</us-gaap:Depreciation>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">674353</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <txmd:PrepaidResearchAndDevelopmentCostsCurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">299498</txmd:PrepaidResearchAndDevelopmentCostsCurrent>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2015-01-01to2015-12-31">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2015-01-01to2015-12-31_custom_SancilioAndCompanyWarrantsMember">P18Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:GrossProfit contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">15636225</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">11354416</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2015-10-01to2015-12-31" unitRef="USD" decimals="-3">4395000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="-3">3377000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">6816001</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="-3">2000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="-3">2859000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="-3">3118000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="-3">3431000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="-3">3815000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="-3">3996000</us-gaap:GrossProfit>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-85077024</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-54217210</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-10-01to2015-12-31" unitRef="USD" decimals="-3">-17843000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-10-01to2014-12-31" unitRef="USD" decimals="-3">-16303000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-28419313</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-03-31" unitRef="USD" decimals="-3">-9183000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-04-01to2014-06-30" unitRef="USD" decimals="-3">-10899000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-07-01to2014-09-30" unitRef="USD" decimals="-3">-17832000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-03-31" unitRef="USD" decimals="-3">-20895000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-04-01to2015-06-30" unitRef="USD" decimals="-3">-27227000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-07-01to2015-09-30" unitRef="USD" decimals="-3">-19472000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2014-01-01to2014-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-54217210</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2015-01-01to2015-12-31_RetainedEarningsMember" unitRef="USD" decimals="0">-85077024</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2013-01-01to2013-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-28419313</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-01-01to2015-12-31" unitRef="USDPShares" decimals="INF">-0.49</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-01-01to2014-12-31" unitRef="USDPShares" decimals="INF">-0.36</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-10-01to2015-12-31" unitRef="USDPShares" decimals="INF">-.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-10-01to2014-12-31" unitRef="USDPShares" decimals="INF">-0.10</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="USDPShares" decimals="INF">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-01-01to2014-03-31" unitRef="USDPShares" decimals="INF">-0.06</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-04-01to2014-06-30" unitRef="USDPShares" decimals="INF">-0.07</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2014-07-01to2014-09-30" unitRef="USDPShares" decimals="INF">-0.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-01-01to2015-03-31" unitRef="USDPShares" decimals="INF">-.13</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-04-01to2015-06-30" unitRef="USDPShares" decimals="INF">-.16</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2015-07-01to2015-09-30" unitRef="USDPShares" decimals="INF">-.11</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="AsOf2015-12-31_custom_Warrant1Member" unitRef="USD" decimals="0">128898</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="AsOf2015-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">128898</us-gaap:PrepaidExpenseOtherNoncurrent>
    <us-gaap:PrepaidExpenseOtherNoncurrent contextRef="AsOf2014-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">463720</us-gaap:PrepaidExpenseOtherNoncurrent>
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">980985</txmd:PrepaidManufacturingCostsNoncurrent>
    <txmd:PrepaidManufacturingCostsNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">963543</txmd:PrepaidManufacturingCostsNoncurrent>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">146081</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">113640</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">3994</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="USD" decimals="0">2496</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember_us-gaap_InternetDomainNamesMember" unitRef="USD" decimals="0">91743</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">19401</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember" unitRef="USD" decimals="0">49845</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <dei:DocumentPeriodEndDate contextRef="From2015-01-01to2015-12-31">2015-12-31</dei:DocumentPeriodEndDate>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2013-02-24to2013-02-25_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="From2013-03-12to2013-03-13_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">200000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:RepaymentsOfDebt contextRef="From2013-03-19to2013-03-21_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">401085</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfLinesOfCredit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">500000</us-gaap:RepaymentsOfLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">500000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">4691847</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">945485</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">365583</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2015-01-01to2015-12-31_CommonStockMember" unitRef="Shares" decimals="INF">1177682</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">365583</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2015-01-01to2015-12-31_custom_Warrant2Member" unitRef="Shares" decimals="INF">232197</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2016-01-01to2016-01-31_custom_SubsequentEvent1Member" unitRef="Shares" decimals="INF">500000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">260027</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1503922</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2015-01-01to2015-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2014-01-01to2014-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">260027</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="From2013-01-01to2013-12-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">1451934</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:InvestmentIncomeInterest contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">17442</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">37309</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">27234</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncome contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">95719</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">46569</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">34544</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OperatingIncomeLoss contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-85190185</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-54041061</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-25808244</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">100826410</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">65395477</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">32624245</us-gaap:OperatingExpenses>
    <us-gaap:DepreciationAndAmortization contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">62400</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">52467</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">58145</us-gaap:DepreciationAndAmortization>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">72042774</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">43218938</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">13551263</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">28721236</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">22124072</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">19014837</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostOfGoodsSold contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">4506673</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">3671803</us-gaap:CostOfGoodsSold>
    <us-gaap:CostOfGoodsSold contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1959597</us-gaap:CostOfGoodsSold>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">113161</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-176149</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-2611069</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-85077024</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-54217210</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-28419313</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2015-01-01to2015-12-31" unitRef="Shares" decimals="INF">173174229</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2014-01-01to2014-12-31" unitRef="Shares" decimals="INF">149727228</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2013-01-01to2013-12-31" unitRef="Shares" decimals="INF">127569731</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:InterestAndDebtExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1165981</us-gaap:InterestAndDebtExpense>
    <us-gaap:OtherNonoperatingExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">2944</us-gaap:OtherNonoperatingExpense>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">366000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">366000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">181000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">365</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2015-01-01to2015-12-31_CommonStockMember" unitRef="USD" decimals="0">1178</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">180635</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2015-01-01to2015-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">364822</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2014-01-01to2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">181000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2016-01-01to2016-01-31_custom_SubsequentEvent1Member" unitRef="USD" decimals="0">1285000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">6777835</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4609811</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3254083</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4609811</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2015-01-01to2015-12-31_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6777835</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">3254083</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-79044119</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-45520996</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-20768069</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-150068</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">3698887</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">239450</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">2875320</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-522613</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-1079967</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">457828</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-3200955</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4212912</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">472851</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">17442</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">37309</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">565706</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">773532</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-680281</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1386319</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-491960</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">138495</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-571592</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">917656</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">458028</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1068619</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:OtherNoncashExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">2944</us-gaap:OtherNoncashExpense>
    <us-gaap:AmortizationOfDeferredCharges contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">260027</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:AmortizationOfDeferredCharges contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1451934</us-gaap:AmortizationOfDeferredCharges>
    <us-gaap:ShareBasedCompensation contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">7189699</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">4970312</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">3844155</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1102680</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">22157</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-5436</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-15493</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">-584361</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-606756</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">-583561</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-10686</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">103737</us-gaap:IncreaseDecreaseInRestrictedCash>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">165257</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">30962</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">40790</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">419104</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">586480</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">439034</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">13344748</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">-2829653</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:CashPeriodIncreaseDecrease contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">52637786</us-gaap:CashPeriodIncreaseDecrease>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">92973228</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">43298099</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">73989416</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">366000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">181000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">1232579</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">345746</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">30910</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">91374649</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">42771353</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">78650353</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">13927916</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">12722431</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">-1255485</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2015-01-01to2015-12-31_custom_Warrant2Member" unitRef="Shares" decimals="INF">-310000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <txmd:ClassOfWarrantOrRighstContractualLifeBeginningOustanding contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember">P3Y</txmd:ClassOfWarrantOrRighstContractualLifeBeginningOustanding>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="AsOf2013-12-31_WarrantMember" unitRef="USDPShares" decimals="INF">2.83</us-gaap:FairValueAssumptionsExercisePrice>
    <us-gaap:FairValueAssumptionsExercisePrice contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">6.35</us-gaap:FairValueAssumptionsExercisePrice>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">.0102</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.0088</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsRiskFreeInterestRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.0112</us-gaap:FairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">.6059</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember" unitRef="Pure" decimals="INF">0.4429</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedVolatilityRate contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember" unitRef="Pure" decimals="INF">0.4589</us-gaap:FairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MinimumMember">P5Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedTerm contextRef="From2013-01-01to2013-12-31_us-gaap_WarrantMember_us-gaap_MaximumMember">P6Y</us-gaap:FairValueAssumptionsExpectedTerm>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:FairValueAssumptionsExpectedDividendRate contextRef="From2013-01-01to2013-12-31_WarrantMember" unitRef="Pure" decimals="INF">0.00</us-gaap:FairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">-102500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">8.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">43996311</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">146864184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2015-12-31_us-gaap_InternalRevenueServiceIRSMember" unitRef="USD" decimals="0">192601415</us-gaap:OperatingLossCarryforwards>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="INF">.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="INF">.0473</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">0.058</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">0.058</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="INF">-.3897</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">-.509</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">-0.324</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2015-01-01to2015-12-31" unitRef="Pure" decimals="INF">.0024</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2014-01-01to2014-12-31" unitRef="Pure" decimals="INF">.111</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2013-01-01to2013-12-31" unitRef="Pure" decimals="INF">-0.084</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2015-01-01to2015-12-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2014-01-01to2014-12-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2013-01-01to2013-12-31" unitRef="Pure" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">79499633</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">43091437</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOtherLossCarryforwards contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">14773537</us-gaap:DeferredTaxAssetsOtherLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">186347</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">547511</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">79685980</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">43091437</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15321048</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">79685980</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">43091437</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2013-12-31" unitRef="USD" decimals="0">15321048</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2014-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2013-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LeaseAndRentalExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">446099</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">361793</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2013-07-01to2013-12-31" unitRef="USD" decimals="0">180894</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2013-01-01to2013-06-30" unitRef="USD" decimals="0">60168</us-gaap:LeaseAndRentalExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-12-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">17856851</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">2868474</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2014-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">16792443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">20725325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:AdvertisingExpense contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">792574</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="From2014-01-01to2014-12-31" unitRef="USD" decimals="0">698871</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">11739</us-gaap:AdvertisingExpense>
    <us-gaap:CashFDICInsuredAmount contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">250000</us-gaap:CashFDICInsuredAmount>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2015-12-31" unitRef="Pure" decimals="INF">14</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember" unitRef="Pure" decimals="INF">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2015-12-31_us-gaap_PatentsMember" unitRef="Pure" decimals="INF">1</txmd:NumberOfIssuedPatents>
    <txmd:NumberOfIssuedPatents contextRef="AsOf2015-12-31_custom_Patents1Member" unitRef="Pure" decimals="INF">12</txmd:NumberOfIssuedPatents>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">10000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.06</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise contextRef="From2015-01-01to2015-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">114</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <txmd:NumberOfStockOptionsExercisedInCashlessExercise contextRef="From2014-01-01to2014-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">130380</txmd:NumberOfStockOptionsExercisedInCashlessExercise>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">50000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2014-07-28to2014-07-29_custom_GoldmanSachsMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2013-03-11to2013-03-14_custom_JefferiesLLCMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:AdditionalPeriodForPurchaseShare contextRef="From2016-01-06to2016-01-12_us-gaap_SubsequentEventMember">P30D</txmd:AdditionalPeriodForPurchaseShare>
    <txmd:StockExpectedToIssuedDuringPeriodShares contextRef="From2013-03-19to2013-03-20_custom_JefferiesLLCMember" unitRef="Shares" decimals="INF">4411765</txmd:StockExpectedToIssuedDuringPeriodShares>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2015-02-09to2015-02-10_custom_CowenAndCompanyLLCMember" unitRef="Shares" decimals="INF">2037036</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2015-07-08to2015-07-09_custom_StifelUnderwritersMember" unitRef="Shares" decimals="INF">576923</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2014-07-28to2014-07-29_custom_GoldmanSachsMember" unitRef="Shares" decimals="INF">1284796</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <txmd:StockIssuedDuringPeriodSharesNewIssues1 contextRef="From2013-04-12to2013-04-18_custom_JefferiesLLCMember" unitRef="Shares" decimals="INF">1954587</txmd:StockIssuedDuringPeriodSharesNewIssues1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance contextRef="From2013-05-01to2013-05-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">850000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance contextRef="From2015-01-01to2015-12-31_custom_OutsideConsultantMember" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Shares" decimals="INF">1300000</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrantsMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember">P6Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1 contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member">P5Y</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrantsMember" unitRef="Pure" decimals="INF">0.4589</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember" unitRef="Pure" decimals="INF">.4584</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.4429</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Pure" decimals="INF">.4471</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrantsMember" unitRef="Pure" decimals="INF">0.0112</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember" unitRef="Pure" decimals="INF">.0141</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0.0088</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Pure" decimals="INF">.0074</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrantsMember" unitRef="Pure" decimals="INF">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember" unitRef="Pure" decimals="INF">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Pure" decimals="INF">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="Pure" decimals="INF">0</us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">283333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">283333</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">405066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">462196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2013-01-01to2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="USD" decimals="0">1711956</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2012-05-01to2012-05-31_custom_Warrant1Member" unitRef="USD" decimals="0">1532228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="From2013-12-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="USD" decimals="0">233500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:RestrictedStockExpense contextRef="From2013-01-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="USD" decimals="0">180072</us-gaap:RestrictedStockExpense>
    <us-gaap:RestrictedStockExpense contextRef="From2014-01-01to2014-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="USD" decimals="0">53428</us-gaap:RestrictedStockExpense>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2015-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:InterestPaid contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">212853</us-gaap:InterestPaid>
    <txmd:WarrantsIssuedForFinancing contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1711956</txmd:WarrantsIssuedForFinancing>
    <txmd:WarrantsIssuedForServices contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">462196</txmd:WarrantsIssuedForServices>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2015-01-01to2015-12-31_us-gaap_MinimumMember">P6M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ReturnPeriodOfUnsalablePrescriptionProducts contextRef="From2015-01-01to2015-12-31_us-gaap_MaximumMember">P24M</txmd:ReturnPeriodOfUnsalablePrescriptionProducts>
    <txmd:ShelfLifeOfPrescriptionProducts contextRef="From2015-01-01to2015-12-31">P24M</txmd:ShelfLifeOfPrescriptionProducts>
    <txmd:PrepaidVendorDeposits contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">159489</txmd:PrepaidVendorDeposits>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2016-02-22" unitRef="Shares" decimals="INF">196150311</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityPublicFloat contextRef="AsOf2015-06-30" unitRef="USD" decimals="0">738931545</dei:EntityPublicFloat>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">1109883</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1427263</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">1615251</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2014-12-31" unitRef="USD" decimals="0">1228588</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">40580</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">40580</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">40580</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">40580</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">40580</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <txmd:NumberOfStockOptionsExercised contextRef="From2015-01-01to2015-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">417</txmd:NumberOfStockOptionsExercised>
    <txmd:NumberOfStockOptionsExercised contextRef="From2014-01-01to2014-12-31_us-gaap_OptionMember" unitRef="Shares" decimals="INF">136607</txmd:NumberOfStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">50</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2014-01-01to2014-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">-50</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2013-05-08to2013-05-11_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">405066</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2013-06-29to2013-06-30_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">462196</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2015-01-01to2015-12-31_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">154068</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2015-01-01to2015-12-31_custom_OutsideConsultantMember" unitRef="USD" decimals="0">139142</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2014-01-01to2014-12-31_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">154068</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2013-01-01to2013-12-31_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">77034</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2015-01-01to2015-12-31_custom_Warrant1Member" unitRef="USD" decimals="0">257796</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2014-01-01to2014-12-31_custom_Warrant1Member" unitRef="USD" decimals="0">309165</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2013-01-01to2013-12-31_custom_Warrant1Member" unitRef="USD" decimals="0">360528</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">6.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-12-31_custom_OutsideConsultantMember" unitRef="USDPShares" decimals="INF">3.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <txmd:WarrantsGrantedToPurchaseCommonStockExpectedToVestShares contextRef="AsOf2015-12-31_custom_SancilioAndCompanyWarrantsMember" unitRef="Shares" decimals="INF">283333</txmd:WarrantsGrantedToPurchaseCommonStockExpectedToVestShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2013-01-31_custom_MultipleAdvanceRevolvingCreditNoteMember" unitRef="Shares" decimals="INF">1250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2015-12-31_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">77026</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:DeferredFinanceCostsNoncurrentNet contextRef="AsOf2015-12-31_custom_SancilioAndCompanyWarrantsMember" unitRef="USD" decimals="0">464000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">12422432</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">104909091</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue>
    <txmd:ClassOfWarrantOrRighstContractualLifeClosingOustanding contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember">P1Y8M12D</txmd:ClassOfWarrantOrRighstContractualLifeClosingOustanding>
    <txmd:ClassOfWarrantOrRighstContractualLifeVestedAndExercisable contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember">P1Y7M6D</txmd:ClassOfWarrantOrRighstContractualLifeVestedAndExercisable>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">36623875</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">107344752</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2015-12-31_custom_LongTermIncentiveCompensationPlan2009Member" unitRef="Shares" decimals="INF">3607852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2015-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">7050000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">2.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">4.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">0.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">131523505</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USD" decimals="0">15340679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">1.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="USDPShares" decimals="INF">7.46</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">19800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2015-01-01to2015-12-31" unitRef="USDPShares" decimals="INF">4.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2015-01-01to2015-12-31" unitRef="USD" decimals="0">3186371</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:LitigationSettlementExpense contextRef="From2015-01-01to2015-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">29000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RelatedPartyTransactionAmountsOfTransaction contextRef="From2015-01-01to2015-12-31_us-gaap_DirectorMember" unitRef="USD" decimals="0">175000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
    <us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement contextRef="From2015-01-01to2015-12-31_us-gaap_DirectorMember">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We entered into a settlement agreement with Pernix according to which Pernix&#13;paid us $175,000 in cash.&lt;/p&gt;</us-gaap:RelatedPartyTransactionTermsAndMannerOfSettlement>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">493790</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">507087</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">388976</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2015-12-31" unitRef="USD" decimals="0">1389853</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">1711956</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">1711956</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">867262</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">867262</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty contextRef="From2013-01-01to2013-12-31" unitRef="USD" decimals="0">36284</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty>
    <txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty contextRef="From2013-01-01to2013-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">36284</txmd:AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 1 &amp;#150; THE COMPANY&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;TherapeuticsMD, Inc., a Nevada corporation, or&#13;TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed;&#13;BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.&#13;Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to&#13;as &amp;#147;our company,&amp;#148; &amp;#147;we,&amp;#148; &amp;#147;our,&amp;#148; or &amp;#147;us.&amp;#148;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Nature of Business&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We are a women&amp;#146;s health care product company&#13;focused on creating and commercializing products targeted exclusively for women. As of the date of these consolidated financial&#13;statements, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of our advanced&#13;hormone therapy pharmaceutical products. The drug candidates used in our clinical trials are designed to alleviate the symptoms&#13;of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and&#13;vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or&#13;in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect&#13;profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the&#13;administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded&#13;and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The accompanying consolidated financial statements&#13;include the accounts of our company and our wholly owned subsidiaries, VitaMed, BocaGreen and VitaCare. All intercompany balances&#13;and transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Cash&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify"&gt;&lt;font style="font-weight: normal"&gt;We&#13;maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation (the &amp;#147;FDIC&amp;#148;)&#13;insured limits of $250,000 per bank. We have never experienced any losses related to these funds.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Trade Accounts Receivable and Allowance for&#13;Doubtful Accounts&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Trade accounts receivable are customer obligations&#13;due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide&#13;an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,&#13;and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write&#13;off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection&#13;efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase&#13;in the allowance for doubtful accounts. &lt;font style="color: #252525"&gt;To the extent data we use to calculate these estimates does&#13;not accurately reflect bad debts; adjustments to these reserves may be &lt;/font&gt;required.&lt;/p&gt;</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Inventories&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;Inventories&#13;represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or market&#13;using the average-cost method. Any costs of manufacturing the prescription products associated with the deferred revenue (as discussed&#13;in Revenue Recognition) prior to January 1 , 2015, were recorded as deferred costs and included in inventory, until such time as&#13;the related deferred revenue was recognized. &lt;/font&gt;We review our inventory for excess or obsolete inventory and write-down obsolete&#13;or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product&#13;improvements rendering previous versions obsolete.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Pre-Launch&#13;Inventory&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;Inventory&#13;costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is&#13;probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit&#13;cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research&#13;and development expenses during the period the costs are incurred. We have not capitalized any pre-launch inventory to date.&lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Fixed Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We state fixed assets at cost, net of accumulated&#13;depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair&#13;costs to operating expenses as incurred. &lt;font style="letter-spacing: -0.15pt"&gt;We compute depreciation using the straight-line&#13;method over the estimated useful lives of the related assets, which range from three to seven years.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We capitalize software and&amp;#160;software&amp;#160;development&amp;#160;costs&amp;#160;incurred&#13;to create and acquire computer software for internal use, principally related to software coding and application development. We&#13;begin to capitalize&amp;#160;software development&amp;#160;costs&amp;#160;when both the preliminary project stage is completed and it is probable&#13;that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized&#13;in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into&#13;service over the estimated useful life, generally five to seven years.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Intangible&#13;&lt;/u&gt;&lt;/font&gt;&lt;u&gt;Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Patents&#13;and Trademarks&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;We have adopted the provisions&#13;of &lt;/font&gt;Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, &lt;font style="letter-spacing: -0.15pt"&gt;350,&#13;&lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or &lt;/font&gt;ASC 350&lt;font style="letter-spacing: -0.15pt"&gt;. Capitalized patent costs,&#13;net of accumulated amortization, include legal costs incurred for patent applications. &lt;/font&gt;In accordance with ASC 350, &lt;font style="letter-spacing: -0.15pt"&gt;once&#13;a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.&#13;If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, 2015, we had 14 issued&#13;patents (See Note 7). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks&#13;are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate&#13;that their carrying amount may not be recoverable.&lt;/font&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Impairment of Long-Lived Assets&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We review the carrying values of fixed assets and&#13;long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their&#13;carrying values may not be recoverable. Such events or circumstances may include, among others, the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;significant declines in an asset&amp;#146;s market price;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;significant deterioration in an asset&amp;#146;s physical condition;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;significant changes in the nature or extent of an asset&amp;#146;s use&#13;or operation;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;significant adverse changes in the business climate that could impact&#13;an asset&amp;#146;s value, including adverse actions or assessments by regulators; &lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;accumulation of costs significantly in excess of original expectations&#13;related to the acquisition or construction of an asset;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;current-period operating or cash flow losses combined with a history&#13;of such losses or a forecast that demonstrates continuing losses associated with an asset&amp;#146;s use; and&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#183;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;expectations that it is more likely than not that an asset will be&#13;sold or otherwise disposed of significantly before the end of its previously estimated useful life.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;If impairment indicators are present, we determine&#13;whether an impairment loss should be recognized by testing the applicable asset or asset group&amp;#146;s carrying value for recoverability.&#13;This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent&#13;of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future&#13;cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective&#13;carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment&#13;in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.&#13;In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and&#13;the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then&#13;we record a loss for the difference between the assets&amp;#146; fair value and respective carrying values. We determine the fair&#13;value of the assets using an &amp;#147;income approach&amp;#148; based upon a forecast of all the expected discounted future net cash flows&#13;associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market&#13;share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial&#13;relationships, market conditions, and available external information about future trends. We believe our current assumptions and&#13;estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates,&#13;resulting in the need for an impairment charge in future periods. There was no impairment of long-lived assets to be held and used&#13;during the years ended December 31, 2015, 2014 and 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We perform impairment tests for intangible&amp;#160;assets&amp;#160;with&amp;#160;indefinite&amp;#160;useful&amp;#160;lives&amp;#160;annually,&#13;or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible&#13;asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value&#13;of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss&#13;is recognized in an amount equal to that excess. There was no impairment of indefinite lived intangible assets during the years&#13;ended December 31, 2015, 2014 and 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our financial instruments consist primarily of&#13;cash, accounts receivable, accounts payable and accrued expenses. The carrying amount of cash, accounts receivable, accounts payable&#13;and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered&#13;Level 1 assets under the fair value hierarchy.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We categorize our assets and liabilities that are&#13;valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, &lt;i&gt;Fair Value Measurements.&#13;&lt;/i&gt; The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities&#13;(Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet&#13;at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;unadjusted quoted prices in active markets&#13;for identical assets or liabilities;&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;quoted prices for similar assets or liabilities&#13;in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,&#13;for substantially the full term of the financial instrument; and&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"&gt;&lt;tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;unobservable inputs for the asset or liability.&lt;/td&gt;&#13;&lt;/tr&gt;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;At December 31, 2015 and 2014, we had no assets&#13;or liabilities that were valued at fair value on a recurring basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The fair value of indefinite-lived assets is measured&#13;on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. There&#13;was no impairment of intangible assets during the years ended December 31, 2015, 2014 and 2013.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We account for income taxes under the asset and&#13;liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences&#13;between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure&#13;deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related&#13;temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of&#13;a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount&#13;that will more likely than not be realized.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;,&#13;we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in&#13;an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest&#13;amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in&#13;the period in which those changes in judgment occur.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We recognize both interest and penalties related&#13;to uncertain tax positions as part of the income tax provision. At December 31, 2015 and 2014, we had no tax positions relating&#13;to open tax returns that were considered to be uncertain.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our tax returns are subject to review by the Internal&#13;Revenue Service three years after they are filed. Currently, years filed after 2012 are subject to review.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Share-Based Compensation&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;We measure the compensation&#13;costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements&#13;over the period during which employees are required to provide services. Share-based compensation arrangements include options,&#13;restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans.&#13;As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over&#13;the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model,&#13;an acceptable model in accordance with ASC 718 to value options. Calculating share-based compensation expense requires the input&#13;of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award,&#13;stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent&#13;our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result,&#13;if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.&lt;/font&gt;&lt;font style="font-size: 10pt"&gt;&#13;&lt;/font&gt;&lt;font style="font-size: 10pt"&gt; &lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Equity instruments (&amp;#147;instruments&amp;#148;)&#13;issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, &lt;i&gt;Equity - Based&#13;Payments to Non-Employees&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or ASC 505&lt;i&gt;. &lt;/i&gt;ASC 505&lt;i&gt; &lt;/i&gt;defines the measurement date and recognition period for&#13;such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the&#13;earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized&#13;each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees&#13;can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value&#13;related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined&#13;in ASC 505.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We recognize the compensation expense for all share-based&#13;compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We&#13;generally recognize the compensation expense on a straight-line basis over the employee&amp;#146;s requisite service period. We estimate&#13;the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from&#13;our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:DebtPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Debt Discounts&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Costs incurred from parties that are providing&#13;long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based&#13;on the relative fair value of the debt and warrants to the total proceeds. We amortize discounts over the life of the related debt&#13;using the effective interest rate method.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We recognize revenue on arrangements in accordance&#13;with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an&#13;arrangement exists, the service is performed, and collectability is reasonably assured.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our over-the-counter (OTC) and prescription prenatal&#13;vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary&#13;difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal&#13;vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product&#13;primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing&#13;similar marketing techniques. The revenue that is generated by us from major external customers is all generated from sales of&#13;our prescription prenatal vitamin products which is disclosed in Note 13. There are no major external customers for our OTC prenatal&#13;vitamin or other products.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;OTC Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We generate OTC revenue from product sales primarily&#13;to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have&#13;passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include&#13;shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually&#13;receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC&#13;sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce&#13;OTC customers. We recognize revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;i&gt;&lt;u&gt;Prescription Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We sell our name brand and generic prescription&#13;products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of&#13;sales discounts, chargebacks, and customer rebates.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We accept returns of unsalable prescription products&#13;from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription&#13;products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns&#13;based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015,&#13;we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date,&#13;we could not reasonably estimate the amount of future returns.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We offer various rebate programs in an effort to&#13;maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed&#13;to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the&#13;allowance for consumer rebates that we have offered based on our experience and industry averages, which is reviewed, and adjusted&#13;if necessary, on a quarterly basis.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Segment Reporting&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We are managed and operated as one business, which&#13;is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single&#13;management team that reports to the President of our Company. We do not operate separate lines of business with respect to any&#13;of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived&#13;from sales in the United States. Accordingly, we view our business as one reportable operating segment.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Shipping and Handling Costs&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We expense all shipping and handling costs as incurred.&#13;We include these costs in cost of goods sold on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Advertising&#13;Costs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We expense advertising costs when incurred. Advertising&#13;costs were $792,574, $698,871 and $11,739 during the years ended December 31, 2015, 2014 and 2013, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Research and Development Expenses&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"&gt;Research and development,&#13;or R&amp;#38;D, expenses include internal R&amp;#38;D activities, services of external contract research organizations, or CROs, costs&#13;of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;#38;D activity&#13;expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be&#13;expensed in future research and development activities are capitalized, and were $1,138,073 at December 31, 2015, of which $1,009,175&#13;was included in other current assets and $128,898 was included in long term prepaid expense on the accompanying consolidated balance&#13;sheets. Advance payments to be expensed in future R&amp;#38;D activities were $1,175,082 at December 31, 2014, of which $711,362 was&#13;included in other current assets and $463,720 was included in long term prepaid expense on the accompanying consolidated balance&#13;sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include&#13;regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as&#13;R&amp;#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes,&#13;clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that&#13;were classified as R&amp;#38;D expenses related to designing experiments to generate data for patents and to further the formulation&#13;development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding&#13;R&amp;#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing,&#13;and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;#38;D activities and other activity&#13;expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance&#13;of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;#38;D&#13;activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review&#13;and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable&#13;to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress&#13;to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Earnings Per Share&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We calculate earnings per share, or EPS, in accordance&#13;with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation and disclosure of two EPS amounts: basic and diluted. We&#13;compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock,&#13;outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding&#13;plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our&#13;Common Stock consist of options and warrants and were excluded from the calculation of diluted earnings per share because their&#13;effect would have been anti-dilutive due to the net loss reported by us.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The table below presents the potentially dilutive&#13;securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they&#13;were not antidilutive for the periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 35%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;20,725,325&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16,792,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;15,632,742&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,722,431&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,927,916&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,293,499&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33,447,756&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,720,359&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;29,926,241&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Subsequent to December 31, 2015, we issued 17,424,242&#13;shares of our Common Stock at a public offering price of $8.25 per share. In January 2016, certain individuals exercised stock&#13;options to purchase 281,657 shares of our Common Stock for approximately $758,000 in cash. In addition, warrants to purchase 500,000&#13;shares of our Common Stock were exercised for $1,285,000 in cash. See Note 16 - Subsequent Events for more details.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The table below presents the potentially&#13;dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders&#13;if they were not antidilutive for the periods presented.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="10" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;As of December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2013&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 35%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;20,725,325&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16,792,443&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;15,632,742&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,722,431&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,927,916&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,293,499&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33,447,756&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,720,359&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;29,926,241&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;u&gt;Concentration of Credit Risk and other Risks and Uncertainties &lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially expose us&#13;to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions&#13;in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. The Company has not experienced&#13;any historical losses on its deposits of cash.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Concentration of credit risk with respect to our&#13;trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacies. Credit is extended&#13;to our customers based on an evaluation of a customer&amp;#146;s financial condition, and collateral is not required.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:UseOfEstimates contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Our consolidated financial statements have been&#13;prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation&#13;of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,&#13;liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including&#13;those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions&#13;that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying&#13;values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material&#13;amounts, from these estimates under different assumptions or conditions.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;u&gt;Recently Issued Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;In November 2015,&#13;the FASB issued Accounting Standards Update, or ASU, No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred&#13;Taxes. This guidance requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet&#13;instead of separating deferred taxes into current and noncurrent amounts. Also, companies will no longer allocate valuation allowances&#13;between current and noncurrent deferred tax assets because those allowances also will be classified as noncurrent. For public business&#13;entities, the guidance is effective for financial statements issued for annual periods beginning December 15, 2016, and interim&#13;periods within those annual periods. Companies can adopt the guidance either prospectively or retrospectively. We adopted&lt;/font&gt;&amp;#160;&lt;font style="font-size: 10pt"&gt;this&#13;guidance in the fourth quarter of 2015. The adoption of this guidance did not have a material impact on our consolidated financial&#13;statements or disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In July 2015, the FASB issued ASU 2015-11, Inventory&#13;(Topic 330), simplifying the Measurement of Inventory. This guidance requires entities to measure inventory at the lower of cost&#13;or net realizable value rather than at the lower of cost or market (LOCOM). The guidance applies only to inventories for which&#13;cost is determined by methods other than last-in first-out (LIFO) or the retail inventory method (RIM). Entities that use LIFO&#13;or RIM will continue to use existing impairment models. The new guidance does not change the calculation of net realizable value&#13;that entities are required to calculate when applying existing LOCOM guidance. Net realizable value is the estimated selling price&#13;in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Under the new&#13;guidance, however, entities will no longer need to calculate other measures of &amp;#147;market.&amp;#148; The guidance is effective&#13;for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years.&#13;Early adoption is permitted. We are currently evaluating the impact of this guidance, if any, on our consolidated financial statements&#13;and disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2015, the FASB issued ASU No. 2015-10,&#13;Technical Corrections and Improvements, to correct differences between original guidance and the ASC clarify the guidance, correct&#13;references and make minor improvements affecting a variety of topics. Amendments that the FASB deemed more substantive are effective&#13;for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-10&#13;did not have a material effect on our consolidated financial statements and disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In August 2014, the FASB issued ASU No. 2014-15,&#13;Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#146;s Ability&#13;to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there are conditions and events that raise&#13;substantial doubt about the entity&amp;#146;s ability to continue as a going concern within one year after the financial statements&#13;are issued (or available to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods&#13;ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted&#13;for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect the&#13;adoption of ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2014, the FASB and the International Accounting&#13;Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&amp;#146;s core principle&#13;is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the&#13;consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will&#13;need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations&#13;in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction&#13;price to each separate performance obligations. In July 2015, the FASB approved the proposal to defer the effective date of ASU&#13;2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities&#13;for annual reporting periods beginning after December 15, 2017 and interim periods therein. We are currently evaluating the impact&#13;of ASU 2014-09 on our consolidated financial statements and disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;We do not believe there would have been a material&#13;effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards&#13;been adopted in the current period.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 4 &amp;#150; OTHER CURRENT ASSETS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Other current assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;695,421&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;394,878&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;674,353&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;299,498&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;369,812&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;181,186&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;334,822&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;411,864&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid vendor deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;159,489&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other receivables-related party (Note 12)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;249,981&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,233,897&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,537,407&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Other current assets consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;695,421&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;394,878&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;674,353&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;299,498&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other prepaid costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;369,812&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;181,186&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid consulting&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;334,822&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;411,864&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid vendor deposits&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;159,489&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#151;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other receivables-related party (Note 12)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;249,981&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;2,233,897&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,537,407&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 5 &amp;#150; FIXED ASSETS, NET&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Fixed assets, net consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accounting system in process&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;149,699&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;69,454&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53,895&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;351,303&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;186,045&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(152,711&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(122,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;198,592&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,293&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Depreciation expense for the years ended December&#13;31, 2015, 2014, and 2013 was $29,959, $28,987 and $47,883, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Fixed assets, net consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 70%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Equipment&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;132,150&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accounting system in process&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;149,699&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Furniture and fixtures&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;69,454&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;53,895&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;351,303&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;186,045&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(152,711&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(122,752&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL FIXED ASSETS, NET&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;198,592&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;63,293&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <txmd:PrepaidExpensesDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 6 &amp;#150;PREPAID EXPENSE&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expense (long-term) consists of the&#13;following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 74%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;980,985&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;963,543&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development&amp;#160;&amp;#160;costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;128,898&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;463,720&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL PREPAID EXPENSE&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,109,883&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,427,263&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;</txmd:PrepaidExpensesDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Prepaid expense (long-term) consists of the&#13;following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 74%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid manufacturing costs&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;980,985&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;963,543&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Prepaid research and development&amp;#160;&amp;#160;costs&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;128,898&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;463,720&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;TOTAL PREPAID EXPENSE&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,109,883&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,427,263&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&amp;#160;&amp;#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;font style="background-color: white"&gt;Estimated amortization&#13;expense for the next five years is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 30%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Year Ending &lt;br /&gt;&#13;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Estimated &lt;br /&gt;&#13;Amortization&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;40,580&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;40,580&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;40,580&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;40,580&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;40,580&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;u&gt;NOTE 8 &amp;#150; OTHER CURRENT LIABILITIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Other current liabilities consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 74%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued clinical trial costs&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,725,377&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,706,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,108,143&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;814,205&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued compensated absences&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;562,096&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;442,430&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;546,264&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;185,965&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;224,300&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;90,446&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;210,309&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;276,470&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued rent&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;83,527&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,368&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued royalties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;46,851&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;72,710&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;32,659&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;160,503&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,539,526&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,840,639&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Other current liabilities consist of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 74%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued clinical trial costs&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,725,377&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1,706,542&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued payroll, bonuses and commission costs&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,108,143&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;814,205&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued compensated absences&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;562,096&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;442,430&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Other accrued expenses&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;546,264&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;185,965&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for coupons and returns&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;224,300&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;90,446&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued legal and accounting expense&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;210,309&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;276,470&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued rent&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;83,527&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,368&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Accrued royalties&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;46,851&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;72,710&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Allowance for wholesale distributor fees&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;32,659&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;160,503&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;7,539,526&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;3,840,639&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 9 &amp;#150; NOTES PAYABLE&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Issuance and Payment of Multiple Advance&#13;Revolving Credit Note&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 31, 2013, we entered into a&#13;business loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the&#13;Revolving Credit Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal&#13;amount, at a stated interest rate of 6% per annum. Plato was able to make advances to us from time to time under the&#13;Revolving Credit Note at our request, which advances were of a revolving nature and were able to be made, repaid, and made&#13;from time to time. Interest payments were due and payable on the tenth day following the end of each calendar quarter in&#13;which any interest was accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the&#13;Revolving Credit Note, together with all accrued interest and other amounts payable under the Revolving Credit Note, if any,&#13;was due and payable on February 24, 2014. The Revolving Credit Note was secured by substantially all of our assets. On each&#13;of February 25 and March 13, 2013, $200,000 was drawn against the Revolving Credit Note. On March 21, 2013, we repaid&#13;$401,085, which included accrued interest, and there was no balance outstanding under the Revolving Credit Note as of&#13;December 31, 2013 and February 24, 2014 when it expired. As additional consideration for the Revolving Credit Note, we&#13;granted to Plato a warrant to purchase 1,250,000 shares of our Common Stock at an exercise price of $3.20 per share (See Note&#13;10).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The weighted average fair value per share of&#13;warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2015, 2014 and 2013 are&#13;set forth in the table below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 39%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average fair value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$6.35&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.83&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.02%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.88-1.12%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60.59%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44.29-45.89%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a &lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;</txmd:ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The ranges of&#13;assumptions used in the Black-Scholes Model during the years ended December 31, 2015, 2014 and 2013 are set forth in the table&#13;below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 39%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.47-1.67%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.07-1.77%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.65-1.71%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;58.78-62.94%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;68.05-82.29%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33.35-45.76%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.27-6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 12 &amp;#150; RELATED PARTIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Agreements with Pernix Therapeutics, LLC&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On February 29, 2012, Cooper C. Collins, who&#13;was then president and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors.&#13;From time to time, we have entered into agreements with Pernix in the normal course of business. All such agreements are reviewed&#13;by independent directors of our company or a committee consisting of independent directors of our company.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the years ended December 31, 2015, 2014&#13;and 2013, we did not engage in any transactions with Pernix. As of December 31, 2014 and 2013, there were amounts due to Pernix&#13;of approximately $46,000. Additionally, there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation&#13;matter stemming from a license and supply agreement in the amounts of approximately $250,000 as of the years ended December 31,&#13;2014 and 2013. During the year ended December 31, 2015, we entered into a settlement agreement with Pernix according to which Pernix&#13;paid us $175,000 in cash, resulting in the elimination of the approximately $46,000 outstanding payable and $250,000 outstanding&#13;receivable disclosed above and the recording of approximately $29,000 in settlement fees on the accompanying consolidated financial&#13;statements.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 14 &amp;#150; COMMITMENTS AND CONTINGENCIES&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Operating Lease&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We lease administrative office space in Boca&#13;Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013. The lease expires on September&#13;30, 2018 and we have an option to extend the lease term for a period of five years. On February 18, 2015, we entered into an agreement&#13;with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease.&#13;This addendum was effective beginning April 1, 2015 and will expire with the original lease term on September 30, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The rental expense related to our current lease&#13;during the years ended December 31, 2015 and 2014 was $446,099 and $361,793, respectively. The rental expense during the year ended&#13;December 31, 2013 consisted of $180,894 expense related to our current lease and $60,168 expense related to our prior lease which&#13;expired June 30, 2013. The rental expense during the years ended December 31, 2014 and 2013 was partially offset by the rent income&#13;of $41,613 and $32,963, respectively. We did not sublet any space during the year ended December 31, 2015.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2015, future minimum rental&#13;payments on non-cancelable operating leases are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 35%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;493,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;507,087&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;388,976&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,389,853&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Legal Proceedings&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;From time to time, we are involved in litigation&#13;and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would&#13;have a material effect on our consolidated financial condition, results of operations, or cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Off-Balance Sheet Arrangements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2015, 2014 and 2013, we&#13;had no off-balance sheet arrangements that have had or are reasonably likely to have current or future effect on our financial&#13;condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital&#13;resources that are material to investors.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;u&gt;Employment Agreements&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We have entered into&amp;#160;employment&amp;#160;agreements&amp;#160;with&#13;certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change&#13;in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the&#13;employment agreement.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of December 31, 2015, future minimum rental&#13;payments on non-cancelable operating leases are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 35%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;493,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;507,087&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;388,976&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#151;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,389,853&lt;/td&gt;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 15 &amp;#150; SELECTED QUARTERLY FINANCIAL&#13;DATA (UNAUDITED)&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Summarized quarterly financial data for fiscal years 2015 and 2014&#13;is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 3%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015 Quarters&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;(In thousands, except per share)&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;4&lt;sup&gt;th&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48%; font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;4,475&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;4,848&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;5,190&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;5,630&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,431&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,815&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,996&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,395&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(20,895&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(27,227&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(19,472&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(17,483&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.13&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.16&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.11&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.10&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 3%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014 Quarters&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;(In thousands, except per share)&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;4&lt;sup&gt;th&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,831&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,752&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,186&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,257&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,000&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,859&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,118&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,377&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(9,183&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(10,899&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(17,832&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(16,303&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.07&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.10&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;Summarized quarterly financial data for fiscal years 2015 and 2014&#13;is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 3%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2015 Quarters&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;(In thousands, except per share)&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;4&lt;sup&gt;th&lt;/sup&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48%; font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;4,475&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;4,848&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;5,190&lt;/td&gt;&lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif"&gt;5,630&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,431&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,815&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,996&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,395&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(20,895&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(27,227&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(19,472&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(17,483&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.13&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.16&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.11&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.10&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 3%"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"&gt;2014 Quarters&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="width: 48%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;(In thousands, except per share)&lt;/i&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;1&lt;sup&gt;st&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2&lt;sup&gt;nd&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;3&lt;sup&gt;rd&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;4&lt;sup&gt;th&lt;/sup&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Revenues&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,831&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,752&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,186&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,257&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Gross profit&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,000&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2,859&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,118&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3,377&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Net loss&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(9,183&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(10,899&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(17,832&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(16,303&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif"&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Loss per common share, basic and diluted&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.06&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.07&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.12&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(0.10&lt;/td&gt;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&amp;#160;&lt;/p&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;u&gt;NOTE 16 &amp;#150; SUBSEQUENT EVENTS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;On January&amp;#160;6, 2016, we entered into an underwriting agreement&#13;with Goldman Sachs and Cowen and Company, LLC, as the representatives of the several underwriters, or the Underwriters, relating&#13;to an underwritten public offering of 15,151,515 shares of our Common Stock at a public offering price of $8.25 per share. Under&#13;the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727&#13;additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $134.9&#13;million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering&#13;closed on January&amp;#160;12, 2016.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;&#13;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In January 2016, certain individuals exercised&#13;stock options to purchase 281,657 shares of our Common Stock for approximately $758,000 in cash and warrants to purchase 500,000&#13;shares of our Common Stock were exercised for approximately $1,285,000 in cash.&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.92</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">5263339</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="AsOf2015-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">15461986</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <txmd:EntityCommonStockHeldByNonaffiliates contextRef="AsOf2015-06-30" unitRef="Shares" decimals="INF">94011647</txmd:EntityCommonStockHeldByNonaffiliates>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;NOTE 2 &amp;#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Principles of Consolidation&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed, BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: normal"&gt;&lt;u&gt;Cash&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-weight: normal"&gt;We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation (the &amp;#x201C;FDIC&amp;#x201D;) insured limits of $250,000 per bank. We have never experienced any losses related to these funds.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Trade Accounts Receivable and Allowance for Doubtful Accounts&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. &lt;font style="color: #252525"&gt;To the extent data we use to calculate these estimates does not accurately reflect bad debts; adjustments to these reserves may be &lt;/font&gt;required.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Inventories&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;Inventories represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or market using the average-cost method. Any costs of manufacturing the prescription products associated with the deferred revenue (as discussed in Revenue Recognition) prior to January 1 , 2015, were recorded as deferred costs and included in inventory, until such time as the related deferred revenue was recognized. &lt;/font&gt;We review our inventory for excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product improvements rendering previous versions obsolete.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Pre-Launch Inventory&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research and development expenses during the period the costs are incurred. We have not capitalized any pre-launch inventory to date.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fixed Assets&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expenses as incurred. &lt;font style="letter-spacing: -0.15pt"&gt;We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We capitalize software and&amp;#xA0;software&amp;#xA0;development&amp;#xA0;costs&amp;#xA0;incurred to create and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize&amp;#xA0;software development&amp;#xA0;costs&amp;#xA0;when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally five to seven years.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Intangible &lt;/u&gt;&lt;/font&gt;&lt;u&gt;Assets&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;i&gt;&lt;u&gt;Patents and Trademarks&lt;/u&gt;&lt;/i&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;We have adopted the provisions of &lt;/font&gt;Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, &lt;font style="letter-spacing: -0.15pt"&gt;350, &lt;i&gt;Intangibles - Goodwill and Other&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or &lt;/font&gt;ASC 350&lt;font style="letter-spacing: -0.15pt"&gt;. Capitalized patent costs, net of accumulated amortization, include legal costs incurred for patent applications. &lt;/font&gt;In accordance with ASC 350, &lt;font style="letter-spacing: -0.15pt"&gt;once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, 2015, we had 14 issued patents (See Note 7). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Impairment of Long-Lived Assets&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;significant declines in an asset&amp;#x2019;s market price;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;significant deterioration in an asset&amp;#x2019;s physical condition;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;significant changes in the nature or extent of an asset&amp;#x2019;s use or operation;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;significant adverse changes in the business climate that could impact an asset&amp;#x2019;s value, including adverse actions or assessments by regulators; &lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset&amp;#x2019;s use; and&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group&amp;#x2019;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&amp;#x2019; fair value and respective carrying values. We determine the fair value of the assets using an &amp;#x201C;income approach&amp;#x201D; based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of long-lived assets to be held and used during the years ended December 31, 2015, 2014 and 2013.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We perform impairment tests for intangible&amp;#xA0;assets&amp;#xA0;with&amp;#xA0;indefinite&amp;#xA0;useful&amp;#xA0;lives&amp;#xA0;annually, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. There was no impairment of indefinite lived intangible assets during the years ended December 31, 2015, 2014 and 2013.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Fair Value of Financial Instruments&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Our financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, &lt;i&gt;Fair Value Measurements. &lt;/i&gt; The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;unobservable inputs for the asset or liability.&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At December 31, 2015 and 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. There was no impairment of intangible assets during the years ended December 31, 2015, 2014 and 2013.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Income Taxes&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In accordance with ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2015 and 2014, we had no tax positions relating to open tax returns that were considered to be uncertain.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Our tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after 2012 are subject to review.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Share-Based Compensation&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718 to value options. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.&lt;/font&gt;&lt;font style="font-size: 10pt"&gt; &lt;/font&gt;&lt;font style="font-size: 10pt"&gt; &lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Equity instruments (&amp;#x201C;instruments&amp;#x201D;) issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, &lt;i&gt;Equity - Based Payments to Non-Employees&lt;/i&gt;,&lt;i&gt; &lt;/i&gt;or ASC 505&lt;i&gt;. &lt;/i&gt;ASC 505&lt;i&gt; &lt;/i&gt;defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&amp;#x2019;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Debt Discounts&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Costs incurred from parties that are providing long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based on the relative fair value of the debt and warrants to the total proceeds. We amortize discounts over the life of the related debt using the effective interest rate method.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Revenue Recognition&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Our over-the-counter (OTC) and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note 13. There are no major external customers for our OTC prenatal vitamin or other products.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;OTC Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Prescription Products&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and customer rebates.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We accept returns of unsalable prescription products from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015, we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Segment Reporting&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Shipping and Handling Costs&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="letter-spacing: -0.15pt"&gt;&lt;u&gt;Advertising Costs&lt;/u&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We expense advertising costs when incurred. Advertising costs were $792,574, $698,871 and $11,739 during the years ended December 31, 2015, 2014 and 2013, respectively.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Research and Development Expenses&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Research and development, or R&amp;#38;D, expenses include internal R&amp;#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&amp;#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities are capitalized, and were $1,138,073 at December 31, 2015, of which $1,009,175 was included in other current assets and $128,898 was included in long term prepaid expense on the accompanying consolidated balance sheets. Advance payments to be expensed in future R&amp;#38;D activities were $1,175,082 at December 31, 2014, of which $711,362 was included in other current assets and $463,720 was included in long term prepaid expense on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&amp;#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&amp;#38;D expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding R&amp;#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&amp;#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&amp;#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.&lt;/p&gt;&#13;&lt;p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Earnings Per Share&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We calculate earnings per share, or EPS, in accordance with ASC 260, &lt;i&gt;Earnings Per Share&lt;/i&gt;, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;As of December 31,&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2014&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2013&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 35%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Stock options&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;20,725,325&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16,792,443&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;15,632,742&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Warrants&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;12,722,431&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;13,927,916&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;14,293,499&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;33,447,756&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;30,720,359&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;29,926,241&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Subsequent to December 31, 2015, we issued 17,424,242 shares of our Common Stock at a public offering price of $8.25 per share. In January 2016, certain individuals exercised stock options to purchase 281,657 shares of our Common Stock for approximately $758,000 in cash. In addition, warrants to purchase 500,000 shares of our Common Stock were exercised for approximately $1,285,000 in cash. See Note 16 - Subsequent Events for more details.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Concentration of Credit Risk and other Risks and Uncertainties &lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Financial instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. The Company has not experienced any historical losses on its deposits of cash.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Concentration of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacies. Credit is extended to our customers based on an evaluation of a customer&amp;#x2019;s financial condition, and collateral is not required.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Use of Estimates&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Reclassifications&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Certain 2014 and 2013 amounts have been reclassified to conform to current year presentation.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Recently Issued Accounting Pronouncements&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;In November 2015,&#13;the FASB issued Accounting Standards Update, or ASU, No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred&#13;Taxes. This guidance requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet&#13;instead of separating deferred taxes into current and noncurrent amounts. Also, companies will no longer allocate valuation allowances&#13;between current and noncurrent deferred tax assets because those allowances also will be classified as noncurrent. For public&#13;business entities, the guidance is effective for financial statements issued for annual periods beginning December 15, 2016, and&#13;interim periods within those annual periods. Companies can adopt the guidance either prospectively or retrospectively. We adopted&lt;/font&gt;&amp;#xA0;&lt;font style="font-size: 10pt"&gt;this&#13;guidance in the fourth quarter of 2015. The adoption of this guidance did not have a material impact on our consolidated financial&#13;statements or disclosures.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), simplifying the Measurement of Inventory. This guidance requires entities to measure inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM). The guidance applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does not change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM guidance. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Under the new guidance, however, entities will no longer need to calculate other measures of &amp;#x201C;market.&amp;#x201D; The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact of this guidance, if any, on our consolidated financial statements and disclosures.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In June 2015, the FASB issued ASU No. 2015-10, Technical Corrections and Improvements, to correct differences between original guidance and the ASC clarify the guidance, correct references and make minor improvements affecting a variety of topics. Amendments that the FASB deemed more substantive are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-10 did not have a material effect on our consolidated financial statements and disclosures.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&amp;#x2019;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity&amp;#x2019;s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&amp;#x2019;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. We are currently evaluating the impact of ASU 2014-09 on our consolidated financial statements and disclosures.&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Reclassifications&lt;/u&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Certain 2014 and 2013 amounts have been reclassified to conform to current year presentation.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 3 &amp;#x2013; INVENTORY&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Inventory consists of the following:&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2014&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 70%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Finished product&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;661,167&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;874,294&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Raw material&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;28,986&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;155,341&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Deferred costs&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;152,478&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL INVENTORY&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;690,153&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,182,113&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;Inventory consists of the following:&lt;/p&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31,&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2014&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 70%; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Finished product&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;661,167&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;874,294&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Raw material&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;28,986&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;155,341&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Deferred costs&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;152,478&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;TOTAL INVENTORY&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;690,153&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,182,113&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 7 &amp;#x2013; INTANGIBLE ASSETS, NET&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2015 and 2014:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Gross &lt;br /&gt; Carrying &lt;br /&gt; Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Net &lt;br /&gt;Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- &lt;br /&gt; Average Remaining Amortization &lt;br /&gt; Period (yrs.)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; width: 48%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#xAE;&lt;/sup&gt; software patent&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(4,493&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;27,458&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;13.75&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;705,752&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(49,845&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;655,907&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;17&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (in process)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;774,165&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;774,165&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157,721&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157,721&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,761,332&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(146,081&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,615,251&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2014&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Gross &lt;br /&gt; Carrying &lt;br /&gt; Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Net &lt;br /&gt;Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- &lt;br /&gt; Average Remaining Amortization &lt;br /&gt; Period (yrs.)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; width: 48%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#xAE;&lt;/sup&gt; software patent&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(2,496&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;29,455&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;14.75&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;439,184&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(19,401&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;419,783&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;18&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (in process)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103,368&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103,368&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,342,228&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(113,640&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,228,588&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="background-color: white"&gt;We amortize&#13;the approved hormone therapy drug candidate patents using straight-line method over the estimated useful life of approximately&#13;20 years, which is the life of intellectual property patents.. As of December 31, 2015, the remaining life related to OPERA&amp;#xAE;&#13;patent was approximately 14 years and the remaining life related to the approved hormone therapy drug candidate patents was approximately&#13;17 years. During the years ended December 31, 2015 and 2014, there was no impairment recognized related to intangible assets.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="background-color: white"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="background-color: white"&gt;In&#13;addition to numerous pending patent applications, as of December 31, 2015, we had fourteen issued patents, including:&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white"&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0; &lt;font style="background-color: white"&gt;12 utility patents that relate to our combination progesterone and estradiol product candidates, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa and South Korea.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0; &lt;font style="background-color: white"&gt;one utility patent that relates to TX-004HR, our applicator-free vaginal estradiol softgel product candidate, which establishes an important intellectual property foundation for TX-004HR, is owned by us and is a U.S. jurisdiction patent with an expiration date in 2033. We have pending patent applications with respect to this patent in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Symbol"&gt;&amp;#xB7;&lt;/font&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&#13;&lt;font style="background-color: white"&gt;one utility patent that relates to our OPERA&amp;#xAE; information technology platform, which&#13;is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029.&lt;/font&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-family: Times New Roman, Times, Serif"&gt;&amp;#xA0; &lt;font style="background-color: white"&gt;&amp;#xA0;&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white"&gt;Amortization expense was $32,441, $23,480, and $10,262 for the years ended December 31, 2015, 2014, and 2013, respectively. Estimated amortization expense for the next five years is as follows:&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 30%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Year Ending &lt;br /&gt; December 31,&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Estimated &lt;br /&gt; Amortization&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2016&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;40,580&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2017&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;40,580&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2018&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;40,580&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2019&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;40,580&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2020&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;40,580&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2015 and 2014:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Gross &lt;br /&gt; Carrying &lt;br /&gt; Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Net &lt;br /&gt;Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- &lt;br /&gt; Average Remaining Amortization &lt;br /&gt; Period (yrs.)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; width: 48%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#xAE;&lt;/sup&gt; software patent&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(4,493&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;27,458&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;13.75&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;705,752&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(49,845&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;655,907&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;17&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (in process)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;774,165&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;774,165&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157,721&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;157,721&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,761,332&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(146,081&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,615,251&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;December 31, 2014&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Gross &lt;br /&gt; Carrying &lt;br /&gt; Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Accumulated Amortization&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Net &lt;br /&gt;Amount&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted- &lt;br /&gt; Average Remaining Amortization &lt;br /&gt; Period (yrs.)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Amortizable intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; width: 48%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;OPERA&lt;sup&gt;&amp;#xAE;&lt;/sup&gt; software patent&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;31,951&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(2,496&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;29,455&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;14.75&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Development costs of corporate website&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(91,743&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Approved hormone therapy drug candidate patents&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;439,184&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(19,401&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;419,783&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;18&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Hormone therapy drug candidate patents (in process)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;675,982&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Non-amortizable intangible assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Multiple trademarks for vitamins/supplements&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103,368&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;103,368&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;indefinite&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;Total&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,342,228&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(113,640&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;1,228,588&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2015-01-01to2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2015-01-01to2015-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P13Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2015-01-01to2015-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P17Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2014-01-01to2014-12-31_us-gaap_ComputerSoftwareIntangibleAssetMember">P14Y9M</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="From2014-01-01to2014-12-31_custom_ApprovedHormoneTherapyDrugCandidatePatentsMember">P18Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:ConcentrationRiskDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 13 - BUSINESS CONCENTRATIONS&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We purchase our products from several suppliers with approximately 60%, 82% and 98% of our purchases supplied by one vendor for the years ended December 31, 2015, 2014 and 2013, respectively.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the year ended December 31, 2015, two customers each generated more than 10% of our total revenues and during the years ended December 31, 2014 and 2013, four customers each generated more than 10% of our total revenues. Revenue generated from two major customers combined accounted for approximately 67% of total revenue during the year ended December 31, 2015. Revenue generated from four major customers combined accounted for approximately 75% and 79% of our recognized revenue during the years ended December 31, 2014 and 2013, respectively.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Customers that generated more than 10% of our sales are designated as customers &amp;#x201C;A&amp;#x201D;, &amp;#x201C;B&amp;#x201D;, &amp;#x201C;C&amp;#x201D; and &amp;#x201C;D&amp;#x201D;. During the year ended December 31, 2015, customer A generated $8,848,243 in revenues and customer B generated approximately $4,843,463 in revenues. During the year ended December 31, 2014 customers A, B, C and D generated $1,609,950, $1,586,903, $1,804,018 and $4,053,838 in sales, respectively. During the year ended December 31, 2013, customers A, B, C and D generated $1,221,212, $1,711,417, $2,588,626 and $1,312,192 in sales, respectively.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Prior to January 1, 2015, we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns. Revenue generated by major customers accounted for approximately 97% of deferred revenue for both periods ended December 31, 2014 and 2013. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. As a result no deferred revenue was recorded for the year ended December 31, 2015.&lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 10 &amp;#x2013; STOCKHOLDERS&amp;#x2019; EQUITY&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Preferred Stock&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At December 31, 2015, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred stock were issued or outstanding.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Common Stock&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At December 31, 2015, we had 350,000,000 shares of Common Stock authorized for issuance, of which 177,928,041 shares of our Common Stock were issued and outstanding. During the year ended December 31, 2015, our stockholders&amp;#x2019; approved an amendment to our articles of incorporation to increase the number of authorized shares of Common Stock from 250,000,000 to 350,000,000.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Issuances During 2015&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus&amp;#xA0;&amp;#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July&amp;#xA0;15, 2015 and we issued 4,423,077 shares of our Common Stock.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our Common Stock.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;During the year ended December 31, 2015, certain individuals exercised stock options to purchase 612,867 shares of Common Stock for $1,232,579 in cash. Also during the same period, stock options to purchase 417 shares of Common Stock were exercised pursuant to the options&amp;#x2019; cashless exercise provisions, wherein 114 shares of Common Stock were issued.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Subsequent to December 31, 2015, we issued 17,424,242 shares of our Common Stock in an underwritten public offering at a public offering price of $8.25 per share. In January 2016, certain individuals exercised stock options to purchase 281,657 shares of our Common Stock for approximately $758,000 in cash. In addition, warrants to purchase 500,000 shares of our Common Stock were exercised for approximately $1,285,000 in cash. See Note 16 - Subsequent Events for more details.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Issuances During 2014&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On July 29, 2014, we entered into an underwriting agreement with Goldman Sachs &amp;#38; Co, or Goldman Sachs, as the representative of the underwriters named therein, or the Goldman Sachs Underwriters, relating to an underwritten public offering of 8,565,310 shares of Common Stock. The price to the public in the offering was $4.67 per share. Under the terms of the underwriting agreement, we granted the Goldman Sachs Underwriters a 30-day option to purchase up to an additional 1,284,796 shares of Common Stock. On July 30, 2014, the Goldman Sachs Underwriters exercised their option to purchase the additional 1,284,796 shares of Common Stock. Net proceeds from this offering were approximately $42.8 million, after deducting underwriting discounts and commissions and other offering expenses. The offering closed on August 4, 2014 and we issued 9,850,106 shares of our Common Stock.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;During the year ended December 31, 2014, certain individuals exercised stock options to purchase 860,800 shares of our Common Stock. Stock options to purchase shares of our Common Stock were exercised as follows: (i) 724,193 options for $345,746 in cash and (ii) 136,607 options, pursuant to the stock options&amp;#x2019; cashless provision, wherein 130,380 shares of Common Stock were issued. In addition, during 2014, we issued 50,000 shares of Common Stock to an employee upon the vesting of restricted stock units that were granted in December 2013.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Issuances During 2013&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On March 14, 2013, we entered into an underwriting agreement with Jefferies LLC as the representative of the underwriters named therein, or the Jefferies Underwriters, relating to the issuance and sale of 29,411,765 shares of our Common Stock. The price to the public in the offering was $1.70 per share. In addition, under the terms of the underwriting agreement, we granted the Jefferies Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of our Common Stock. The offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters exercised their option to purchase an additional 1,954,587 shares of our Common Stock, which were issued on April 18, 2013. The net proceeds to us from this offering were approximately $48.5 million, after deducting underwriting discounts and commissions and other offering expenses payable by us.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;On September 25, 2013, we entered into an underwriting agreement with Stifel, Nicolaus &amp;#38; Company, Incorporated, as the representative of the underwriters named therein, relating to the issuance and sale of 13,750,000 shares of our Common Stock. The price to the public in the offering was $2.40 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;During the year ended December 31, 2013, certain individuals exercised options to purchase an aggregate of 75,423 shares of our Common Stock for approximately $31,000.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Warrants to Purchase Common Stock&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;As of December 31, 2015, we had warrants outstanding to purchase an aggregate of 12,722,431 shares of our Common Stock with a weighted-average contractual remaining life of 1.7 years, and exercise prices ranging from $0.24 to $6.35 per share, resulting in a weighted average exercise price of $1.93 per share.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;During the year ended December 31, 2015, we granted warrants to purchase 50,000 shares of Common Stock to an outside consultant at an exercise price of $6.35, vesting ratably over a 12 month period, with an expiration date of April 6, 2020. The grant date fair value of this warrant was $3.27. During the year ended December 31, 2015, we recorded $139,142 as non-cash compensation in the accompanying consolidated financial statements related to this warrant.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In January 2013, we issued warrants to purchase 1,250,000 shares of our Common Stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant (see NOTE 9 above for more details). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. During the years ended December 31, 2015, 2014 and 2013, $0, $260,027 and $1,451,934, respectively, was recorded as financing costs in connection with the issuance of the Plato Warrant on the accompanying consolidated financial statements.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In May 2013, we entered into a consulting agreement with SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to issue to SCI a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;1.&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0 0 0 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;2.&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During the years ended December 31 2015, 2014 and 2013, we recorded $154,068, $154,068 and $77,034, respectively, as non-cash compensation in the accompanying consolidated financial statements related to this warrant. As of December 31, 2015, there was a remaining balance of $77,026 related to this warrant which was included in other current assets in the accompanying consolidated financial statements; and&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0 0 0 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"&gt;&lt;/td&gt;&#13;&lt;td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"&gt;3.&lt;/td&gt;&#13;&lt;td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that this event will not occur before December 2016.&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In May 2012, we issued warrants to purchase an aggregate of 1,300,000 shares of Common Stock to an unaffiliated entity for services to be rendered over approximately five years beginning in May 2012. Services provided are to include (a) services in support of our drug development efforts, including services in support our ongoing and future drug development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at $1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. At December 31, 2015, we had $257,796 reported as prepaid expense-short term and $128,898 recorded as prepaid expense-long term associated with these warrants. During the years ended December 31, 2015, 2014 and 2013, we recorded $257,796, $309,165 and $360,528, respectively as non-cash compensation with respect to these warrants in the accompanying consolidated financial statements. The contract will expire upon the commercial manufacture of a drug product. We have determined that the process will take approximately five years.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;As of December 31, 2015, unamortized costs associated with the SCI warrants issued in 2013 and 2012 totaled approximately $464,000 and will be recognized over a period of eighteen months.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&lt;u&gt;Warrant exercises&lt;/u&gt;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&amp;#xA0;&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;During the year ended December 31, 2015, certain individuals and an entity exercised warrants to purchase 1,255,485 shares of Common Stock as follows: (i) 945,485 shares of Common Stock were issued for $366,000 in cash and (ii) warrants to purchase 310,000 shares of Common Stock were exercised pursuant to the warrants&amp;#x2019; cashless exercise provisions, wherein 232,197 shares of Common Stock were issued.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;During the year ended December 31, 2014, certain individuals exercised warrants to purchase 365,583 shares of Common Stock for $181,000 in cash.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Summary of our Warrant activity during the year ended December 31, 2015:&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of &lt;br /&gt; Shares &lt;br /&gt; Under &lt;br /&gt; Warrants&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted &lt;br /&gt;Average &lt;br /&gt;Remaining &lt;br /&gt;Contractual &lt;br /&gt;Life in Years&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate &lt;br /&gt;Intrinsic &lt;br /&gt; Value&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 48%; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;13,927,916&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.82&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.0&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;36,623,875&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Granted&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.35&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Exercised&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(1,255,485&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.79&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7,282,404&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Expired&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Cancelled/Forfeited&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;12,722,431&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.93&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.7&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;107,344,752&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at December 31, 2015&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;12,422,432&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.92&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.6&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;104,909,091&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2015, 2014 and 2013 are set forth in the table below.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 39%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 3%; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Weighted average fair value&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$6.35&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;$2.83&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.02%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.88-1.12%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;60.59%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;44.29-45.89%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;n/a &lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We have used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2011-2015.&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;u&gt;Options to Purchase Common Stock of the Company&lt;/u&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. Prior to the merger with VitaMed, no Awards had been issued under the 2009 Plan. As of December 31, 2015, there were non-qualified stock options to purchase 17,856,851 shares of Common Stock outstanding under the 2009 Plan. As of December 31, 2015, there were 3,607,852 shares available to be issued under 2009 Plan.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In 2012, we adopted the 2012 Stock Incentive&#13;Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive&#13;for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.&#13;The Awards available under the 2012 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock&#13;units, performance stock, performance units, and other stock or cash awards as described in the 2012 Plan. Generally, the options&#13;vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by&#13;paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date&#13;provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option&#13;is issued. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of December 31, 2015, there were&#13;non-qualified stock options to purchase 2,868,474 shares of Common Stock outstanding under the 2012 Plan. As of December 31, 2015,&#13;there were 7,050,000 shares available to be issued under 2012 Plan.&lt;/p&gt;&#13;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#160;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2015, 2014 and 2013 are set forth in the table below.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 39%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2015&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2014&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 3%; text-align: center; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;2013&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free interest rate&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;1.47-1.67%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.07-1.77%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.65-1.71%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Volatility&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;58.78-62.94%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;68.05-82.29%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;33.35-45.76%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Term (in years)&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5.27-6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;5-6.25&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;Dividend yield&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;0.00%&lt;/font&gt;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual terms of the stock option using the simplified method.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;A summary of activity under the 2009 and 2012 Plans and related information during the year ended December 31, 2015 is as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of &lt;br /&gt; Shares &lt;br /&gt; Under &lt;br /&gt; Options&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted &lt;br /&gt;Average &lt;br /&gt;Remaining &lt;br /&gt;Contractual &lt;br /&gt;Life in Years&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate &lt;br /&gt;Intrinsic &lt;br /&gt; Value&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 48%; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16,792,443&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.88&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.9&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;43,996,311&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Granted&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,685,000&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;8.14&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Exercised&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(613,284&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.01&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Expired&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(102,500&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.68&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Cancelled/Forfeited&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(36,334&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.02&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,725,325&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.28&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.5&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;146,864,184&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at December 31, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,461,986&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.86&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.5&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;131,523,505&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Unvested at December 31, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,263,339&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7.46&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;9.4&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;15,340,679&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At December 31, 2015, our outstanding options had exercise prices ranging from $0.10 to $8.92 per share.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;The weighted average grant date fair value per share of options granted during the year ended December 31, 2015 was $4.45. The total intrinsic value of options exercised during the year ended December 31, 2015 was $3,186,371.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;Share-based compensation expense related to options recognized in our results of operations for the years ended December 31, 2015, 2014 and 2013 was $6,621,658, $4,393,455 and $3,200,655, respectively, and it is based on awards vested. We estimate forfeitures at the time of grant and revise the forfeiture rate in subsequent periods if actual forfeitures differ from the estimates. At December 31, 2015, total unrecognized estimated compensation expense related to unvested options was approximately $19.8 million, &lt;/font&gt;which may be adjusted for future changes in forfeitures&lt;font style="font-size: 10pt"&gt;. This cost is expected to be recognized over a weighted-average period of 1.7 years. No tax benefit was realized due to a continued pattern of operating losses. &lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;In December 2013, we granted a restricted stock unit, or the RSU, under our 2012 Plan to an employee for 50,000 shares of our Common Stock having a fair value of $233,500. During the years ended December 31, 2014 and 2013, we recorded $53,428 and $180,072, respectively, of non-cash compensation related to the RSU on the accompanying consolidated financial statements. The RSU was issued in June 2014.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <txmd:ScheduleOfWarrantRollForwardTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Summary of our Warrant activity during the year ended December 31, 2015:&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of &lt;br /&gt; Shares &lt;br /&gt; Under &lt;br /&gt; Warrants&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted &lt;br /&gt;Average &lt;br /&gt;Remaining &lt;br /&gt;Contractual &lt;br /&gt;Life in Years&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate &lt;br /&gt;Intrinsic &lt;br /&gt; Value&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 48%; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;13,927,916&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.82&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.0&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;36,623,875&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Granted&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;50,000&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.35&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Exercised&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(1,255,485&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;0.79&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7,282,404&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Expired&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Cancelled/Forfeited&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;12,722,431&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.93&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.7&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;107,344,752&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at December 31, 2015&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif"&gt;12,422,432&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.92&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.6&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;104,909,091&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</txmd:ScheduleOfWarrantRollForwardTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred income tax asset as of December 31, 2015, 2014, and 2013 are as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2014&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2013&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Deferred Income Tax Assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 61%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Net operating losses&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;79,499,633&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;43,091,437&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;14,773,537&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;R&amp;#38;D Credit&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;186,347&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;547,511&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Total deferred income tax asset&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;79,685,980&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;43,091,437&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;15,321,048&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Valuation allowance&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(79,685,980&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(43,091,437&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(15,321,048&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Deferred income tax assets, net&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;A summary of activity under the 2009 and 2012 Plans and related information during the year ended December 31, 2015 is as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Number of &lt;br /&gt; Shares &lt;br /&gt; Under &lt;br /&gt; Options&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted &lt;br /&gt; Average &lt;br /&gt; Exercise &lt;br /&gt; Price&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Weighted &lt;br /&gt;Average &lt;br /&gt;Remaining &lt;br /&gt;Contractual &lt;br /&gt;Life in Years&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;Aggregate &lt;br /&gt;Intrinsic &lt;br /&gt; Value&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 48%; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2014&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;16,792,443&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.88&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.9&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;43,996,311&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Granted&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4,685,000&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;8.14&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Exercised&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(613,284&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.01&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Expired&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(102,500&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;2.68&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;Cancelled/Forfeited&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(36,334&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.02&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Balance at December 31, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;20,725,325&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;3.28&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;6.5&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;146,864,184&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Vested and Exercisable at December 31, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;15,461,986&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;1.86&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.5&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;131,523,505&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;Unvested at December 31, 2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;5,263,339&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;7.46&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;9.4&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;15,340,679&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;u&gt;NOTE 11 &amp;#x2013; INCOME TAXES &lt;/u&gt;&lt;/b&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;font style="background-color: white"&gt;For the years ended December 31, 2015, 2014 and 2013, there was no provision for income taxes, current or deferred.&amp;#xA0; All product sales are derived from sales in the United States.&lt;br /&gt;&lt;/font&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;At December 31, 2015, we had a federal net operating loss carry forward of $192,601,415 available to offset future taxable income through 2035. The federal carryforwards will begin to expire in 2021.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2014&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2013&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 58%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Federal statutory tax rate&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;35.0&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.73&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.8&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.8&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Adjustment in valuation allowances&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(38.97&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(50.9)&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(32.4&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Permanent and other differences&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.24&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11.1&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(8.4&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Provision (benefit) for income taxes&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred income tax asset as of December 31, 2015, 2014, and 2013 are as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2014&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2013&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Deferred Income Tax Assets:&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 61%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Net operating losses&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;79,499,633&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;43,091,437&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;14,773,537&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;R&amp;#38;D Credit&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;186,347&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;547,511&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Total deferred income tax asset&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;79,685,980&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;43,091,437&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;15,321,048&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Valuation allowance&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(79,685,980&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(43,091,437&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(15,321,048&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Deferred income tax assets, net&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&amp;#x2014;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;We believe that it is more likely than not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on our balance sheet and as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2015.&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Unrecognized Tax Benefits&lt;/i&gt;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;As of the period ended December 31, 2015, we have no unrecognized tax benefits.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2015-01-01to2015-12-31">&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:&lt;/p&gt;&#13;&lt;p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;&#13;&lt;table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2015&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2014&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;2013&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; width: 58%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Federal statutory tax rate&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;34.0&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="width: 2%; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;35.0&lt;/td&gt;&#13;&lt;td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;State tax rate, net of federal tax benefit&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;4.73&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.8&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;5.8&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Adjustment in valuation allowances&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(38.97&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(50.9)&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="text-align: right; font: 10pt Times New Roman, Times, Serif"&gt;(32.4&lt;/td&gt;&#13;&lt;td style="text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Permanent and other differences&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;0.24&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;11.1&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;(8.4&lt;/td&gt;&#13;&lt;td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;)%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"&gt;&#13;&lt;td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;Provision (benefit) for income taxes&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"&gt;&amp;#xA0;&lt;/td&gt;&#13;&lt;td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;font style="font: 10pt Times New Roman, Times, Serif"&gt;&amp;#x2014;&lt;/font&gt;&lt;/td&gt;&#13;&lt;td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/td&gt;&#13;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="margin: 0; font: 10pt Times New Roman, Times, Serif"&gt;&amp;#xA0;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2015-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">1009175</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2014-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">711362</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2015-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">1138073</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2014-12-31_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" decimals="0">1175082</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2014-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2015-12-31_us-gaap_WarrantMember" unitRef="USDPShares" decimals="INF">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue contextRef="From2015-01-01to2015-12-31_us-gaap_WarrantMember" unitRef="USD" decimals="0">7282404</txmd:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2014-01-01to2014-12-31_us-gaap_EmployeeStockOptionMember">P6Y10M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm contextRef="From2015-01-01to2015-12-31_us-gaap_EmployeeStockOptionMember">P9Y4M24D</txmd:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="From2013-12-01to2013-12-31_custom_NonQualified2012StockIncentivePlanMember" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>txmd-20151231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.11b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20151231\txmd_123115.xfr; Date: 2016%2D02%2D25T23:12:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x801D0006 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +6spw7xRiXhun8uCbn1MSaOLWbP9w5dzuelBtm9/HVnq/ycsd4np4i4/976GwZoH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31" xmlns:us-roles="http://fasb.org/us-roles/2015-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2015-01-31" xmlns:txmd="http://therapeuticsmd.com/20151231" elementFormDefault="qualified" targetNamespace="http://therapeuticsmd.com/20151231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
	  <link:definition>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
	  <link:definition>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
	  <link:definition>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Company" id="Company">
	  <link:definition>00000007 - Disclosure - THE COMPANY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
	  <link:definition>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/Inventory" id="Inventory">
	  <link:definition>00000009 - Disclosure - INVENTORY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" id="OtherCurrentAssets">
	  <link:definition>00000010 - Disclosure - OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" id="FixedAssetsNet">
	  <link:definition>00000011 - Disclosure - FIXED ASSETS, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpense" id="PrepaidExpense">
	  <link:definition>00000012 - Disclosure - PREPAID EXPENSE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssets" id="IntangibleAssets">
	  <link:definition>00000013 - Disclosure - INTANGIBLE ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" id="OtherCurrentLiabilities">
	  <link:definition>00000014 - Disclosure - OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000015 - Disclosure - NOTES PAYABLE</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000016 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000017 - Disclosure - INCOME TAXES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedParties" id="RelatedParties">
	  <link:definition>00000018 - Disclosure - RELATED PARTIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" id="BusinessConcentrations">
	  <link:definition>00000019 - Disclosure - BUSINESS CONCENTRATIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" id="SelectedQuarterlyFinancialData">
	  <link:definition>00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000022 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
	  <link:definition>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryTables" id="InventoryTables">
	  <link:definition>00000025 - Disclosure - INVENTORY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" id="OtherCurrentAssetsTables">
	  <link:definition>00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" id="FixedAssetsNetTables">
	  <link:definition>00000027 - Disclosure - FIXED ASSETS, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" id="PrepaidExpenseTables">
	  <link:definition>00000028 - Disclosure - PREPAID EXPENSE (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
	  <link:definition>00000029 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" id="OtherCurrentLiabilitiesTables">
	  <link:definition>00000030 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000031 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000032 - Disclosure - INCOME TAXES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" id="SelectedQuarterlyFinancialDataTables">
	  <link:definition>00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" id="SummaryOfSignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
	  <link:definition>00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/InventoryDetails" id="InventoryDetails">
	  <link:definition>00000037 - Disclosure - INVENTORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" id="OtherCurrentAssetsDetails">
	  <link:definition>00000038 - Disclosure - OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" id="FixedAssetsNetDetailsNarrative">
	  <link:definition>00000039 - Disclosure - FIXED ASSETS, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" id="FixedAssetsNetDetails">
	  <link:definition>00000040 - Disclosure - FIXED ASSETS, NET (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" id="PrepaidExpenseDetails">
	  <link:definition>00000041 - Disclosure - PREPAID EXPENSE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" id="IntangibleAssetsDetailsNarrative">
	  <link:definition>00000042 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" id="IntangibleAssetsDetails">
	  <link:definition>00000043 - Disclosure - INTANGIBLE ASSETS (Details )</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" id="IntangibleAssetsDetails1">
	  <link:definition>00000044 - Disclosure - INTANGIBLE ASSETS (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" id="OtherCurrentLiabilitiesDetails">
	  <link:definition>00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000046 - Disclosure - NOTES PAYABLE (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" id="StockholdersEquityDetailsNarrative1">
	  <link:definition>00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" id="StockholdersEquityDetailsNarrative2">
	  <link:definition>00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" id="StockholdersEquityDetailsNarrative3">
	  <link:definition>00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative4" id="StockholdersEquityDetailsNarrative4">
	  <link:definition>00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 4)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" id="StockholdersEquityDetails">
	  <link:definition>00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" id="StockholdersEquityDetails1">
	  <link:definition>00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" id="StockholdersEquityDetails2">
	  <link:definition>00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" id="StockholdersEquityDetails3">
	  <link:definition>00000055 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000056 - Disclosure - INCOME TAXES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
	  <link:definition>00000057 - Disclosure - INCOME TAXES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" id="IncomeTaxesDetails1">
	  <link:definition>00000058 - Disclosure - INCOME TAXES (Details 1)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" id="RelatedPartiesDetailsNarrative">
	  <link:definition>00000059 - Disclosure - RELATED PARTIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" id="BusinessConcentrationsDetailsNarrative">
	  <link:definition>00000060 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
	  <link:definition>00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" id="SelectedQuarterlyFinancialDataDetails">
	  <link:definition>00000063 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" id="SubsequentEventsDetailsNarative">
	  <link:definition>00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20151231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20151231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20151231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="txmd-20151231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <element id="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" name="ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" name="ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:dateItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" name="ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidConsultingCurrent" name="PrepaidConsultingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchDevelopmentCostsNoncurrent" name="PrepaidResearchDevelopmentCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SalesDiscountsReturnsAndAllowancesGoods1" name="SalesDiscountsReturnsAndAllowancesGoods1" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AllowanceForWholesaleDistributorFeesCurrent" name="AllowanceForWholesaleDistributorFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CapitalLeaseObligationsTerm" name="CapitalLeaseObligationsTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" name="IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidResearchAndDevelopmentCostsCurrent" name="PrepaidResearchAndDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidManufacturingCostsNoncurrent" name="PrepaidManufacturingCostsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" name="ClassOfWarrantOrRighstContractualLifeBeginningOustanding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfIssuedPatents" name="NumberOfIssuedPatents" nillable="true" xbrli:periodType="instant" type="xbrli:integerItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercisedInCashlessExercise" name="NumberOfStockOptionsExercisedInCashlessExercise" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdditionalPeriodForPurchaseShare" name="AdditionalPeriodForPurchaseShare" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockExpectedToIssuedDuringPeriodShares" name="StockExpectedToIssuedDuringPeriodShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StockIssuedDuringPeriodSharesNewIssues1" name="StockIssuedDuringPeriodSharesNewIssues1" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedForFinancing" name="WarrantsIssuedForFinancing" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsIssuedForServices" name="WarrantsIssuedForServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" name="ReturnPeriodOfUnsalablePrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShelfLifeOfPrescriptionProducts" name="ShelfLifeOfPrescriptionProducts" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidVendorDeposits" name="PrepaidVendorDeposits" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfStockOptionsExercised" name="NumberOfStockOptionsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares" name="WarrantsGrantedToPurchaseCommonStockExpectedToVestShares" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" name="ClassOfWarrantOrRighstContractualLifeClosingOustanding" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" name="ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty" name="AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_PrepaidExpensesDisclosureTextBlock" name="PrepaidExpensesDisclosureTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" name="ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="num:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_EntityCommonStockHeldByNonaffiliates" name="EntityCommonStockHeldByNonaffiliates" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ScheduleOfWarrantRollForwardTableTextBlock" name="ScheduleOfWarrantRollForwardTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SancilioAndCompanyWarrantsMember" name="SancilioAndCompanyWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_LongTermIncentiveCompensationPlan2009Member" name="LongTermIncentiveCompensationPlan2009Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NonQualified2012StockIncentivePlanMember" name="NonQualified2012StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredRevenueConcentrationRiskMember" name="DeferredRevenueConcentrationRiskMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_HormoneTherapyDrugCandidatePatentsMember" name="HormoneTherapyDrugCandidatePatentsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleTrademarksForVitaminsSupplementsMember" name="MultipleTrademarksForVitaminsSupplementsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" name="ApprovedHormoneTherapyDrugCandidatePatentsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk1Member" name="CustomerConcentrationRisk1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk2Member" name="CustomerConcentrationRisk2Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk3Member" name="CustomerConcentrationRisk3Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CustomerConcentrationRisk4Member" name="CustomerConcentrationRisk4Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_MultipleAdvanceRevolvingCreditNoteMember" name="MultipleAdvanceRevolvingCreditNoteMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CowenAndCompanyLLCMember" name="CowenAndCompanyLLCMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Option1Member" name="Option1Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StifelUnderwritersMember" name="StifelUnderwritersMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_GoldmanSachsMember" name="GoldmanSachsMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OutsideConsultantMember" name="OutsideConsultantMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_JefferiesLLCMember" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_StifelNicolausAndCompanyMember" name="StifelNicolausAndCompanyMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Patents1Member" name="Patents1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Warrant1Member" name="Warrant1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_Warrant2Member" name="Warrant2Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredSalesRevenueNetMember" name="DeferredSalesRevenueNetMember" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SubsequentEvent1Member" name="SubsequentEvent1Member" abstract="true" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_CommitmentsAndContingenciesTablesAbstract" name="CommitmentsAndContingenciesTablesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_OtherCurrentAssetsAbstract" name="OtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAbstract" name="WarrantsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" name="WarrantsAndRightsWeightedAverageContractualRemainingLife" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOfSharesUnderWarrantAbstract" name="NumberOfSharesUnderWarrantAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageExercisePriceAbstract" name="WeightedAverageExercisePriceAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_WeightedAverageRemainingContractualLifeAbstract" name="WeightedAverageRemainingContractualLifeAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeGrants" name="ClassOfWarrantOrRighstContractualLifeGrants" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeExercises" name="ClassOfWarrantOrRighstContractualLifeExercises" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" name="ClassOfWarrantOrRighstContractualLifeExpirations" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" name="ClassOfWarrantOrRighstContractualLifeForfeitures" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_AggregateIntrinsicValueAbstract" name="AggregateIntrinsicValueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" name="SummaryOfActivityUnder2009And2012PlansAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_NumberOptionsAbstract" name="NumberOptionsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="txmd_DeferredIncomeTaxAssetsAbstract" name="DeferredIncomeTaxAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>txmd-20151231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.11b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20151231\txmd_123115.xfr; Date: 2016%2D02%2D25T23:12:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x801D0006 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20151231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20151231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20151231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20151231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20151231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20151231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20151231.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20151231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20151231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayable" xlink:href="txmd-20151231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20151231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20151231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20151231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20151231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20151231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20151231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20151231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20151231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20151231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20151231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20151231.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20151231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20151231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20151231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20151231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20151231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20151231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20151231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20151231.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:href="txmd-20151231.xsd#FixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20151231.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20151231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20151231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20151231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20151231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:href="txmd-20151231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative4" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative4" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20151231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20151231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20151231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20151231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20151231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20151231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20151231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20151231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:href="txmd-20151231.xsd#SubsequentEventsDetailsNarative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsNoncurrent" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapGrossProfit" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="loc_us-gaapAmortizationOfDeferredCharges" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDeferredCharges" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:calculationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:calculationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashPeriodIncreaseDecrease" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayable" xlink:title="00000015 - Disclosure - NOTES PAYABLE" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000025 - Disclosure - INVENTORY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000027 - Disclosure - FIXED ASSETS, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000028 - Disclosure - PREPAID EXPENSE (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000029 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000030 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000032 - Disclosure - INCOME TAXES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000037 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000038 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidVendorDeposits" xlink:label="loc_txmdPrepaidVendorDeposits" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_txmdPrepaidVendorDeposits" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000039 - Disclosure - FIXED ASSETS, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:title="00000040 - Disclosure - FIXED ASSETS, NET (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000041 - Disclosure - PREPAID EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseNoncurrent" xlink:to="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="loc_txmdPrepaidManufacturingCostsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseNoncurrent" xlink:to="loc_txmdPrepaidManufacturingCostsNoncurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details )">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000044 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:title="00000046 - Disclosure - NOTES PAYABLE (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:title="00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative4" xlink:title="00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 4)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000055 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000056 - Disclosure - INCOME TAXES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000057 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000058 - Disclosure - INCOME TAXES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000059 - Disclosure - RELATED PARTIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000060 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000063 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:title="00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>txmd-20151231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.11b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20151231\txmd_123115.xfr; Date: 2016%2D02%2D25T23:12:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x801D0006 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20151231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20151231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20151231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20151231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20151231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20151231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20151231.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20151231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20151231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayable" xlink:href="txmd-20151231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20151231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20151231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20151231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20151231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20151231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20151231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20151231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20151231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20151231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20151231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20151231.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20151231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20151231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20151231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20151231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20151231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20151231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20151231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20151231.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:href="txmd-20151231.xsd#FixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20151231.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20151231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20151231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20151231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20151231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:href="txmd-20151231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative4" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative4" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20151231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20151231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20151231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20151231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20151231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20151231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20151231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20151231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:href="txmd-20151231.xsd#SubsequentEventsDetailsNarative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther_50" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty" xlink:label="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty_50" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="15" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayable" xlink:title="00000015 - Disclosure - NOTES PAYABLE" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000025 - Disclosure - INVENTORY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000027 - Disclosure - FIXED ASSETS, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000028 - Disclosure - PREPAID EXPENSE (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000029 - Disclosure - INTANGIBLE ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000030 - Disclosure - OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - STOCKHOLDERS' EQUITY (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000032 - Disclosure - INCOME TAXES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsCurrent_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseOtherNoncurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseOtherNoncurrent_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdvertisingExpense_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfIssuedPatents_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts_120" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_100" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000037 - Disclosure - INVENTORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000038 - Disclosure - OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000039 - Disclosure - FIXED ASSETS, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:title="00000040 - Disclosure - FIXED ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_80" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000041 - Disclosure - PREPAID EXPENSE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Patents1Member" xlink:label="loc_txmdPatents1Member_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents1Member_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfIssuedPatents_100" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details )">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract_170" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_170" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill_170" xlink:type="arc" order="11" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000044 - Disclosure - INTANGIBLE ASSETS (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:title="00000046 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateAtPeriodEnd_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateAtPeriodEnd_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_50" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StifelUnderwritersMember" xlink:label="loc_txmdStifelUnderwritersMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdStifelUnderwritersMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="loc_txmdCowenAndCompanyLLCMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdCowenAndCompanyLLCMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdGoldmanSachsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaapDerivativeByNatureAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeByNatureAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_us-gaapOptionMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Option1Member" xlink:label="loc_txmdOption1Member_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_txmdOption1Member_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_130" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_130" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_130" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_130" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_130" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_130" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="loc_txmdNumberOfStockOptionsExercised_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercised_130" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise_130" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare_130" xlink:type="arc" order="8" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_JefferiesLLCMember" xlink:label="loc_txmdJefferiesLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdJefferiesLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StifelNicolausAndCompanyMember" xlink:label="loc_txmdStifelNicolausAndCompanyMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdStifelNicolausAndCompanyMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaapDerivativeByNatureAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeByNatureAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_us-gaapOptionMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StockExpectedToIssuedDuringPeriodShares" xlink:label="loc_txmdStockExpectedToIssuedDuringPeriodShares_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockExpectedToIssuedDuringPeriodShares_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_80" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_80" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_OutsideConsultantMember" xlink:label="loc_txmdOutsideConsultantMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultantMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaapDerivativeByNatureAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeByNatureAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_us-gaapWarrantMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_60" xlink:type="arc" order="62" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember_90" xlink:type="arc" order="91" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsNoncurrentNet_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapDeferredFinanceCostsNoncurrentNet_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_190" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_190" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_190" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares" xlink:label="loc_txmdWarrantsGrantedToPurchaseCommonStockExpectedToVestShares_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_txmdWarrantsGrantedToPurchaseCommonStockExpectedToVestShares_190" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_190" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_190" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_190" xlink:to="loc_us-gaapAmortizationOfFinancingCosts_190" xlink:type="arc" order="22" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:title="00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Warrant1Member" xlink:label="loc_txmdWarrant1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_70" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_70" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_70" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_70" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_70" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_70" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_70" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_70" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_70" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseOtherNoncurrent_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWarrantsAbstract_70" xlink:to="loc_us-gaapPrepaidExpenseOtherNoncurrent_70" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative4" xlink:title="00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapStockOptionMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Warrant2Member" xlink:label="loc_txmdWarrant2Member_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant2Member_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_150" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_150" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_150" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_150" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_150" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_150" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_150" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedStockExpense_150" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_150" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_150" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_150" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_150" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_150" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="loc_txmdNumberOfSharesUnderWarrantAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfSharesUnderWarrantAbstract_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_20" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_20" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_20" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract_20" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_20" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract_20" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_20" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_20" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_20" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_20" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract_20" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeBeginningOustanding_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_20" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeBeginningOustanding_20" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeGrants_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_20" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeGrants_20" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExercises_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_20" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExercises_20" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_20" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations_20" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_20" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeClosingOustanding_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_20" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeClosingOustanding_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_20" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract_20" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_20" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_20" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_20" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_20" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_20" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_20" xlink:type="arc" order="29" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapFairValueAssumptionsExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExercisePrice_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_100" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000055 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOptionsAbstract" xlink:label="loc_txmdNumberOptionsAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOptionsAbstract_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_30" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdNumberOptionsAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_30" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_30" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_30" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_30" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_30" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_30" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_txmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract_30" xlink:to="loc_txmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_30" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_30" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_30" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_txmdAggregateIntrinsicValueAbstract_30" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_30" xlink:type="arc" order="30" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000056 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000057 - Disclosure - INCOME TAXES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000058 - Disclosure - INCOME TAXES (Details 1)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000059 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueFromRelatedParties_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000060 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="loc_txmdCustomerConcentrationRisk1Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk1Member_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmdCustomerConcentrationRisk2Member_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk2Member_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmdCustomerConcentrationRisk3Member_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk3Member_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmdCustomerConcentrationRisk4Member_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk4Member_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_DeferredSalesRevenueNetMember" xlink:label="loc_txmdDeferredSalesRevenueNetMember_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_txmdDeferredSalesRevenueNetMember_190" xlink:type="arc" order="191" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1_220" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet_220" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet_220" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000063 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:title="00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SubsequentEvent1Member" xlink:label="loc_txmdSubsequentEvent1Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_txmdSubsequentEvent1Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_40" xlink:type="arc" order="8" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>txmd-20151231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.11b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20151231\txmd_123115.xfr; Date: 2016%2D02%2D25T23:12:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x801D0006 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US">Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="us-gaap_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="us-gaap_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="us-gaap_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="txmd_SancilioAndCompanyWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SancilioAndCompanyWarrantsMember_lbl" xml:lang="en-US">SCI - Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_lbl" xml:lang="en-US">2009 Long Term Incentive Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="txmd_NonQualified2012StockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_lbl" xml:lang="en-US">2012 Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="us-gaap_SupplierConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplierConcentrationRiskMember" xlink:to="us-gaap_SupplierConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplierConcentrationRiskMember_lbl" xml:lang="en-US">Supplier Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_DeferredRevenueConcentrationRiskMember" xlink:label="txmd_DeferredRevenueConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredRevenueConcentrationRiskMember" xlink:to="txmd_DeferredRevenueConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredRevenueConcentrationRiskMember_lbl" xml:lang="en-US">Deferred revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DirectorMember" xlink:label="us-gaap_DirectorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DirectorMember" xlink:to="us-gaap_DirectorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DirectorMember_lbl" xml:lang="en-US">Pernix Therapeutics LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember_lbl" xml:lang="en-US">OPERA software patent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="us-gaap_InternetDomainNamesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternetDomainNamesMember" xlink:to="us-gaap_InternetDomainNamesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternetDomainNamesMember_lbl" xml:lang="en-US">Development costs for corporate website [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Hormone therapy drug candidate patents - In Process [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_lbl" xml:lang="en-US">Multiple trademarks for vitamins/supplements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_lbl" xml:lang="en-US">Approved Hormone Therapy Drug Candidate Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xml:lang="en-US">Sales Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="txmd_CustomerConcentrationRisk1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk1Member" xlink:to="txmd_CustomerConcentrationRisk1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk1Member_lbl" xml:lang="en-US">Customer A [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="txmd_CustomerConcentrationRisk2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk2Member" xlink:to="txmd_CustomerConcentrationRisk2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk2Member_lbl" xml:lang="en-US">Customer B [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="txmd_CustomerConcentrationRisk3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk3Member" xlink:to="txmd_CustomerConcentrationRisk3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk3Member_lbl" xml:lang="en-US">Customer C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="txmd_CustomerConcentrationRisk4Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk4Member" xlink:to="txmd_CustomerConcentrationRisk4Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CustomerConcentrationRisk4Member_lbl" xml:lang="en-US">Customer D [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:to="txmd_MultipleAdvanceRevolvingCreditNoteMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember_lbl" xml:lang="en-US">Multiple Advance Revolving Credit Note (Plato Warrant) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageMember" xlink:label="us-gaap_WeightedAverageMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageMember" xlink:to="us-gaap_WeightedAverageMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageMember_lbl" xml:lang="en-US">Weighted Average [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="txmd_CowenAndCompanyLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CowenAndCompanyLLCMember" xlink:to="txmd_CowenAndCompanyLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CowenAndCompanyLLCMember_lbl" xml:lang="en-US">Cowen and Company, LLC (Underwriters) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OptionMember" xlink:label="us-gaap_OptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Options exercised [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="us-gaap_DerivativeByNatureAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeByNatureAxis" xlink:to="us-gaap_DerivativeByNatureAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeByNatureAxis_lbl" xml:lang="en-US">Derivative, by Nature [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Option1Member" xlink:label="txmd_Option1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Option1Member" xlink:to="txmd_Option1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Option1Member_lbl" xml:lang="en-US">Options exercised 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StifelUnderwritersMember" xlink:label="txmd_StifelUnderwritersMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelUnderwritersMember" xlink:to="txmd_StifelUnderwritersMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StifelUnderwritersMember_lbl" xml:lang="en-US">Stifel Underwriters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_GoldmanSachsMember" xlink:label="txmd_GoldmanSachsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_GoldmanSachsMember_lbl" xml:lang="en-US">Goldman Sachs Underwriters [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_OutsideConsultantMember" xlink:label="txmd_OutsideConsultantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultantMember" xlink:to="txmd_OutsideConsultantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OutsideConsultantMember_lbl" xml:lang="en-US">Outside Consultant Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_JefferiesLLCMember" xlink:label="txmd_JefferiesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_JefferiesLLCMember" xlink:to="txmd_JefferiesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_JefferiesLLCMember_lbl" xml:lang="en-US">Jefferies LLC (Underwriters) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StifelNicolausAndCompanyMember" xlink:label="txmd_StifelNicolausAndCompanyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelNicolausAndCompanyMember" xlink:to="txmd_StifelNicolausAndCompanyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StifelNicolausAndCompanyMember_lbl" xml:lang="en-US">Stifel, Nicolaus &amp; Company (Underwriters) [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event- Underwriting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xml:lang="en-US">Accounting System in Process [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Utility Patent TX-004HR [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Patents1Member" xlink:label="txmd_Patents1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents1Member" xlink:to="txmd_Patents1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Patents1Member_lbl" xml:lang="en-US">Utility Patent Progesterone and Estradiol Products [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Warrant1Member" xlink:label="txmd_Warrant1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant1Member" xlink:to="txmd_Warrant1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Warrant1Member_lbl" xml:lang="en-US">Warrants - Unaffiliated Entity [Member] [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Warrant2Member" xlink:label="txmd_Warrant2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant2Member" xlink:to="txmd_Warrant2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_Warrant2Member_lbl" xml:lang="en-US">Warrants - Issued [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_DeferredSalesRevenueNetMember" xlink:label="txmd_DeferredSalesRevenueNetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredSalesRevenueNetMember" xlink:to="txmd_DeferredSalesRevenueNetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredSalesRevenueNetMember_lbl" xml:lang="en-US">Deferred Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SubsequentEvent1Member" xlink:label="txmd_SubsequentEvent1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubsequentEvent1Member" xlink:to="txmd_SubsequentEvent1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SubsequentEvent1Member_lbl" xml:lang="en-US">Subsequent Event - Exercises [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xml:lang="en-US">Related to Research and Development Activities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="txmd_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DocumentAndEntityInformationAbstract" xlink:to="txmd_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity a Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity a Voluntary Filer</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity's Reporting Status Current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_lbl" xml:lang="en-US">Entity Common Stock, Shares held by Nonaffiliates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $81,910 and $96,916, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsAbstract_lbl" xml:lang="en-US">Other Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseNoncurrent_lbl" xml:lang="en-US">Prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="us-gaap_AssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current Liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies - See Note 14</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock - par value $0.001; 350,000,000 and 250,000,000 shares authorized; 177,928,041 and 156,097,019 issued and outstanding, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Allowance for doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="us-gaap_SalesRevenueNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesRevenueNet_lbl" xml:lang="en-US">Revenues, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="us-gaap_CostOfGoodsSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsSold" xlink:to="us-gaap_CostOfGoodsSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_GrossProfit_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Sales, general, and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="us-gaap_OtherExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpensesAbstract" xlink:to="us-gaap_OtherExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpensesAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Miscellaneous income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="us-gaap_AmortizationOfFinancingCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="us-gaap_InterestAndDebtExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestAndDebtExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="us-gaap_OtherNonoperatingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingExpense_lbl" xml:lang="en-US">Loan guaranty costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income (expense)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Provision for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDilutedAbstract_lbl" xml:lang="en-US">Loss per share, basic and diluted:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_2_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Shares issued in offerings, net of cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued in offerings, net of cost, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Shares issued for exercise of options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Shares issued in exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Shares issued in exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Shares issued for exercise of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Shares issued for exercise of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Warrants issued for financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US">Warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty_lbl" xml:lang="en-US">Warrants issued as compensation-related party</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_3_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash flows used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for (recovery of) doubtful accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of debt discount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="us-gaap_AmortizationOfDeferredCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDeferredCharges" xlink:to="us-gaap_AmortizationOfDeferredCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDeferredCharges_lbl" xml:lang="en-US">Amortization of deferred financing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashExpense_lbl" xml:lang="en-US">Loan guaranty costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_lbl" xml:lang="en-US">Other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_lbl" xml:lang="en-US">Other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Patent costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_lbl" xml:lang="en-US">Refund (payment) of security deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash flows used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from sale of common stock, net of costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="us-gaap_ProceedsFromLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLinesOfCredit" xlink:to="us-gaap_ProceedsFromLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLinesOfCredit_lbl" xml:lang="en-US">Proceeds bank line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="us-gaap_RepaymentsOfLinesOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_lbl" xml:lang="en-US">Repayment of bank line of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayment of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash flows provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="us-gaap_CashPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase (decrease) in cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_Cash_2_lbl" xml:lang="en-US">Cash, beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_Cash_3_lbl" xml:lang="en-US">Cash, end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="us-gaap_InterestPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaid" xlink:to="us-gaap_InterestPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaid_lbl" xml:lang="en-US">Cash paid for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xml:lang="en-US">Cash paid for income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsIssuedForFinancing" xlink:label="txmd_WarrantsIssuedForFinancing" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForFinancing" xlink:to="txmd_WarrantsIssuedForFinancing_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedForFinancing_lbl" xml:lang="en-US">Warrants issued for financing</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsIssuedForServices" xlink:label="txmd_WarrantsIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForServices" xlink:to="txmd_WarrantsIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_WarrantsIssuedForServices_lbl" xml:lang="en-US">Warrants issued for services</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">THE COMPANY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_lbl" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="us-gaap_OtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentAssetsTextBlock" xlink:to="us-gaap_OtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expense and Other Assets [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidExpensesDisclosureTextBlock" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpensesDisclosureTextBlock" xlink:to="txmd_PrepaidExpensesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">INTANGIBLE ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureAbstract_lbl" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">NOTES PAYABLE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_2_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl" xml:lang="en-US">Risks and Uncertainties [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock_lbl" xml:lang="en-US">BUSINESS CONCENTRATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xml:lang="en-US">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_lbl" xml:lang="en-US">Trade Accounts Receivable and Allowance for Doubtful Accounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventories</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt Discounts</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Reporting</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShippingAndHandlingCostPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock_lbl" xml:lang="en-US">Advertising Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk and other Risks and Uncertainties</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassifications</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of potentially dilutive securities in our calculation of diluted net loss per share allocable to common stockholders</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_lbl" xml:lang="en-US">Schedule of prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_lbl" xml:lang="en-US">Schedule of intangible assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_lbl" xml:lang="en-US">Schedule of warrant activity</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used in the Black-Scholes Model of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of assumptions used in the Black-Scholes Model of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of plan activity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of tax rate reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CommitmentsAndContingenciesTablesAbstract" xlink:label="txmd_CommitmentsAndContingenciesTablesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CommitmentsAndContingenciesTablesAbstract" xlink:to="txmd_CommitmentsAndContingenciesTablesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CommitmentsAndContingenciesTablesAbstract_lbl" xml:lang="en-US">Commitments And Contingencies Tables</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum rental payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of quarterly unaudited summary information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Advance payments - total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Advance payments - other assets current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_lbl" xml:lang="en-US">Advance payments - long term prepaid expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="us-gaap_AdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvertisingExpense" xlink:to="us-gaap_AdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvertisingExpense_lbl" xml:lang="en-US">Advertising costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="us-gaap_CashFDICInsuredAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFDICInsuredAmount" xlink:to="us-gaap_CashFDICInsuredAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFDICInsuredAmount_lbl" xml:lang="en-US">Federal insurance limits</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfIssuedPatents" xlink:label="txmd_NumberOfIssuedPatents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfIssuedPatents_lbl" xml:lang="en-US">Number of issued patents</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_lbl" xml:lang="en-US">Return period of unsalable prescription products</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="txmd_ShelfLifeOfPrescriptionProducts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_lbl" xml:lang="en-US">Shelf life of prescription products</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-dilutive shares excluded from earnings per share calculation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryNetAbstract_lbl" xml:lang="en-US">Inventory</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished product</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw material</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="us-gaap_DeferredCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCostsCurrent" xlink:to="us-gaap_DeferredCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCostsCurrent_lbl" xml:lang="en-US">Deferred costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">TOTAL INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="txmd_OtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OtherCurrentAssetsAbstract" xlink:to="txmd_OtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_OtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_lbl" xml:lang="en-US">Prepaid research and development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="txmd_PrepaidConsultingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidConsultingCurrent_lbl" xml:lang="en-US">Prepaid consulting</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidVendorDeposits" xlink:label="txmd_PrepaidVendorDeposits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidVendorDeposits" xlink:to="txmd_PrepaidVendorDeposits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidVendorDeposits_lbl" xml:lang="en-US">Prepaid vendor deposits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="us-gaap_DueFromRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedPartiesCurrent" xlink:to="us-gaap_DueFromRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedPartiesCurrent_lbl" xml:lang="en-US">Other receivables-related party (Note 12)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT ASSETS</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_2_lbl" xml:lang="en-US">Depreciation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Fixed assets, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">TOTAL FIXED ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsNoncurrent" xlink:to="txmd_PrepaidManufacturingCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent_lbl" xml:lang="en-US">Prepaid manufacturing costs</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_lbl" xml:lang="en-US">Prepaid research and development costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseNoncurrent_2_lbl" xml:lang="en-US">TOTAL PREPAID EXPENSE</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_2_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Useful Life</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract_lbl" xml:lang="en-US">Finite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated Amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl" xml:lang="en-US">Weighted average remaining amortization period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_lbl" xml:lang="en-US">Gross Carrying Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_2_lbl" xml:lang="en-US">Net Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract_lbl" xml:lang="en-US">Estimated amortization expense for the year:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="txmd_AccruedClinicalTrialCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US">Accrued clinical trial costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedSalariesCurrent_lbl" xml:lang="en-US">Accrued payroll, bonuses and commission costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued compensated absences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_lbl" xml:lang="en-US">Allowance for coupons and returns</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Accrued legal and accounting expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="us-gaap_AccruedRentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRentCurrent" xlink:to="us-gaap_AccruedRentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRentCurrent_lbl" xml:lang="en-US">Accrued rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_lbl" xml:lang="en-US">Allowance for wholesale distributor fees</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_2_lbl" xml:lang="en-US">TOTAL OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_lbl" xml:lang="en-US">Maximum borrowing amount</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts_lbl" xml:lang="en-US">Proceeds from revolving credit note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Repayment of revolving credit note</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of shares upon warrant exercise (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per unit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares issued during the period (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Common stock issued during the period</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_lbl" xml:lang="en-US">Additional common stock issued under offering (shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of common stock issued during period for stock options exercised (shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_2_lbl" xml:lang="en-US">Value of common stock issued during period for stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="txmd_NumberOfStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercised" xlink:to="txmd_NumberOfStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockOptionsExercised_lbl" xml:lang="en-US">Number of stock options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_lbl" xml:lang="en-US">Number of stock options exercised in cashless exercise</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="txmd_AdditionalPeriodForPurchaseShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AdditionalPeriodForPurchaseShare_lbl" xml:lang="en-US">Number of days of the option to purchase shares</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StockExpectedToIssuedDuringPeriodShares" xlink:label="txmd_StockExpectedToIssuedDuringPeriodShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockExpectedToIssuedDuringPeriodShares" xlink:to="txmd_StockExpectedToIssuedDuringPeriodShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_StockExpectedToIssuedDuringPeriodShares_lbl" xml:lang="en-US">Total Additional common stock to be issued under offering (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsAbstract" xlink:label="txmd_WarrantsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAbstract" xlink:to="txmd_WarrantsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAbstract_lbl" xml:lang="en-US">Warrants:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_lbl" xml:lang="en-US">Weighted-average contractual remaining life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_lbl" xml:lang="en-US">Fair value of grant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance_lbl" xml:lang="en-US">Warrants granted to purchase common stock (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_lbl" xml:lang="en-US">Non-cash compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value (per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNoncurrentNet_lbl" xml:lang="en-US">Unamortized costs of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_lbl" xml:lang="en-US">Expiration date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_lbl" xml:lang="en-US">Vesting date of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate_lbl" xml:lang="en-US">Risk free rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:to="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_lbl" xml:lang="en-US">Forfeited warrants granted to purchase common stock (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested warrants granted to purchase common stock (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares" xlink:label="txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares" xlink:to="txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares_lbl" xml:lang="en-US">Warrants granted to purchase common stock expected to vest (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Unamortized noncash compensation associated with warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Recognition period of unamortized costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_2_lbl" xml:lang="en-US">Financing costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_2_lbl" xml:lang="en-US">Prepaid expenses - current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseOtherNoncurrent" xlink:to="us-gaap_PrepaidExpenseOtherNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseOtherNoncurrent_2_lbl" xml:lang="en-US">Prepaid expenses - noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Number of shares authorized for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Number of shares available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Option exercise prices (in dollars per shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Share-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Total unrecognized estimated compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2_lbl" xml:lang="en-US">Recognized weighted-average period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2_lbl" xml:lang="en-US">Grant - restricted stock unit (shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="us-gaap_RestrictedStockExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockExpense" xlink:to="us-gaap_RestrictedStockExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockExpense_lbl" xml:lang="en-US">Restricted stock expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value (per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Intrinsic value of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="txmd_NumberOfSharesUnderWarrantAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfSharesUnderWarrantAbstract" xlink:to="txmd_NumberOfSharesUnderWarrantAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOfSharesUnderWarrantAbstract_lbl" xml:lang="en-US">Number of shares under warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Warrants cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="txmd_WeightedAverageExercisePriceAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageExercisePriceAbstract" xlink:to="txmd_WeightedAverageExercisePriceAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageExercisePriceAbstract_lbl" xml:lang="en-US">Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:to="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WeightedAverageRemainingContractualLifeAbstract_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Life</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeGrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants_lbl" xml:lang="en-US">Warrants granted</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_lbl" xml:lang="en-US">Warrants expired</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_lbl" xml:lang="en-US">Warrants cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="txmd_AggregateIntrinsicValueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AggregateIntrinsicValueAbstract" xlink:to="txmd_AggregateIntrinsicValueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_AggregateIntrinsicValueAbstract_lbl" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Warrants outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Warrants exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2_lbl" xml:lang="en-US">Warrants outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_lbl" xml:lang="en-US">Vested and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="us-gaap_FairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExercisePrice" xlink:to="us-gaap_FairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Weighted average fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedTerm" xlink:to="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedTerm_lbl" xml:lang="en-US">Term (in years)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:to="txmd_SummaryOfActivityUnder2009And2012PlansAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SummaryOfActivityUnder2009And2012PlansAbstract_lbl" xml:lang="en-US">Summary of Activity under 2009 and 2012 Plans:</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOptionsAbstract" xlink:label="txmd_NumberOptionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOptionsAbstract" xlink:to="txmd_NumberOptionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_NumberOptionsAbstract_lbl" xml:lang="en-US">Number Options</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Options Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Options Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Options Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Options Cancelled/Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Unvested</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:to="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, beginning</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Options outstanding, ending</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Vested and exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US">Unvested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Federal statutory tax rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State tax rate, net of federal tax benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Adjustment in valuation allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Permanent and other differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Provision (Benefit) for Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_DeferredIncomeTaxAssetsAbstract" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredIncomeTaxAssetsAbstract" xlink:to="txmd_DeferredIncomeTaxAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred Income Tax Assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOtherLossCarryforwards_lbl" xml:lang="en-US">Net operating losses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">R&amp;D Credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred income tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:to="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement_lbl" xml:lang="en-US">Manner of Settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="us-gaap_DueFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueFromRelatedParties" xlink:to="us-gaap_DueFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueFromRelatedParties_lbl" xml:lang="en-US">Receivables- legal fee reimbursement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableRelatedPartiesCurrent_lbl" xml:lang="en-US">Payable - related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US">Settlement fees</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Proceeds from settlement agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="us-gaap_ConcentrationRiskTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTable_lbl" xml:lang="en-US">Concentration Risk [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="us-gaap_ConcentrationRiskLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskLineItems_lbl" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNet" xlink:to="us-gaap_SalesRevenueNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SalesRevenueNet_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="txmd_CapitalLeaseObligationsTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_CapitalLeaseObligationsTerm_lbl" xml:lang="en-US">Non-cancelable operating lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rental Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xml:lang="en-US">Rental income</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract_lbl" xml:lang="en-US">Future minimum rental payments, year ending December 31,</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2016</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2018</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Minimum lease payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_GrossProfit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrossProfit_2_lbl" xml:lang="en-US">Gross profit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Loss per common share, basic and diluted (in dollars per shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AccruedClinicalTrialCostsCurrent" xlink:to="txmd_AccruedClinicalTrialCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AccruedClinicalTrialCostsCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:to="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AllowanceForWholesaleDistributorFeesCurrent_doc" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CapitalLeaseObligationsTerm" xlink:to="txmd_CapitalLeaseObligationsTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CapitalLeaseObligationsTerm_doc" xml:lang="en-US">The total term (in months) of the company's outstanding lease obligation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are expired in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights_doc" xml:lang="en-US">Refer to numbers of shares forfeit during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:to="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights_doc" xml:lang="en-US">Date the warrants or rights are vesting in CCYY-MM-DD format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CowenAndCompanyLLCMember" xlink:to="txmd_CowenAndCompanyLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CowenAndCompanyLLCMember_doc" xml:lang="en-US">Refers to cowen and company llc member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk1Member" xlink:to="txmd_CustomerConcentrationRisk1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk1Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk2Member" xlink:to="txmd_CustomerConcentrationRisk2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk2Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk3Member" xlink:to="txmd_CustomerConcentrationRisk3Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk3Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_CustomerConcentrationRisk4Member" xlink:to="txmd_CustomerConcentrationRisk4Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_CustomerConcentrationRisk4Member_doc" xml:lang="en-US">Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredRevenueConcentrationRiskMember" xlink:to="txmd_DeferredRevenueConcentrationRiskMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredRevenueConcentrationRiskMember_doc" xml:lang="en-US">Deferred Revenue Concentration Risk Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:to="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_HormoneTherapyDrugCandidatePatentsMember_doc" xml:lang="en-US">Hormone Therapy Drug Candidate Patents Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:to="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet_doc" xml:lang="en-US">Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_LongTermIncentiveCompensationPlan2009Member" xlink:to="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_LongTermIncentiveCompensationPlan2009Member_doc" xml:lang="en-US">Long Term Incentive Compensation Plan 2009 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:to="txmd_MultipleAdvanceRevolvingCreditNoteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleAdvanceRevolvingCreditNoteMember_doc" xml:lang="en-US">Multiple Advance Revolving Credit Note Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:to="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_MultipleTrademarksForVitaminsSupplementsMember_doc" xml:lang="en-US">Multiple Trademarks For Vitamins Supplements Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NonQualified2012StockIncentivePlanMember" xlink:to="txmd_NonQualified2012StockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NonQualified2012StockIncentivePlanMember_doc" xml:lang="en-US">Non Qualified 2012 Stock Incentive Plan Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidConsultingCurrent" xlink:to="txmd_PrepaidConsultingCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidConsultingCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidExpensesDisclosureTextBlock" xlink:to="txmd_PrepaidExpensesDisclosureTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidExpensesDisclosureTextBlock_doc" xml:lang="en-US">Disclosure of prepaid expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidManufacturingCostsNoncurrent" xlink:to="txmd_PrepaidManufacturingCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidManufacturingCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of manufacturing contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:to="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchAndDevelopmentCostsCurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_doc" xml:lang="en-US">Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; non-current portion.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:to="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SalesDiscountsReturnsAndAllowancesGoods1_doc" xml:lang="en-US">Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SancilioAndCompanyWarrantsMember" xlink:to="txmd_SancilioAndCompanyWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SancilioAndCompanyWarrantsMember_doc" xml:lang="en-US">Sancilio And Company Warrants Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:to="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife_doc" xml:lang="en-US">This item provides the weighted-average contractual remaining life of warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidVendorDeposits" xlink:to="txmd_PrepaidVendorDeposits_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_PrepaidVendorDeposits_doc" xml:lang="en-US">It represents as a prepaid vendor deposits.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Option1Member" xlink:to="txmd_Option1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Option1Member_doc" xml:lang="en-US">Option 1 member</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelUnderwritersMember" xlink:to="txmd_StifelUnderwritersMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StifelUnderwritersMember_doc" xml:lang="en-US">Stifel Underwriters</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_GoldmanSachsMember" xlink:to="txmd_GoldmanSachsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_GoldmanSachsMember_doc" xml:lang="en-US">Goldman Sachs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_OutsideConsultantMember" xlink:to="txmd_OutsideConsultantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_OutsideConsultantMember_doc" xml:lang="en-US">Outside consultant</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">The number of shares into which fully or partially vested non option equity instruments outstanding as of the balance sheet date can be currently converted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding_doc" xml:lang="en-US">Refers to class of warrant or righst contractual life beginning oustanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeGrants_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants granted in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants exercised in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants expired in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants cancelled or forfeited in the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding_doc" xml:lang="en-US">Refers to class of warrant or righst contractual life closing oustanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable_doc" xml:lang="en-US">The weighted average remaining contractual life of warrants vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_doc" xml:lang="en-US">Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredIncomeTaxAssetsAbstract" xlink:to="txmd_DeferredIncomeTaxAssetsAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredIncomeTaxAssetsAbstract_doc" xml:lang="en-US">Deferred Income Tax Assets:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfIssuedPatents" xlink:to="txmd_NumberOfIssuedPatents_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfIssuedPatents_doc" xml:lang="en-US">Number of issued patents.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:to="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercisedInCashlessExercise_doc" xml:lang="en-US">Number of options exercised in the cashless transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_JefferiesLLCMember" xlink:to="txmd_JefferiesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_JefferiesLLCMember_doc" xml:lang="en-US">Jefferies LLC Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StifelNicolausAndCompanyMember" xlink:to="txmd_StifelNicolausAndCompanyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StifelNicolausAndCompanyMember_doc" xml:lang="en-US">Stifel Nicolaus And company Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdditionalPeriodForPurchaseShare" xlink:to="txmd_AdditionalPeriodForPurchaseShare_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdditionalPeriodForPurchaseShare_doc" xml:lang="en-US">Refers to additonal period for purchase of shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockExpectedToIssuedDuringPeriodShares" xlink:to="txmd_StockExpectedToIssuedDuringPeriodShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockExpectedToIssuedDuringPeriodShares_doc" xml:lang="en-US">Refers to numbers of share expected to be issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:to="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_StockIssuedDuringPeriodSharesNewIssues1_doc" xml:lang="en-US">Number of new stock issued during the period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares" xlink:to="txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares_doc" xml:lang="en-US">As of the balance sheet date, the number of shares into which expected to vest warrants outstanding can be converted under the consulting agreement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForFinancing" xlink:to="txmd_WarrantsIssuedForFinancing_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedForFinancing_doc" xml:lang="en-US">Warrants issued in the period for financing in a noncash transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForServices" xlink:to="txmd_WarrantsIssuedForServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_WarrantsIssuedForServices_doc" xml:lang="en-US">Warrants issued in the period for servcies in a noncash transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:to="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ReturnPeriodOfUnsalablePrescriptionProducts_doc" xml:lang="en-US">Period the company accepts returns of unsalable prescription products from customers following product expiration.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShelfLifeOfPrescriptionProducts" xlink:to="txmd_ShelfLifeOfPrescriptionProducts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShelfLifeOfPrescriptionProducts_doc" xml:lang="en-US">Period shelf life of prescription products from date of manufacture.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Patents1Member" xlink:to="txmd_Patents1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Patents1Member_doc" xml:lang="en-US">Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_NumberOfStockOptionsExercised" xlink:to="txmd_NumberOfStockOptionsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_NumberOfStockOptionsExercised_doc" xml:lang="en-US">Number of share options (or share units) exercised during the current period pursuant to the options' cashless exercise provisions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant1Member" xlink:to="txmd_Warrant1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Warrant1Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_Warrant2Member" xlink:to="txmd_Warrant2Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_Warrant2Member_doc" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_DeferredSalesRevenueNetMember" xlink:to="txmd_DeferredSalesRevenueNetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_DeferredSalesRevenueNetMember_doc" xml:lang="en-US">Deferred revenue when it serves as a benchmark in a concentration of risk calculation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SubsequentEvent1Member" xlink:to="txmd_SubsequentEvent1Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SubsequentEvent1Member_doc" xml:lang="en-US">Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty" xlink:to="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty_doc" xml:lang="en-US">Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants to related party.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:to="txmd_ScheduleOfWarrantRollForwardTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfWarrantRollForwardTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:to="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock_doc" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">As of the balance sheet date, the weighted-average exercise price for outstanding warrants that are fully vested and exercisable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_EntityCommonStockHeldByNonaffiliates" xlink:to="txmd_EntityCommonStockHeldByNonaffiliates_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_EntityCommonStockHeldByNonaffiliates_doc" xml:lang="en-US">Indicates the number pf common stock held by non-affiliates of the registrant as stated on cover of related periodic report.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_doc" xml:lang="en-US">Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on warrants exercised (or share units converted) into shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:to="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Weighted average remaining contractual term for unvested options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_2_lbl" xml:lang="en-US">Assets, Noncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndDebtExpense" xlink:to="us-gaap_InterestAndDebtExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestAndDebtExpense_2_lbl" xml:lang="en-US">Interest and Debt Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingExpense" xlink:to="us-gaap_OtherNonoperatingExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingExpense_2_lbl" xml:lang="en-US">Other Nonoperating Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_2_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_2_lbl" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInRestrictedCash" xlink:to="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInRestrictedCash_2_lbl" xml:lang="en-US">Increase (Decrease) in Restricted Cash</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLinesOfCredit_2_lbl" xml:lang="en-US">Repayments of Lines of Credit</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashPeriodIncreaseDecrease" xlink:to="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_WarrantsIssuedForServices" xlink:to="txmd_WarrantsIssuedForServices_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_WarrantsIssuedForServices_3_lbl" xml:lang="en-US">WarrantsIssuedForServices</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_2_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNetAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNetAbstract_2_lbl" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:to="txmd_PrepaidResearchDevelopmentCostsNoncurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_PrepaidResearchDevelopmentCostsNoncurrent_3_lbl" xml:lang="en-US">PrepaidResearchDevelopmentCostsNoncurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_2_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsGrossExcludingGoodwill_2_lbl" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_3_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeGrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeGrants_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeGrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExercises_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeExercises</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeExpirations_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeExpirations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:to="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ClassOfWarrantOrRighstContractualLifeForfeitures_3_lbl" xml:lang="en-US">ClassOfWarrantOrRighstContractualLifeForfeitures</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:to="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_FairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>txmd-20151231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.11b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: P:\EDGARizer\Clients\TherapeuticsMD\XBRL\20151231\txmd_123115.xfr; Date: 2016%2D02%2D25T23:12:33Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x801D0006 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:href="txmd-20151231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:href="txmd-20151231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="txmd-20151231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:href="txmd-20151231.xsd#ConsolidatedStatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="txmd-20151231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="txmd-20151231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Company" xlink:href="txmd-20151231.xsd#Company" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/Inventory" xlink:href="txmd-20151231.xsd#Inventory" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:href="txmd-20151231.xsd#OtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:href="txmd-20151231.xsd#FixedAssetsNet" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpense" xlink:href="txmd-20151231.xsd#PrepaidExpense" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssets" xlink:href="txmd-20151231.xsd#IntangibleAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:href="txmd-20151231.xsd#OtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayable" xlink:href="txmd-20151231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquity" xlink:href="txmd-20151231.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxes" xlink:href="txmd-20151231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedParties" xlink:href="txmd-20151231.xsd#RelatedParties" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:href="txmd-20151231.xsd#BusinessConcentrations" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:href="txmd-20151231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:href="txmd-20151231.xsd#SelectedQuarterlyFinancialData" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEvents" xlink:href="txmd-20151231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryTables" xlink:href="txmd-20151231.xsd#InventoryTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:href="txmd-20151231.xsd#OtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:href="txmd-20151231.xsd#FixedAssetsNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:href="txmd-20151231.xsd#PrepaidExpenseTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:href="txmd-20151231.xsd#IntangibleAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:href="txmd-20151231.xsd#OtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:href="txmd-20151231.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:href="txmd-20151231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:href="txmd-20151231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:href="txmd-20151231.xsd#SelectedQuarterlyFinancialDataTables" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="txmd-20151231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/InventoryDetails" xlink:href="txmd-20151231.xsd#InventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:href="txmd-20151231.xsd#OtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:href="txmd-20151231.xsd#FixedAssetsNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:href="txmd-20151231.xsd#FixedAssetsNetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:href="txmd-20151231.xsd#PrepaidExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:href="txmd-20151231.xsd#IntangibleAssetsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:href="txmd-20151231.xsd#IntangibleAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:href="txmd-20151231.xsd#IntangibleAssetsDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:href="txmd-20151231.xsd#OtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:href="txmd-20151231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative4" xlink:href="txmd-20151231.xsd#StockholdersEquityDetailsNarrative4" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails2" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:href="txmd-20151231.xsd#StockholdersEquityDetails3" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:href="txmd-20151231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:href="txmd-20151231.xsd#IncomeTaxesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:href="txmd-20151231.xsd#IncomeTaxesDetails1" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:href="txmd-20151231.xsd#RelatedPartiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:href="txmd-20151231.xsd#BusinessConcentrationsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="txmd-20151231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:href="txmd-20151231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:href="txmd-20151231.xsd#SelectedQuarterlyFinancialDataDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:href="txmd-20151231.xsd#SubsequentEventsDetailsNarative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_DocumentAndEntityInformationAbstract" xlink:label="loc_txmdDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_EntityCommonStockHeldByNonaffiliates" xlink:label="loc_txmdEntityCommonStockHeldByNonaffiliates" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_txmdEntityCommonStockHeldByNonaffiliates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheets" xlink:title="00000002 - Statement - CONSOLIDATED BALANCE SHEETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsAbstract" xlink:label="loc_us-gaapOtherAssetsAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapOtherAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="loc_us-gaapDepositsAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapDepositsAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsNoncurrent" xlink:label="loc_us-gaapAssetsNoncurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherAssetsAbstract" xlink:to="loc_us-gaapAssetsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:title="00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations" xlink:title="00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaapCostOfGoodsSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapCostOfGoodsSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaapSellingGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapSellingGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherExpensesAbstract" xlink:label="loc_us-gaapOtherExpensesAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOtherExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaapOtherNonoperatingIncome" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncome" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaapInterestAndDebtExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapInterestAndDebtExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaapOtherNonoperatingExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapOtherNonoperatingExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherExpensesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareBasicAndDilutedAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:title="00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty" xlink:label="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows" xlink:title="00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaapAmortizationOfDebtDiscountPremium" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDebtDiscountPremium" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfDeferredCharges" xlink:label="loc_us-gaapAmortizationOfDeferredCharges" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAmortizationOfDeferredCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="loc_us-gaapOtherNoncashExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapOtherNoncashExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaapIncreaseDecreaseInInventories" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInInventories" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaapIncreaseDecreaseInDeferredRevenue" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherCurrentLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCash" xlink:label="loc_us-gaapIncreaseDecreaseInRestrictedCash" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInRestrictedCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromLinesOfCredit" xlink:label="loc_us-gaapProceedsFromLinesOfCredit" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromLinesOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfLinesOfCredit" xlink:label="loc_us-gaapRepaymentsOfLinesOfCredit" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLinesOfCredit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaapCashPeriodIncreaseDecrease" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_2" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCash_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaapInterestPaid" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaapIncomeTaxesPaid" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsIssuedForFinancing" xlink:label="loc_txmdWarrantsIssuedForFinancing" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_txmdWarrantsIssuedForFinancing" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsIssuedForServices" xlink:label="loc_txmdWarrantsIssuedForServices" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNoncashInvestingAndFinancingItemsAbstract" xlink:to="loc_txmdWarrantsIssuedForServices" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Company" xlink:title="00000007 - Disclosure - THE COMPANY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies" xlink:title="00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/Inventory" xlink:title="00000009 - Disclosure - INVENTORY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssets" xlink:title="00000010 - Disclosure - OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaapOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNet" xlink:title="00000011 - Disclosure - FIXED ASSETS, NET">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpense" xlink:title="00000012 - Disclosure - PREPAID EXPENSE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidExpensesDisclosureTextBlock" xlink:label="loc_txmdPrepaidExpensesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_txmdPrepaidExpensesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssets" xlink:title="00000013 - Disclosure - INTANGIBLE ASSETS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaapIntangibleAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapIntangibleAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilities" xlink:title="00000014 - Disclosure - OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayable" xlink:title="00000015 - Disclosure - NOTES PAYABLE">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS' EQUITY">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - INCOME TAXES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedParties" xlink:title="00000018 - Disclosure - RELATED PARTIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrations" xlink:title="00000019 - Disclosure - BUSINESS CONCENTRATIONS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="loc_us-gaapConcentrationRiskDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingencies" xlink:title="00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData" xlink:title="00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaapQuarterlyFinancialInformationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapQuarterlyFinancialInformationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:label="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaapDebtPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapDebtPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:label="loc_us-gaapShippingAndHandlingCostPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShippingAndHandlingCostPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="loc_us-gaapAdvertisingCostsPolicyTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapAdvertisingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryTables" xlink:title="00000025 - Disclosure - INVENTORY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsTables" xlink:title="00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:label="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetTables" xlink:title="00000027 - Disclosure - FIXED ASSETS, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseTables" xlink:title="00000028 - Disclosure - PREPAID EXPENSE (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:label="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_us-gaapScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsTables" xlink:title="00000029 - Disclosure - INTANGIBLE ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:label="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables" xlink:title="00000030 - Disclosure - OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherCurrentLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityTables" xlink:title="00000031 - Disclosure - STOCKHOLDERS' EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaapStockholdersEquityNoteAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ScheduleOfWarrantRollForwardTableTextBlock" xlink:label="loc_txmdScheduleOfWarrantRollForwardTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_txmdScheduleOfWarrantRollForwardTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:label="loc_txmdScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_txmdScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityNoteAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesTables" xlink:title="00000032 - Disclosure - INCOME TAXES (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables" xlink:title="00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CommitmentsAndContingenciesTablesAbstract" xlink:label="loc_txmdCommitmentsAndContingenciesTablesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdCommitmentsAndContingenciesTablesAbstract" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables" xlink:title="00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" xlink:title="00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaapBalanceSheetLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapBalanceSheetLocationAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaapBalanceSheetLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationAxis" xlink:to="loc_us-gaapBalanceSheetLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapBalanceSheetLocationDomain" xlink:to="loc_us-gaapPrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaapOtherAssetsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseOtherNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPrepaidExpenseOtherNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaapAdvertisingExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaapCashFDICInsuredAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashFDICInsuredAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfIssuedPatents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ReturnPeriodOfUnsalablePrescriptionProducts" xlink:label="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdReturnPeriodOfUnsalablePrescriptionProducts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShelfLifeOfPrescriptionProducts" xlink:label="loc_txmdShelfLifeOfPrescriptionProducts" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdShelfLifeOfPrescriptionProducts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:title="00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/InventoryDetails" xlink:title="00000037 - Disclosure - INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNetAbstract" xlink:label="loc_us-gaapInventoryNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNetAbstract" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCurrent" xlink:label="loc_us-gaapDeferredCostsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapDeferredCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryNetAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentAssetsDetails" xlink:title="00000038 - Disclosure - OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_OtherCurrentAssetsAbstract" xlink:label="loc_txmdOtherCurrentAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="loc_txmdOtherCurrentAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidResearchAndDevelopmentCostsCurrent" xlink:label="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidResearchAndDevelopmentCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidConsultingCurrent" xlink:label="loc_txmdPrepaidConsultingCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidConsultingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidVendorDeposits" xlink:label="loc_txmdPrepaidVendorDeposits" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_txmdPrepaidVendorDeposits" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedPartiesCurrent" xlink:label="loc_us-gaapDueFromRelatedPartiesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapDueFromRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative" xlink:title="00000039 - Disclosure - FIXED ASSETS, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/FixedAssetsNetDetails" xlink:title="00000040 - Disclosure - FIXED ASSETS, NET (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaapEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapSoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaapFurnitureAndFixturesMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapFurnitureAndFixturesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/PrepaidExpenseDetails" xlink:title="00000041 - Disclosure - PREPAID EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsAbstract" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidManufacturingCostsNoncurrent" xlink:label="loc_txmdPrepaidManufacturingCostsNoncurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_txmdPrepaidManufacturingCostsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_PrepaidResearchDevelopmentCostsNoncurrent" xlink:label="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_txmdPrepaidResearchDevelopmentCostsNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseNoncurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative" xlink:title="00000042 - Disclosure - INTANGIBLE ASSETS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Patents1Member" xlink:label="loc_txmdPatents1Member" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdPatents1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfIssuedPatents" xlink:label="loc_txmdNumberOfIssuedPatents" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfIssuedPatents" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails" xlink:title="00000043 - Disclosure - INTANGIBLE ASSETS (Details )">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="loc_us-gaapComputerSoftwareIntangibleAssetMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapComputerSoftwareIntangibleAssetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternetDomainNamesMember" xlink:label="loc_us-gaapInternetDomainNamesMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapInternetDomainNamesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdApprovedHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_HormoneTherapyDrugCandidatePatentsMember" xlink:label="loc_txmdHormoneTherapyDrugCandidatePatentsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdHormoneTherapyDrugCandidatePatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_MultipleTrademarksForVitaminsSupplementsMember" xlink:label="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_txmdMultipleTrademarksForVitaminsSupplementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsNetAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:label="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_txmdIndefiniteLivedIntangibleAssetsExcludingGoodwillNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IntangibleAssetsDetails1" xlink:title="00000044 - Disclosure - INTANGIBLE ASSETS (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapGoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails" xlink:title="00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaapOtherLiabilitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AccruedClinicalTrialCostsCurrent" xlink:label="loc_txmdAccruedClinicalTrialCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAccruedClinicalTrialCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="loc_us-gaapAccruedSalariesCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedSalariesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SalesDiscountsReturnsAndAllowancesGoods1" xlink:label="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdSalesDiscountsReturnsAndAllowancesGoods1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaapAccruedRentCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRentCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AllowanceForWholesaleDistributorFeesCurrent" xlink:label="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_txmdAllowanceForWholesaleDistributorFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaapOtherLiabilitiesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOtherLiabilitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/NotesPayableDetailsNarrative" xlink:title="00000046 - Disclosure - NOTES PAYABLE (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableAbstract" xlink:label="loc_us-gaapNotesPayableAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNotesPayableAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaapLineOfCreditFacilityInterestRateAtPeriodEnd" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapLineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StifelUnderwritersMember" xlink:label="loc_txmdStifelUnderwritersMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdStifelUnderwritersMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CowenAndCompanyLLCMember" xlink:label="loc_txmdCowenAndCompanyLLCMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdCowenAndCompanyLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_GoldmanSachsMember" xlink:label="loc_txmdGoldmanSachsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdGoldmanSachsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaapDerivativeByNatureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeByNatureAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Option1Member" xlink:label="loc_txmdOption1Member" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_txmdOption1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfStockOptionsExercised" xlink:label="loc_txmdNumberOfStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfStockOptionsExercisedInCashlessExercise" xlink:label="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOfStockOptionsExercisedInCashlessExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1" xlink:title="00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_JefferiesLLCMember" xlink:label="loc_txmdJefferiesLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdJefferiesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StifelNicolausAndCompanyMember" xlink:label="loc_txmdStifelNicolausAndCompanyMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_txmdStifelNicolausAndCompanyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaapDerivativeByNatureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeByNatureAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OptionMember" xlink:label="loc_us-gaapOptionMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_us-gaapOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StockExpectedToIssuedDuringPeriodShares" xlink:label="loc_txmdStockExpectedToIssuedDuringPeriodShares" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockExpectedToIssuedDuringPeriodShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_StockIssuedDuringPeriodSharesNewIssues1" xlink:label="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdStockIssuedDuringPeriodSharesNewIssues1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2" xlink:title="00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SancilioAndCompanyWarrantsMember" xlink:label="loc_txmdSancilioAndCompanyWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdSancilioAndCompanyWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_OutsideConsultantMember" xlink:label="loc_txmdOutsideConsultantMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdOutsideConsultantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeByNatureAxis" xlink:label="loc_us-gaapDerivativeByNatureAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeByNatureAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DerivativeNameDomain" xlink:label="loc_us-gaapDerivativeNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeByNatureAxis" xlink:to="loc_us-gaapDerivativeNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaapLongtermDebtTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLongtermDebtTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaapLongtermDebtTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeAxis" xlink:to="loc_us-gaapLongtermDebtTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_MultipleAdvanceRevolvingCreditNoteMember" xlink:label="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLongtermDebtTypeDomain" xlink:to="loc_txmdMultipleAdvanceRevolvingCreditNoteMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:label="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdWarrantsAndRightsWeightedAverageContractualRemainingLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:label="loc_us-gaapDeferredFinanceCostsNoncurrentNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapDeferredFinanceCostsNoncurrentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightVestingDateOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:label="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares" xlink:label="loc_txmdWarrantsGrantedToPurchaseCommonStockExpectedToVestShares" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_txmdWarrantsGrantedToPurchaseCommonStockExpectedToVestShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaapAmortizationOfFinancingCosts" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapAmortizationOfFinancingCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3" xlink:title="00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Warrant1Member" xlink:label="loc_txmdWarrant1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WarrantsAbstract" xlink:label="loc_txmdWarrantsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWarrantsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapIssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:label="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseOtherNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseOtherNoncurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWarrantsAbstract" xlink:to="loc_us-gaapPrepaidExpenseOtherNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative4" xlink:title="00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 4)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_LongTermIncentiveCompensationPlan2009Member" xlink:label="loc_txmdLongTermIncentiveCompensationPlan2009Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdLongTermIncentiveCompensationPlan2009Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NonQualified2012StockIncentivePlanMember" xlink:label="loc_txmdNonQualified2012StockIncentivePlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_txmdNonQualified2012StockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_Warrant2Member" xlink:label="loc_txmdWarrant2Member" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_txmdWarrant2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RestrictedStockExpense" xlink:label="loc_us-gaapRestrictedStockExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRestrictedStockExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails" xlink:title="00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOfSharesUnderWarrantAbstract" xlink:label="loc_txmdNumberOfSharesUnderWarrantAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaapClassOfWarrantOrRightOutstanding_2" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOfSharesUnderWarrantAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeBeginningOustanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeBeginningOustanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeGrants" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeGrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeGrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExercises" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExercises" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeExpirations" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeExpirations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeForfeitures" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeForfeitures" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeClosingOustanding" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeClosingOustanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:label="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdClassOfWarrantOrRighstContractualLifeVestedAndExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:label="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_txmdShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails1" xlink:title="00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaapClassOfWarrantOrRightAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaapClassOfWarrantOrRightDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightAxis" xlink:to="loc_us-gaapClassOfWarrantOrRightDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaapFairValueAssumptionsExpectedTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails2" xlink:title="00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaapMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/StockholdersEquityDetails3" xlink:title="00000055 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SummaryOfActivityUnder2009And2012PlansAbstract" xlink:label="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdSummaryOfActivityUnder2009And2012PlansAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_NumberOptionsAbstract" xlink:label="loc_txmdNumberOptionsAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdNumberOptionsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdNumberOptionsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WeightedAverageExercisePriceAbstract" xlink:label="loc_txmdWeightedAverageExercisePriceAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWeightedAverageExercisePriceAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageExercisePriceAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_WeightedAverageRemainingContractualLifeAbstract" xlink:label="loc_txmdWeightedAverageRemainingContractualLifeAbstract" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_txmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdWeightedAverageRemainingContractualLifeAbstract" xlink:to="loc_txmdSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AggregateIntrinsicValueAbstract" xlink:label="loc_txmdAggregateIntrinsicValueAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAggregateIntrinsicValueAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdAggregateIntrinsicValueAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000056 - Disclosure - INCOME TAXES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaapInternalRevenueServiceIRSMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_us-gaapInternalRevenueServiceIRSMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails" xlink:title="00000057 - Disclosure - INCOME TAXES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/IncomeTaxesDetails1" xlink:title="00000058 - Disclosure - INCOME TAXES (Details 1)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_DeferredIncomeTaxAssetsAbstract" xlink:label="loc_txmdDeferredIncomeTaxAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOtherLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOtherLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_txmdDeferredIncomeTaxAssetsAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative" xlink:title="00000059 - Disclosure - RELATED PARTIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DirectorMember" xlink:label="loc_us-gaapDirectorMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_us-gaapDirectorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement" xlink:label="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionTermsAndMannerOfSettlement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DueFromRelatedParties" xlink:label="loc_us-gaapDueFromRelatedParties" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapDueFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaapAccountsPayableRelatedPartiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAccountsPayableRelatedPartiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:label="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionAmountsOfTransaction" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative" xlink:title="00000060 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="loc_us-gaapRisksAndUncertaintiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaapConcentrationRiskTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRisksAndUncertaintiesAbstract" xlink:to="loc_us-gaapConcentrationRiskTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaapConcentrationRiskLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaapConcentrationRiskByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaapConcentrationRiskTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByTypeAxis" xlink:to="loc_us-gaapConcentrationRiskTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SupplierConcentrationRiskMember" xlink:label="loc_us-gaapSupplierConcentrationRiskMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapSupplierConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaapCustomerConcentrationRiskMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_us-gaapCustomerConcentrationRiskMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk1Member" xlink:label="loc_txmdCustomerConcentrationRisk1Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk2Member" xlink:label="loc_txmdCustomerConcentrationRisk2Member" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk3Member" xlink:label="loc_txmdCustomerConcentrationRisk3Member" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CustomerConcentrationRisk4Member" xlink:label="loc_txmdCustomerConcentrationRisk4Member" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTypeDomain" xlink:to="loc_txmdCustomerConcentrationRisk4Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaapConcentrationRiskByBenchmarkAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapConcentrationRiskByBenchmarkAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaapConcentrationRiskBenchmarkDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskByBenchmarkAxis" xlink:to="loc_us-gaapConcentrationRiskBenchmarkDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaapSalesRevenueNetMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_us-gaapSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_DeferredSalesRevenueNetMember" xlink:label="loc_txmdDeferredSalesRevenueNetMember" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskBenchmarkDomain" xlink:to="loc_txmdDeferredSalesRevenueNetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaapRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskTable" xlink:to="loc_us-gaapRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaapRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeAxis" xlink:to="loc_us-gaapRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaapMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRangeMember" xlink:to="loc_us-gaapMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaapConcentrationRiskPercentage1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapConcentrationRiskPercentage1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapConcentrationRiskLineItems" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_CapitalLeaseObligationsTerm" xlink:label="loc_txmdCapitalLeaseObligationsTerm" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_txmdCapitalLeaseObligationsTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="loc_us-gaapOperatingLeasesRentExpenseSubleaseRentals1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeasesRentExpenseSubleaseRentals1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails" xlink:title="00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract" xlink:label="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapContractualObligationFiscalYearMaturityScheduleAbstract" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails" xlink:title="00000063 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaapSalesRevenueNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapSalesRevenueNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaapGrossProfit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapGrossProfit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapQuarterlyFinancialInformationDisclosureAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative" xlink:title="00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_SubsequentEvent1Member" xlink:label="loc_txmdSubsequentEvent1Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_txmdSubsequentEvent1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="txmd-20151231.xsd#txmd_AdditionalPeriodForPurchaseShare" xlink:label="loc_txmdAdditionalPeriodForPurchaseShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_txmdAdditionalPeriodForPurchaseShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>txmd001_v1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd001_v1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    /   _^X #D%D
M;V)E &3      ?_; (0 !@0$! 4$!@4%!@D&!08)"P@&!@@+# H*"PH*#! ,
M# P,# P0# X/$ \.#!,3%!03$QP;&QL<'Q\?'Q\?'Q\?'P$'!P<-# T8$! 8
M&A41%1H?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?'Q\?
M'Q\?'Q\?'Q\?_\  $0@!70)8 P$1  (1 0,1 ?_$ +L  0 " P$! 0
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M./\ $ -@['[.TSH<?X@!L'8_9VF=#C_$ -@['[.TSH<?X@!L'8_9VF=#C_$
M-@['[.TSH<?X@!L'8_9VF=#C_$ -@['[.TSH<?X@!L'8_9VF=#C_ ! #8.Q^
MSM,Z''^( ;!V/V=IG0X_Q #8.Q^SM,Z''^( B+QLFS6+2K;[%!IK3S5/E+;<
M1$82I*DLJ-*DF2,2,C 26[G\OK8]4P?[9 "Q
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MG'D(D226<=DS(EK)LB->4N$\I'I 9.R&&4DIUQ+:34E)&LR21J4>"2T]TS/
M@&,:;$E(6N,\AY+:UM+4@R41.-GE6D\.ZDRP,@&W,0"+KMV6S;Z&EURJQ:8A
M\S)A4MU#)+-.E1)SF6.&.D!MHMP4.NQ#F4:>Q48A+-LWXKB74$M.!FG,@S+$
ML0'8F0PIU3*7$F\@B4MLC(U)2K$DF9<)$>!X ,7IT-E]B.Z\A#\DU)CM*,B4
MX:$FM1(+NX)+$\.X B*S?EE42;S&L5V#3YF4G.;R9#;3F16.5651D>!X )II
M]EUI#K2TN-.))3;B3(TJ298D9&6@R,@'B),=Q;C;;B5K:,B=2DR,TF98D2B+
M@Q+2 SS$ ](R/@                   !"WO_A=?]6R_H%@.?=S^7UL>J8/
M]L@!8@                                   :I2'5QG4,JR/*0I+:_X
M5&6!'^@P'RFTZC:[5(MZUI5!DOW539#!RHG-74+8F-GB_/7*4E+9H,S4YG)P
M\Y*PTXX (,JU=!)D<UJ59=NGF]4.Y*>\AXH<1"([RHRHQ&@FD*)TFB9-I1FL
MCTX@.THEV4^0X\BM5F5S&10'F6WG5K;<54'4M3TN)R^6WDTY/@MGI+ !$VW=
M5=]$*J$.HUVKRTTRH.7!'5GRM&AW+#7#6XTMM+AZ<#;)>*,5&1F1 %LU2Z*D
M=0IK-5JA4M^HT=$:6EZ:\ZAF0IQ$LFI<MEAU1>01*42<J3X, '=><RY(,64E
MNL3HL6'6)#+;:USVS?:3%8U23FQ&I#B#)6=2<Z30LS/'@ ;*]7[B6KG$R57:
M76%TV$[:=+CH<4B1,4V9O(EDRUJG%Z[!+B7<I$C21%W EJ8W<[=S1ZL]4JDH
MW[CDTYZFJ<6J"F#S=:BRLF64B)Q!&ES]&. #9O,J,Z/7GT2JE5Z;'33DKMM-
M)0\I$BI9W,S;VJ0X2U:&B2VY@@R,_P! =^[RCSV+NNFK5'G)5*6BF\Y:6XM3
M!.G";4Z325'D\ES%)8'H+0 B=W3RXMPPJ91YU2GQ<)9W!#J<)$8H+AJ-QLT+
M2TW\HX\HR,M8X2BT]P!+[Q+71+N*ANQU.L-UM[T3<*6$^3)@);<D)0\9%Y."
MVLA+X<JU)[H"K7Y4+WC;PC@P*@JE0VDPDV\PAN>IETCT/EJHC3C#OE>0I+QE
ME3@98<(#1(N:X%[TXK45^IL(3678=0A/.RWF3AZM:4+U"8Z(;+2EDDVU:Q2S
MT'CP@)]JB5V;N86IQV?5JK4FH\NH1I3JUNN-I=;7(C-(5ER$ME"D9"X3/3P@
M,:S<-#K4"IR;*I<LZS!H\EMJK1XKT,XQ8I4F(6L2TI;BC3BE"4GEP[F(#C<K
ME3NNY4-4NHU2+0)E0A-%(82_$,V3ILEQXFS<2E2$J>2@C5@7E%WP$0Q/OB!3
M(LURHU>6N12BFU(G-8LVSA52.V9M-I2612HBG,Z4EBLM.DP'54KDJ<VJS:]$
M;J4J'%75SI1MMN-/$R=.AY3CZUM61*EYU),T'W3(C,! 1)=2JM.J[<^?57:#
M!J5"G17TO5!];:#D&F4:)$AEE]U*,"-65&5*BQ(@%RFU:\H$-51A',EKFSZK
M16HYDM1-N2))^CI1H,M"&C1E-?\ "H!$UR5?T/>$BEHK#["(KD!JC(>*H.IE
ML$VV4AQ:([3D=Y3B]82S>5BCAT$ ^F;RXI/[O[A0EG7.G3I)-().=1J-I6!)
M(B,\?> 5:_910Y]+9J$ZJ4:W50'%-R**EU*UU(E()MMTXZ'%_P!/$T(,LJCQ
MQQX %6>F5NF.U>KU8ZLBX*A0J*<IF,XZPDOEEMR7,R&I"&=5F2;FK0:T9E92
MT@-^[N=7)]P4GGKLJ9$A5J<4"3)YTZ917:4:DF3TMMIY:#<-1)4LN'@[@";N
M>@7K.NR[)5M5%,&0W"@:J,]$9?;E*)#QFA+KQ'D5E\DL,2(S(S(!4:Y4;@BL
MV]#MV?+HMO-T>.FB$^B>3RIR5K0\W(1"9<)QUO*@C:=(D'W" 3:I<FW;KK%1
MD2:@C_YFFR:V2$R76.9.T\VU.(:2E6+?.<$F2<33@1'P ,X$NYJP3DQR=5H[
M4:G5B?%8)3S!K>;GNHBI=3@2CRM896S[F&C0 L>[F+6H%8YI,J51J4>518$]
MU=16IW),<4XE[5J419,22DS;+07> ?1                  !"WO_A=?]6R
M_H%@.?=S^7UL>J8/]L@!8@                                    'F
M !A[H!E]T!'1XE(MZBZF.A,.ET]I;F4C,TMMIQ<6>)F9]\P$-0MXE J5IE<L
MYPJ+#0M3,M%06AI3#B5920X>.4C41I47N&0#MDWU9D2'!FR:Y!9B5(\*?(7(
M;2V_IP^349X*T@.Y=;I"%.(5-92IIYN*ZDUEBE]XDJ;;/3\)9+3@7=Q 11;Q
M;!,E87%3O(6VRO\ W+6A;_\ 22?E<*\- #O.Z+<*ME03JD4JTI.<J=KD:\TX
M8XZO'-P:?> >4BZ;:K$F5%I-4BSY,%626S'>0XML\</+))F9:2P <C]\T&',
MJS-4DMTUBD/,,.RY3B&VEKD,$^DDFHR_=/# !RUO>5:]*I)UIR6Q(HW,U343
M&7VE$M!.I:(FTYB-6*E_"X"/1P@.EV^K:C1),ZH5&)!IS#K;3<UV0UJW-<TE
MU'=\DS2O0D].&G@ ;J==U*J58;IT!:93#U/34V)[*TK8<:6Z;1$DTF>.E.(#
MD/>);$=J>[5YK-(9A3GJ?K9KJ&TN.,(0M2D&9]YS@X0$HFY: J,])34HZHT9
MIN1(>)U)H0R\1J;<4K' DK26*3[H#%%TVVY6E4-%4BJK"$9UTXGD&^22+'$V
M\<W!I 0]2WI6+!HE1K":Q%F1:4M#<THSS;BFUN+)M*3\K1B9@.M[>%8K#CK;
M]P0&W&&U//(7);)26T88J,C/@+,7A =,J\[3BN4]N3683*ZJ254U*WVR.0E7
MP3:Q/RB/'09 -;E[V>W4GJ6JLPRJ<=#BWX6O;UR4LIS.9F\<2RITG[@#.V[N
MHEP6W'N.GR$'2Y#9NZY:DD2$IQS9U8FE)IP\K3H 0EP[W+,I=KKN")4(U5C<
MY;@L)C2622N2ZHDDV;JU$A&!'F4:CT)+$![=^\9R@.TN'&HS]4JE3;)XH;+S
M#61LEMMJP<<4E+B\[I$E*.'W" =L^_:;#GT*GKB3.=UU;:4-J94CFQ.(6LCD
MJ41)0KY,TY,<V/N .5.\9@Z_S!5,DII"IJZ4FO*4US<YZ",U,ZO/K<N9)H)S
M+ES: 'MM[PVJU5(\1=+DP(M29=DT*>^IHVYK3)D2U)2A2EMGE4E:4K(C-)X@
M+AA[H!@ 9?= "21 /0                 !"WO_ (77_5LOZ!8#GW<_E];'
MJF#_ &R %B                                         5V_*!.N&W
MUT2,Z3+%0=:9J;N8T+*%FQD$T:2/RUH+(7OX@*54]TU0BE4XU',ZC3YKD6H-
MIJ%1EM3&JC&Q:4ZS,03KC9J9R95'FPRX88& XJCNQOI^B4M!/,.UV.W*8.I)
MFKC.L-2'B=2TX:(RF)K98?*$XPG.>D!+2;'O;TRI*%P'Z9(J5+JTN8I;C3^L
MA---/-H82A2/+-C.E6?_ )<.Z X__$M5*WN8(3"*7LS+HI+Q/+SN0\3I+S9,
M<G"9JX<>X 0]U-98O%4U[)*I:ZFFKE)549B,CA)+Y,Z>A.I<4E18)6:R\GA(
M!);NK&N>WJ\^])4S$H:(ZF(]-:E.3D9C<)25,:]EMV*V1$?R6L6G3HPP =E3
ML:I3+F=J*M0N(NM4^IDA9F:M5#A&PKR<IEGUAD:?" AI6["NKIU1C,JB(.1$
MJS,9!J42"<G5!,M@E8(/!.1."C(M!]\!MK-FW\\Z_.IRHS+\RHHFR8C<DV%&
MV<!N,IMN6<=];>5Q!XY$$I2?WD@.G=AN_KUL.Q%5-R.YS>GO0UFPXXYBXY/=
ME$9&ZDE&61TM*CQQ =$2PZBFYX]3DE'=BLUBHU+(9FI1-RXB6&L"-.&<E$>/
M>(!&PMUU798MJ,;T=$2,RW%N5@C49/L1'SEQ4L^27 [Y*L</),P'/ W4UB/>
M#TR02)5,.IR:LS*<J$PL%R"7@VJGI23!J2;AH->LP-/[N(#CI^ZZ]8]%K=.2
MJ+'AOPVHU+IBYCLUDG67D.I-MYUA#\=C*@TDT:G"+''N:0L,#=_4"JT6IRV(
MA.)N"36I"2,W%$V_"5'0DE&A.9:5J+O:" 5%.Y.Y41X;#FIEM/TZ/3:BVFI3
M(3;7-W'%8Y&$&4AM27<<JLIDHN$!<6MWTY$I#^$8EE<:ZRIW2:SC*C*8(C,T
MXFYI+09\'= ;8MDUI_=1LA..-&J"(W-4.-J4]'7J5YFU+(TMJRN$DLZ<.Z9:
M0'!L1=52FOU>IQZ= F/R:1_L8;JW6M12Y)O+<6XIIK,XM*S2DLF@B(L0'9O8
MMJX*]$A,4ZETVL14/-J>BSU+9=:63J%$\T^A+ADG*1DLB(E8:2/N .[9*L)H
MEHP'9A395"E1I$^6ZI6+I,,.-K-)GF4:LSA89CX.$P$2FQKF55?1CAP]E2K#
ME=YTE;G/#4XI3Q139-&0B)Y>.LUGP=&7$!MM"S;KA5&B,UA4--+M:*]$I;T5
M;BGI6M)+27'FUH2361E&!I)2L5'CB1 /H0                       (6]
M_P#"Z_ZME_0+ <^[G\OK8]4P?[9 "Q
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M>N.U1599;8DJ:JK\626H<SH2XRN(AM)$I;:LR5:2,!>\" ," ," ," ," ,
M                        $+>_^%U_U;+^@6 Y]W/Y?6QZI@_VR %B
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MT:-;^O5!)]V1*R\XERY#TM]:6\20@W7U+7E1B>5..! )D
M                $+>_^%U_U;+^@6 Y]W/Y?6QZI@_VR %B
M
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M3:2Q 3SI?)+_ )3_ & *_NX_P&WO5\?Z,@%C
M
M     5G>=^7-S>K)?T*@&S=S^7UL>J8/]L@!8@    &+W])?\I_L 5[=Q_@-
MO>KX_P!&0"Q@
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M%C
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M!-[N?R^MCU3!_MD +$ 8$   #%[^DO\ E/\ 8 KV[C_ ;>]7Q_HR 6,
M
M         ,0#$ Q( Q 8K6E"%*49)2DL5*/01$6DS,!\<O*\(M7FLS9K#S]F
M0Y!L-MLF23FR4I,S49J-/R:<!MLV1HIF?5+M[7M;;9F*XZG;N[O>SH\YBA4>
ME28SD]U6,AXVU&:L#41*41XX)(L"'-/=^Y+;N/QFVE9M:8Q#ZP0N\P   !6=
MYWY<W-ZLE_0J ;-W/Y?6QZI@_P!L@!8@    &+W])?\ *?[ %>W<?X#;WJ^/
M]&0"Q@
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MTQGLO-IR3;*8VVM3K1CPGXA14VVM3K1CPGX@#;:U.M&/"?B -MK4ZT8\)^(
MVVM3K1CPGX@#;:U.M&/"?B 5[>+=MMRK!N*.Q4&7'G:=*0VVDSQ-1LJ(B(!P
MT&RYM=L6WDHKTR#3)]#@QJK3$):=:>9YLE*B;-U*E,*6E1I4I'#[Y )5S==#
M755+.I2-GURBJ#EO96M0J62"02];EUV302]7FPS:0&5"W<R*2ZI[T]*EO182
MJ;05OML'S&.HR/024I)Y?D(+,OA))$ ]G[MD3*PY*75Y**9,?CS:M1TH:U,J
M5%)!(<-9IUC:5:I!K0D\%90&5N[N44>JQI2ZK)G0J6AYJA4YY+240T2#^4+.
MA*5NGE+(DUGY*= "WN_T5_RG^P!7MW'^ V]ZOC_1D L8
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M^V0 L0    #%[^DO^4_V *]NX_P&WO5\?Z,@%C
M                                    &M^0PPVIUYQ+32"Q6M9DE)%[
MIGH B,SB%-G[S8#LA4&VXCU>GEH_VQ&3"#_YW3T8>\,IW1RCC+OIV%L9V3%*
M_%S[*7I<1YKFJOH^"K_^IIIY<2_A<=/2?ZQ'3:W.5_N-.K_UUZK?Y3_LL]!M
M:@T)K5TR$W',R\ITBS.*_F6>*C%ZTB.3DW=SLVS^Z<_Z)? A=@
M"/KE;I]%IC]1GN:N.PG$^^H^XE)=U2CX!-*S:<01&56LZBU"J5%5X5]O+,>3
MEI,%6DHT<^ \#_?40WVWBL=%?FM,XX0O(YU0        !6=YWY<W-ZLE_0J
M:+$J]*AV-:$>7-8C2)5*@IBLNNH0MU11V]#:5&1J/3W $\[<%!9J**8]4HK=
M2<P)N"MYM+ZLQ8IP:-6<\>YH ;8E5IDUU]J',9DNQ5ZN4VRXAQ32_P"%PDF9
MI/W# ':K3&IS5/=F,MSWTFMB(IQ!/+2GA-#9GF41>X0!'JM,DRGXD:8R_*BF
M12H[;B%N-&? 3B$F:DX^Z Z'?Z2_Y3_8 KV[C_ ;>]7Q_HR 6,
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M?J]-XZ1R0!K+U^KTWCI') &LO7ZO3>.D<D :R]?J]-XZ1R0!K+U^KTWCI')
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ML;633TKFR#UKQGW3S*X/T#OKJB'R>[O-FR,3.*^4<(6+ :.4P!& $@
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M-;AZ<I&?[J>X&W;U3PY0BTK&,D     !B(R/$+0M.9!DHM)8D>):- 9'HD
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MG\DLN[E/]@"O[N/\!M[U?'^C(!8P
M            &N1)CQF5OR'$M,MEF6XLR2DB+NF9A,IK$S.(YJ1*ONIUJ0N!
M94/GJB/*[5WR-$1KW4F>E9C'W)GA6'H1V5=<=6Z>G_CX_P#1U4;=W%;EE5;@
MD*KE8/3KG_Z+9]YIKX)8":ZHYSQE7;WTS7IUQT5_K*WD@B+ BT#5P,B
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M_!H\!!,QD%CB1.*1@;@B-<VXV:SWE-4=.F,?\IYK@5E6@1:*+"+'2>##9:?
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M'57Y+3%H6#_Q9!7_ %GFM/"341E!##[?;X[)5Q+;'W46VRYK#-S/PFI&5O\
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M U$0!F >._TE_P I_L 5[=Q_@-O>KX_T9 +&
M             &"$?6*[2:/$5+J4E$9A/[RSTF?>2DM*C]X1:T5XRUU:KWG%
M8S*G>G;QNT]7;S*J-1E:%5B4GY9Q/=U+7<]\8S>UO3R=_L:M''9/5?\ QCE\
MT];5C42A+.0TE4NI.:7JC)/6/J,^'RC^#[Q"]=<5_5S;^]OMX<J^4+&-'*
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MBJ%46XD. 27E59AS5(9:)I1K)"=49ZU2=49*+$\P#OW<+M^%6Z&]1IB5G4*
MN;=;FO-PCDI4R:7Y)J4>1W6*>29G@>!&7< <MSKIRJY7JHY(+;.!6:<Q;;>N
M,G>;.ICY&V6B,LS3VL>UF!8'IQX &W=X=*37+5F4Z1K*_5XT]=W$EY3CBU((
MC-4E!J/(IN1Y",2+#$TEH ?6*K)J#$8U0X?/%GB2D:Q+6"<#\K%7" J6[^J7
M"BQZ"AJB&ZVF#')#G.FDYBU98'@?  G_ $O<W4!]+9 /2]S=0'TMD ]+W-U
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M/X2TYO*-/<(<?<^IG?FMWI:YNH#Z6R,%#TO<W4!]+9 /2]S=0'TMD ]+W-U
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MY_+ZV/5,'^V0 L0    #%[^DO^4_V *]NX_P&WO5\?Z,@%C
M       Q ,0'F((RP>D-,(-;RTMH+A6LR2DOTF"8XJ]4MX]ETXS3(JK*G"_T
MV3-Y7@;)0SG;6/%UZ^QW7Y5E%'O/<F8IH5O5&I'P$XIO4-^<K$5]V9Y1+7^/
MZ8_?>M?F\.7O;J1_(PZ?16C_ 'GEF^Z7NX)Q+]09O/AA/3VM?&U_Z!;O[AGE
M_P#.75,>2?PF(9%'1X2Q_8(G7:><H^\UUX5UQ^L\7;!W5V1%63BX'/'BX79:
MU/&?OYCR_J%HU55O^1W3XX_3@LD.FP(2,D.,U'1_"TA*"_Z2(7B,..VRUN<S
M+:M]AO\ J.)1_,9%^T)M$>*KD>KU%8_JSF$F7"6L2?[!G/<:X_NA&55N>]F$
MO0TTI\GDMN$[(6G'*9)T$C$\.$>=W?Y"(F.B<J6OA)MW)6JBA*J325:I?P9,
ME1(0?ND1:3'1'=;+Q^ROU3U>4-,Z'5DQU2:_7D0(A:5HCX-)P[V=6DPCMMVS
MU6^4+1$JTU6*-(D&S:5#=K\LCP54968HR3[YK<X?T8#MU_B]=.-_Z\97C7'B
ME6[#KU:RJNNK*.-PE2*?BS'(OX5*+2H=4;:T]$'5CDMM(M^C4>.3%,B-1&RX
M=6DB4?\ ,KX1_I&-KVMSE$SE(8"J                      $8 2
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M_)<6([,=I+3#:6FD%@EM!$E)%[A$,)S,J-@
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M(3%%W?VE2%$Y&IZ')!:3DR/EG3/OYEXX?H%+;K2K-IE8LI$6!:!FAZ
M                                                *SO._+FYO5DO
MZ%0#9NY_+ZV/5,'^V0 L0    #%[^DO^4_V *]NX_P !M[U?'^C(!8P
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MUI\59M*Q)(BT%P%P$,E7H
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M3O=25+BFN5 -IWNI*EQ37*@&T[W4E2XIKE0#:=[J2I<4URH!M.]U)4N*:Y4
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M &<.R[6AU]^X(U,8:K,DE:Z8DCS&:\,ZB+'*E2\/*418GW0$P\1:I?\ *?[
M%?W<?X#;WJ^/]&0"Q@                   UR([,AAQAYM+C3J32XVHL4J
M2>@R,A.9CD(2V+*H5M\X.G,X+DK-2W%GF42<<4MI/^%/<%]NZU^?),V3^!#-
M
M      K.\[\N;F]62_H5 -F[G\OK8]4P?[9 "Q     ,7OZ2_P"4_P!@"O;N
M/\!M[U?'^C(!8P                    #
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M-!@              9D7">&.@@               ",CX#QPT
M    9D6&)X8Z"Q[X               !&1\!X]S1WR      %9WG?ES<WJR7
M]"H!LW<_E];'JF#_ &R $Q5HKDRE38C:\CDAAQI"_P"%3B#21_H,P'S>TRKA
M3J/*F4&; ;M*ANT^7G0@U2I!DR6KADA9ZY&$8U$K06DB :"I5P.U [>]$2D$
M]<?IXJTI*"BHB*<YQI7FS$^1_):O+[O  W632[@](VM3)='DP$VA'E,SI[Y(
M)B0MUO4-E&6E2C<)9?**/ L,"(](#Z/4:>Y-9)M$Q^'IQ-<8VR49&6&4]8AP
ML/T *[3K#GTZ!'@0KIJC42*VEJ.UEA*RMH+!*<51C,\"[X#IV2K?:RJ>9 ^[
M &R5;[653S('W8 V2K?:RJ>9 ^[ &R5;[653S('W8!IE614Y3:6W[JJBD(<;
M=266"7EM+)Q!Z(Q<"DD8#=LG6^UE4\R!]V -DJWVLJGF0/NP!LE6^UE4\R!]
MV -DJWVLJGF0/NP!LE6^UE4\R!]V -DJWVLJGF0/NP!LE6^UE4\R!]V -DJW
MVLJGF0/NP!LE6^UE4\R!]V -DJWVLJGF0/NP!LE6^UM4\R!]V :8UCU.-K=3
M=541KW%/.^3!/%:\,3TQCPX. !NV2K?:RJ>9 ^[ &R5;[653S('W8 V2K?:R
MJ>9 ^[ &R5;[653S('W8 V2K?:RJ>9 ^[ &R5;[653S('W8 V2K?:RJ>9 ^[
M &R5;[653S('W8 V2K?:RJ>9 ^[ &R5;[653S('W8!IE6/4Y26TO755%$TXA
MYOR8)8+;/,D]$8N ^X V[)5OM;5/,@?=@'NR5;[653S('W8 V2K?:RJ>9 ^[
M &R5;[653S('W8 V2K?:RJ>9 ^[ &R5;[653S('W8 V2K?:RJ>9 ^[ &R5;[
M653S('W8 V2K?:RJ>9 ^[ &R5;[653S('W8 V2K?:RJ>9 ^[ -,:QZG&2XEF
MZJHA+KBWEEE@GBMQ691Z8Q\)F W;)5OM95/,@?=@#9*M]K*IYD#[L ;)5OM9
M5/,@?=@#9*M]K*IYD#[L ;)5OM95/,@?=@#9*M]K*IYD#[L ;)5OM95/,@?=
M@#9*M]K*IYD#[L ;)5OM95/,@?=@#9*M]K*IYD#[L T2;'J<DV3>NJJ*..ZE
MYKR8)8.)(R(]$8OXCT& W[)5OM95/,@?=@#9*M]K*IYD#[L ;)5OM95/,@?=
M@#9*M]K*IYD#[L ;)5OM95/,@?=@#9*M]K*IYD#[L ;)5OM95/,@?=@#9*M]
MK*IYD#[L ;)5OM95/,@?=@#9*M]K*IYD#[L ;)5OM95/,@?=@&F+9%4BMJ;8
MNJJ)0IQQU198)^6ZLW%GIC'PJ49@-VR5;[653S('W8 V2K?:RJ>9 ^[ &R5;
M[653S('W8 V2K?:RJ>9 ^[ (6];1JAV=7=?<]3?9*GRE.,K3")*R2RH\IFF.
ME6!X:<# 3N[G\OK8]4P?[9 "Q &!=X P+O        'P *36;QNJG5DE'1F2
MMTIT>FD\Z^I$Z0Y(-*==&8)"D+;0I? :R49)4?< <U'WB5B9483TFEMMV]65
MRVJ+*8>4[*4N&2U%KF30E!:]#2U-Y5GWC &MY-2?H4R8FC''JI5@J)3J;)=)
M)J==U>K7(6@G";\EPU+2G-@18<("?L^X*A5F)S%4C-Q*M2Y2H<]EA:G6342$
MN(<:6I*%&A;;B3\I)&0"P         (RXZA5(%*<?I4 ZE45*0U&BYM6@UN+
M)&=Q>!Y6T8YEF1&>!< "G-[P;J6YZ#32X2KJ.>J C+*<.FFEN,4MQ[7:K6_)
MH,D*1DQ)1@-W_DR;Z+H<@J*ZJ14:BBF5(R6GF\-TI?,W<7#P4X>LTMD2=):3
MP 3%0NV5%O2DVZFFNG&J!/&Y5'#)+1*:9-U+;18FIQ7D^4>!$7NF LP
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M#3AE3HQ[O= 2-C7)(N2UH%9DQ2@R)9.:R(2]83:FW5MFG/@6/P $\
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M6?<;];AO56KLRZ/2Y;D^G,-Q"9E&ZM+B$I?>2O5J0VEY1>0VDU:,Q@+D7
M "%O?_"Z_P"K9?T"P'/NY_+ZV/5,'^V0 L0          CJC<5$IKZ6)\YF,
M\M.=+;BR2HT8X9L.]B Y=MK3ZVC>>0!MM:?6T;SR -MK3ZVC>>0!MM:?6T;S
MR -MK3ZVC>>0!MM:76T;SR -MK3ZVC>>0!MM:76T;C" -MK2ZVC<80!MM:76
MT;C" -MK3ZVC>>0!MM:?6T;SR -MK3ZVC>>0!MM:?6T;SR -MK3ZVC>>0!MM
M:?6T;SR -MK3ZVC>>0!MM:?6T;SR -MK2ZVC>>0!MM:76T;C" -MK2ZVC<80
M!MM:76T;C" -MK3ZVC>>0!MM:?6T;SR -MK3ZVC>>0!MM:?6T;SR -MK3ZVC
M>>0!MM:?6T;SR -MK3ZVC>>0!MM:?6T;SR -MK2ZVC<80!MM:76T;SR -MK3
MZVC>>0!MM:76T;C" -MK3ZVC>>0!MM:?6T;SR -MK3ZVC>>0!MM:?6T;SR -
MMK3ZVC>>0!MM:?6T;SR -MK3ZVC>>0!MM:76T;SR -MK3ZVC>>0!MM:76T;S
MR -MK3ZVC>>0!MM:?6T;SR -MK2ZVC>>0!MM:?6T;SR -MK2ZVC<80!MM:?6
MT;SR -MK3ZVC>>0!MM:?6T;SR -MK3ZVC>>0!MM:76T;C" -MK3ZVC>>0!MM
M:?6T;SR -MK2ZVC<80!MM:76T;C" -MK2ZVC<80!MM:?6T;SR -MK2ZVC<80
M!MM:?6T;SR ;8UVVU*DM1H]2CNOO*RM-)6692L#/ B[IX$ E@$+>_P#A=?\
M5LOZ!8#GW<_E];'JF#_;( 6(          01.$U=\]Q1&:44R,HR(L3P)^0>
M@BX3 0O_ ):H)8__ !]5T?8U^,='VUO.%NG+C_\ ,M*]**C'2Y_-R:)9+)D]
M=F,\-+7"2?\ FQ$_:6QG,)]N786]J@FHB]'U0L3PQ.&OQB/MK8SF#HESW'3Z
MX_>M%1$N:IP(%63(<=@L%$)M'-FFU))&MCN++.:CSXJ/W,!SRHKL/>I=U)MH
MI=7@LS5R(Q.TIYE;JW5K.:F)_N6VVST?*I61-$9X:.$!T0-[MRR8\U]VE1XK
M=(B+?J*Y'.V5..ZQ;+*6&5-:XDK4E.A:,W<P,\ &$#>Q><UI,)%*@1ZTV_/:
ME)EONL,$B RS(S)3E4ZE2VW_ (*M*>$^\ V1M]-0FUY#$6C.%2E(:0IU;<DW
M$OO1"E)4;J6^;$A.8D&DUYS^$7> ;*IO%N.54J Q2SB-1Y4%JH5/%Q2G/]Q"
ME/$TW@2B+*;&9)GPZ.X [:/?]S2J?)FM08DB'"A$E#;DHFYS\Y$-N3AE4A#6
MK7K<N.)'^]A@ A6=YEQSI-OS'7$4]$21+*Y8"&W4$;#:8Y$;B)3;;S9MIE:S
M1H/#'$R 90*M=5QWA(IBK@F4NGOO.RH?,TQB<3&YLRMEO,\T\1D9.:P]&.)\
M. "]V'59U0H:N>R2FO1)<J&FH))*2DMQGE-)>P1Y.*B3Y671CC@ JDJ^KRBI
M>9IL>+4'TOUN0XN:XMDD1J7(2E#2-4A6*E)<RD9_I 3]MWA5ZS67\8\2/0T&
M;#1JD'SXWT--NJS-9<FK,G<"P5CHQX# 2MRW9 M]MA<MB4^3YFE!165/&64L
M3S8< I>\5=';]M;;.(F(_651KN^:#%IZWJ?3IAR24DDE,86PS@9X'BO$]/>&
M4]Q'E+OT_B+VMB;5^4Y:+=WU,3([JZG39!.H7E1S!I<A&7 C\HS,L%>X(KW,
M3'*4]Q^'M2>%J_/@DJKO":J5L5Y=&3-I]0AP77V),F,;:4*(L$J3FQ2HTGIP
M,;4V1;DX>Y[2VJ,S->/E.40]O*JU-<G1ZEBJL4:EN)F4YE!JU\Y4AIF(\RDB
M-:D2=9B@B]TN%(NY7$Q=EWUBV*?"BS)?IN'+?B5=EI,>FU:4AEO6-/,,U)&1
M!*0M"UI-..'  [*/.KESNQ&TW54*8U%IBGGGT,1&%JD-RWF%G*;=;D(Q;U65
M>K423/$RT& X5[VZPF7;#SR7N9-QV'[D=CQ77(Q\]5J6U+>2E:(Y(27./*5I
M29 .^NW!7<+@K:+E]&2*),=B4V@&A@V'S802T(D$XDWUKE%I1D6G C+ C =F
M\"K7 5<I,.$Y6V6WH#\EZ-06X;CY.I<:2G6\\(TY$YS+R>Z Y*5=^\&!5DL5
MAN+(BLG28U6-2]6ZT].;RK4PEM)H5@LR4O,K#^$!S4_?!=,U^7';I$4G7>9K
MHKJW'VVG6ILSFA*<UB$N&23P5G2C!7[N/" S@[T[Z6TR]*H].)DVFY;YM27C
M5S?GAPG202F_ZAK\M&)X9=!Z0&Z?O@JL&Y*E#73&GJ1';GE"EH6ZA2Y%.(LZ
M%K<0E"DF9X*-LE$CNF9@,[FWGW50(].B/4R++K3Z93\OF)RYD8F8N0\J-0RM
MU#BR=+^H1)3PF>D!C5]Z%9DVF[*I+,>)4I"*KS=,A:C-HJ>@U)4I)$?E8<.C
M C]P!TP[XNDZHY2F6H3TIJ2\Y.=ER%,LIC,(C$XB,9-XFHUR#-.?@+A/2 BZ
M[O8N'TC6Z;&BML0D1Y_HJJM:S/KJ<I*7,=<A*',<W^F1I(]&8P%CNZ[*Y1:S
M.*"E$K54V$Y&A/*U;1R)50YJ:U+22E%Y*B\ "#J^\B]$TV?";AT^-6J;'J+U
M2?.2M+&2&:4)5$SHQ4M6M2K!S06&!\) ,X&]BNRKD>H[--(XK9NPVISZ)*$\
MZCQM>;KSVK*,32C++E2O.7PL, %MLV\%W!:Q7$[&.,PZ;BFHB3-QY#;9Y<'"
M+_4S$9X%W,!6]HK&91,L]NJ9]5F\0KQCA_D:>5OHCKAH;WATI<E;11Y)I219
M<J,RS/\ >(T$>)8"L?DZ3.,2K[D.IJ]J:XZALHTPC6HDD9L*PQ,\-.D7KW])
MF(Q;Z+=2D5*^+EIDFN-2Y/\ LY=53#H,LDI+4.MO,I<AK/# ]:VI2VS/3\(N
M\.]8C;SJC(NJO1DOJB4MYB6S0)DV.XS!1*IR#S.<[4E+;J'CSJ,B4>"6P'#$
MKMW-19=(J%5JD*IR?1[C;DHJ>^M+4F:W'=D0I45)L&V9.8$AUO$N'$P$A6KH
MKEL1Z]0TU>76IA%":I,TXZ),UE^>;J7$J:BMH)TV&F3?(B;QR\.(#=&O&IW)
M3;;AIJ;MOKG-3"K$TFT-RRDT[(AR.A$E"DM+6:E.'F1CE+07= =L*X:\[8=<
M=CU>/)F0)#D.E5]XVFFI"/D]6XI1%J-9BX;6;#(:RX.X @J?=-Z0I<:FJE2>
M<LU.,51AUM,94I,1]A]>#4B 6H>2X;!Y/)2I)E@>)& [X^]&Z'&F&E4^G%.K
M+463033*6MAMJ8[JTE-42,R5I_\ ;(R4>@@'7:]]UF;>\RWYJ&TJ-2'=<E>>
M*DDPVEN1XCI)3KG-8LW#S894?J#"7=M=@WO<<1R3K(#C;$2B132G!$]4=IPD
MI,BQ5K=>:C(S_=T (6D[U;FALVS#?9;JR'BA,5RHJ)Q#J7)KZF$+Q2A,=)^2
M2LF8U*QX"+2 Z*%O.NJ5=D.+48S$>)666#@$V;BH["><R&U*?<-)'KWB8RM-
MD>!GW>^'"G?!=U:@RO1E.:IZUK8>I\F2W+;03!SFXSC;JW&D(<6HG,2-HU)+
M3W< %ZO&N52+(7"@NFPXS2:A4W'$EF,UQT);:068CT9W<Q^\0"%NNZJOS.C-
MT:JL,RJC2W)&=;C*"<6I<5*%(6X2FTK7K5I:-7DYS+$!VV+7:N5-KL6H+GR:
MG1S)9PJFF-SM!+9-Q"3?A?(/I<-)FA24D9<!@(F!<E0I%$A794+H.J^DX#TQ
M5"4VPEE;B&#?R0UMI2XT3.!I6;JEZ.' P'DK>7>L5Y=+73J8[662<>>6U)>5
M$YNF(J6G!636:S*@TY3+#22N !ZUO*O.2]%@,TVFLU*H.)5$YQ*=)A,=V%SU
M&M42,QN)2DT*))8=TM #6C?)4WZO0T1J8VNDU'F34]W,Z;C#\]!J01.&A+)D
M6!8))1J4G3@1 /86\FZI,2$]5(+$)$[T=-B'!>4XOF\F5J7&G2=;^%A@?D]_
M#$CT@(J-OQNR;!6_$MW,M\FI$,S:FY6XSBE$>=!LI<D+3@6F,2RTX\! +&NZ
M5U2LV\27$NPZJB%5(NK/,AM234VZA)FE"C2K.DRS$1XD8#Z. A;W_P +K_JV
M7] L!S[N?R^MCU3!_MD +$          ("<S6XUPN5"%!1-8?B-1S(WR94E;
M3KJ^!258D9.D S]*73U$CIB/B ,>?W)K=;L^WK<N76<[;S9<<<,<F. #+TI=
M/42.F(^( T.O5UV4Q*<MUI<F,2RCO'+;-39.$1+RGDT9B+2 XG:4\[#YF[:$
M1<0V5Q385(:-&I<42UMY3;PRJ41'AWP&F-;[46 [3HUE06H+S)Q7HR'F2;6P
M:C4;:DZO2G,LST]\!$O[N:4Z]!(K*@HI\+7**FI<C\W<<>)HM:M)M_#23!$1
M@)I='4NM-UQ=G0E5AI&J:GF^SKDH(LI))>KQT)/#W@'(Q9].8;U3%B4YIO6D
M_E0ZPDM:DU&E>AOA+6*P]\P'05OM%,5-V*@G+7&*"I\WF#6<4DY-29ZOX&7R
M<.]H 8P[;8AP2@1+*@L0B0\WS=#S)(R22)+Z<-7P.$DB5W\ &NJVG"JY)34[
M'@3"2:323SS*L#0V32<,6^XVDD^\ [X<2I0G8SD.V&8W,XYQ(S;4MM"&V5*2
MHT)2ELB(L4$ <SG9E*V4C9ED^E9\Y:TE*,E2"/Y/_5,B-?? <R[?;7.=GJLN
M"<UYE$9V3KV=8IEO#*V:M7CE+*7@(!,^E+IZB1TQ'Q &N1*N"2T;4FW67VC,
MC-MR4TM.)<&A39D":VF)S'!C%?KD1!HBVVQ'0H\5):DM((SX,3)+9!$83:\V
MG,SE[+D5^9&=BRK=:?C/)-#K*Y;:DJ2?"1D: 5<DB%-DU!JI2+4C.U!DD):E
MKDM&ZDFU&M!$K5XX)4HS+O& YJQ04UHG2J]F0I^O-M3QOOLK-2FB,FSQ-OA2
M2C(C <L^S*746XC4ZPZ=(:@-ZB$AQU@TM-$>.1!:O DXZ< $KS>H<VEQMEHQ
M1Y__ 'K/.6LCN*":P66KP/Y-))]X@$;5K2@5B6B95+&I\R6TA+3<EUYE3B4H
M+!)$O5YO)_=/N=P!,)=KJ9+<HK=:YRTT;#;QRT&LFE&1FC,:,<#-)'^@!K<:
MJCKSCSEKQU.O+:==6<IHS4Y'TLJ,]7I-&'D]X!&T^UH=.?<D0+'I\5]U:77'
M6GF$*4M#A.I49DW^ZXDE%WC =94V03>K*T8I(U>IRE):PU>MUV3^GP:WR_?
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@LI-(HZ&#@2B=6W4Y2UDC4JS&E)P$$9D7 68O?(!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>txmd002_v2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 txmd002_v2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" )^!+ # 2(  A$! Q$!_\0
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M_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\
MAD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.
M^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A
M_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\
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M_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\
MQJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:K
MU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5H
MH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /
M*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_
M (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&
M3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X
M(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_
M $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$
M;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A
M_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\
M_A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2
M]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8_
M_&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJ
MC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X
M9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O
M@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?
M]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&
M_A__ .$O8_\ QJO5:* /*O\ AD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?
M_P#A+V/_ ,:KU6B@#RK_ (9.^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\
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M_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\
MAD[X(?\ 1&_A_P#^$O8__&J/^&3O@A_T1OX?_P#A+V/_ ,:KU6B@#RK_ (9.
M^"'_ $1OX?\ _A+V/_QJC_AD[X(?]$;^'_\ X2]C_P#&J]5HH \J_P"&3O@A
M_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\ QJO5:* /*O\ AD[X(?\
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M_P#&J]5HH \J_P"&3O@A_P!$;^'_ /X2]C_\:H_X9.^"'_1&_A__ .$O8_\
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MFC?^D,->JUY5^R=_R:S\&_\ L3-&_P#2&&O5: "BBB@ HHHH **** "BBB@
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M:#XF\5Z3X%;4_A=X2OYM-U+7)M99=2D6VD\J[N+>T,#B>*)@V6>=';RY"%)
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MGXR?]B9K/_I#-0 ?LG?\FL_!O_L3-&_](8:]5KRK]D[_ )-9^#?_ &)FC?\
MI##7JM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7GOQR^$H^,'@RWTVWU,Z)K>FZC:Z
MSH^J>3YRVE[;R"2)VCW+YB'!5ER,JS<@X->A44 >'WGA7XQ_$G4/#=GXIN-
M\!Z#IMW%J&I3>#=>O;J\U9XB"ML"UM;?9H&;)?YI2R@)QDM7%ZY^SG\18_ ?
MCSX5Z'J/AT> O%VHWUR=?N[F=-4TNVOIFENX%M%A,=PP,DH20SQX$@RAV?-]
M244 ?-7B#]F/7[SP'^T'X>TZ]TR/_A/H8X-%:XFEQ J:9#:#[21&=OSQ$_('
MX(/7BL_]IOX4:O'H?BSQL;BR_LK2?A+K^@3P[W\]KB5(I591LVE-L#Y)8')7
M@\D?4M% 'S)X&^&?Q ^+%O\ ";6/'$GAW2-'\)V*ZC8OH-U/<76I7<MBUO'-
M(LD4:VJHDSOY:M,2Y7YP%^;@?#7['?C_ ,.^#?!WA2QTCX=:,NA^(]+UG6/%
M%C/<-J7BE+*]\U6NE-J#%*49Y"QFG^?Y055BP^V:* /%_"OP7UO0_"OQHTR>
MZT]Y_&FL:GJ&GM'(Y6*.XM8XHQ,2@*L&0D[0PQC!/2N(\4?L^>*M6^%OA'P1
MJG@3X8?$G3=)\,6^E+_PDUQ<6LVGWJP"*::"86EP71P$(VK Z[,[CN&SUOXZ
M?%S_ (4WX+@U2VTG_A(=<U'4;71](T5;D6[7UY/($2/S-K;0!O=F"MA8V..*
ME^&_QGT/Q]\&M(^(]U+#X;T>ZL/ME[_:EPL2:<R9$\<TC;57RG5U9CC[IZ4
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M(;=YH[FTN&L( (5D3RBD\LS%9$(;*G=[-H/[.^AVK>(+CQ1J^K_$34=<TO\
ML.\O_$QM_,_L[YLVJK;0PQJA9W9F";V)&YCM7;1\+_LSZ5H.K^'[O4O%OBCQ
M9:^&X98- TW7;BV>#2O,C\K>AB@CDFD6(F-9+AY656;G+$D ^?\ P/\ $+XQ
M:WX)_9]UR[^*5R]Y\2IFT[5(/[%T\0649M)KA;BU @W+<A;?&96EB+R,?*"@
M)53QIK/CCQY)X?\ "5SXN>YUSPS\:4T2Q\47=C;BY^S#2I;D2/%%&D#3(L[J
MI\L(2B%E/S _2^@_LW^&O#WA_P"%FCVU]JSVOPYG^T:2\LT1>=OLTMOBX(C
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC;_!_P !V=O%!!X(\.001*$CCCTFW544#   3@ =JYGPY_R=-\0_^Q,\,_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'_V)GAG_ -+M>KU6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M('_AN/$/_P @T?\ #2WA'_H$?$#_ ,-QXA_^0:]5HH \J_X:6\(_] CX@?\
MAN/$/_R#1_PTMX1_Z!'Q _\ #<>(?_D&O5:* /*O^&EO"/\ T"/B!_X;CQ#_
M /(-'_#2WA'_ *!'Q _\-QXA_P#D&O5:* /*O^&EO"/_ $"/B!_X;CQ#_P#(
M-'_#2WA'_H$?$#_PW'B'_P"0:]5HH \J_P"&EO"/_0(^('_AN/$/_P @T?\
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M6\(_] CX@?\ AN/$/_R#1_PTMX1_Z!'Q _\ #<>(?_D&O5:* /*O^&EO"/\
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M?$#_ ,-QXA_^0:]5HH \J_X:6\(_] CX@?\ AN/$/_R#1_PTMX1_Z!'Q _\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[$S6?_2&:@"E^S/K%CX=_9!^%.JZG=PV&FV/@72;FZNKA@L<,2:?$SNQ/0
MDGVI-%_:I\&^(?@EHOQ/T^WU:ZT?7+G[#H^FI;+_ &AJ-RT[P10Q1[]NYV0D
M;F4*OS.4 ;'COANU\5^(OV:?V<_#]EX%UKQ?X%F\(Z1>^(4T2[T^.6Y\JRMS
M!9LMW=09AD?YY""<K$(R,2-CSGX8ZI<R?!/]G?6M3T:\T'1-%^)MTMU<:@UL
MT1$\NH112[HY7V*)YTBR^T[^@*E68 ^Q/!OQTT;Q+-XIL]7TW4_!&L^&(4N]
M5TKQ$(%E@M71GCN1)!++#)$P20;DD;!C=6"D8K&\%_M+Z/XNUSPU8W7A?Q-X
M7LO%22R>'-7URVMX[75PB>:!&(YWEA9X@952XCB9E5L#*D#PW]H/0=0\>?%3
M]H6#PV#>7-I\(DT>XAMHQ(QO9I;R:*$_[?E8.T\XE0XY%='X_P!8TWQUH_[)
M\'AV\M[F6^\0V&L6@M]LA-E;Z;.UPX Z*H=$)'"EU!Y(H ]W^)GQ8T_X:R:)
M9-I>I^(_$&N7#6VEZ#HJ1-=W;(A>5@9I(XD2- 69Y)%4<#)9E!QM-_:,\)W'
MP]\4>+=4&H>&X?"UQ+9ZYI>J6X^W6%PFTB%DB:19&</&8S$SK()$VDYKC_BE
M_P 2O]L#X)ZI>LL6FW.E:[I,$T@4)]MD6VE2,,3]]XX)L#OL;'>O _B_:OJM
MA^TSXHLF%SX;M/&_AA[J2&)7CVZ>+$Z@Q;H1& 0_]TQ.#C!H ^LO ?QRM?%W
MBX>%=6\*^(O OB.73_[5L].\21VNZ]M0X1Y(GMIYDS&S('C9ED7S$)7!S7I=
M?/?CR:'Q'^V3\&ETNYAN9-*\.:[J=]Y.V3%K/]EA@8D?=5Y VT]&\ML9P:]Q
M\26^L76AW46@7]CIFL,H^SW>I63WEO&<C)>%)H6<8R,"1>2#SC! //?#G_)T
MWQ#_ .Q,\,_^EVO5ZK7R_H&@_&$_M)>.HX_'7@==27PEX>:>X;P5>&%XC>:U
MY:+'_:P*LK"4LQ=@P= %382_I?\ PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PC
MGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_
M .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA
M_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__
M ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.
M^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\
MES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_
MPCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQ
MO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*
M'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_
M /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@
M[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y
M<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >
MJT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y
M5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PC
MGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_
M .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA
M_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__
M ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.
M^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\
MES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_
MPCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQ
MO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*
M'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_
M /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@
M[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y
M<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >
MJT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y
M5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PC
MGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_
M .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA
M_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__
M ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.
M^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\
MES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_
MPCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQ
MO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*
M'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_
M /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@
M[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y
M<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >
MJT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y
M5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PC
MGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_
M .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA
M_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__
M ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.
M^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\
MES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_
MPCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQ
MO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*
M'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_
M /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@
M[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y
M<T >JT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >
MJT5Y5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y
M5_PCGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PC
MGQO_ .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_
M .BA_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA
M_#__ ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__
M ,(.^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JT5Y5_PCGQO_ .BA_#__ ,(.
M^_\ ES1_PCGQO_Z*'\/_ /P@[[_Y<T >JU@^//%,7@GP7K>O3;2NGVDDZJW1
MV"G:OXM@?C7$?\(Y\;_^BA_#_P#\(.^_^7->.?M%O\3OLF@>"==\6>%]='B>
M\2!+30_#5SITR[9$VL\DFH7 *;F7Y=@SC.X;2#T8>G[6K&#V_3J7%<TDCT3]
MC_PM+I/PO?7;W<^I>(KN2^ED?[Q0$JF?J0S?\#KW2O'-#\!_&7P[HUAI5C\0
M/ $=E8P);0JW@2])"(H5<G^V1S@"KW_".?&__HH?P_\ _"#OO_ES4UJGM:DI
M]Q2ES-L]5HKRK_A'/C?_ -%#^'__ (0=]_\ +FC_ (1SXW_]%#^'_P#X0=]_
M\N:Q).J^+'_)+/&7_8&O/_1#UU=>%?$+0?C##X!\2R:GXZ\#WFFKIERUU;VG
M@J\@FEB$3;T21M6<(Q7(#%' )!*MC!]UH *\J_:Q_P"36?C)_P!B9K/_ *0S
M5ZK7E7[6/_)K/QD_[$S6?_2&:@ _9._Y-9^#?_8F:-_Z0PUW*^!?#:^%KCPR
M/#VE#PW<))'-HXLHOL<JR,6D5H=NPABS%@1R6)/6N&_9._Y-9^#?_8F:-_Z0
MPUZK0!A>#? ?AKX=Z.=)\*>'=)\,:7YC3?8=&LHK2#S&P&?9&H7<<#)QG@52
M\,_"GP3X+U[4=<\/>#M T'6M2+&^U+3-+@M[FZW/O;S9$0,^6^8[B<GGK754
M4 <MJ'PK\%:MX9N_#E]X/T&\\/7ERUY<Z3<:9 ]I-.TGF-*\178SF3YRQ&2W
M.<UJ:#X5T3PKX?M]"T71[#2-#MT,4.FV%JD%M&A))58E 4 DDX [FM6B@#F/
M _PM\&?#&&[A\'>$="\)PW;*]S'H>FPV2S,H(4N(E7<0"<9Z9-=/110!Y5X<
M_P"3IOB'_P!B9X9_]+M>KU6O*O#G_)TWQ#_[$SPS_P"EVO5ZK0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7&AZ?I,XCU&Y<896&"(XST9B""",@ AN<@']";*U6QLX+9&D=(8UC5II#(Y
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M110!RGQ8_P"26>,O^P->?^B'KJZY3XL?\DL\9?\ 8&O/_1#UU= !7E7[6/\
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MI\(_]!?X@?\ AQ_$/_R=1_PS3X1_Z"_Q _\ #C^(?_DZO5:* /*O^&:?"/\
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MB!_X<?Q#_P#)U>JT5PMN3NS(\J_X9I\(_P#07^('_AQ_$/\ \G4?\,T^$?\
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M_P#R=1_PS3X1_P"@O\0/_#C^(?\ Y.KU6B@#RK_AFGPC_P!!?X@?^''\0_\
MR=1_PS3X1_Z"_P 0/_#C^(?_ ).KU6HIKJ&WDA266.-YFV1*[ %VP6PH[G )
MP.P- 'E__#-/A'_H+_$#_P ./XA_^3J/^&:?"/\ T%_B!_X<?Q#_ /)U>JT4
M >5?\,T^$?\ H+_$#_PX_B'_ .3J/^&:?"/_ $%_B!_X<?Q#_P#)U>JT4 >5
M?\,T^$?^@O\ $#_PX_B'_P"3J/\ AFGPC_T%_B!_X<?Q#_\ )U>JT4 >5?\
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M<D#)Z#) YZU^;7Q?^,WBGQ]X].IWSW&BRZ7.5L;"-F1K!E;\#YF0-S=<CL
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MY]G-,N3"^,9'KZX.1D ]0"-JBBG=M68!1112 **** "BBB@ HHHH Y3XL?\
M)+/&7_8&O/\ T0]=77*?%C_DEGC+_L#7G_HAZZN@ KRK]K'_ )-9^,G_ &)F
ML_\ I#-7JM>5?M8_\FL_&3_L3-9_](9J #]D[_DUGX-_]B9HW_I##7JM>5?L
MG?\ )K/P;_[$S1O_ $AAKU6@ HHHH **** "BBB@#RKPY_R=-\0_^Q,\,_\
MI=KU>JUY5X<_Y.F^(?\ V)GAG_TNUZO5: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"
M&\O(-/M9KJZFCM[:%#)+-*P5$4#)8D\  =ZJZ#KVG>*-(MM4TF\BO]/N5WQ7
M$+95AT_ @Y!!Y!!!KY"_;6^)VM?V]%X.MKNVAT,1)//':7 >69^NV<#E ."$
M[\-D\!?-OV?]-^(7C:^F\*^%M=U#1=#ED6?4;FW=ECMUZ%L@@[B. H(W8&>!
MD>Q#+^:A[:4K?Y'0J-X\S9]X^+OB1X7\!PF37]=LM,.-PBFE!E8?[,8RS?@#
M7CFI_M=PZY>/IWP^\(ZMXNO1QYWE-'"OHV &;'^\$^M;7A']D/P'X>F%UJD-
MUXHU G<\^J2DH6[GRUP#_P "W5[)INE66BV:6FGV=O86J?<@MHEC1?HJ@ 5R
MWPU/9.3^Y?YD>XO,^0OB+\%?C+\;H#KGB--+TV6R@;['HD4Y!.>2% +*&/JS
M9. #@#CE?V:_V<M8\8>)(]>UE;S1-'TJYX*EH;B>>-L%$/!4*PPS#D$8'.2/
MO&BMUF%14W3BDO3H5[:5K(****\HP"BBB@ HHHH **** "BBB@ HHHH *^9O
MBVI^"/Q^\/?$* "'0=>_XEVL8^ZK< N?^ A']S$WK7TS7%?&3X>Q?$_X=:OH
M+!1<RQ^9:2-_!.GS(<]@3\I]F-=6'J*G4][X7H_1EP=GKL=HK!U#*0RD9!'(
M-+7C7[*_Q#E\:?#6/3M09AK>@/\ V==QR##[5R(V(]=HVG/.4:O9:RJTW2FX
M/H*2Y78****R)"BBB@ HHHH **** "BBB@ HHK*UCQ5H_A^^TVSU+4K:RNM2
ME\BSAFD"M,^,[5'Y#ZD#J0"TF]$!JU\^?&3XV:KK7B(?#GX:?Z;XGN"8KW48
MC^[L%Z, W0,/XF_AZ#+=(?B]\9]8\8>)#\-OABWVG6YB8]0U>(XCLD'#A7'0
MC^)^W1<L>/2/@W\&='^#OA[['9?Z7J=QAKW4I%Q).WI_LJ.RY]^22:[X0CAX
MJI55V]E^K\OS-4E!<TB'X*_!/2O@]H;1PL+_ %NZ&Z^U21?GE;KM7/(0'MWZ
MGFO1Z**XISE4DY2=VS-MR=V07UC;ZG9SVEW!'<VLZ&.6&90R.I&""#U%?+WB
M+PKXA_92\13^)O"<<VK_  ]NY VHZ.S$M:=MP)S@<\/]%;/!KZHIDT,=S#)#
M-&LL4BE'C< JRD8((/4$5K1K.E=-7B]T5&7+Z&)X)\<:/\0_#MMK>AW:W=C.
M,>CQL.J.O\+#N/QY!!K>KY=\:_#[7_V;?$=SXX^'\37OA68[M7\/DDK&@ZLO
M4[1DD,.4]UR![+X;^.'@WQ'X-M?$JZU;6.GS3);,+R01O#.W B<9X;OZ8!;.
M.:TJ4-%.EK%_>O)CE'K'8[VBD!SR.12UQF84444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !7B7[3/QZE^$&AP6.EV\DFOZDC?9[B2(F"W4<%\D89Q
MV7MP6XP&]EU#4+;2K&>\O)X[6TMT,DLTS!410,EB3T %?*NN3:K^V)XQ_LS3
M#)I?PWT6?=)J+18DNI<$93/<@G"_P@Y;DA:[L)3C*?/47N+?^OT-::5[O9'@
M?A'QMJ/CG6M"\+>,->UB\\+3ZGY\\$&Z>5Y)#R<?>.6/;.-S$ D\_I%I&D66
M@Z7:Z=IUM'9V-M&(H8(5PJ*.@ KQGX"_LPZ=\)+VXU;4IXM9UTR.EM<!"$MX
M<D J#T=EZGMG XR3[E6V/Q$*TU&ELBJLE)^Z%%%%>68!1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!RGQ8_Y)9XR_[ UY_P"B'KJZY3XL?\DL\9?]
M@:\_]$/75T %>5?M8_\ )K/QD_[$S6?_ $AFKU6O*OVL?^36?C)_V)FL_P#I
M#-0 ?LG?\FL_!O\ [$S1O_2&&O5:\J_9._Y-9^#?_8F:-_Z0PUZK0 4444 %
M%%% !1110!Y5X<_Y.F^(?_8F>&?_ $NUZO5:\J\.?\G3?$/_ +$SPS_Z7:]7
MJM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%9WB'Q#IWA71;O5M6NX['3[5#)-/*<!1_4D\ #DD@
M"O/=4_:6\!:;X#@\4C5UN+>X#+!8QX-T\@^]&8\_*1D9)X&0<\C.L:4ZGPJY
M2BWLCTR^OK?3;.:[NYX[6UA4O+-,X1$4=22> *^<?%GQV\3?%[6I_"7PBMG\
MM3LO/$LP*1Q*>"4)'RCK\Q!8_P *]ZSK/PCX[_:FO(=2\5/-X2^'ZN)+;28#
MB:Z7JK'(Y_WV&/[J\DU]'>%?".C^"-%@TG0["'3K"'[L4(ZGNS'JS'N22377
MRT\+\7O3[=%Z]V::0WU9YAX#_99\(^&=!O8-;MQXHU?4HV6]U*^&6);D^7DY
M3GG=G=GG/8>A?#_X>Z)\,O#<&B:%;>1:Q_,\CD&69^[NV!EC^78  8KI:*YI
MUJE2_/*]S-R<MV%%%%8$A1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 ?,OB+_BQ7[3ECK2[H?#'C4>1==DCN2P!8_P# RC9/:1_2OIJO,_VB/AM_
MPL[X7ZEI\$7F:I:C[;88ZF9 ?E'^\I9?JP]*YW]G?]H+1_B+HFDZ#?7AB\6P
M68$\4P(^T%"5+(Q^\Q50Y'^T<9P<>A4BZ]%54M8Z/]'^AJ_>CS+H>W4445YY
MD%%%% !112$XY/ H 6LJX\5:/:>(K709M2MHM9NHFG@L6D ED1>K ?G]<-CH
M<>9_%S]I;PK\/=%OX].U:QU;Q(B%;>QA=I4$G3]XR A<==I()QCC.1\#ZQXQ
MU[6O%LGB&]U"Y?7FG$_VH,5D1P?EVX^[C   Z8 %>MA<OGB$Y2T7]?@;TZ3E
MJS]6:P/$GC[PWX/4G6]>T_2CC(2ZN41S]%)R?P%?/7AGX0?%KXK:+;:CXS^(
M.H:!;7*[_P"S+6/RY"AZ>8J%%4GK@AB.XST[+PW^QS\.]%82WUM?:_<9W%]0
MNB 6[G;'M!_'-<[HT*;M.I=^2_5V)Y8QW9!XH_;,\!Z.LD.CF^\27V"L4=G;
MM'&S]@6?!QGNJM[ U\8?%#QIXE\<>,+G5/$_G0:B<;+61&C%M'U1$0\JN#GW
MSDY)S7Z6^'?!'A[PC'LT31-/TH8P3:6R1L?J0,G\:P_''P9\)_$37-(U?7-,
M6YO=-?<C#@3+SB.48^= 3NQZCT)!Z\-B\/AY7C!^M]32%2$'HCS7]C#PW>Z+
M\-)KF^T&'2VOI_-AOLGS[V+'#.IZ*/X<'!!)P/O-] TBJ$4*H"J!@ # %+7F
M5JCK5'4?4PE+F=PHHHK$D**** $90RD$9!X(-?F-\;O#]]X:^)FN6U[H4/AQ
M99S-#8VK,T'EDG:T;'[P/)X  )(PN-H_3JN.^)'PF\-_%:RM+;Q!9&?[+,LL
M4T3;)%P063=UVL!@C\L$ CT<%BEA9MR6C-J<^1ZGRW\#OVG=9^'7A.WL_%VB
MZMJGAQ1MT_58826C4':8]SX5U'0?-E<8Y& />O#G[57PT\1[5'B!=-F;_EEJ
M4+PX^KD;/_'J]2LM.M=-L(;&UMX[>SAC$4<$:!41 ,!0.F,5R?B/X*^!/%FX
MZIX4TN:1NLT< AE/_ TPWZT5*V'K2<I0:OV?Z Y0D[M'2Z/X@TOQ!;^?I>I6
M>I0_\]+.=)5_-2:P_B%\4?#?POL;6Z\1:@MFEU,L,**I=V)(W,%'.U0<D]A[
MD ^5:Q^Q;X-EG^U:#J6L>&[M?N-;7/F(O_?0W?\ CU?*GQV\"^,/ OBQ;+Q7
MJ-YK:"/98:G=3/*LT(/ 4L3MQGE,\$^A!.V'PM#$3M&?RM9E0IQD]&?I-9WD
M&H6L-U:S1W%M,@DBFB8,CJ1D,"."".]35\9?LB_%_P#X0^YN?"OBS6O[+TZ5
M$ETRWU&)D56<Y.V4G"(P.0",$G((YW?9BL&4$'(/((KBQ%"6'J.#V[F4XN#L
M+1117*0%%%% !6=XA\0Z=X5T6[U;5KN.QT^U0R33RG 4?U)/  Y)( J[<7$5
MI!)//(D,,:EWDD8*JJ.223T%?!O[5WQ6D^(WBHZ=H.L'5_"VFQ+(RV<+"%)L
M[6=VZ2<D -PHW8'4D]F%P[Q-3EV74TIPYW8^U? OCS1?B/X=M];T*[%U92_*
M01AXG'5'7^%AZ>X(R"#70U^;_P "/'?B?X5:M_PDUG8ZE<>$_-6#5?(MFD@=
M>N,Y"K( <@DC&>X)!^X/A_\ 'CP3\2O+CT?6HEOF_P"8?=_N;C/H%;[W_ 21
M6V*P<J$FX:Q_+U*J4W%Z;'H%%%%>:8A4-W>0:?:S7-S-';VT*&22:5@J(H&2
MQ)Z #O3KBXBM8))YY$AAC4N\DC!550,DDGH .]?+?BOQ-K7[5?BR?PCX4GDT
M_P"']A(IU/5P"/M1!R N>HR/E7OC<W8#HHT75;;=HK=EQCS>@WQ!KNM?M:>+
MIO#GAZ:;2_AOILJ_;]2"E6O6!R  >O\ LJ>G#-SM4?2OA?PQIG@W0;/1]'M$
MLM/M4V1Q(/S)/<D\DGDDYJ/PCX1TKP+X?M-%T6T6ST^U7:D:]2>[,>[$\DGK
M6S55JRG:$%:*V_S?F.4KZ+8****Y3,**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@#E/BQ_R2SQE_V!KS_P!$/75URGQ8_P"26>,O^P->?^B'
MKJZ "O*OVL?^36?C)_V)FL_^D,U>JUY5^UC_ ,FL_&3_ +$S6?\ TAFH \@\
M%?"_PWXX_9?_ &?==^(&N6</PW\+^"M/U'5= U6-?[/OY?[/MQ#+=,SA6CAP
M["-E969U)^Z,^9^'M+OY? _@_P *C2]1\/\ PI^(7Q0D72O#MZDD3KX?%I)<
M?9GC9MT-O<3V[N(#@>7*5P%;;7H?@GX%Z_\ &+]GK]FN]LO$^C66C^'_  GI
M-Z_A_7] EU2ROKO[! (9Y5CN[<L8OF**Q9=S;B,JN/7?%OP;\4_$?PC9V_BC
MQ;H__"6Z-J\.M:!KNAZ!):0V-Q$,)YMO-=SF96#2*X$B;DD(&T@/0!X7X^U8
M_LS^-?CGI'P\L(O#VAQ?#,>+K/2=,M1'966I1R7-N9H85PD9=4B+!5 8Q;CS
MDG0U+X<Z!\!KC]G;Q+X.TR/3-?UK7K30M>U*UB_TG7(;RSF>=[Y\[KA_.C2;
M?*696!(/)!]CT']GTZA>>.]5^(6LVOC#6?&&F1Z'>_8-.;3K*#3D20+;PPM-
M,X)::9V=I6)+C&T*!69X3_9W\0VNM>!#XN\=0^*-!\"%WT&QM]&^Q7$DWDM;
MPS7L_GR+.\<+N!Y<<"EG+%3@  &7\=-/M?B)^T5\)_AYXALX]5\&76GZOKE_
MH]W%YEI?SVPMTMUG0_+(J&=I C KN5&QE1CQ7QGKVH_#'PI\?_AWX5N+K0_#
MUCXL\/Z;I2:?NC72K;5OLGVJ&V96'DH#+,RJF!&9?EQP!],^.?@[X@\8:IX;
M\3V_BC3-*\>>&KR[?3-431'DLVL[CY'M;BV-SOD!C"9=)HSYD:N HRAR(_V7
M;#6OASXZT+Q5KLVL:]XTU :MJFNV-LMIY-U&(Q:M:PLT@B6 00[%=I"2A+,V
MXT <G%X(\/\ P%_:J^&.C> -"L_"NA>+-#U>UU;2]'ME@M9WLQ!+;W$D:87S
M5\R5/-(+$2;23QCZ)\2>)M'\&Z'=:SK^K6.AZ/:*&N-0U*Y2WMX02%!>1R%4
M$D#D]2*\X\%_!WQ''\2+/QSX]\76/BO7-+TJ32-+CTC16TNUMXY71[B9T:XG
M:2:0Q1#(=454P$!8FO6J /E_0/VF_@]#^TEXZU.3XK^!TTVY\)>'K:"\;Q'9
MB&66.\UII(U?S,,R+-$64'($B$_>&?2_^&L?@A_T63X?_P#A46/_ ,=H\.?\
MG3?$/_L3/#/_ *7:]7JM 'E7_#6/P0_Z+)\/_P#PJ+'_ ..T?\-8_!#_ *+)
M\/\ _P *BQ_^.UZK10!Y5_PUC\$/^BR?#_\ \*BQ_P#CM'_#6/P0_P"BR?#_
M /\ "HL?_CM>JT4 >5?\-8_!#_HLGP__ /"HL?\ X[1_PUC\$/\ HLGP_P#_
M  J+'_X[7JM% 'E7_#6/P0_Z+)\/_P#PJ+'_ ..T?\-8_!#_ *+)\/\ _P *
MBQ_^.UZK10!Y5_PUC\$/^BR?#_\ \*BQ_P#CM'_#6/P0_P"BR?#_ /\ "HL?
M_CM>JT4 >5?\-8_!#_HLGP__ /"HL?\ X[1_PUC\$/\ HLGP_P#_  J+'_X[
M7JM% 'E7_#6/P0_Z+)\/_P#PJ+'_ ..T?\-8_!#_ *+)\/\ _P *BQ_^.UZK
M10!Y5_PUC\$/^BR?#_\ \*BQ_P#CM'_#6/P0_P"BR?#_ /\ "HL?_CM>JT4
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M2>22>2222>37NSQ?U>C]6C\6S?3S^9U.IR1Y%N>>_P##6/P0_P"BR?#_ /\
M"HL?_CM'_#6/P0_Z+)\/_P#PJ+'_ ..UZK17@G*>5?\ #6/P0_Z+)\/_ /PJ
M+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM>JT4 >5?\ #6/P0_Z+)\/_ /PJ+'_X
M[1_PUC\$/^BR?#__ ,*BQ_\ CM>JT4 >5?\ #6/P0_Z+)\/_ /PJ+'_X[1_P
MUC\$/^BR?#__ ,*BQ_\ CM>JT4 >5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$
M/^BR?#__ ,*BQ_\ CM>JT4 >5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR
M?#__ ,*BQ_\ CM>JT4 >5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__
M ,*BQ_\ CM>JT4 >5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*B
MQ_\ CM>JT4 >5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\
MCM>JT4 >5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM>J
MT4 >5?\ #6/P0_Z+)\/_ /PJ+'_X[1_PUC\$/^BR?#__ ,*BQ_\ CM>JT4 ?
M.OQB_:B^'>I_#W5;?P9\;_AW::XZ?(S>*+$.R?Q+&WG81R.C'I['##X4T_Q#
M%I<UGJ\&LVNFJLD<L&J27T=O#&Q8;)//9@BC)'S%@/>OUUK%M?!>AV/BB[\1
MP:7;Q:Y=Q+!/?*O[QT7H/\3U.%SG QZF$QOU:$H\M[_UKY&].IR)JQ\96O\
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ML23RK_AK'X(?]%D^'_\ X5%C_P#':/\ AK'X(?\ 19/A_P#^%18__':]5HH
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M(C#R.$4L1,2!DCH#7OE*%2%17@[EXG!XC!M1Q$'%ON>5?\-8_!#_ *+)\/\
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MM?GL#GV%>IU[49QJ*\7<_-:^'K86?LZT7%^9Y5_PUC\$/^BR?#__ ,*BQ_\
MCM'_  UC\$/^BR?#_P#\*BQ_^.UZK15G.>5?\-8_!#_HLGP__P#"HL?_ ([1
M_P -8_!#_HLGP_\ _"HL?_CM>JT4 >5?\-8_!#_HLGP__P#"HL?_ ([1_P -
M8_!#_HLGP_\ _"HL?_CM>JT4 >5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#
M_HLGP_\ _"HL?_CM>JT4 >5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLG
MP_\ _"HL?_CM>JT4 >5?\-8_!#_HLGP__P#"HL?_ ([1_P -8_!#_HLGP_\
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ML>[$\_H. *]"/^RPYW\<MO)=_P#(V7[M7ZLW+>WBL[>*""-(8(E"1QQJ%5%
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MM/RV/HZOEG]I_P"'_@/QY)=ZGI?BOPYIGC6S)CN+6?5+>'[45X,<@9QMD&,
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MC_A6/QW\?<^(O'MKX5LWZVVCJ?-0=QF,+G_OX:E_X81\ _\ 07\1G_MYM_\
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MW'9DE%><^*/VB/AWX1WK>^*;*:9>/)L6-R^?0^6#@_7%>:W_ .U])XC\^U\
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MU!XR#794S;#TH.4U)6[QDOT.)U$MSW:*9)XDDC=9(W 974Y# ]"#W%/KYO\
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M60L T;1L5S&.=KMBND_X23XW_P#1//A__P"%Y??_ "FH_P"$D^-__1//A_\
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MNLH]5HKRK_A)/C?_ -$\^'__ (7E]_\ *:C_ (23XW_]$\^'_P#X7E]_\IJ
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M&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\
MZ)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\
M/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\
MPO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[
M_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4
MU'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"
M2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&_
M_HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGG
MP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\
M_"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\O
MO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-
M0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK
M17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7
M_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?
M&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\
MZ)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\
M/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\
MPO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[
M_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4
MU'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"
M2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&_
M_HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGG
MP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\
M_"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\O
MO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-
M0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK
M17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7
M_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?
M&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\
MZ)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\
M/_\ PO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\
MPO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[
M_P"4U'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4
MU'_"2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"
M2?&__HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&_
M_HGGP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGG
MP_\ _"\OO_E-0!ZK17E7_"2?&_\ Z)Y\/_\ PO+[_P"4U'_"2?&__HGGP_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUZO5: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y3XL?\
M)+/&7_8&O/\ T0]=77*?%C_DEGC+_L#7G_HAZZN@ KRK]K'_ )-9^,G_ &)F
ML_\ I#-7JM>5?M8_\FL_&3_L3-9_](9J #]D[_DUGX-_]B9HW_I##7JM>5?L
MG?\ )K/P;_[$S1O_ $AAKU6@ HK@?CK\4O\ A37POU;Q3'IYU:]@:&ULK#>4
M%Q=3S)! C, =JF21,M@X&3@]*Y+PO\1_'7A3XP:%X!^(<_A_6'\2:1<ZCI>J
M^&].N+!(I[5HQ<6TL4L\^X;9D=)0ZYVL"@X) /:Z*\H^+OQ+\0Z-XX\%> ?!
MRZ;#XG\3_:[G^TM9MI;FTL+.U5&FD:&.2)I79I(HU7S$&7+$_+M;SBZ_:>\6
M:7%J?@FYTW1Y_BI;^+K;PC;7,4$Z:5-]IM_M<5^T1=I%1;;>S0>:27C*B0!@
MX /IZBO(OAG\2O$[?%7Q-\-?&YTF]UW3=.M=;L=8T.SFL[:]LYGDB(:"668Q
MR1RQ.#B5PRLI&TY ]=H \J\.?\G3?$/_ +$SPS_Z7:]7JM>5>'/^3IOB'_V)
MGAG_ -+M>KU6@ HHHH **** "BBB@ HHHH **** "BL/Q#XPT_PSJWAC3;WS
M?M/B+47TRR\M-R^<MI<79WG/ \JUEY]=H[UN4 %%%% !1110 4444 %%%% !
M1110 45A^.O&&G_#OP3XA\5:MYHTK0].N-3N_(3?)Y,,32/M7(R=JG [FMR@
M HHHH **** "BBB@ HHHH **** "BBL/P+XPT_XB>"?#WBK2?-.E:YIUOJ=I
MYZ;)/)FB61-RY.#M89'8T ;E%%% !1110 4444 %%%% !1110 445A^'O&&G
M^)M6\3Z;9>;]I\.ZBFF7OF)M7SFM+>[&PYY'E747/KN':@#<HHHH **** "B
MBB@ HHHH **** "BBL.\\8:?8^-M)\*R>;_:NIZ=>:G;X3,?DVLMK'+EL\'=
M>0X'<;O2@#<HHHH **** "BBB@ HHHH **** "BBL/QCXPT_P-I-OJ6I^;]F
MGU&QTQ/)3<WG7=W#:0\9Z>;.F3V&3VH W**** "BBB@ HHHH **** "BBB@
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MVGW-S]ET ^9!;R3R0IM.E[1M:ZG.0 3OY) 7&M_PIOQ=_P!%V^('_@#X>_\
ME577>!_BEX,^)T-W-X.\7:%XLAM&5+F30]2AO5A9@2H<Q,VTD XSUP:3PA\4
M_!?Q!O=1L_"WB_0?$MYIK!;VWT?4X;N2U)) $JQL2ARK#YL<J?2@#DO^%-^+
MO^B[?$#_ , ?#W_RJH_X4WXN_P"B[?$#_P  ?#W_ ,JJ[S6/&?A_P_;ZK/JF
MNZ;IL&DP+<ZA)>7D<2V<+;MLDQ8CRU.QL,V =I]#4/A/X@>%O'VAOK7ACQ)I
M'B/1HW:-]1TF_BNK=64 LIDC8J" 02,\9H XG_A3?B[_ *+M\0/_  !\/?\
MRJH_X4WXN_Z+M\0/_ 'P]_\ *JNN\#_%+P9\3H;N;P=XNT+Q9#:,J7,FAZE#
M>K"S E0YB9MI(!QGK@UMR:Q80ZM;Z7)?6R:G<0R7$-DTJB:2)"BO(J9W%5,D
M8) P"ZYZB@#S;_A3?B[_ *+M\0/_  !\/?\ RJH_X4WXN_Z+M\0/_ 'P]_\
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MLIR"#T(/I0!Y;_PIOQ=_T7;X@?\ @#X>_P#E51_PIOQ=_P!%V^('_@#X>_\
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M$_#J\L+3Q7XQT#PQ=:@2+.#6=4@M'N<$ ^6LC O@LHXS]X>M '*?\*;\7?\
M1=OB!_X ^'O_ )54?\*;\7?]%V^('_@#X>_^55>EZAJEEI,<4E]=P6:331V\
M;7$JQAY78*D8)/+,Q  ')) %<[:?%KP/J'C6;P=:^,_#]SXNAW"70(=4@:_3
M:NYMUN'\P87DY7@<T <M_P *;\7?]%V^('_@#X>_^55'_"F_%W_1=OB!_P"
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M6DQQ27UW!9I--';QM<2K&'E=@J1@D\LS$  <DD 4 >:?\*;\7?\ 1=OB!_X
M^'O_ )54?\*;\7?]%V^('_@#X>_^55=3X6^+7@?QSK=_HWAOQGX?\0:QI^XW
MFGZ7JD%S<6VUMC>9&CEDPWRG(&#Q3M6^*_@G0/%UEX4U3QCH&F^*+[8;71+O
M5((KVXWDA/+@9@[;B"!@')!Q0!RG_"F_%W_1=OB!_P" /A[_ .55'_"F_%W_
M $7;X@?^ /A[_P"55>DZIK%AH=NEQJ-];:?!)-';I+=2K&K2R.(XXP6(!9G9
M54=26 ')K%\<?$[P=\,[:UN/&'BS0_"EO=.8[>77-2ALTF8#)5#*RAB!S@4
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MQ$T<ZMX4\1:3XGTOS&A^W:->Q7<'F+@LF^-BNX9&1G/(H X?_A3?B[_HNWQ
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M/85?H \J_P"%-^+O^B[?$#_P!\/?_*JC_A3?B[_HNWQ _P# 'P]_\JJ]5HH
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MB@#SZV_9RUJS\5:CXDB^-GQ 36M0LK;3[FY^RZ ?,@MY)Y(4VG2]HVM=3G(
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M&0!]4_$O]G31?B1X-\(>&5US6?#6E^%[JVN[&/2!:.KO;IM@$T=S;S1R*G#
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ME$*]'X+^%?A_P#/>MH]LT%O<6=GIT=HVTQ6MI;1&.&WB&,A!N=L,2=TC<XP
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M4-4\ _!;X6P-J\G@?Q/:^)/$OC&Z:.232YHY3/(LLX0>;?71+(RIRJ,Q<!<
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M]$^.O KQZEJ/C+POX=T?6OB#)I@T>WD\0:C/;6HM3)O:/*1S; 6.Y@D8,A5
MS !2M_XB_"_2/B9H^C:9J,MU9VNDZO8ZS;BQ9$/G6DRS1(=RL-A9 "  <=".
MM9?C3X,P>)O%R^*]'\3ZYX(\3-9+IMSJ>@BT=KNU5VD2*2.[MYX_E=G965%<
M;F&[!Q0!R/[%-UI[?LU^$M.T][PMH_VC2;R&^B2*2"[@N)(YX@B.ZK&D@94
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M7A5)8_#FD:Y<V\EKI =/*!C,<"2S,D1,2O<22LJLV#EB3V5U\,]+O/BMIOQ
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MX;\(_M)>$/"5U*VH#Q9?VUC>:Y>RW$DEU)I5F1-<3MOD8M*Y=FP3R<#H*W_
M>I>+_P!F=/@_\//%-WX<UOP_K C\,6']@Z;<6<^G3PV;RH9));B472,('4N$
M@.2&VX)5?4]+^!WABPT_XB:?<QW&K:=X\OYK_6+.^D!C)EMHK:2./8JE4,<*
M]26!).[IC/\ "?P#LO#VO:)JFJ^*?$'C)_#Z,FA0:\;3R]*W1F)FC-O;Q-(Y
MB.S?.TC8S@@LQ8 ]1HHHH **** "OD+Q9I<W@WQW^T):^)O ^N>*G\>6</\
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M!P*] O?A/H.L-XO&L1S:U%XJLH].U*&\8;6M4B:/R5V!2JGS)6/.=TK$$#
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MM@3AMQR6YQ@  ^??"W_"P_V0/AKH%QXLU#PKK>@77B)+?4]/TBPNDO(I]2U
MYN%O9)]LVV6X#&,VT7RD@-E06]<_:Q_Y-9^,G_8F:S_Z0S52T#]F'0=!.C:>
M=?U[4?!VAW<=]H_@^]>U;3M/FC??"R.MNMRXB8DHLL[J#C@[5VW?VL?^36?C
M)_V)FL_^D,U !^R=_P FL_!O_L3-&_\ 2&&O5:\J_9._Y-9^#?\ V)FC?^D,
M->JT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/Q _\#O#W_RUKU6B@#RK_A<GB[_HA/Q _P# [P]_\M:/^%R>+O\ HA/Q _\
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M#W_RUH_X7)XN_P"B$_$#_P #O#W_ ,M:]5HH \J_X7)XN_Z(3\0/_ [P]_\
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MN2TDT2^341=MMVV_V PBY,A#JP419*'?C;S0!G?\+D\7?]$)^('_ ('>'O\
MY:T?\+D\7?\ 1"?B!_X'>'O_ ):UE>'_ -J[P=J/@V3Q+J(OK&R?6;_2;.WL
MM.O-0N[A;5W$DQMH8#-& J$N&0"(_*Y!KM]!^,7@[Q1K-MI6DZTFH:A<22I'
M#!!*V1'%%,TA.W B\NXMV64G8PFBVL=ZY .=_P"%R>+O^B$_$#_P.\/?_+6C
M_A<GB[_HA/Q _P# [P]_\M:]5HH \J_X7)XN_P"B$_$#_P #O#W_ ,M:/^%R
M>+O^B$_$#_P.\/?_ "UKU6B@#RK_ (7)XN_Z(3\0/_ [P]_\M:/^%R>+O^B$
M_$#_ ,#O#W_RUKU6B@#RK_A<GB[_ *(3\0/_  .\/?\ RUH_X7)XN_Z(3\0/
M_ [P]_\ +6O5:* /*O\ A<GB[_HA/Q _\#O#W_RUH_X7)XN_Z(3\0/\ P.\/
M?_+6O5:* /*O^%R>+O\ HA/Q _\  [P]_P#+6C_A<GB[_HA/Q _\#O#W_P M
M:]5HH \J_P"%R>+O^B$_$#_P.\/?_+6C_A<GB[_HA/Q _P# [P]_\M:]5HH
M\J_X7)XN_P"B$_$#_P #O#W_ ,M:/^%R>+O^B$_$#_P.\/?_ "UKU6L_5/$&
MEZ(8QJ.I6=@9/N?:ITCW8]-Q&:F4E%7D[(#SK_A<GB[_ *(3\0/_  .\/?\
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ML[FRANX9;V*T:XM9Y81'=1(TJDO 77E!N&]30!9_X7)XN_Z(3\0/_ [P]_\
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MJUPLGVI0K1Y!9=HW-D  N_\ "Y/%W_1"?B!_X'>'O_EK1_PN3Q=_T0GX@?\
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MA5UE8;8RQXK,G_:M^&MND*OJ>K_;I#<+_9*^&M3;4D, B:7?9"V\]-J3PO\
M-&/DD5Q\O- %C_A<GB[_ *(3\0/_  .\/?\ RUH_X7)XN_Z(3\0/_ [P]_\
M+6M#_A>?A>.;6[J75;'^P=,T.QUXWT#3RR/;W33B)A&(<,'\G""-W=V)78OR
M;Z=U^TOX M-!M]6:_P!6DCFEN(C8V_AW4IM0@,&WSS/9);FX@5-\99I8U4"6
M(YQ(F0"/_A<GB[_HA/Q _P# [P]_\M:/^%R>+O\ HA/Q _\  [P]_P#+6NF\
M+_$:U\3>*M4T5(XQY-G:ZII]Y;SB:'4+&=6"3HP  (>.12H+8'EMG]X .OH
M\J_X7)XN_P"B$_$#_P #O#W_ ,M:/^%R>+O^B$_$#_P.\/?_ "UKU6B@#RK_
M (7)XN_Z(3\0/_ [P]_\M:/^%R>+O^B$_$#_ ,#O#W_RUKU6B@#RK_A<GB[_
M *(3\0/_  .\/?\ RUH_X7)XN_Z(3\0/_ [P]_\ +6O5:* /*O\ A<GB[_HA
M/Q _\#O#W_RUH_X7)XN_Z(3\0/\ P.\/?_+6O5:* /*O^%R>+O\ HA/Q _\
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M&_\ Z)Y\/_\ PO+[_P"4U 'JM%>5?\))\;_^B>?#_P#\+R^_^4U'_"2?&_\
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M;BP\7_V;833O)!9?V89?(C+$K'O,^6VC W'DXS7J7_#)/PH_Z%3_ ,J-W_\
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MB<8:)02V#@<UT'_"2?&__HGGP_\ _"\OO_E-1_PDGQO_ .B>?#__ ,+R^_\
ME-0!6\7?L]Z!;>"+;0/A]X;\-^#8O^$BTC6KF'3;".QAF6UOH)Y"1#'\TACA
M*KD==H) Y'/^*/@[X^CD\<W'AW4K$1^(?%46KRZ>NKW.E/>6 TRWM6MVOH(7
MFM7\Z$2[H5)*H%WKO;'4_P#"2?&__HGGP_\ _"\OO_E-1_PDGQO_ .B>?#__
M ,+R^_\ E-0!Y1\)_P!EGQEX+\,_%/3]4OM):;Q5H<^FV&W5+N_>*22[U2X_
MTBXGB$D@']H1J9#N9MC,1GKZ%X_^"NN>*M+\>6UI=:?&^O> E\+6QFDD 2Z
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MIPNYXD\M'\V1"%SG'RL,\D]?6N-_X23XW_\ 1//A_P#^%Y??_*:C_A)/C?\
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M,.JW,_B*:<'2Y_+BBN D,4)^UQND095,ENRODEV5MJ[O_"2?&_\ Z)Y\/_\
MPO+[_P"4U'_"2?&__HGGP_\ _"\OO_E-0 OA_P  ^+/#'P!\/>%M'GTS2_$^
MD6-K!Y=Q.U_977DE?,@EF>%'*3*K(T@B#)YFX*VW:?+%_9G\21Z+K$VA>&/
M_P /97O=%OK7PCX;U";^R+B:QOTNGN)95LXA%+*BB'*6S$"-"S.-JIZE_P )
M)\;_ /HGGP__ /"\OO\ Y34?\))\;_\ HGGP_P#_  O+[_Y34 <QI/P0\5)X
MJTW3;V31T\$:1XEU'Q3::A#=RRZG<37:W)-M)"\(2-4DOISYRRL66-!L7<Q&
M8OP/\?ZQ\(;;X6:U%X2/A'2K;3].@N(;FYDN=5@MKJW;?-'Y*):DP0N#$IG#
M/(,2(J?-W7_"2?&__HGGP_\ _"\OO_E-1_PDGQO_ .B>?#__ ,+R^_\ E-0!
M2\2?";Q)K/[/GC;X:K>6$LESIEWHV@WUQ-)S:O!L@%UB,E6CW>62N_<L8?AG
M*KS>C_LZ^(-.^*FE>))+_2Y--TSQ-)J-K"F]98]/:PO@8^(\&3[9J5PW4+Y0
M3G<"#V/_  DGQO\ ^B>?#_\ \+R^_P#E-1_PDGQO_P"B>?#_ /\ "\OO_E-0
M!Y[J'P+^)6N?&+1?$FK:E8W]EI&N7E]%>R>)K\++92V]U!#;C21 +2&2)+E%
M\X.\C^62S?.0+4'[,.JW7@_X.:;>:C8V^K> O#K6<>H6[22"'4UCM!#/$I5?
M,C#6[[@^W<KXQ\QQW'_"2?&__HGGP_\ _"\OO_E-1_PDGQO_ .B>?#__ ,+R
M^_\ E-0!YI\/?V9_$NC_ !%CUC7;;3/L8U2_\0?:K?Q=K-T(KR\CE\R*'36\
MJS0(]S.HN,$O&!F)7D9E[;1?@[X@'[)*_"_4Y-/M]>A\,/X?2XL;F26V=D@,
M,,NYHXV 8*C,N/EW,H9L;CJ_\))\;_\ HGGP_P#_  O+[_Y34?\ "2?&_P#Z
M)Y\/_P#PO+[_ .4U &-'I'CAO%4'Q(\(:%I<]YKV@VFEZMX=\5W]QI,EI);2
MSNCK+';7!8@W$R,NP*P".KD=>5N_V>O$]GX<L]%O_#'P^^+.CW$MQJ=UHOB[
M=9P:=J<]S<7$\]I)]DNV='^U-&%<*R"($,?,95]#_P"$D^-__1//A_\ ^%Y?
M?_*:C_A)/C?_ -$\^'__ (7E]_\ *:@ O/@_K%U\#M#\'GQ-YOB;1UL;BUUZ
M[A>=3>6LL<T;2(TA=XRT85@9-Y4GYMW-9FL>"?B7\7-%\2:'XUET'P=X?U+0
MKO2?[/\ #5_+JDEQ-<(4^T23S6MN8UB7.V)%.XN2SX 4Z?\ PDGQO_Z)Y\/_
M /PO+[_Y34?\))\;_P#HGGP__P#"\OO_ )34 <CI?P9\>>(_B1H/CKQ8/#FE
MZIIT]A;OI^BWL]U"]M;07P,PEDMXF\QY;[B(KM18\^8Q8@<K^T-\ /%&M? G
MQ!9:>+;4+ZUUCQ%XA6TM1+++<0W5EJ4<,,2+'EYBUW$-G3AL,>,^L?\ "2?&
M_P#Z)Y\/_P#PO+[_ .4U'_"2?&__ *)Y\/\ _P +R^_^4U '&6?PS^*NK:!K
M&L/<Z#X9\52Z1IFC6%MI5[/Y4MK;S-+/YLSVX>VDG61XALCE-N/F5I&Z8?P5
M_9I\9^!_BUJWBW69M-ATZ^M-1C2S_P"$CU#7+J&2XBTN-5:[O(EDE4?V>YRQ
M!4.J@8''I_\ PDGQO_Z)Y\/_ /PO+[_Y34?\))\;_P#HGGP__P#"\OO_ )34
M >3V?[)'B-OAO>>'[W4M--W_ ,(=X7T> VM[<PJ]]I-Q-<,#-&B2Q0R,T2B6
M,^8H+,%!5<QR?LT^,;71S<6>@:$=:O+RZNIV7XB^(X=0M&>&WAC9=9P]Q<*4
MMUWPF**,[(.IAW/ZY_PDGQO_ .B>?#__ ,+R^_\ E-1_PDGQO_Z)Y\/_ /PO
M+[_Y34 ,^'OAK7D^)+WVLW%QJ!T'PY9Z!)K%Q:FW.JWA;SKF=$Z;!B'!4E=S
MR+G]V:]8KRK_ (23XW_]$\^'_P#X7E]_\IJ/^$D^-_\ T3SX?_\ A>7W_P I
MJ /5:*\J_P"$D^-__1//A_\ ^%Y??_*:C_A)/C?_ -$\^'__ (7E]_\ *:@#
MU6BO*O\ A)/C?_T3SX?_ /A>7W_RFH_X23XW_P#1//A__P"%Y??_ "FH ]5H
MKRK_ (23XW_]$\^'_P#X7E]_\IJ/^$D^-_\ T3SX?_\ A>7W_P IJ /5:*\J
M_P"$D^-__1//A_\ ^%Y??_*:C_A)/C?_ -$\^'__ (7E]_\ *:@#U6BO*O\
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M_P#R91_P^K^"'_0K?$#_ ,%UC_\ )E 'W_17P!_P^K^"'_0K?$#_ ,%UC_\
M)E'_  ^K^"'_ $*WQ _\%UC_ /)E 'W_ $5\ ?\ #ZOX(?\ 0K?$#_P76/\
M\F4?\/J_@A_T*WQ _P#!=8__ "90!]_T5\ ?\/J_@A_T*WQ _P#!=8__ "91
M_P /J_@A_P!"M\0/_!=8_P#R90!]_P!%? '_  ^K^"'_ $*WQ _\%UC_ /)E
M'_#ZOX(?]"M\0/\ P76/_P F4 ??]%? '_#ZOX(?]"M\0/\ P76/_P F4?\
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M]"M\0/\ P76/_P F4 ??]%? '_#ZOX(?]"M\0/\ P76/_P F4?\ #ZOX(?\
M0K?$#_P76/\ \F4 ??\ 17P!_P /J_@A_P!"M\0/_!=8_P#R91_P^K^"'_0K
M?$#_ ,%UC_\ )E 'W_17P!_P^K^"'_0K?$#_ ,%UC_\ )E'_  ^K^"'_ $*W
MQ _\%UC_ /)E 'W_ $5\ ?\ #ZOX(?\ 0K?$#_P76/\ \F4?\/J_@A_T*WQ
M_P#!=8__ "90!]_T5\ ?\/J_@A_T*WQ _P#!=8__ "91_P /J_@A_P!"M\0/
M_!=8_P#R90!]_P!%? '_  ^K^"'_ $*WQ _\%UC_ /)E'_#ZOX(?]"M\0/\
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M4 ??]%? '_#ZOX(?]"M\0/\ P76/_P F4?\ #ZOX(?\ 0K?$#_P76/\ \F4
M??\ 17P!_P /J_@A_P!"M\0/_!=8_P#R91_P^K^"'_0K?$#_ ,%UC_\ )E '
MW_17P!_P^K^"'_0K?$#_ ,%UC_\ )E'_  ^K^"'_ $*WQ _\%UC_ /)E 'W_
M $5\ ?\ #ZOX(?\ 0K?$#_P76/\ \F4?\/J_@A_T*WQ _P#!=8__ "90!]_T
M5\ ?\/J_@A_T*WQ _P#!=8__ "91_P /J_@A_P!"M\0/_!=8_P#R90!]_P!%
M? '_  ^K^"'_ $*WQ _\%UC_ /)E'_#ZOX(?]"M\0/\ P76/_P F4 ??]%?
M'_#ZOX(?]"M\0/\ P76/_P F4?\ #ZOX(?\ 0K?$#_P76/\ \F4 ??\ 17P!
M_P /J_@A_P!"M\0/_!=8_P#R91_P^K^"'_0K?$#_ ,%UC_\ )E 'W_17P!_P
M^K^"'_0K?$#_ ,%UC_\ )E'_  ^K^"'_ $*WQ _\%UC_ /)E 'W_ $5\ ?\
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M?$#_ ,%UC_\ )E'_  ^K^"'_ $*WQ _\%UC_ /)E 'W_ $5\ ?\ #ZOX(?\
M0K?$#_P76/\ \F4?\/J_@A_T*WQ _P#!=8__ "90!]_T5\ ?\/J_@A_T*WQ
M_P#!=8__ "91_P /J_@A_P!"M\0/_!=8_P#R90!]_P!%? '_  ^K^"'_ $*W
MQ _\%UC_ /)E'_#ZOX(?]"M\0/\ P76/_P F4 ??]%? '_#ZOX(?]"M\0/\
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1I"MVS!0S@DA2<9P#TH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789732272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Feb. 22, 2016</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TherapeuticsMD, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000025743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity a Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity a Voluntary Filer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity's Reporting Status Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 738,931,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_EntityCommonStockHeldByNonaffiliates', window );">Entity Common Stock, Shares held by Nonaffiliates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,011,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196,150,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_EntityCommonStockHeldByNonaffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates the number pf common stock held by non-affiliates of the registrant as stated on cover of related periodic report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_EntityCommonStockHeldByNonaffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789923984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 64,706,355<span></span>
</td>
<td class="nump">$ 51,361,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $81,910 and $96,916, respectively</a></td>
<td class="nump">3,049,715<span></span>
</td>
<td class="nump">2,154,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">690,153<span></span>
</td>
<td class="nump">1,182,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,233,897<span></span>
</td>
<td class="nump">1,537,407<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">70,680,120<span></span>
</td>
<td class="nump">56,235,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net</a></td>
<td class="nump">198,592<span></span>
</td>
<td class="nump">63,293<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,615,251<span></span>
</td>
<td class="nump">1,228,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Prepaid expense</a></td>
<td class="nump">1,109,883<span></span>
</td>
<td class="nump">1,427,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Security deposit</a></td>
<td class="nump">125,000<span></span>
</td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total other assets</a></td>
<td class="nump">2,850,134<span></span>
</td>
<td class="nump">2,780,851<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">73,728,846<span></span>
</td>
<td class="nump">59,079,488<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,126,174<span></span>
</td>
<td class="nump">6,327,129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">$ 7,539,526<span></span>
</td>
<td class="nump">3,840,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">522,613<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">$ 10,665,700<span></span>
</td>
<td class="nump">$ 10,690,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies - See Note 14</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock - par value $0.001; 350,000,000 and 250,000,000 shares authorized; 177,928,041 and 156,097,019 issued and outstanding, respectively</a></td>
<td class="nump">$ 177,928<span></span>
</td>
<td class="nump">$ 156,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid in capital</a></td>
<td class="nump">282,712,078<span></span>
</td>
<td class="nump">182,982,846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(219,826,860)<span></span>
</td>
<td class="num">(134,749,836)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">63,063,146<span></span>
</td>
<td class="nump">48,389,107<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 73,728,846<span></span>
</td>
<td class="nump">$ 59,079,488<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3-4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 3<br> -Subparagraph a(1)<br> -Article 5<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 12<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.10-17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 18<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.32)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 25<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Article 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789970096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 81,910<span></span>
</td>
<td class="nump">$ 96,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">350,000,000<span></span>
</td>
<td class="nump">250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">177,928,041<span></span>
</td>
<td class="nump">156,097,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">177,928,041<span></span>
</td>
<td class="nump">156,097,019<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5074-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789580880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues, net</a></td>
<td class="nump">$ 20,142,898<span></span>
</td>
<td class="nump">$ 15,026,219<span></span>
</td>
<td class="nump">$ 8,775,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="nump">4,506,673<span></span>
</td>
<td class="nump">3,671,803<span></span>
</td>
<td class="nump">1,959,597<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">15,636,225<span></span>
</td>
<td class="nump">11,354,416<span></span>
</td>
<td class="nump">6,816,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Sales, general, and administrative</a></td>
<td class="nump">28,721,236<span></span>
</td>
<td class="nump">22,124,072<span></span>
</td>
<td class="nump">19,014,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">72,042,774<span></span>
</td>
<td class="nump">43,218,938<span></span>
</td>
<td class="nump">13,551,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">62,400<span></span>
</td>
<td class="nump">52,467<span></span>
</td>
<td class="nump">58,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expense</a></td>
<td class="nump">100,826,410<span></span>
</td>
<td class="nump">65,395,477<span></span>
</td>
<td class="nump">32,624,245<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(85,190,185)<span></span>
</td>
<td class="num">(54,041,061)<span></span>
</td>
<td class="num">(25,808,244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpensesAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Miscellaneous income, net</a></td>
<td class="nump">95,719<span></span>
</td>
<td class="nump">46,569<span></span>
</td>
<td class="nump">34,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">17,442<span></span>
</td>
<td class="nump">37,309<span></span>
</td>
<td class="nump">27,234<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(260,027)<span></span>
</td>
<td class="num">(1,503,922)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,165,981)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Loan guaranty costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,944)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">113,161<span></span>
</td>
<td class="num">(176,149)<span></span>
</td>
<td class="num">(2,611,069)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(85,077,024)<span></span>
</td>
<td class="num">(54,217,210)<span></span>
</td>
<td class="num">(28,419,313)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (85,077,024)<span></span>
</td>
<td class="num">$ (54,217,210)<span></span>
</td>
<td class="num">$ (28,419,313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Loss per share, basic and diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">173,174,229<span></span>
</td>
<td class="nump">149,727,228<span></span>
</td>
<td class="nump">127,569,731<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 8<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 10<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of other income amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) profits on securities (net of losses), and (d) miscellaneous other income items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51677171&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6787855232">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2012</a></td>
<td class="nump">$ 99,785<span></span>
</td>
<td class="nump">$ 50,580,400<span></span>
</td>
<td class="num">$ (52,113,313)<span></span>
</td>
<td class="num">$ (1,433,128)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2012</a></td>
<td class="nump">99,784,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 45,117<span></span>
</td>
<td class="nump">78,605,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,650,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost, shares</a></td>
<td class="nump">45,116,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">30,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, shares</a></td>
<td class="nump">75,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,254,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,254,083<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued for financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,711,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,711,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Warrants issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty', window );">Warrants issued as compensation-related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,419,313)<span></span>
</td>
<td class="num">(28,419,313)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2013</a></td>
<td class="nump">$ 144,977<span></span>
</td>
<td class="nump">135,086,056<span></span>
</td>
<td class="num">(80,532,626)<span></span>
</td>
<td class="nump">$ 54,698,407<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2013</a></td>
<td class="nump">144,976,757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,976,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 9,850<span></span>
</td>
<td class="nump">42,761,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,771,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost, shares</a></td>
<td class="nump">9,850,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options</a></td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">344,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345,746<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, shares</a></td>
<td class="nump">854,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in exercise of warrants</a></td>
<td class="nump">$ 365<span></span>
</td>
<td class="nump">180,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in exercise of warrants, shares</a></td>
<td class="nump">365,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for exercise of restricted stock units</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="num">(50)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for exercise of restricted stock units, shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,609,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,609,811<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,217,210)<span></span>
</td>
<td class="num">(54,217,210)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2014</a></td>
<td class="nump">$ 156,097<span></span>
</td>
<td class="nump">182,982,846<span></span>
</td>
<td class="num">(134,749,836)<span></span>
</td>
<td class="nump">$ 48,389,107<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2014</a></td>
<td class="nump">156,097,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,097,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 20,040<span></span>
</td>
<td class="nump">91,354,609<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,374,649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost, shares</a></td>
<td class="nump">20,040,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options</a></td>
<td class="nump">$ 613<span></span>
</td>
<td class="nump">1,231,966<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,232,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, shares</a></td>
<td class="nump">612,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in exercise of warrants</a></td>
<td class="nump">$ 1,178<span></span>
</td>
<td class="nump">364,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in exercise of warrants, shares</a></td>
<td class="nump">1,177,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,777,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,777,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(85,077,024)<span></span>
</td>
<td class="num">(85,077,024)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2015</a></td>
<td class="nump">$ 177,928<span></span>
</td>
<td class="nump">$ 282,712,078<span></span>
</td>
<td class="num">$ (219,826,860)<span></span>
</td>
<td class="nump">$ 63,063,146<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Dec. 31, 2015</a></td>
<td class="nump">177,928,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">177,928,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdjustmentsToAdditionalPaidInCapitalWarrantIssuedRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183637&amp;loc=d3e4724-112606<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Warrant<br> -URI http://asc.fasb.org/extlink&amp;oid=6528364<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777213056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (85,077,024)<span></span>
</td>
<td class="num">$ (54,217,210)<span></span>
</td>
<td class="num">$ (28,419,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">29,959<span></span>
</td>
<td class="nump">28,987<span></span>
</td>
<td class="nump">47,883<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">32,441<span></span>
</td>
<td class="nump">23,480<span></span>
</td>
<td class="nump">10,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for (recovery of) doubtful accounts</a></td>
<td class="nump">22,157<span></span>
</td>
<td class="num">(5,436)<span></span>
</td>
<td class="num">(15,493)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,102,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">7,189,699<span></span>
</td>
<td class="nump">4,970,312<span></span>
</td>
<td class="nump">3,844,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDeferredCharges', window );">Amortization of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260,027<span></span>
</td>
<td class="nump">1,451,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Loan guaranty costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(917,656)<span></span>
</td>
<td class="num">(458,028)<span></span>
</td>
<td class="num">(1,068,619)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">491,960<span></span>
</td>
<td class="num">(138,495)<span></span>
</td>
<td class="nump">571,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="num">(773,532)<span></span>
</td>
<td class="nump">680,281<span></span>
</td>
<td class="num">(1,386,319)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(17,442)<span></span>
</td>
<td class="num">(37,309)<span></span>
</td>
<td class="num">(565,706)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,200,955)<span></span>
</td>
<td class="nump">4,212,912<span></span>
</td>
<td class="nump">472,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(522,613)<span></span>
</td>
<td class="num">(1,079,967)<span></span>
</td>
<td class="nump">457,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="nump">3,698,887<span></span>
</td>
<td class="nump">239,450<span></span>
</td>
<td class="nump">2,875,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150,068)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(79,044,119)<span></span>
</td>
<td class="num">(45,520,996)<span></span>
</td>
<td class="num">(20,768,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Patent costs</a></td>
<td class="num">(419,104)<span></span>
</td>
<td class="num">(586,480)<span></span>
</td>
<td class="num">(439,034)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of fixed assets</a></td>
<td class="num">(165,257)<span></span>
</td>
<td class="num">(30,962)<span></span>
</td>
<td class="num">(40,790)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCash', window );">Refund (payment) of security deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,686<span></span>
</td>
<td class="num">(103,737)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows used in investing activities</a></td>
<td class="num">(584,361)<span></span>
</td>
<td class="num">(606,756)<span></span>
</td>
<td class="num">(583,561)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, net of costs</a></td>
<td class="nump">91,374,649<span></span>
</td>
<td class="nump">42,771,353<span></span>
</td>
<td class="nump">78,650,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">1,232,579<span></span>
</td>
<td class="nump">345,746<span></span>
</td>
<td class="nump">30,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">366,000<span></span>
</td>
<td class="nump">181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds bank line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLinesOfCredit', window );">Repayment of bank line of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(500,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Repayment of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,691,847)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">92,973,228<span></span>
</td>
<td class="nump">43,298,099<span></span>
</td>
<td class="nump">73,989,416<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Increase (decrease) in cash</a></td>
<td class="nump">13,344,748<span></span>
</td>
<td class="num">(2,829,653)<span></span>
</td>
<td class="nump">52,637,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, beginning of period</a></td>
<td class="nump">51,361,607<span></span>
</td>
<td class="nump">54,191,260<span></span>
</td>
<td class="nump">1,553,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, end of period</a></td>
<td class="nump">$ 64,706,355<span></span>
</td>
<td class="nump">$ 51,361,607<span></span>
</td>
<td class="nump">54,191,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Cash paid for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">212,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForFinancing', window );">Warrants issued for financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,711,956<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsIssuedForServices', window );">Warrants issued for services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 462,196<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedForFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued in the period for financing in a noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsIssuedForFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants issued in the period for servcies in a noncash transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization of deferred charges applied against earnings during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating liabilities not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other noncurrent operating liabilities not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other assets used in operating activities not separately disclosed in the statement of cash flows. May include changes in other current assets, other noncurrent assets, or a combination of other current and noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Investing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.5)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Financing Activities<br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780289264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>THE COMPANY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">THE COMPANY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><u>NOTE 1 &#150; THE COMPANY</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">TherapeuticsMD, Inc., a Nevada corporation, or
TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed;
BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare.
Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to
as &#147;our company,&#148; &#147;we,&#148; &#147;our,&#148; or &#147;us.&#148;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Nature of Business</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are a women&#146;s health care product company
focused on creating and commercializing products targeted exclusively for women. As of the date of these consolidated financial
statements, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of our advanced
hormone therapy pharmaceutical products. The drug candidates used in our clinical trials are designed to alleviate the symptoms
of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and
vaginal discomfort. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or
in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect
profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the
administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded
and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=35735333&amp;loc=d3e288-107754<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 272<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6373374&amp;loc=d3e70478-108055<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774291728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif"><font style="letter-spacing: -0.15pt"><u>NOTE 2 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u></font></p>
<p style="margin: 0pt 0; text-align: justify; font: bold 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><u>Principles of Consolidation</u></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The accompanying consolidated financial statements include the accounts of our company and our wholly owned subsidiaries, VitaMed, BocaGreen and VitaCare. All intercompany balances and transactions have been eliminated in consolidation.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-weight: normal"><u>Cash</u></font></p>
<p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-weight: normal">We maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation (the &#x201C;FDIC&#x201D;) insured limits of $250,000 per bank. We have never experienced any losses related to these funds.</font></p>
<p style="margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Trade Accounts Receivable and Allowance for Doubtful Accounts</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Trade accounts receivable are customer obligations due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information, and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase in the allowance for doubtful accounts. <font style="color: #252525">To the extent data we use to calculate these estimates does not accurately reflect bad debts; adjustments to these reserves may be </font>required.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="letter-spacing: -0.15pt"><u>Inventories</u></font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="letter-spacing: -0.15pt">Inventories represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or market using the average-cost method. Any costs of manufacturing the prescription products associated with the deferred revenue (as discussed in Revenue Recognition) prior to January 1 , 2015, were recorded as deferred costs and included in inventory, until such time as the related deferred revenue was recognized. </font>We review our inventory for excess or obsolete inventory and write-down obsolete or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product improvements rendering previous versions obsolete.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="letter-spacing: -0.15pt"><i><u>Pre-Launch Inventory</u></i></font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="letter-spacing: -0.15pt">Inventory costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research and development expenses during the period the costs are incurred. We have not capitalized any pre-launch inventory to date.</font></p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Fixed Assets</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We state fixed assets at cost, net of accumulated depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair costs to operating expenses as incurred. <font style="letter-spacing: -0.15pt">We compute depreciation using the straight-line method over the estimated useful lives of the related assets, which range from three to seven years.</font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We capitalize software and&#xA0;software&#xA0;development&#xA0;costs&#xA0;incurred to create and acquire computer software for internal use, principally related to software coding and application development. We begin to capitalize&#xA0;software development&#xA0;costs&#xA0;when both the preliminary project stage is completed and it is probable that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into service over the estimated useful life, generally five to seven years.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="letter-spacing: -0.15pt"><u>Intangible </u></font><u>Assets</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="letter-spacing: -0.15pt"><i><u>Patents and Trademarks</u></i></font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><font style="letter-spacing: -0.15pt">We have adopted the provisions of </font>Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, <font style="letter-spacing: -0.15pt">350, <i>Intangibles - Goodwill and Other</i>,<i> </i>or </font>ASC 350<font style="letter-spacing: -0.15pt">. Capitalized patent costs, net of accumulated amortization, include legal costs incurred for patent applications. </font>In accordance with ASC 350, <font style="letter-spacing: -0.15pt">once a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method. If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, 2015, we had 14 issued patents (See Note 7). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate that their carrying amount may not be recoverable.</font></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Impairment of Long-Lived Assets</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We review the carrying values of fixed assets and long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances may include, among others, the following:</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#xB7;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">significant declines in an asset&#x2019;s market price;</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"></p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#xB7;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">significant deterioration in an asset&#x2019;s physical condition;</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"></p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#xB7;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">significant changes in the nature or extent of an asset&#x2019;s use or operation;</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"></p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#xB7;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">significant adverse changes in the business climate that could impact an asset&#x2019;s value, including adverse actions or assessments by regulators; </font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"></p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#xB7;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"></p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#xB7;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset&#x2019;s use; and</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif"></p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#xB7;</font></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.</font></td>
</tr>
</table>
<p style="margin-bottom: 0pt; margin-top: 0pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group&#x2019;s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets&#x2019; fair value and respective carrying values. We determine the fair value of the assets using an &#x201C;income approach&#x201D; based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of long-lived assets to be held and used during the years ended December 31, 2015, 2014 and 2013.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We perform impairment tests for intangible&#xA0;assets&#xA0;with&#xA0;indefinite&#xA0;useful&#xA0;lives&#xA0;annually, or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. There was no impairment of indefinite lived intangible assets during the years ended December 31, 2015, 2014 and 2013.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Fair Value of Financial Instruments</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Our financial instruments consist primarily of cash, accounts receivable, accounts payable and accrued expenses. The carrying amount of cash, accounts receivable, accounts payable and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <i>Fair Value Measurements. </i> The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">unadjusted quoted prices in active markets for identical assets or liabilities;</td>
</tr>
</table>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and</td>
</tr>
</table>
<p style="margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif"></p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0pt; margin-top: 0; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">unobservable inputs for the asset or liability.</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At December 31, 2015 and 2014, we had no assets or liabilities that were valued at fair value on a recurring basis.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The fair value of indefinite-lived assets is measured on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. There was no impairment of intangible assets during the years ended December 31, 2015, 2014 and 2013.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Income Taxes</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In accordance with ASC 740, <i>Income Taxes</i>, we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in the period in which those changes in judgment occur.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We recognize both interest and penalties related to uncertain tax positions as part of the income tax provision. At December 31, 2015 and 2014, we had no tax positions relating to open tax returns that were considered to be uncertain.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Our tax returns are subject to review by the Internal Revenue Service three years after they are filed. Currently, years filed after 2012 are subject to review.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><u>Share-Based Compensation</u></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">We measure the compensation costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements over the period during which employees are required to provide services. Share-based compensation arrangements include options, restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans. As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model, an acceptable model in accordance with ASC 718 to value options. Calculating share-based compensation expense requires the input of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award, stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result, if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.</font><font style="font-size: 10pt"> </font><font style="font-size: 10pt"> </font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Equity instruments (&#x201C;instruments&#x201D;) issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, <i>Equity - Based Payments to Non-Employees</i>,<i> </i>or ASC 505<i>. </i>ASC 505<i> </i>defines the measurement date and recognition period for such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined in ASC 505.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We recognize the compensation expense for all share-based compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We generally recognize the compensation expense on a straight-line basis over the employee&#x2019;s requisite service period. We estimate the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Debt Discounts</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Costs incurred from parties that are providing long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based on the relative fair value of the debt and warrants to the total proceeds. We amortize discounts over the life of the related debt using the effective interest rate method.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Revenue Recognition</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We recognize revenue on arrangements in accordance with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and collectability is reasonably assured.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Our over-the-counter (OTC) and prescription prenatal vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing similar marketing techniques. The revenue that is generated by us from major external customers is all generated from sales of our prescription prenatal vitamin products which is disclosed in Note 13. There are no major external customers for our OTC prenatal vitamin or other products.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i><u>OTC Products</u></i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We generate OTC revenue from product sales primarily to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce OTC customers. We recognize revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i><u>Prescription Products</u></i></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We sell our name brand and generic prescription products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of sales discounts, chargebacks, and customer rebates.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We accept returns of unsalable prescription products from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015, we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We offer various rebate programs in an effort to maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the allowance for consumer rebates that we have offered based on our experience and industry averages, which is reviewed, and adjusted if necessary, on a quarterly basis.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Segment Reporting</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We are managed and operated as one business, which is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single management team that reports to the President of our Company. We do not operate separate lines of business with respect to any of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived from sales in the United States. Accordingly, we view our business as one reportable operating segment.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Shipping and Handling Costs</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We expense all shipping and handling costs as incurred. We include these costs in cost of goods sold on the accompanying consolidated financial statements.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="letter-spacing: -0.15pt"><u>Advertising Costs</u></font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We expense advertising costs when incurred. Advertising costs were $792,574, $698,871 and $11,739 during the years ended December 31, 2015, 2014 and 2013, respectively.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Research and Development Expenses</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Research and development, or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&#38;D activity expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be expensed in future research and development activities are capitalized, and were $1,138,073 at December 31, 2015, of which $1,009,175 was included in other current assets and $128,898 was included in long term prepaid expense on the accompanying consolidated balance sheets. Advance payments to be expensed in future R&#38;D activities were $1,175,082 at December 31, 2014, of which $711,362 was included in other current assets and $463,720 was included in long term prepaid expense on the accompanying consolidated balance sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as R&#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes, clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that were classified as R&#38;D expenses related to designing experiments to generate data for patents and to further the formulation development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing, and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</p>
<p style="background-color: white; margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Earnings Per Share</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We calculate earnings per share, or EPS, in accordance with ASC 260, <i>Earnings Per Share</i>, which requires the computation and disclosure of two EPS amounts: basic and diluted. We compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock, outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our Common Stock consist of options and warrants and were excluded from the calculation of diluted earnings per share because their effect would have been anti-dilutive due to the net loss reported by us.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 80%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="10" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">As of December 31,</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2015</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2014</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2013</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 35%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Stock options</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">20,725,325</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">16,792,443</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">15,632,742</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif">Warrants</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,722,431</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,927,916</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,293,499</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,447,756</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,720,359</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">29,926,241</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Subsequent to December 31, 2015, we issued 17,424,242 shares of our Common Stock at a public offering price of $8.25 per share. In January 2016, certain individuals exercised stock options to purchase 281,657 shares of our Common Stock for approximately $758,000 in cash. In addition, warrants to purchase 500,000 shares of our Common Stock were exercised for approximately $1,285,000 in cash. See Note 16 - Subsequent Events for more details.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><u>Concentration of Credit Risk and other Risks and Uncertainties </u></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Financial instruments that potentially expose us to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. The Company has not experienced any historical losses on its deposits of cash.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Concentration of credit risk with respect to our trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacies. Credit is extended to our customers based on an evaluation of a customer&#x2019;s financial condition, and collateral is not required.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Use of Estimates</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material amounts, from these estimates under different assumptions or conditions.</p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Reclassifications</u></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u></u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Certain 2014 and 2013 amounts have been reclassified to conform to current year presentation.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Recently Issued Accounting Pronouncements</u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">In November 2015,
the FASB issued Accounting Standards Update, or ASU, No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred
Taxes. This guidance requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet
instead of separating deferred taxes into current and noncurrent amounts. Also, companies will no longer allocate valuation allowances
between current and noncurrent deferred tax assets because those allowances also will be classified as noncurrent. For public
business entities, the guidance is effective for financial statements issued for annual periods beginning December 15, 2016, and
interim periods within those annual periods. Companies can adopt the guidance either prospectively or retrospectively. We adopted</font>&#xA0;<font style="font-size: 10pt">this
guidance in the fourth quarter of 2015. The adoption of this guidance did not have a material impact on our consolidated financial
statements or disclosures.</font></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">&#160;</font></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In July 2015, the FASB issued ASU 2015-11, Inventory (Topic 330), simplifying the Measurement of Inventory. This guidance requires entities to measure inventory at the lower of cost or net realizable value rather than at the lower of cost or market (LOCOM). The guidance applies only to inventories for which cost is determined by methods other than last-in first-out (LIFO) or the retail inventory method (RIM). Entities that use LIFO or RIM will continue to use existing impairment models. The new guidance does not change the calculation of net realizable value that entities are required to calculate when applying existing LOCOM guidance. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Under the new guidance, however, entities will no longer need to calculate other measures of &#x201C;market.&#x201D; The guidance is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. Early adoption is permitted. We are currently evaluating the impact of this guidance, if any, on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In June 2015, the FASB issued ASU No. 2015-10, Technical Corrections and Improvements, to correct differences between original guidance and the ASC clarify the guidance, correct references and make minor improvements affecting a variety of topics. Amendments that the FASB deemed more substantive are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-10 did not have a material effect on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#x2019;s Ability to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there are conditions and events that raise substantial doubt about the entity&#x2019;s ability to continue as a going concern within one year after the financial statements are issued (or available to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect the adoption of ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In May 2014, the FASB and the International Accounting Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#x2019;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligations. In July 2015, the FASB approved the proposal to defer the effective date of ASU 2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities for annual reporting periods beginning after December 15, 2017 and interim periods therein. We are currently evaluating the impact of ASU 2014-09 on our consolidated financial statements and disclosures.</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We do not believe there would have been a material effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780273312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 3 &#x2013; INVENTORY</u></b></p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Inventory consists of the following:</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2015</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2014</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 70%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Finished product</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">661,167</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">874,294</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif">Raw material</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">28,986</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">155,341</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif">Deferred costs</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">152,478</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif">TOTAL INVENTORY</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">690,153</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,182,113</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a, b, c<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774347808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">OTHER CURRENT ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><u>NOTE 4 &#150; OTHER CURRENT ASSETS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Other current assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 70%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid insurance</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">695,421</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">394,878</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">674,353</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">299,498</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other prepaid costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">369,812</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">181,186</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid consulting</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">334,822</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">411,864</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid vendor deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">159,489</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#151;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other receivables-related party (Note 12)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">249,981</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,233,897</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,537,407</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780258496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">FIXED ASSETS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><u>NOTE 5 &#150; FIXED ASSETS, NET</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fixed assets, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 70%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Equipment</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">132,150</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">132,150</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accounting system in process</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">149,699</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">69,454</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">53,895</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">351,303</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">186,045</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accumulated depreciation</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(152,711</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(122,752</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">198,592</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">63,293</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Depreciation expense for the years ended December
31, 2015, 2014, and 2013 was $29,959, $28,987 and $47,883, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13-14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774433280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidExpensesDisclosureTextBlock', window );">PREPAID EXPENSE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 6 &#150;PREPAID EXPENSE</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expense (long-term) consists of the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 74%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid manufacturing costs</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">980,985</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">963,543</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development&#160;&#160;costs</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">128,898</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">463,720</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;TOTAL PREPAID EXPENSE</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,109,883</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,427,263</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidExpensesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidExpensesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6776561952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 7 &#x2013; INTANGIBLE ASSETS, NET</u></b></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2015 and 2014:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Gross <br /> Carrying <br /> Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Accumulated Amortization</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net <br />Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- <br /> Average Remaining Amortization <br /> Period (yrs.)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizable intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; width: 48%; text-align: left; font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#xAE;</sup> software patent</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(4,493</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">27,458</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">13.75</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">705,752</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(49,845</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">655,907</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">17</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents (in process)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">774,165</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">774,165</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">Non-amortizable intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">157,721</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">157,721</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Total</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,761,332</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(146,081</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,615,251</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>

<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2014</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Gross <br /> Carrying <br /> Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Accumulated Amortization</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net <br />Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- <br /> Average Remaining Amortization <br /> Period (yrs.)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizable intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; width: 48%; text-align: left; font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#xAE;</sup> software patent</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(2,496</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">29,455</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">14.75</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">439,184</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(19,401</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">419,783</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">18</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents (in process)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">675,982</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">675,982</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Non-amortizable intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103,368</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103,368</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Total</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,342,228</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(113,640</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,228,588</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="background-color: white">We amortize
the approved hormone therapy drug candidate patents using straight-line method over the estimated useful life of approximately
20 years, which is the life of intellectual property patents.. As of December 31, 2015, the remaining life related to OPERA&#xAE;
patent was approximately 14 years and the remaining life related to the approved hormone therapy drug candidate patents was approximately
17 years. During the years ended December 31, 2015 and 2014, there was no impairment recognized related to intangible assets.</font></p>

<p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="background-color: white">&#160;</font></p>

<p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify"><font style="background-color: white">In
addition to numerous pending patent applications, as of December 31, 2015, we had fourteen issued patents, including:</font></p>

<p style="margin: 0; font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white"></font></p>
<p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Symbol">&#xB7;</font><font style="font-family: Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; <font style="background-color: white">12 utility patents that relate to our combination progesterone and estradiol product candidates, which are owned by us and are U.S. jurisdiction patents with expiration dates in 2032. We have pending patent applications with respect to certain of these patents in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa and South Korea.</font></font></p>
<p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Symbol">&#xB7;</font><font style="font-family: Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0; <font style="background-color: white">one utility patent that relates to TX-004HR, our applicator-free vaginal estradiol softgel product candidate, which establishes an important intellectual property foundation for TX-004HR, is owned by us and is a U.S. jurisdiction patent with an expiration date in 2033. We have pending patent applications with respect to this patent in Argentina, Australia, Brazil, Canada, Europe, Israel, Japan, Mexico, Russia, South Africa, and South Korea.</font></font></p>
<p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Symbol">&#xB7;</font><font style="font-family: Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;
<font style="background-color: white">one utility patent that relates to our OPERA&#xAE; information technology platform, which
is owned by us and is a U.S. jurisdiction patent with an expiration date in 2029.</font>&#xA0;&#xA0;&#xA0;&#xA0;</font></p>
<p style="margin: 0 0 0 0.5in; text-align: justify; text-indent: 0in; font: 10pt Times New Roman, Times, Serif"><font style="font-family: Times New Roman, Times, Serif">&#xA0; <font style="background-color: white">&#xA0;</font></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white">Amortization expense was $32,441, $23,480, and $10,262 for the years ended December 31, 2015, 2014, and 2013, respectively. Estimated amortization expense for the next five years is as follows:</font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 30%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Year Ending <br /> December 31,</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Estimated <br /> Amortization</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif">2016</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">40,580</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2017</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">40,580</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2018</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">40,580</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2019</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">40,580</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2020</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">40,580</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16265-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774432480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b><u>NOTE 8 &#150; OTHER CURRENT LIABILITIES</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other current liabilities consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 74%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued clinical trial costs</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">3,725,377</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,706,542</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued payroll, bonuses and commission costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,108,143</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">814,205</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued compensated absences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">562,096</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">442,430</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">546,264</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">185,965</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Allowance for coupons and returns</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">224,300</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">90,446</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued legal and accounting expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">210,309</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">276,470</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued rent</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">83,527</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,368</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued royalties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">46,851</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">72,710</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Allowance for wholesale distributor fees</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,659</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">160,503</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,539,526</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,840,639</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6776573168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 9 &#150; NOTES PAYABLE</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Issuance and Payment of Multiple Advance
Revolving Credit Note</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On January 31, 2013, we entered into a
business loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the
Revolving Credit Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal
amount, at a stated interest rate of 6% per annum. Plato was able to make advances to us from time to time under the
Revolving Credit Note at our request, which advances were of a revolving nature and were able to be made, repaid, and made
from time to time. Interest payments were due and payable on the tenth day following the end of each calendar quarter in
which any interest was accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the
Revolving Credit Note, together with all accrued interest and other amounts payable under the Revolving Credit Note, if any,
was due and payable on February 24, 2014. The Revolving Credit Note was secured by substantially all of our assets. On each
of February 25 and March 13, 2013, $200,000 was drawn against the Revolving Credit Note. On March 21, 2013, we repaid
$401,085, which included accrued interest, and there was no balance outstanding under the Revolving Credit Note as of
December 31, 2013 and February 24, 2014 when it expired. As additional consideration for the Revolving Credit Note, we
granted to Plato a warrant to purchase 1,250,000 shares of our Common Stock at an exercise price of $3.20 per share (See Note
10).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780243776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 10 &#x2013; STOCKHOLDERS&#x2019; EQUITY</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Preferred Stock</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At December 31, 2015, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred stock were issued or outstanding.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Common Stock</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At December 31, 2015, we had 350,000,000 shares of Common Stock authorized for issuance, of which 177,928,041 shares of our Common Stock were issued and outstanding. During the year ended December 31, 2015, our stockholders&#x2019; approved an amendment to our articles of incorporation to increase the number of authorized shares of Common Stock from 250,000,000 to 350,000,000.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><i><u>Issuances During 2015</u></i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On July 9, 2015, we entered into an underwriting agreement with Stifel, Nicolaus&#xA0;&#38; Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters, or the Stifel Underwriters, relating to an underwritten public offering of 3,846,154 shares of Common Stock at a public offering price of $7.80 per share. Under the terms of the underwriting agreement, we granted the Stifel Underwriters a 30-day option to purchase up to an aggregate of 576,923 additional shares of Common Stock, which option was exercised in full. The net proceeds to us from the offering were approximately $32.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on July&#xA0;15, 2015 and we issued 4,423,077 shares of our Common Stock.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On February 10, 2015, we entered into an underwriting agreement, or the Cowen Agreement, with Cowen and Company, LLC, as the representative of the several underwriters, or the Cowen Underwriters, relating to an underwritten public offering of 13,580,246 shares of Common Stock, at a public offering price of $4.05 per share. Under the terms of the Cowen Agreement, we granted the Cowen Underwriters a 30-day option to purchase up to an aggregate of 2,037,036 additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $59.1 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering closed on February 17, 2015 and we issued 15,617,282 shares of our Common Stock.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2015, certain individuals exercised stock options to purchase 612,867 shares of Common Stock for $1,232,579 in cash. Also during the same period, stock options to purchase 417 shares of Common Stock were exercised pursuant to the options&#x2019; cashless exercise provisions, wherein 114 shares of Common Stock were issued.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Subsequent to December 31, 2015, we issued 17,424,242 shares of our Common Stock in an underwritten public offering at a public offering price of $8.25 per share. In January 2016, certain individuals exercised stock options to purchase 281,657 shares of our Common Stock for approximately $758,000 in cash. In addition, warrants to purchase 500,000 shares of our Common Stock were exercised for approximately $1,285,000 in cash. See Note 16 - Subsequent Events for more details.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i><u>Issuances During 2014</u></i></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On July 29, 2014, we entered into an underwriting agreement with Goldman Sachs &#38; Co, or Goldman Sachs, as the representative of the underwriters named therein, or the Goldman Sachs Underwriters, relating to an underwritten public offering of 8,565,310 shares of Common Stock. The price to the public in the offering was $4.67 per share. Under the terms of the underwriting agreement, we granted the Goldman Sachs Underwriters a 30-day option to purchase up to an additional 1,284,796 shares of Common Stock. On July 30, 2014, the Goldman Sachs Underwriters exercised their option to purchase the additional 1,284,796 shares of Common Stock. Net proceeds from this offering were approximately $42.8 million, after deducting underwriting discounts and commissions and other offering expenses. The offering closed on August 4, 2014 and we issued 9,850,106 shares of our Common Stock.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2014, certain individuals exercised stock options to purchase 860,800 shares of our Common Stock. Stock options to purchase shares of our Common Stock were exercised as follows: (i) 724,193 options for $345,746 in cash and (ii) 136,607 options, pursuant to the stock options&#x2019; cashless provision, wherein 130,380 shares of Common Stock were issued. In addition, during 2014, we issued 50,000 shares of Common Stock to an employee upon the vesting of restricted stock units that were granted in December 2013.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i><u>Issuances During 2013</u></i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On March 14, 2013, we entered into an underwriting agreement with Jefferies LLC as the representative of the underwriters named therein, or the Jefferies Underwriters, relating to the issuance and sale of 29,411,765 shares of our Common Stock. The price to the public in the offering was $1.70 per share. In addition, under the terms of the underwriting agreement, we granted the Jefferies Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of our Common Stock. The offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters exercised their option to purchase an additional 1,954,587 shares of our Common Stock, which were issued on April 18, 2013. The net proceeds to us from this offering were approximately $48.5 million, after deducting underwriting discounts and commissions and other offering expenses payable by us.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">On September 25, 2013, we entered into an underwriting agreement with Stifel, Nicolaus &#38; Company, Incorporated, as the representative of the underwriters named therein, relating to the issuance and sale of 13,750,000 shares of our Common Stock. The price to the public in the offering was $2.40 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2013, certain individuals exercised options to purchase an aggregate of 75,423 shares of our Common Stock for approximately $31,000.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><u>Warrants to Purchase Common Stock</u></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of December 31, 2015, we had warrants outstanding to purchase an aggregate of 12,722,431 shares of our Common Stock with a weighted-average contractual remaining life of 1.7 years, and exercise prices ranging from $0.24 to $6.35 per share, resulting in a weighted average exercise price of $1.93 per share.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The valuation methodology used to determine the fair value of our warrants is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2015, we granted warrants to purchase 50,000 shares of Common Stock to an outside consultant at an exercise price of $6.35, vesting ratably over a 12 month period, with an expiration date of April 6, 2020. The grant date fair value of this warrant was $3.27. During the year ended December 31, 2015, we recorded $139,142 as non-cash compensation in the accompanying consolidated financial statements related to this warrant.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In January 2013, we issued warrants to purchase 1,250,000 shares of our Common Stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant (see NOTE 9 above for more details). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. During the years ended December 31, 2015, 2014 and 2013, $0, $260,027 and $1,451,934, respectively, was recorded as financing costs in connection with the issuance of the Plato Warrant on the accompanying consolidated financial statements.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In May 2013, we entered into a consulting agreement with SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our Common Stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to issue to SCI a warrant to purchase 850,000 shares of our Common Stock at $2.01 per share that has vested or will vest, as applicable, as follows:</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">1.</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;</td>
</tr>
</table>
<p style="margin: 0 0 0 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">2.</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. During the years ended December 31 2015, 2014 and 2013, we recorded $154,068, $154,068 and $77,034, respectively, as non-cash compensation in the accompanying consolidated financial statements related to this warrant. As of December 31, 2015, there was a remaining balance of $77,026 related to this warrant which was included in other current assets in the accompanying consolidated financial statements; and</td>
</tr>
</table>
<p style="margin: 0 0 0 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="margin-bottom: 0; margin-top: 0; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td>
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif">3.</td>
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that this event will not occur before December 2016.</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In May 2012, we issued warrants to purchase an aggregate of 1,300,000 shares of Common Stock to an unaffiliated entity for services to be rendered over approximately five years beginning in May 2012. Services provided are to include (a) services in support of our drug development efforts, including services in support our ongoing and future drug development and commercialization efforts, regulatory approval efforts, third-party investment and financing efforts, marketing efforts, chemistry, manufacturing and controls efforts, drug launch and post-approval activities, and other intellectual property and know-how transfer associated therewith; (b) services in support of our efforts to successfully obtain New Drug Approval; and (c) other consulting services as mutually agreed upon from time to time in relation to new drug development opportunities. The warrants were valued at $1,532,228 on the date of the issuance using an exercise price of $2.57; a term of five years; a volatility of 44.71%; risk free rate of 0.74%; and a dividend yield of 0%. At December 31, 2015, we had $257,796 reported as prepaid expense-short term and $128,898 recorded as prepaid expense-long term associated with these warrants. During the years ended December 31, 2015, 2014 and 2013, we recorded $257,796, $309,165 and $360,528, respectively as non-cash compensation with respect to these warrants in the accompanying consolidated financial statements. The contract will expire upon the commercial manufacture of a drug product. We have determined that the process will take approximately five years.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of December 31, 2015, unamortized costs associated with the SCI warrants issued in 2013 and 2012 totaled approximately $464,000 and will be recognized over a period of eighteen months.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><i><u>Warrant exercises</u></i></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><i>&#xA0;</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2015, certain individuals and an entity exercised warrants to purchase 1,255,485 shares of Common Stock as follows: (i) 945,485 shares of Common Stock were issued for $366,000 in cash and (ii) warrants to purchase 310,000 shares of Common Stock were exercised pursuant to the warrants&#x2019; cashless exercise provisions, wherein 232,197 shares of Common Stock were issued.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">During the year ended December 31, 2014, certain individuals exercised warrants to purchase 365,583 shares of Common Stock for $181,000 in cash.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><i>Summary of our Warrant activity during the year ended December 31, 2015:</i></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of <br /> Shares <br /> Under <br /> Warrants</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted <br />Average <br />Remaining <br />Contractual <br />Life in Years</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate <br />Intrinsic <br /> Value</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 48%; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2014</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">13,927,916</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.82</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">3.0</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">36,623,875</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Granted</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">50,000</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.35</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Exercised</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(1,255,485</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.79</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">7,282,404</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Expired</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Cancelled/Forfeited</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2015</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">12,722,431</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.93</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.7</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">107,344,752</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at December 31, 2015</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">12,422,432</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.92</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.6</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">104,909,091</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The weighted average fair value per share of warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2015, 2014 and 2013 are set forth in the table below.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 39%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 3%; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2013</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average fair value</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$6.35</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$2.83</font></td>
</tr>
<tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1.02%</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a </font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.88-1.12%</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Volatility</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">60.59%</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a </font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">44.29-45.89%</font></td>
</tr>
<tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Term (in years)</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a </font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a </font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of the award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We have used the historical volatility of peer entities due to the lack of sufficient historical data of our stock price during 2011-2015.</p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Options to Purchase Common Stock of the Company</u></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In 2009, we adopted the 2009 Long Term Incentive Compensation Plan, or the 2009 Plan, to provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other stock and cash incentives, or the Awards. The Awards available under the 2009 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, and other stock or cash awards as described in the 2009 Plan. There are 25,000,000 shares authorized for issuance thereunder. Generally, the options vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option is issued. Prior to the merger with VitaMed, no Awards had been issued under the 2009 Plan. As of December 31, 2015, there were non-qualified stock options to purchase 17,856,851 shares of Common Stock outstanding under the 2009 Plan. As of December 31, 2015, there were 3,607,852 shares available to be issued under 2009 Plan.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In 2012, we adopted the 2012 Stock Incentive
Plan, or the 2012 Plan, a non-qualified plan that was amended in August 2013. The 2012 Plan was designed to serve as an incentive
for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.
The Awards available under the 2012 Plan consist of stock options, stock appreciation rights, restricted stock, restricted stock
units, performance stock, performance units, and other stock or cash awards as described in the 2012 Plan. Generally, the options
vest annually over four years or as determined by our board of directors, upon each option grant. Options may be exercised by
paying the price for shares or on a cashless exercise basis after they have vested and prior to the specified expiration date
provided and applicable exercise conditions are met, if any. The expiration date is generally ten years from the date the option
is issued. There are 10,000,000 shares of Common Stock authorized for issuance thereunder. As of December 31, 2015, there were
non-qualified stock options to purchase 2,868,474 shares of Common Stock outstanding under the 2012 Plan. As of December 31, 2015,
there were 7,050,000 shares available to be issued under 2012 Plan.</p>

<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The valuation methodology used to determine the fair value of stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The ranges of assumptions used in the Black-Scholes Model during the years ended December 31, 2015, 2014 and 2013 are set forth in the table below.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 39%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></td>
<td style="padding-left: 5.4pt; padding-right: 5.4pt; width: 3%; text-align: center; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 5.4pt; padding-right: 5.4pt; width: 14%; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2013</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1.47-1.67%</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.07-1.77%</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.65-1.71%</font></td>
</tr>
<tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Volatility</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">58.78-62.94%</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">68.05-82.29%</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">33.35-45.76%</font></td>
</tr>
<tr style="background-color: #cceeff; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Term (in years)</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5.27-6.25</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td>
</tr>
<tr style="background-color: white; vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected term. Estimated volatility is a measure of the amount by which the price of our Common Stock is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual terms of the stock option using the simplified method.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">A summary of activity under the 2009 and 2012 Plans and related information during the year ended December 31, 2015 is as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of <br /> Shares <br /> Under <br /> Options</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted <br />Average <br />Remaining <br />Contractual <br />Life in Years</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate <br />Intrinsic <br /> Value</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 48%; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2014</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">16,792,443</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.88</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.9</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">43,996,311</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Granted</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,685,000</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">8.14</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Exercised</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(613,284</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.01</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Expired</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(102,500</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.68</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Cancelled/Forfeited</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(36,334</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.02</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2015</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">20,725,325</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.28</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.5</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">146,864,184</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at December 31, 2015</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15,461,986</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.86</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.5</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">131,523,505</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Unvested at December 31, 2015</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,263,339</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">7.46</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">9.4</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">15,340,679</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At December 31, 2015, our outstanding options had exercise prices ranging from $0.10 to $8.92 per share.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The weighted average grant date fair value per share of options granted during the year ended December 31, 2015 was $4.45. The total intrinsic value of options exercised during the year ended December 31, 2015 was $3,186,371.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">Share-based compensation expense related to options recognized in our results of operations for the years ended December 31, 2015, 2014 and 2013 was $6,621,658, $4,393,455 and $3,200,655, respectively, and it is based on awards vested. We estimate forfeitures at the time of grant and revise the forfeiture rate in subsequent periods if actual forfeitures differ from the estimates. At December 31, 2015, total unrecognized estimated compensation expense related to unvested options was approximately $19.8 million, </font>which may be adjusted for future changes in forfeitures<font style="font-size: 10pt">. This cost is expected to be recognized over a weighted-average period of 1.7 years. No tax benefit was realized due to a continued pattern of operating losses. </font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">In December 2013, we granted a restricted stock unit, or the RSU, under our 2012 Plan to an employee for 50,000 shares of our Common Stock having a fair value of $233,500. During the years ended December 31, 2014 and 2013, we recorded $53,428 and $180,072, respectively, of non-cash compensation related to the RSU on the accompanying consolidated financial statements. The RSU was issued in June 2014.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Preferred Stock<br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section E<br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 4<br> -Section C<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780215408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 11 &#x2013; INCOME TAXES </u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="background-color: white">For the years ended December 31, 2015, 2014 and 2013, there was no provision for income taxes, current or deferred.&#xA0; All product sales are derived from sales in the United States.<br /></font></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">At December 31, 2015, we had a federal net operating loss carry forward of $192,601,415 available to offset future taxable income through 2035. The federal carryforwards will begin to expire in 2021.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2015</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2014</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2013</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 58%; text-align: left; font: 10pt Times New Roman, Times, Serif">Federal statutory tax rate</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">34.0</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">34.0</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">35.0</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">State tax rate, net of federal tax benefit</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.73</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.8</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.8</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Adjustment in valuation allowances</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(38.97</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(50.9)</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(32.4</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Permanent and other differences</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.24</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11.1</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8.4</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Provision (benefit) for income taxes</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#x2014;</font></td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#x2014;</font></td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#x2014;</font></td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred income tax asset as of December 31, 2015, 2014, and 2013 are as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2015</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2014</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2013</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Deferred Income Tax Assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 61%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Net operating losses</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">79,499,633</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">43,091,437</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">14,773,537</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;R&#38;D Credit</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">186,347</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">547,511</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Total deferred income tax asset</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">79,685,980</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">43,091,437</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">15,321,048</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Valuation allowance</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(79,685,980</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(43,091,437</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(15,321,048</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Deferred income tax assets, net</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We believe that it is more likely than not that we will not generate sufficient future taxable income to realize the tax benefits related to the deferred tax assets on our balance sheet and as such, a valuation allowance has been established against the deferred tax assets for the period ended December 31, 2015.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><i>Unrecognized Tax Benefits</i></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">As of the period ended December 31, 2015, we have no unrecognized tax benefits.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780254288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 12 &#150; RELATED PARTIES</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Agreements with Pernix Therapeutics, LLC</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On February 29, 2012, Cooper C. Collins, who
was then president and largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors.
From time to time, we have entered into agreements with Pernix in the normal course of business. All such agreements are reviewed
by independent directors of our company or a committee consisting of independent directors of our company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">During the years ended December 31, 2015, 2014
and 2013, we did not engage in any transactions with Pernix. As of December 31, 2014 and 2013, there were amounts due to Pernix
of approximately $46,000. Additionally, there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation
matter stemming from a license and supply agreement in the amounts of approximately $250,000 as of the years ended December 31,
2014 and 2013. During the year ended December 31, 2015, we entered into a settlement agreement with Pernix according to which Pernix
paid us $175,000 in cash, resulting in the elimination of the approximately $46,000 outstanding payable and $250,000 outstanding
receivable disclosed above and the recording of approximately $29,000 in settlement fees on the accompanying consolidated financial
statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph b<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6775019136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">BUSINESS CONCENTRATIONS</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><b><u>NOTE 13 - BUSINESS CONCENTRATIONS</u></b></p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We purchase our products from several suppliers with approximately 60%, 82% and 98% of our purchases supplied by one vendor for the years ended December 31, 2015, 2014 and 2013, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">We sell our prescription prenatal vitamin products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. During the year ended December 31, 2015, two customers each generated more than 10% of our total revenues and during the years ended December 31, 2014 and 2013, four customers each generated more than 10% of our total revenues. Revenue generated from two major customers combined accounted for approximately 67% of total revenue during the year ended December 31, 2015. Revenue generated from four major customers combined accounted for approximately 75% and 79% of our recognized revenue during the years ended December 31, 2014 and 2013, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Customers that generated more than 10% of our sales are designated as customers &#x201C;A&#x201D;, &#x201C;B&#x201D;, &#x201C;C&#x201D; and &#x201C;D&#x201D;. During the year ended December 31, 2015, customer A generated $8,848,243 in revenues and customer B generated approximately $4,843,463 in revenues. During the year ended December 31, 2014 customers A, B, C and D generated $1,609,950, $1,586,903, $1,804,018 and $4,053,838 in sales, respectively. During the year ended December 31, 2013, customers A, B, C and D generated $1,221,212, $1,711,417, $2,588,626 and $1,312,192 in sales, respectively.</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Prior to January 1, 2015, we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date, we could not reasonably estimate the amount of future returns. Revenue generated by major customers accounted for approximately 97% of deferred revenue for both periods ended December 31, 2014 and 2013. As of January 1, 2015, we started estimating returns based on historical return rates and recorded actual product returns against this reserve as received. As a result no deferred revenue was recorded for the year ended December 31, 2015.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6327-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780273312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 14 &#150; COMMITMENTS AND CONTINGENCIES</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Operating Lease</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We lease administrative office space in Boca
Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013. The lease expires on September
30, 2018 and we have an option to extend the lease term for a period of five years. On February 18, 2015, we entered into an agreement
with the same lessors to lease additional administrative office space in the same location, pursuant to an addendum to such lease.
This addendum was effective beginning April 1, 2015 and will expire with the original lease term on September 30, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The rental expense related to our current lease
during the years ended December 31, 2015 and 2014 was $446,099 and $361,793, respectively. The rental expense during the year ended
December 31, 2013 consisted of $180,894 expense related to our current lease and $60,168 expense related to our prior lease which
expired June 30, 2013. The rental expense during the years ended December 31, 2014 and 2013 was partially offset by the rent income
of $41,613 and $32,963, respectively. We did not sublet any space during the year ended December 31, 2015.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2015, future minimum rental
payments on non-cancelable operating leases are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Years Ending December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 35%; text-align: left; font: 10pt Times New Roman, Times, Serif">2016</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">493,790</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2017</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">507,087</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">388,976</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2019</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</font></td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,389,853</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Legal Proceedings</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">From time to time, we are involved in litigation
and proceedings in the ordinary course of business. We are not currently involved in any legal proceeding that we believe would
have a material effect on our consolidated financial condition, results of operations, or cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Off-Balance Sheet Arrangements</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2015, 2014 and 2013, we
had no off-balance sheet arrangements that have had or are reasonably likely to have current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that are material to investors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><u>Employment Agreements</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have entered into&#160;employment&#160;agreements&#160;with
certain of our executives that provide for compensation and certain other benefits. Under certain circumstances, including a change
in control, some of these agreements provide for severance or other payments, if those circumstances occur during the term of the
employment agreement.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6776579600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 15 &#150; SELECTED QUARTERLY FINANCIAL
DATA (UNAUDITED)</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Summarized quarterly financial data for fiscal years 2015 and 2014
is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 3%">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015 Quarters</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><i>(In thousands, except per share)</i></font></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">1<sup>st</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2<sup>nd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">3<sup>rd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">4<sup>th</sup></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 48%; font: 10pt Times New Roman, Times, Serif">Revenues</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif">4,475</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif">4,848</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif">5,190</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif">5,630</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,431</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,815</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,996</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,395</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(20,895</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(27,227</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(19,472</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(17,483</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Loss per common share, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.13</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.16</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.11</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.10</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 3%">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014 Quarters</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 48%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><i>(In thousands, except per share)</i></font></td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">1<sup>st</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2<sup>nd</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">3<sup>rd</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">4<sup>th</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Revenues</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,831</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,752</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,186</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,257</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,859</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,118</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,377</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(9,183</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(10,899</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(17,832</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(16,303</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Loss per common share, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.06</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.07</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.12</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.10</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the quarterly financial data in the annual financial statements.  The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e765-108305<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=51655806&amp;loc=d3e725-108305<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 6<br> -Section G<br> -Subsection 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 302<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780221824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><u>NOTE 16 &#150; SUBSEQUENT EVENTS</u></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">On January&#160;6, 2016, we entered into an underwriting agreement
with Goldman Sachs and Cowen and Company, LLC, as the representatives of the several underwriters, or the Underwriters, relating
to an underwritten public offering of 15,151,515 shares of our Common Stock at a public offering price of $8.25 per share. Under
the terms of the underwriting agreement, we granted the Underwriters a 30-day option to purchase up to an aggregate of 2,272,727
additional shares of Common Stock, which option was exercised in full. The net proceeds from the offering were approximately $134.9
million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by us. The offering
closed on January&#160;12, 2016.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2016, certain individuals exercised
stock options to purchase 281,657 shares of our Common Stock for approximately $758,000 in cash and warrants to purchase 500,000
shares of our Common Stock were exercised for approximately $1,285,000 in cash.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790254416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Principles of Consolidation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The accompanying consolidated financial statements
include the accounts of our company and our wholly owned subsidiaries, VitaMed, BocaGreen and VitaCare. All intercompany balances
and transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal"><u>Cash</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; letter-spacing: -0.15pt; text-align: justify"><font style="font-weight: normal">We
maintain cash at financial institutions that at times may exceed the Federal Deposit Insurance Corporation (the &#147;FDIC&#148;)
insured limits of $250,000 per bank. We have never experienced any losses related to these funds.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Trade Accounts Receivable and Allowance for Doubtful Accounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Trade Accounts Receivable and Allowance for
Doubtful Accounts</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trade accounts receivable are customer obligations
due under normal trade terms. We review accounts receivable for uncollectible accounts and credit card charge-backs and provide
an allowance for doubtful accounts, which is based upon a review of outstanding receivables, historical collection information,
and existing economic conditions. We consider trade accounts receivable past due for more than 90 days to be delinquent. We write
off delinquent receivables against our allowance for doubtful accounts based on individual credit evaluations, the results of collection
efforts, and specific circumstances of customers. We record recoveries of accounts previously written off when received as an increase
in the allowance for doubtful accounts. <font style="color: #252525">To the extent data we use to calculate these estimates does
not accurately reflect bad debts; adjustments to these reserves may be </font>required.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>Inventories</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="letter-spacing: -0.15pt">Inventories
represent packaged vitamins, nutritional products and supplements and raw materials, which are valued at the lower of cost or market
using the average-cost method. Any costs of manufacturing the prescription products associated with the deferred revenue (as discussed
in Revenue Recognition) prior to January 1 , 2015, were recorded as deferred costs and included in inventory, until such time as
the related deferred revenue was recognized. </font>We review our inventory for excess or obsolete inventory and write-down obsolete
or otherwise unmarketable inventory to its estimated net realizable value. Obsolescence may occur due to product expiring or product
improvements rendering previous versions obsolete.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i><u>Pre-Launch
Inventory</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><font style="letter-spacing: -0.15pt">Inventory
costs associated with product candidates that have not yet received regulatory approval are capitalized if we believe there is
probable future commercial use and future economic benefit. If the probability of future commercial use and future economic benefit
cannot be reasonably determined, then pre-launch inventory costs associated with such product candidates are expensed as research
and development expenses during the period the costs are incurred. We have not capitalized any pre-launch inventory to date.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Fixed Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We state fixed assets at cost, net of accumulated
depreciation. We charge maintenance costs, which do not significantly extend the useful lives of the respective assets, and repair
costs to operating expenses as incurred. <font style="letter-spacing: -0.15pt">We compute depreciation using the straight-line
method over the estimated useful lives of the related assets, which range from three to seven years.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We capitalize software and&#160;software&#160;development&#160;costs&#160;incurred
to create and acquire computer software for internal use, principally related to software coding and application development. We
begin to capitalize&#160;software development&#160;costs&#160;when both the preliminary project stage is completed and it is probable
that the software will be used as intended. Capitalized software costs include only external direct costs and services utilized
in developing or obtaining computer software. Capitalized software costs are amortized on a straight-line basis when placed into
service over the estimated useful life, generally five to seven years.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>Intangible
</u></font><u>Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="letter-spacing: -0.15pt"><i><u>Patents
and Trademarks</u></i></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><font style="letter-spacing: -0.15pt">We have adopted the provisions
of </font>Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, <font style="letter-spacing: -0.15pt">350,
<i>Intangibles - Goodwill and Other</i>,<i> </i>or </font>ASC 350<font style="letter-spacing: -0.15pt">. Capitalized patent costs,
net of accumulated amortization, include legal costs incurred for patent applications. </font>In accordance with ASC 350, <font style="letter-spacing: -0.15pt">once
a patent is granted, we amortize the capitalized patent costs over the remaining life of the patent using the straight-line method.
If the patent is not granted, we write-off any capitalized patent costs at that time. As of December 31, 2015, we had 14 issued
patents (See Note 7). We capitalize external costs, consisting primarily of legal costs, related to securing our trademarks. Trademarks
are perpetual and are not amortized. We review intangible assets for impairment annually or when events or circumstances indicate
that their carrying amount may not be recoverable.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Impairment of Long-Lived Assets</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We review the carrying values of fixed assets and
long-lived intangible assets to be held and used for impairment whenever events or changes in circumstances indicate that their
carrying values may not be recoverable. Such events or circumstances may include, among others, the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">significant declines in an asset&#146;s market price;</font></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">significant deterioration in an asset&#146;s physical condition;</font></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">significant changes in the nature or extent of an asset&#146;s use
or operation;</font></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">significant adverse changes in the business climate that could impact
an asset&#146;s value, including adverse actions or assessments by regulators; </font></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">accumulation of costs significantly in excess of original expectations
related to the acquisition or construction of an asset;</font></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">current-period operating or cash flow losses combined with a history
of such losses or a forecast that demonstrates continuing losses associated with an asset&#146;s use; and</font></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></p>

<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Symbol">&#183;</font></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif"><font style="font-size: 10pt">expectations that it is more likely than not that an asset will be
sold or otherwise disposed of significantly before the end of its previously estimated useful life.</font></td></tr></table>

<p style="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If impairment indicators are present, we determine
whether an impairment loss should be recognized by testing the applicable asset or asset group&#146;s carrying value for recoverability.
This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent
of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future
cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective
carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment
in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used.
In our assessments, we also consider changes in asset utilization, including, if applicable, the temporary idling of capacity and
the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then
we record a loss for the difference between the assets&#146; fair value and respective carrying values. We determine the fair
value of the assets using an &#147;income approach&#148; based upon a forecast of all the expected discounted future net cash flows
associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market
share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial
relationships, market conditions, and available external information about future trends. We believe our current assumptions and
estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates,
resulting in the need for an impairment charge in future periods. There was no impairment of long-lived assets to be held and used
during the years ended December 31, 2015, 2014 and 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We perform impairment tests for intangible&#160;assets&#160;with&#160;indefinite&#160;useful&#160;lives&#160;annually,
or more frequently if events occur or circumstances change that would more likely than not reduce the fair value of an intangible
asset below its carrying value. The impairment test for assets with indefinite lives consists of a comparison of the fair value
of the asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss
is recognized in an amount equal to that excess. There was no impairment of indefinite lived intangible assets during the years
ended December 31, 2015, 2014 and 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Fair Value of Financial Instruments</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our financial instruments consist primarily of
cash, accounts receivable, accounts payable and accrued expenses. The carrying amount of cash, accounts receivable, accounts payable
and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered
Level 1 assets under the fair value hierarchy.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We categorize our assets and liabilities that are
valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by ASC 820, <i>Fair Value Measurements.
</i> The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities
(Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet
at fair value are categorized based on a hierarchy of inputs, as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"><b>Level 1</b></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">unadjusted quoted prices in active markets
for identical assets or liabilities;</td>
</tr></table>



<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"><b>Level 2</b></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">quoted prices for similar assets or liabilities
in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration,
for substantially the full term of the financial instrument; and</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: justify; text-indent: 0in"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify; font: 10pt Times New Roman, Times, Serif">
<td style="width: 0.5in; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 0.75in; text-align: left; font: 10pt Times New Roman, Times, Serif"><b>Level 3</b></td><td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">unobservable inputs for the asset or liability.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">At December 31, 2015 and 2014, we had no assets
or liabilities that were valued at fair value on a recurring basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fair value of indefinite-lived assets is measured
on a non-recurring basis using significant unobservable inputs (Level 3) in connection with any required impairment test. There
was no impairment of intangible assets during the years ended December 31, 2015, 2014 and 2013.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Income Taxes</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We account for income taxes under the asset and
liability method. We recognize deferred tax assets and liabilities for the estimated future tax consequences attributable to differences
between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. We measure
deferred tax assets and liabilities using enacted tax rates expected to apply to taxable income in the years in which the related
temporary differences are expected to be recovered or settled. We recognize the effect on deferred tax assets and liabilities of
a change in tax rates when the rate change is enacted. Valuation allowances are recorded to reduce deferred tax assets to the amount
that will more likely than not be realized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In accordance with ASC 740, <i>Income Taxes</i>,
we recognize the effect of uncertain income tax positions only if the positions are more likely than not of being sustained in
an audit, based on the technical merits of the position. We measure recognized uncertain income tax positions using the largest
amount that has a likelihood of being realized that is greater than 50%. Changes in recognition or measurement are reflected in
the period in which those changes in judgment occur.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize both interest and penalties related
to uncertain tax positions as part of the income tax provision. At December 31, 2015 and 2014, we had no tax positions relating
to open tax returns that were considered to be uncertain.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our tax returns are subject to review by the Internal
Revenue Service three years after they are filed. Currently, years filed after 2012 are subject to review.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Share-Based Compensation</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">We measure the compensation
costs of share-based compensation arrangements based on the grant-date fair value and recognize the costs in the financial statements
over the period during which employees are required to provide services. Share-based compensation arrangements include options,
restricted stock, restricted stock units, performance-based awards, share appreciation rights, and employee share purchase plans.
As such, compensation cost is measured on the date of grant at fair value. We amortize such compensation amounts, if any, over
the respective service periods of the award. We use the Black-Scholes-Merton option pricing model, or the Black-Scholes Model,
an acceptable model in accordance with ASC 718 to value options. Calculating share-based compensation expense requires the input
of highly subjective judgment and assumptions, including forfeiture rates, estimates of expected life of the share-based award,
stock price volatility and risk-free interest rates. The assumptions used in calculating the fair value of share-based awards represent
our best estimates, but these estimates involve inherent uncertainties and the application of management judgment. As a result,
if factors change and we use different assumptions, our share-based compensation expense could be materially different in the future.</font><font style="font-size: 10pt">
</font><font style="font-size: 10pt"> </font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Equity instruments (&#147;instruments&#148;)
issued to non-employees are recorded on the basis of the fair value of the instruments, as required by ASC 505, <i>Equity - Based
Payments to Non-Employees</i>,<i> </i>or ASC 505<i>. </i>ASC 505<i> </i>defines the measurement date and recognition period for
such instruments. In general, the measurement date is when either (a) a performance commitment, as defined, is reached or (b) the
earlier of (i) the non-employee performance is complete or (ii) the instruments are vested. The estimated expense is recognized
each period based on the current fair value of the award. As a result, the amount of expense related to awards to non-employees
can fluctuate significantly during the period from the date of the grant through the final measurement date. The measured value
related to the instruments is recognized over a period based on the facts and circumstances of each particular grant as defined
in ASC 505.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize the compensation expense for all share-based
compensation granted, net of estimated forfeitures, based on the grant date fair value estimated in accordance with ASC 718. We
generally recognize the compensation expense on a straight-line basis over the employee&#146;s requisite service period. We estimate
the forfeiture rate based on our historical experience of forfeitures. If our actual forfeiture rate is materially different from
our estimate, share-based compensation expense could be significantly different from what we have recorded in the current period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Discounts</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Debt Discounts</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Costs incurred from parties that are providing
long-term financing, which include warrants issued in connection with the underlying debt, are reflected as a debt discount based
on the relative fair value of the debt and warrants to the total proceeds. We amortize discounts over the life of the related debt
using the effective interest rate method.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Revenue Recognition</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We recognize revenue on arrangements in accordance
with ASC 605, Revenue Recognition. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an
arrangement exists, the service is performed, and collectability is reasonably assured.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our over-the-counter (OTC) and prescription prenatal
vitamin products are generally variations of the same product with slight modifications in formulation and marketing. The primary
difference between our OTC and prescription prenatal vitamin products is the source of payment. Purchasers of our OTC prenatal
vitamin products pay for the product directly while purchasers of our prescription prenatal vitamin products pay for the product
primarily via third-party payers. Both OTC and prescription prenatal vitamin products share the same marketing support team utilizing
similar marketing techniques. The revenue that is generated by us from major external customers is all generated from sales of
our prescription prenatal vitamin products which is disclosed in Note 13. There are no major external customers for our OTC prenatal
vitamin or other products.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>OTC Products</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We generate OTC revenue from product sales primarily
to retail consumers. We recognize revenue from product sales upon shipment, when the rights of ownership and risk of loss have
passed to the consumer. We include outbound shipping and handling fees in revenues, net, and bill them upon shipment. We include
shipping expenses in cost of goods sold. A majority of our OTC customers pay for our products with credit cards, and we usually
receive the cash settlement in two to three banking days. Credit card sales minimize accounts receivable balances relative to OTC
sales. We provide an unconditional 30-day money-back return policy under which we accept product returns from our retail and eCommerce
OTC customers. We recognize revenue from OTC sales, net of estimated returns, sales discounts, and eCommerce fees.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i><u>Prescription Products</u></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We sell our name brand and generic prescription
products primarily through drug wholesalers and retail pharmacies. We recognize revenue from prescription product sales, net of
sales discounts, chargebacks, and customer rebates.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We accept returns of unsalable prescription products
from customers within a return period of six months prior to and up to 12 months following product expiration. Our prescription
products currently have a shelf life of 24 months from the date of manufacture. As of January 1, 2015, we started estimating returns
based on historical return rates and recorded actual product returns against this reserve as received. Prior to January 1, 2015,
we deferred the recognition of revenue on prescription products until the right of return no longer existed as prior to that date,
we could not reasonably estimate the amount of future returns.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We offer various rebate programs in an effort to
maintain a competitive position in the marketplace and to promote sales and customer loyalty. The consumer rebate program is designed
to enable the end user to submit a coupon to us. If the coupon qualifies, we send a rebate check to the end user. We estimate the
allowance for consumer rebates that we have offered based on our experience and industry averages, which is reviewed, and adjusted
if necessary, on a quarterly basis.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Segment Reporting</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are managed and operated as one business, which
is focused on creating and commercializing products targeted exclusively for women. Our business operations are managed by a single
management team that reports to the President of our Company. We do not operate separate lines of business with respect to any
of our products and we do not prepare discrete financial information with respect to separate products. All product sales are derived
from sales in the United States. Accordingly, we view our business as one reportable operating segment.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Shipping and Handling Costs</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense all shipping and handling costs as incurred.
We include these costs in cost of goods sold on the accompanying consolidated financial statements.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="letter-spacing: -0.15pt"><u>Advertising
Costs</u></font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We expense advertising costs when incurred. Advertising
costs were $792,574, $698,871 and $11,739 during the years ended December 31, 2015, 2014 and 2013, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Research and Development Expenses</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Research and development,
or R&#38;D, expenses include internal R&#38;D activities, services of external contract research organizations, or CROs, costs
of their clinical research sites, manufacturing, scale-up and validation costs, and other activities. Internal R&#38;D activity
expenses include laboratory supplies, salaries, benefits, and non-cash share-based compensation expenses. Advance payments to be
expensed in future research and development activities are capitalized, and were $1,138,073 at December 31, 2015, of which $1,009,175
was included in other current assets and $128,898 was included in long term prepaid expense on the accompanying consolidated balance
sheets. Advance payments to be expensed in future R&#38;D activities were $1,175,082 at December 31, 2014, of which $711,362 was
included in other current assets and $463,720 was included in long term prepaid expense on the accompanying consolidated balance
sheets. CRO activity expenses include preclinical laboratory experiments and clinical trial studies. Other activity expenses include
regulatory consulting and legal fees and costs. The activities undertaken by our regulatory consultants that were classified as
R&#38;D expenses include assisting, consulting with, and advising our in-house staff with respect to various FDA submission processes,
clinical trial processes, and scientific writing matters, including preparing protocols and FDA submissions. Legal activities that
were classified as R&#38;D expenses related to designing experiments to generate data for patents and to further the formulation
development process for our pipeline technologies. Outside legal counsel also provided professional research and advice regarding
R&#38;D, patents and regulatory matters. These consulting and legal expenses were direct costs associated with preparing, reviewing,
and undertaking work for our clinical trials and investigative drugs. We charge internal R&#38;D activities and other activity
expenses to operations as incurred. We make payments to CROs based on agreed-upon terms, which may include payments in advance
of a study starting date. We expense nonrefundable advance payments for goods and services that will be used in future R&#38;D
activities when the activity has been performed or when the goods have been received rather than when the payment is made. We review
and accrue CRO expenses and clinical trial study expenses based on services performed and rely on estimates of those costs applicable
to the completion stage of a study as provided by CROs. Estimated accrued CRO costs are subject to revisions as such studies progress
to completion. We charge revisions expense in the period in which the facts that give rise to the revision become known.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Earnings Per Share</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We calculate earnings per share, or EPS, in accordance
with ASC 260, <i>Earnings Per Share</i>, which requires the computation and disclosure of two EPS amounts: basic and diluted. We
compute basic EPS based on the weighted-average number of shares of common stock, par value $0.001 per share, or Common Stock,
outstanding during the period. We compute diluted EPS based on the weighted-average number of shares of our Common Stock outstanding
plus all potentially dilutive shares of our Common Stock outstanding during the period. Such potentially dilutive shares of our
Common Stock consist of options and warrants and were excluded from the calculation of diluted earnings per share because their
effect would have been anti-dilutive due to the net loss reported by us.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below presents the potentially dilutive
securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they
were not antidilutive for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">As of December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 35%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Stock options</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">20,725,325</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">16,792,443</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">15,632,742</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,722,431</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,927,916</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,293,499</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,447,756</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,720,359</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">29,926,241</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Subsequent to December 31, 2015, we issued 17,424,242
shares of our Common Stock at a public offering price of $8.25 per share. In January 2016, certain individuals exercised stock
options to purchase 281,657 shares of our Common Stock for approximately $758,000 in cash. In addition, warrants to purchase 500,000
shares of our Common Stock were exercised for $1,285,000 in cash. See Note 16 - Subsequent Events for more details.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and other Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><u>Concentration of Credit Risk and other Risks and Uncertainties </u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially expose us
to concentrations of credit risk consist primarily of cash and trade accounts receivable. Cash is on deposit with financial institutions
in the United States and these deposits generally exceed the amount of insurance provided by the FDIC. The Company has not experienced
any historical losses on its deposits of cash.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Concentration of credit risk with respect to our
trade accounts receivable from our customers is primarily limited to drug wholesalers and retail pharmacies. Credit is extended
to our customers based on an evaluation of a customer&#146;s financial condition, and collateral is not required.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Use of Estimates</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our consolidated financial statements have been
prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The preparation
of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates, including
those related to contingencies, on an ongoing basis. We base our estimates on historical experience and on various other assumptions
that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying
values of assets and liabilities that are not readily apparent from other sources. Actual results may differ, at times in material
amounts, from these estimates under different assumptions or conditions.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u>Reclassifications</u></p>

<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif"><u></u></p>
<p style="margin: 0pt 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Certain 2014 and 2013 amounts have been reclassified to conform to current year presentation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><u>Recently Issued Accounting Pronouncements</u></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><font style="font-size: 10pt">In November 2015,
the FASB issued Accounting Standards Update, or ASU, No. 2015-17, Income Taxes (Topic 740), Balance Sheet Classification of Deferred
Taxes. This guidance requires companies to classify all deferred tax assets and liabilities as noncurrent on the balance sheet
instead of separating deferred taxes into current and noncurrent amounts. Also, companies will no longer allocate valuation allowances
between current and noncurrent deferred tax assets because those allowances also will be classified as noncurrent. For public business
entities, the guidance is effective for financial statements issued for annual periods beginning December 15, 2016, and interim
periods within those annual periods. Companies can adopt the guidance either prospectively or retrospectively. We adopted</font>&#160;<font style="font-size: 10pt">this
guidance in the fourth quarter of 2015. The adoption of this guidance did not have a material impact on our consolidated financial
statements or disclosures.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In July 2015, the FASB issued ASU 2015-11, Inventory
(Topic 330), simplifying the Measurement of Inventory. This guidance requires entities to measure inventory at the lower of cost
or net realizable value rather than at the lower of cost or market (LOCOM). The guidance applies only to inventories for which
cost is determined by methods other than last-in first-out (LIFO) or the retail inventory method (RIM). Entities that use LIFO
or RIM will continue to use existing impairment models. The new guidance does not change the calculation of net realizable value
that entities are required to calculate when applying existing LOCOM guidance. Net realizable value is the estimated selling price
in the ordinary course of business, less reasonably predictable costs of completion, disposal and transportation. Under the new
guidance, however, entities will no longer need to calculate other measures of &#147;market.&#148; The guidance is effective
for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years.
Early adoption is permitted. We are currently evaluating the impact of this guidance, if any, on our consolidated financial statements
and disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2015, the FASB issued ASU No. 2015-10,
Technical Corrections and Improvements, to correct differences between original guidance and the ASC clarify the guidance, correct
references and make minor improvements affecting a variety of topics. Amendments that the FASB deemed more substantive are effective
for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. The adoption of ASU 2015-10
did not have a material effect on our consolidated financial statements and disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In August 2014, the FASB issued ASU No. 2014-15,
Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity&#146;s Ability
to Continue as a Going Concern. ASU 2014-15 requires management to evaluate whether there are conditions and events that raise
substantial doubt about the entity&#146;s ability to continue as a going concern within one year after the financial statements
are issued (or available to be issued when applicable) and, if so, disclose that fact. ASU 2014-15 is effective for annual periods
ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted
for annual or interim reporting periods for which the financial statements have not previously been issued. We do not expect the
adoption of ASU 2014-15 to have a material effect on our consolidated financial statements and disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2014, the FASB and the International Accounting
Standards Board (IASB) issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The standard&#146;s core principle
is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the
consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will
need to use more judgment and make more estimates than under previous guidance. These may include identifying performance obligations
in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction
price to each separate performance obligations. In July 2015, the FASB approved the proposal to defer the effective date of ASU
2014-09 standard by one year. Early adoption is permitted after December 15, 2016, and the standard is effective for public entities
for annual reporting periods beginning after December 15, 2017 and interim periods therein. We are currently evaluating the impact
of ASU 2014-09 on our consolidated financial statements and disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We do not believe there would have been a material
effect on the accompanying consolidated financial statements had any other recently issued, but not yet effective, accounting standards
been adopted in the current period.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising costs. For those costs that cannot be capitalized, discloses whether such costs are expensed as incurred or the first period in which the advertising takes place. For direct response advertising costs that are capitalized, describes those assets and the accounting policy used, including a description of the qualifying activity, the types of costs capitalized and the related amortization period. An entity also may disclose its accounting policy for cooperative advertising arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51677389&amp;loc=d3e8384-108330<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51662920&amp;loc=d3e8275-108329<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash<br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Cash Equivalents<br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 203<br> -Paragraph 02-03<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 1<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6875567&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28088331&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51676700&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph k<br> -Article 1<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02, 03<br> -Article 3A<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs incurred to obtain or issue debt, the effects of refinancings, method of amortizing deferred financing costs and original issue discount, and classifications of debt on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51717228&amp;loc=d3e202-110218<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 5<br> -Section CC<br> -Subsection 3<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Financial Reporting Release (FRR)<br> -Number 206<br> -Paragraph b<br> -Subparagraph i, ii<br> -Chapter 2<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 6<br> -Subparagraph a<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassifications that affects the comparability of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5144-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 4<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Research and Development<br> -URI http://asc.fasb.org/extlink&amp;oid=6523717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 13<br> -Section B<br> -Paragraph Question 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Shipping Costs<br> -URI http://asc.fasb.org/extlink&amp;oid=51575562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6408413&amp;loc=d3e221937-122793<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51671805&amp;loc=d3e60635-111653<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51667946&amp;loc=d3e61069-111654<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Handling Costs<br> -URI http://asc.fasb.org/extlink&amp;oid=51575068<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6773983312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of potentially dilutive securities in our calculation of diluted net loss per share allocable to common stockholders</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below presents the potentially
dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders
if they were not antidilutive for the periods presented.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="10" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">As of December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2013</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 35%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Stock options</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">20,725,325</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">16,792,443</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">15,632,742</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Warrants</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">12,722,431</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">13,927,916</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">14,293,499</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">33,447,756</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">30,720,359</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">29,926,241</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774489408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Inventory consists of the following:</p>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="6" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31,</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2015</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2014</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 70%; text-align: justify; font: 10pt Times New Roman, Times, Serif">Finished product</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">661,167</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">874,294</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif">Raw material</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">28,986</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">155,341</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: justify; font: 10pt Times New Roman, Times, Serif">Deferred costs</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">152,478</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 0.25in; text-align: left; font: 10pt Times New Roman, Times, Serif">TOTAL INVENTORY</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">690,153</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,182,113</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 2<br> -Paragraph 6<br> -Subparagraph a,b,c<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780340928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of other current assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other current assets consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 70%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid insurance</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">695,421</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">394,878</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">674,353</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">299,498</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other prepaid costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">369,812</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">181,186</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid consulting</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">334,822</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">411,864</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid vendor deposits</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">159,489</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#151;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other receivables-related party (Note 12)</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">249,981</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT ASSETS</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,233,897</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,537,407</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774351408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of fixed assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fixed assets, net consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 90%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 70%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Equipment</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">132,150</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 12%; text-align: right; font: 10pt Times New Roman, Times, Serif">132,150</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accounting system in process</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">149,699</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Furniture and fixtures</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">69,454</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">53,895</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-left: 5.4pt">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">351,303</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">186,045</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accumulated depreciation</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(152,711</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(122,752</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">TOTAL FIXED ASSETS, NET</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">198,592</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">63,293</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph b<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774919744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of prepaid expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Prepaid expense (long-term) consists of the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 95%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 74%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid manufacturing costs</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">980,985</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">963,543</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Prepaid research and development&#160;&#160;costs</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">128,898</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">463,720</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;&#160;&#160;&#160;&#160;&#160;&#160;TOTAL PREPAID EXPENSE</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,109,883</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,427,263</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><b>&#160;&#160;</b></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777918560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of intangible assets</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">The following table sets forth the gross carrying amount, accumulated amortization and net carrying amount of our intangible assets as of December 31, 2015 and 2014:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2015</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Gross <br /> Carrying <br /> Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Accumulated Amortization</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net <br />Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- <br /> Average Remaining Amortization <br /> Period (yrs.)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizable intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; width: 48%; text-align: left; font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#xAE;</sup> software patent</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(4,493</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">27,458</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">13.75</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">705,752</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(49,845</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">655,907</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">17</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents (in process)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">774,165</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">774,165</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">Non-amortizable intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; font: 10pt Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">157,721</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">157,721</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Total</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,761,332</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(146,081</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,615,251</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif"></p>

<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="14" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">December 31, 2014</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Gross <br /> Carrying <br /> Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Accumulated Amortization</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Net <br />Amount</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted- <br /> Average Remaining Amortization <br /> Period (yrs.)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Amortizable intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; width: 48%; text-align: left; font: 10pt Times New Roman, Times, Serif">OPERA<sup>&#xAE;</sup> software patent</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">31,951</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">(2,496</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">29,455</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">14.75</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Development costs of corporate website</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(91,743</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Approved hormone therapy drug candidate patents</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">439,184</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(19,401</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">419,783</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">18</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Hormone therapy drug candidate patents (in process)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">675,982</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">675,982</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Non-amortizable intangible assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.125in; text-align: left; font: 10pt Times New Roman, Times, Serif">Multiple trademarks for vitamins/supplements</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103,368</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">103,368</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">indefinite</font></td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">Total</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,342,228</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(113,640</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,228,588</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of estimated amortization expense</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><font style="background-color: white">Estimated amortization
expense for the next five years is as follows:</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 30%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Year Ending <br />
December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Estimated <br />
Amortization</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 15%; text-align: right; font: 10pt Times New Roman, Times, Serif">2016</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">40,580</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2017</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">40,580</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2018</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">40,580</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2019</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">40,580</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2020</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">40,580</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780334016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Schedule of other current liabilities</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Other current liabilities consist of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="6" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 74%; text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued clinical trial costs</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">3,725,377</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1,706,542</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued payroll, bonuses and commission costs</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,108,143</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">814,205</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued compensated absences</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">562,096</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">442,430</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Other accrued expenses</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">546,264</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">185,965</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Allowance for coupons and returns</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">224,300</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">90,446</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued legal and accounting expense</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">210,309</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">276,470</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued rent</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">83,527</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">91,368</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Accrued royalties</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">46,851</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">72,710</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Allowance for wholesale distributor fees</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">32,659</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">160,503</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; padding-bottom: 2pt; padding-left: 0.25in; font: 10pt Times New Roman, Times, Serif">TOTAL OTHER CURRENT LIABILITIES</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">7,539,526</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">3,840,639</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777809856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfWarrantRollForwardTableTextBlock', window );">Schedule of warrant activity</a></td>
<td class="text"><p style="margin: 0; font: 10pt Times New Roman, Times, Serif"><i>Summary of our Warrant activity during the year ended December 31, 2015:</i></p>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of <br /> Shares <br /> Under <br /> Warrants</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted <br />Average <br />Remaining <br />Contractual <br />Life in Years</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate <br />Intrinsic <br /> Value</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 48%; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2014</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">13,927,916</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.82</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">3.0</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">36,623,875</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Granted</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">50,000</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.35</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Exercised</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(1,255,485</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">0.79</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">7,282,404</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Expired</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#x2014;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Cancelled/Forfeited</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2015</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">12,722,431</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.93</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.7</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">107,344,752</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at December 31, 2015</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif">12,422,432</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.92</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.6</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">104,909,091</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes Model of warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The weighted average fair value per share of
warrants issued and the assumptions used in the Black-Scholes Model during the years ended December 31, 2015, 2014 and 2013 are
set forth in the table below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 39%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></td>
    <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2013</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Weighted average fair value</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$6.35</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">$2.83</font></td></tr>
<tr style="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1.02%</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.88-1.12%</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Volatility</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">60.59%</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">44.29-45.89%</font></td></tr>
<tr style="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Term (in years)</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">n/a </font></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of assumptions used in the Black-Scholes Model of stock options</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The ranges of
assumptions used in the Black-Scholes Model during the years ended December 31, 2015, 2014 and 2013 are set forth in the table
below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" align="center" style="font: 10pt Times New Roman, Times, Serif; width: 90%; border-collapse: collapse">
<tr style="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 39%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2015</font></td>
    <td style="width: 2%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2014</font></td>
    <td style="width: 3%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 14%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><font style="font: 10pt Times New Roman, Times, Serif">2013</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Risk-free interest rate</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">1.47-1.67%</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.07-1.77%</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.65-1.71%</font></td></tr>
<tr style="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Volatility</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">58.78-62.94%</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">68.05-82.29%</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">33.35-45.76%</font></td></tr>
<tr style="vertical-align: top; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Term (in years)</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5.27-6.25</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">5-6.25</font></td></tr>
<tr style="vertical-align: top; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Dividend yield</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: right; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">0.00%</font></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of plan activity</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">A summary of activity under the 2009 and 2012 Plans and related information during the year ended December 31, 2015 is as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Number of <br /> Shares <br /> Under <br /> Options</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted <br /> Average <br /> Exercise <br /> Price</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Weighted <br />Average <br />Remaining <br />Contractual <br />Life in Years</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Aggregate <br />Intrinsic <br /> Value</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 48%; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2014</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">16,792,443</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">1.88</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">6.9</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">43,996,311</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Granted</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,685,000</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">8.14</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Exercised</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(613,284</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.01</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Expired</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(102,500</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2.68</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;Cancelled/Forfeited</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(36,334</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.02</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Balance at December 31, 2015</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">20,725,325</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3.28</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">6.5</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">146,864,184</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Vested and Exercisable at December 31, 2015</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">15,461,986</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">1.86</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.5</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">131,523,505</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">Unvested at December 31, 2015</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">5,263,339</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">7.46</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">9.4</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">15,340,679</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of warrants, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfShareBasedPaymentAwardWarrantsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ScheduleOfWarrantRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for warrants that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of warrants that were granted, exercised, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ScheduleOfWarrantRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777921328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of tax rate reconciliation</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">A reconciliation between taxes computed at the federal statutory rate and the consolidated effective tax rate is as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2015</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2014</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2013</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 58%; text-align: left; font: 10pt Times New Roman, Times, Serif">Federal statutory tax rate</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">34.0</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">34.0</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="width: 2%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">35.0</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">State tax rate, net of federal tax benefit</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4.73</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.8</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">5.8</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Adjustment in valuation allowances</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(38.97</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(50.9)</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(32.4</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Permanent and other differences</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">0.24</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">11.1</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(8.4</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)%</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Provision (benefit) for income taxes</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#x2014;</font></td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#x2014;</font></td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><font style="font: 10pt Times New Roman, Times, Serif">&#x2014;</font></td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">%</td>
</tr>
</table>
<p style="margin: 0; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">Deferred income taxes result from temporary differences between the amount of assets and liabilities recognized for financial reporting and tax purposes. The components of the net deferred income tax asset as of December 31, 2015, 2014, and 2013 are as follows:</p>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p>
<table align="center" cellpadding="0" cellspacing="0" style="width: 90%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2015</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2014</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td colspan="2" style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2013</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Deferred Income Tax Assets:</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; width: 61%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Net operating losses</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">79,499,633</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">43,091,437</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td>
<td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">14,773,537</td>
<td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;R&#38;D Credit</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">186,347</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">547,511</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Total deferred income tax asset</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">79,685,980</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">43,091,437</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="text-align: right; font: 10pt Times New Roman, Times, Serif">15,321,048</td>
<td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
<tr style="background-color: white; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 1pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;&#xA0;&#xA0;&#xA0;&#xA0;Valuation allowance</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(79,685,980</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(43,091,437</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
<td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#xA0;</td>
<td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(15,321,048</td>
<td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">)</td>
</tr>
<tr style="background-color: #cceeff; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
<td style="padding-bottom: 2pt; padding-left: 5.4pt; text-align: left; font: 10pt Times New Roman, Times, Serif">Deferred income tax assets, net</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td>
<td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#x2014;</td>
<td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#xA0;</td>
</tr>
</table>
<p style="margin: 0; text-align: justify; font: 10pt Times New Roman, Times, Serif">&#xA0;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6622741872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CommitmentsAndContingenciesTablesAbstract', window );"><strong>Commitments And Contingencies Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum rental payments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">As of December 31, 2015, future minimum rental
payments on non-cancelable operating leases are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellpadding="0" cellspacing="0" align="center" style="border-collapse: collapse; width: 50%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td colspan="2" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Years Ending December 31,</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 35%; text-align: left; font: 10pt Times New Roman, Times, Serif">2016</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="width: 10%; text-align: right; font: 10pt Times New Roman, Times, Serif">493,790</td><td style="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2017</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">507,087</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2018</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">388,976</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">2019</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#151;</td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</font></td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 2pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</td><td style="border-bottom: Black 2pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,389,853</td><td style="padding-bottom: 2pt; text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CommitmentsAndContingenciesTablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CommitmentsAndContingenciesTablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780335536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Schedule of quarterly unaudited summary information</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">Summarized quarterly financial data for fiscal years 2015 and 2014
is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 3%">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2015 Quarters</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><i>(In thousands, except per share)</i></font></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">1<sup>st</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2<sup>nd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">3<sup>rd</sup></td><td style="padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">4<sup>th</sup></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="width: 48%; font: 10pt Times New Roman, Times, Serif">Revenues</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif">4,475</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif">4,848</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif">5,190</td><td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="width: 1%; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; width: 1%; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; width: 10%; font: 10pt Times New Roman, Times, Serif">5,630</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,431</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,815</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,996</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,395</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(20,895</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(27,227</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(19,472</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(17,483</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Loss per common share, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.13</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.16</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.11</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.10</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 3%">
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td colspan="14" style="text-align: center; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">2014 Quarters</td><td style="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <td style="width: 48%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"><font style="font: 10pt Times New Roman, Times, Serif"><i>(In thousands, except per share)</i></font></td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">1<sup>st</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">2<sup>nd</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">3<sup>rd</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td><td style="width: 1%; padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="width: 10%; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">4<sup>th</sup></td><td style="width: 1%; padding-bottom: 1pt; text-align: left; font: 10pt Times New Roman, Times, Serif"></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">Revenues</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,831</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,752</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,186</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">4,257</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Gross profit</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,000</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">2,859</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,118</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">3,377</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Net loss</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(9,183</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(10,899</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(17,832</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(16,303</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
<tr style="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">&#160;</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">Loss per common share, basic and diluted</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.06</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.07</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.12</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td><td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="text-align: left; font: 10pt Times New Roman, Times, Serif">$</td><td style="text-align: right; font: 10pt Times New Roman, Times, Serif">(0.10</td><td style="text-align: left; font: 10pt Times New Roman, Times, Serif">)</td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=51825399&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777426432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 12, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 17, 2016 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 792,574<span></span>
</td>
<td class="nump">$ 698,871<span></span>
</td>
<td class="nump">$ 11,739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal insurance limits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShelfLifeOfPrescriptionProducts', window );">Shelf life of prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Related to Research and Development Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Advance payments - total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,138,073<span></span>
</td>
<td class="nump">1,175,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Advance payments - other assets current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,009,175<span></span>
</td>
<td class="nump">711,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Advance payments - long term prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,898<span></span>
</td>
<td class="nump">$ 463,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event- Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost, shares | shares</a></td>
<td class="nump">15,151,515<span></span>
</td>
<td class="nump">17,424,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts', window );">Return period of unsalable prescription products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ReturnPeriodOfUnsalablePrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the company accepts returns of unsalable prescription products from customers following product expiration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ReturnPeriodOfUnsalablePrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShelfLifeOfPrescriptionProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period shelf life of prescription products from date of manufacture.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShelfLifeOfPrescriptionProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774015712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">33,447,756<span></span>
</td>
<td class="nump">30,720,359<span></span>
</td>
<td class="nump">29,926,241<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">12,722,431<span></span>
</td>
<td class="nump">13,927,916<span></span>
</td>
<td class="nump">14,293,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares excluded from earnings per share calculation</a></td>
<td class="nump">20,725,325<span></span>
</td>
<td class="nump">16,792,443<span></span>
</td>
<td class="nump">15,632,742<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Antidilution<br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Diluted Earnings Per Share<br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Contingent Stock Agreement<br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777704816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished product</a></td>
<td class="nump">$ 661,167<span></span>
</td>
<td class="nump">$ 874,294<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw material</a></td>
<td class="nump">28,986<span></span>
</td>
<td class="nump">155,341<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCurrent', window );">Deferred costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,478<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">TOTAL INVENTORY</a></td>
<td class="nump">$ 690,153<span></span>
</td>
<td class="nump">$ 1,182,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of deferred costs capitalized at the end of the reporting period that are expected to be charged against earnings within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6778092304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_OtherCurrentAssetsAbstract', window );"><strong>Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 695,421<span></span>
</td>
<td class="nump">$ 394,878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent', window );">Prepaid research and development costs</a></td>
<td class="nump">674,353<span></span>
</td>
<td class="nump">299,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid costs</a></td>
<td class="nump">369,812<span></span>
</td>
<td class="nump">181,186<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidConsultingCurrent', window );">Prepaid consulting</a></td>
<td class="nump">334,822<span></span>
</td>
<td class="nump">411,864<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidVendorDeposits', window );">Prepaid vendor deposits</a></td>
<td class="nump">159,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedPartiesCurrent', window );">Other receivables-related party (Note 12)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,981<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">TOTAL OTHER CURRENT ASSETS</a></td>
<td class="nump">$ 2,233,897<span></span>
</td>
<td class="nump">$ 1,537,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_OtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_OtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidConsultingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of consulting contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidConsultingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidVendorDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents as a prepaid vendor deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidVendorDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 08<br> -Paragraph k<br> -Subparagraph 2<br> -Article 4<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 8<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5865-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=51662447&amp;loc=d3e5879-108316<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Assets<br> -URI http://asc.fasb.org/extlink&amp;oid=6509628<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777912928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation Expense</a></td>
<td class="nump">$ 29,959<span></span>
</td>
<td class="nump">$ 28,987<span></span>
</td>
<td class="nump">$ 47,883<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6776755184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FIXED ASSETS, NET (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 351,303<span></span>
</td>
<td class="nump">$ 186,045<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(152,711)<span></span>
</td>
<td class="num">(122,752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">TOTAL FIXED ASSETS</a></td>
<td class="nump">198,592<span></span>
</td>
<td class="nump">63,293<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">132,150<span></span>
</td>
<td class="nump">132,150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Accounting System in Process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">149,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets, gross</a></td>
<td class="nump">$ 69,454<span></span>
</td>
<td class="nump">$ 53,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 13<br> -Subparagraph a<br> -Article 5<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 8<br> -Article 7<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6622305120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PREPAID EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract', window );"><strong>Prepaid Expense and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidManufacturingCostsNoncurrent', window );">Prepaid manufacturing costs</a></td>
<td class="nump">$ 980,985<span></span>
</td>
<td class="nump">$ 963,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_PrepaidResearchDevelopmentCostsNoncurrent', window );">Prepaid research and development costs</a></td>
<td class="nump">128,898<span></span>
</td>
<td class="nump">463,720<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">TOTAL PREPAID EXPENSE</a></td>
<td class="nump">$ 1,109,883<span></span>
</td>
<td class="nump">$ 1,427,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidManufacturingCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of manufacturing contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; such periods expire within one year or the normal operating cycle, if longer. Noncurrent portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidManufacturingCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_PrepaidResearchDevelopmentCostsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of unamortized costs of research and development contracts, which will be charged against earnings ratably over the period in which contractually agreed upon services will be provided; non-current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_PrepaidResearchDevelopmentCostsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6789972016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 32,441<span></span>
</td>
<td class="nump">$ 23,480<span></span>
</td>
<td class="nump">$ 10,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">OPERA software patent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member', window );">Utility Patent Progesterone and Estradiol Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Utility Patent TX-004HR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfIssuedPatents', window );">Number of issued patents</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfIssuedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issued patents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfIssuedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777515744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details ) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (146,081)<span></span>
</td>
<td class="num">$ (113,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">1,761,332<span></span>
</td>
<td class="nump">1,342,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net Amount</a></td>
<td class="nump">1,615,251<span></span>
</td>
<td class="nump">1,228,588<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember', window );">Hormone therapy drug candidate patents - In Process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">774,165<span></span>
</td>
<td class="nump">675,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
<td class="nump">774,165<span></span>
</td>
<td class="nump">675,982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember', window );">Multiple trademarks for vitamins/supplements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Indefinite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Gross Carrying Amount</a></td>
<td class="nump">157,721<span></span>
</td>
<td class="nump">103,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet', window );">Net Amount</a></td>
<td class="nump">157,721<span></span>
</td>
<td class="nump">103,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">OPERA software patent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">31,951<span></span>
</td>
<td class="nump">31,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,994)<span></span>
</td>
<td class="num">(2,496)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 27,957<span></span>
</td>
<td class="nump">$ 29,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining amortization period</a></td>
<td class="text">13 years 9 months<span></span>
</td>
<td class="text">14 years 9 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember', window );">Development costs for corporate website [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 91,743<span></span>
</td>
<td class="nump">$ 91,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (91,743)<span></span>
</td>
<td class="num">$ (91,743)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember', window );">Approved Hormone Therapy Drug Candidate Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 705,752<span></span>
</td>
<td class="nump">$ 439,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(49,845)<span></span>
</td>
<td class="num">(19,401)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Amount</a></td>
<td class="nump">$ 655,907<span></span>
</td>
<td class="nump">$ 419,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted average remaining amortization period</a></td>
<td class="text">17 years<span></span>
</td>
<td class="text">18 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_IndefiniteLivedIntangibleAssetsExcludingGoodwillNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_MultipleTrademarksForVitaminsSupplementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InternetDomainNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6778314880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details 1)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated amortization expense for the year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2016</a></td>
<td class="nump">$ 40,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2017</a></td>
<td class="nump">40,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2018</a></td>
<td class="nump">40,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2019</a></td>
<td class="nump">40,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2020</a></td>
<td class="nump">$ 40,580<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6778193520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AccruedClinicalTrialCostsCurrent', window );">Accrued clinical trial costs</a></td>
<td class="nump">$ 3,725,377<span></span>
</td>
<td class="nump">$ 1,706,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll, bonuses and commission costs</a></td>
<td class="nump">2,108,143<span></span>
</td>
<td class="nump">814,205<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Accrued compensated absences</a></td>
<td class="nump">562,096<span></span>
</td>
<td class="nump">442,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">546,264<span></span>
</td>
<td class="nump">185,965<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1', window );">Allowance for coupons and returns</a></td>
<td class="nump">224,300<span></span>
</td>
<td class="nump">90,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and accounting expense</a></td>
<td class="nump">210,309<span></span>
</td>
<td class="nump">276,470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Accrued rent</a></td>
<td class="nump">83,527<span></span>
</td>
<td class="nump">91,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Accrued royalties</a></td>
<td class="nump">46,851<span></span>
</td>
<td class="nump">72,710<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AllowanceForWholesaleDistributorFeesCurrent', window );">Allowance for wholesale distributor fees</a></td>
<td class="nump">32,659<span></span>
</td>
<td class="nump">160,503<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">TOTAL OTHER CURRENT LIABILITIES</a></td>
<td class="nump">$ 7,539,526<span></span>
</td>
<td class="nump">$ 3,840,639<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AccruedClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AccruedClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AllowanceForWholesaleDistributorFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for wholesale distributor fees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AllowanceForWholesaleDistributorFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SalesDiscountsReturnsAndAllowancesGoods1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate allowance consisting of: (i) sales discounts given by the entity, including, but not limited to, early payments of accounts due, (ii) the total deduction from sales during the period arising from goods returned by customers (other than under warranty provisions), and (iii) price reductions (allowance, price protection agreements) given by the entity. Discounts, returns and allowances are a deduction from gross revenue in arriving at net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SalesDiscountsReturnsAndAllowancesGoods1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Current Liabilities<br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of current liabilities (due within one year or within the normal operating cycle if longer) not separately disclosed in the balance sheet. Includes costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered and of liabilities not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777752224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>NOTES PAYABLE (Details Narrative) - Multiple Advance Revolving Credit Note (Plato Warrant) [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 21, 2013</div></th>
<th class="th"><div>Mar. 13, 2013</div></th>
<th class="th"><div>Feb. 25, 2013</div></th>
<th class="th"><div>Jan. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from revolving credit note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayment of revolving credit note</a></td>
<td class="nump">$ 401,085<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares upon warrant exercise (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per unit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790160576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 15, 2015</div></th>
<th class="th"><div>Jul. 09, 2015</div></th>
<th class="th"><div>Feb. 17, 2015</div></th>
<th class="th"><div>Feb. 10, 2015</div></th>
<th class="th"><div>Aug. 04, 2014</div></th>
<th class="th"><div>Jul. 29, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,374,649<span></span>
</td>
<td class="nump">$ 42,771,353<span></span>
</td>
<td class="nump">$ 78,650,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,232,579<span></span>
</td>
<td class="nump">$ 345,746<span></span>
</td>
<td class="nump">$ 30,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeByNatureAxis=us-gaap_OptionMember', window );">Options exercised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,867<span></span>
</td>
<td class="nump">860,800<span></span>
</td>
<td class="nump">75,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,232,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercised', window );">Number of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417<span></span>
</td>
<td class="nump">136,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise', window );">Number of stock options exercised in cashless exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="nump">130,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeByNatureAxis=txmd_Option1Member', window );">Options exercised 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">724,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 345,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_StifelUnderwritersMember', window );">Stifel Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period (shares)</a></td>
<td class="nump">4,423,077<span></span>
</td>
<td class="nump">3,846,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_CowenAndCompanyLLCMember', window );">Cowen and Company, LLC (Underwriters) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,617,282<span></span>
</td>
<td class="nump">13,580,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,037,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_GoldmanSachsMember', window );">Goldman Sachs Underwriters [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,850,106<span></span>
</td>
<td class="nump">8,565,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,284,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalPeriodForPurchaseShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to additonal period for purchase of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalPeriodForPurchaseShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period pursuant to the options' cashless exercise provisions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfStockOptionsExercisedInCashlessExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options exercised in the cashless transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfStockOptionsExercisedInCashlessExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_StockIssuedDuringPeriodSharesNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeByNatureAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeByNatureAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeByNatureAxis=txmd_Option1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeByNatureAxis=txmd_Option1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_StifelUnderwritersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_StifelUnderwritersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_CowenAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_CowenAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_GoldmanSachsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_GoldmanSachsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777698608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 25, 2013</div></th>
<th class="th"><div>Apr. 18, 2013</div></th>
<th class="th"><div>Mar. 20, 2013</div></th>
<th class="th"><div>Mar. 14, 2013</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,374,649<span></span>
</td>
<td class="nump">$ 42,771,353<span></span>
</td>
<td class="nump">$ 78,650,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,232,579<span></span>
</td>
<td class="nump">$ 345,746<span></span>
</td>
<td class="nump">$ 30,910<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeByNatureAxis=us-gaap_OptionMember', window );">Options exercised [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of common stock issued during period for stock options exercised (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,867<span></span>
</td>
<td class="nump">860,800<span></span>
</td>
<td class="nump">75,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Value of common stock issued during period for stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,232,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_JefferiesLLCMember', window );">Jefferies LLC (Underwriters) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,411,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockExpectedToIssuedDuringPeriodShares', window );">Total Additional common stock to be issued under offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,411,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_StockIssuedDuringPeriodSharesNewIssues1', window );">Additional common stock issued under offering (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,954,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=txmd_StifelNicolausAndCompanyMember', window );">Stifel, Nicolaus &amp; Company (Underwriters) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued during the period (shares)</a></td>
<td class="nump">13,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 2.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued during the period</a></td>
<td class="nump">$ 30,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalPeriodForPurchaseShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to additonal period for purchase of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalPeriodForPurchaseShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockExpectedToIssuedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to numbers of share expected to be issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_StockExpectedToIssuedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_StockIssuedDuringPeriodSharesNewIssues1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_StockIssuedDuringPeriodSharesNewIssues1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeByNatureAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeByNatureAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=txmd_StifelNicolausAndCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=txmd_StifelNicolausAndCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6791320624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>May. 11, 2013</div></th>
<th class="th"><div>May. 31, 2013</div></th>
<th class="th"><div>Jan. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,772,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognition period of unamortized costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 260,027<span></span>
</td>
<td class="nump">$ 1,503,922<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember', window );">Multiple Advance Revolving Credit Note (Plato Warrant) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,711,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares upon warrant exercise (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.29%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">260,027<span></span>
</td>
<td class="nump">1,451,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeByNatureAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ .24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeByNatureAxis=us-gaap_WarrantMember', window );">Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember', window );">SCI - Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of grant</a></td>
<td class="nump">$ 462,196<span></span>
</td>
<td class="nump">$ 405,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation</a></td>
<td class="nump">$ 462,196<span></span>
</td>
<td class="nump">$ 405,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 154,068<span></span>
</td>
<td class="nump">$ 154,068<span></span>
</td>
<td class="nump">$ 77,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Unamortized costs of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 464,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights', window );">Vesting date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">45.84%<span></span>
</td>
<td class="nump">45.89%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">1.41%<span></span>
</td>
<td class="nump">1.12%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights', window );">Forfeited warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested warrants granted to purchase common stock (shares)</a></td>
<td class="nump">283,333<span></span>
</td>
<td class="nump">283,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares', window );">Warrants granted to purchase common stock expected to vest (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unamortized noncash compensation associated with warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognition period of unamortized costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember', window );">Outside Consultant Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Warrants granted to purchase common stock (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 139,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights', window );">Expiration date of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr.  06,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are expired in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightExpirationsDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refer to numbers of shares forfeit during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightNumberOfSecuritiesForfeitByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are vesting in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRightVestingDateOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which expected to vest warrants outstanding can be converted under the consulting agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsGrantedToPurchaseCommonStockExpectedToVestShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to issue debt and obtain financing associated with the related debt instruments. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 8<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net amount of long-term deferred finance costs capitalized at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) that have been approved for issuance in the equity-based payment transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=txmd_MultipleAdvanceRevolvingCreditNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeByNatureAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeByNatureAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_SancilioAndCompanyWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_OutsideConsultantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790545120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May. 31, 2012</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 369,812<span></span>
</td>
<td class="nump">$ 181,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant1Member', window );">Warrants - Unaffiliated Entity [Member] [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WarrantsAbstract', window );"><strong>Warrants:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of grant</a></td>
<td class="nump">$ 1,532,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance', window );">Warrants granted to purchase common stock (shares)</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Non-cash compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,796<span></span>
</td>
<td class="nump">$ 309,165<span></span>
</td>
<td class="nump">$ 360,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate', window );">Volatility rate</a></td>
<td class="nump">44.71%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate', window );">Risk free rate</a></td>
<td class="nump">0.74%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses - current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseOtherNoncurrent', window );">Prepaid expenses - noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseOtherNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts paid in advance which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseOtherNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) that have been approved for issuance in the equity-based payment transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSharesApprovedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period an equity-based award is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage amount by which a share price is expected to fluctuate during the expected term of a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing a nonvested share or option award issued to other than an employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=51659978&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777585216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details Narrative 4) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,621,658<span></span>
</td>
<td class="nump">$ 4,393,455<span></span>
</td>
<td class="nump">$ 3,200,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total unrecognized estimated compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366,000<span></span>
</td>
<td class="nump">181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,186,371<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366,000<span></span>
</td>
<td class="nump">$ 181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">945,485<span></span>
</td>
<td class="nump">365,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,255,485)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant2Member', window );">Warrants - Issued [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232,197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(310,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_StockOptionMember', window );">Stock Option [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_StockOptionMember', window );">Stock Option [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Option exercise prices (in dollars per shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member', window );">2009 Long Term Incentive Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,856,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,607,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember', window );">2012 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,868,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Grant - restricted stock unit (shares)</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of grant</a></td>
<td class="nump">$ 233,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedStockExpense', window );">Restricted stock expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,428<span></span>
</td>
<td class="nump">$ 180,072<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section F<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedStockExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncash expense that represents the cost of restricted stock or unit distributed to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedStockExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=txmd_Warrant2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_LongTermIncentiveCompensationPlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=txmd_NonQualified2012StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6776651312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOfSharesUnderWarrantAbstract', window );"><strong>Number of shares under warrant</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning | shares</a></td>
<td class="nump">13,927,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercised | shares</a></td>
<td class="num">(1,255,485)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending | shares</a></td>
<td class="nump">12,722,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Vested and Exercisable | shares</a></td>
<td class="nump">12,422,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Warrants outstanding, beginning</a></td>
<td class="nump">$ 1.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Warrants granted</a></td>
<td class="nump">6.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Warrants exercised</a></td>
<td class="nump">0.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Warrants outstanding, ending</a></td>
<td class="nump">1.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice', window );">Vested and Exercisable</a></td>
<td class="nump">$ 1.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding', window );">Warrants outstanding, beginning</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding', window );">Warrants outstanding, ending</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable', window );">Vested and Exercisable</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Warrants outstanding, beginning | $</a></td>
<td class="nump">$ 36,623,875<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue', window );">Warrants exercised | $</a></td>
<td class="nump">7,282,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Warrants outstanding, ending | $</a></td>
<td class="nump">107,344,752<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue', window );">Vested and Exercisable | $</a></td>
<td class="nump">$ 104,909,091<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to class of warrant or righst contractual life beginning oustanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRighstContractualLifeBeginningOustanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to class of warrant or righst contractual life closing oustanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRighstContractualLifeClosingOustanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average remaining contractual life of warrants vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ClassOfWarrantOrRighstContractualLifeVestedAndExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOfSharesUnderWarrantAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOfSharesUnderWarrantAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested non option equity instruments outstanding as of the balance sheet date can be currently converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of warrants vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsExercisableIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on warrants exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding warrants that are fully vested and exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsVestedAndExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6776803488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 1) - Warrants [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExercisePrice', window );">Weighted average fair value</a></td>
<td class="nump">$ 6.35<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">60.59%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Term (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.88%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.29%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.12%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.89%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed upon price for the exchange of the underlying asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected dividends to be paid to holders of the underlying shares or financial instruments (expressed as a percentage of the share or instrument's price).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Measure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk-free interest rate assumption used in valuing an instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=36462937&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774081248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 2) - Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.47%<span></span>
</td>
<td class="nump">0.07%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">58.78%<span></span>
</td>
<td class="nump">68.05%<span></span>
</td>
<td class="nump">33.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">5 years 3 months 8 days<span></span>
</td>
<td class="text">5 months<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.67%<span></span>
</td>
<td class="nump">1.77%<span></span>
</td>
<td class="nump">1.71%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">62.94%<span></span>
</td>
<td class="nump">82.29%<span></span>
</td>
<td class="nump">45.76%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term</a></td>
<td class="text">6 years 2 months 30 days<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Staff Accounting Bulletin (SAB)<br> -Number Topic 14<br> -Section D<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777884928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOptionsAbstract', window );"><strong>Number Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75,423)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_NumberOptionsAbstract', window );"><strong>Number Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning</a></td>
<td class="nump">16,792,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">4,685,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options Exercised</a></td>
<td class="num">(613,284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Options Expired</a></td>
<td class="num">(102,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options Cancelled/Forfeited</a></td>
<td class="num">(36,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending</a></td>
<td class="nump">20,725,325<span></span>
</td>
<td class="nump">16,792,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and exercisable</a></td>
<td class="nump">15,461,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested</a></td>
<td class="nump">5,263,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">8.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="nump">2.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="nump">2.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="nump">4.02<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending</a></td>
<td class="nump">3.28<span></span>
</td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and exercisable</a></td>
<td class="nump">1.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested</a></td>
<td class="nump">$ 7.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_WeightedAverageRemainingContractualLifeAbstract', window );"><strong>Weighted Average Remaining Contractual Life</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, ending</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 10 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm', window );">Unvested</a></td>
<td class="text">9 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, beginning</a></td>
<td class="nump">$ 43,996,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, ending</a></td>
<td class="nump">146,864,184<span></span>
</td>
<td class="nump">$ 43,996,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable</a></td>
<td class="nump">131,523,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Unvested</a></td>
<td class="nump">$ 15,340,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_NumberOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_NumberOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested options that are exercisable or convertible, in 'PnYnMnDTnHnMnS' format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_WeightedAverageRemainingContractualLifeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_WeightedAverageRemainingContractualLifeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of fully vested and expected to vest options that are exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares into which fully vested and expected to vest stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the weighted-average exercise price for outstanding stock options that are fully vested or expected to vest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6780182272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 192,601,415<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6776566976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory tax rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax rate, net of federal tax benefit</a></td>
<td class="nump">4.73%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Adjustment in valuation allowances</a></td>
<td class="num">(38.97%)<span></span>
</td>
<td class="num">(50.90%)<span></span>
</td>
<td class="num">(32.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent and other differences</a></td>
<td class="nump">0.24%<span></span>
</td>
<td class="nump">11.10%<span></span>
</td>
<td class="num">(8.40%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision (Benefit) for Income Taxes</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6783505168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES (Details 1) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_DeferredIncomeTaxAssetsAbstract', window );"><strong>Deferred Income Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">$ 79,499,633<span></span>
</td>
<td class="nump">$ 43,091,437<span></span>
</td>
<td class="nump">$ 14,773,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">R&amp;D Credit</a></td>
<td class="nump">186,347<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">547,511<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax asset</a></td>
<td class="nump">79,685,980<span></span>
</td>
<td class="nump">$ 43,091,437<span></span>
</td>
<td class="nump">15,321,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">$ (79,685,980)<span></span>
</td>
<td class="num">$ (43,091,437)<span></span>
</td>
<td class="num">$ (15,321,048)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred Income Tax Assets, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_DeferredIncomeTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Income Tax Assets:</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_DeferredIncomeTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Deferred Tax Asset<br> -URI http://asc.fasb.org/extlink&amp;oid=6510090<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOtherLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to other deductible loss carryforwards not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOtherLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6622379792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTIES (Details Narrative) - Pernix Therapeutics LLC [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement', window );">Manner of Settlement</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We entered into a settlement agreement with Pernix according to which Pernix
paid us $175,000 in cash.</p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Receivables- legal fee reimbursement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Payable - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Settlement fees</a></td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Proceeds from settlement agreement</a></td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms and manner of settlement of the related party transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6779060144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS CONCENTRATIONS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">$ 5,630,000<span></span>
</td>
<td class="nump">$ 5,190,000<span></span>
</td>
<td class="nump">$ 4,848,000<span></span>
</td>
<td class="nump">$ 4,475,000<span></span>
</td>
<td class="nump">$ 4,257,000<span></span>
</td>
<td class="nump">$ 4,186,000<span></span>
</td>
<td class="nump">$ 3,752,000<span></span>
</td>
<td class="nump">$ 2,831,000<span></span>
</td>
<td class="nump">$ 20,142,898<span></span>
</td>
<td class="nump">$ 15,026,219<span></span>
</td>
<td class="nump">$ 8,775,598<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=txmd_DeferredSalesRevenueNetMember', window );">Deferred Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember', window );">Supplier Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Sales Revenue [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member', window );">Customer A [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,848,243<span></span>
</td>
<td class="nump">$ 1,609,950<span></span>
</td>
<td class="nump">$ 1,221,212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member', window );">Customer B [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,843,463<span></span>
</td>
<td class="nump">1,586,903<span></span>
</td>
<td class="nump">1,711,417<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member', window );">Customer C [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,804,018<span></span>
</td>
<td class="nump">2,588,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member', window );">Customer D [Member] | Sales Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,053,838<span></span>
</td>
<td class="nump">$ 1,312,192<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=txmd_DeferredSalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=txmd_DeferredSalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=txmd_CustomerConcentrationRisk4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6790223824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2013</div></th>
<th class="th"><div>Jun. 30, 2013</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_CapitalLeaseObligationsTerm', window );">Non-cancelable operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">63 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rental Expense</a></td>
<td class="nump">$ 180,894<span></span>
</td>
<td class="nump">$ 60,168<span></span>
</td>
<td class="nump">$ 446,099<span></span>
</td>
<td class="nump">$ 361,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Rental income</a></td>
<td class="nump">$ 32,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,613<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_CapitalLeaseObligationsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total term (in months) of the company's outstanding lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_CapitalLeaseObligationsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6775147104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract', window );"><strong>Future minimum rental payments, year ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2016</a></td>
<td class="nump">$ 493,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2017</a></td>
<td class="nump">507,087<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2018</a></td>
<td class="nump">388,976<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Minimum lease payments</a></td>
<td class="nump">$ 1,389,853<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationFiscalYearMaturityScheduleAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=6584154&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6453985&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6777553104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELECTED QUARTERLY FINANCIAL DATA (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Jun. 30, 2015</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenues</a></td>
<td class="nump">$ 5,630,000<span></span>
</td>
<td class="nump">$ 5,190,000<span></span>
</td>
<td class="nump">$ 4,848,000<span></span>
</td>
<td class="nump">$ 4,475,000<span></span>
</td>
<td class="nump">$ 4,257,000<span></span>
</td>
<td class="nump">$ 4,186,000<span></span>
</td>
<td class="nump">$ 3,752,000<span></span>
</td>
<td class="nump">$ 2,831,000<span></span>
</td>
<td class="nump">$ 20,142,898<span></span>
</td>
<td class="nump">$ 15,026,219<span></span>
</td>
<td class="nump">$ 8,775,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,395,000<span></span>
</td>
<td class="nump">3,996,000<span></span>
</td>
<td class="nump">3,815,000<span></span>
</td>
<td class="nump">3,431,000<span></span>
</td>
<td class="nump">3,377,000<span></span>
</td>
<td class="nump">3,118,000<span></span>
</td>
<td class="nump">2,859,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">15,636,225<span></span>
</td>
<td class="nump">11,354,416<span></span>
</td>
<td class="nump">6,816,001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (17,843,000)<span></span>
</td>
<td class="num">$ (19,472,000)<span></span>
</td>
<td class="num">$ (27,227,000)<span></span>
</td>
<td class="num">$ (20,895,000)<span></span>
</td>
<td class="num">$ (16,303,000)<span></span>
</td>
<td class="num">$ (17,832,000)<span></span>
</td>
<td class="num">$ (10,899,000)<span></span>
</td>
<td class="num">$ (9,183,000)<span></span>
</td>
<td class="num">$ (85,077,024)<span></span>
</td>
<td class="num">$ (54,217,210)<span></span>
</td>
<td class="num">$ (28,419,313)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per common share, basic and diluted (in dollars per shares)</a></td>
<td class="num">$ (.10)<span></span>
</td>
<td class="num">$ (.11)<span></span>
</td>
<td class="num">$ (.16)<span></span>
</td>
<td class="num">$ (.13)<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.07)<span></span>
</td>
<td class="num">$ (0.06)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
<td class="num">$ (0.36)<span></span>
</td>
<td class="num">$ (0.22)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Net Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.18)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Glossary Other Comprehensive Income<br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 03<br> -Paragraph 19<br> -Article 5<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 04<br> -Paragraph 20<br> -Article 9<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.1.900</span><table class="report" border="0" cellspacing="2" id="idp6774047328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 12, 2016</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Feb. 17, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91,374,649<span></span>
</td>
<td class="nump">$ 42,771,353<span></span>
</td>
<td class="nump">$ 78,650,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,232,579<span></span>
</td>
<td class="nump">345,746<span></span>
</td>
<td class="nump">$ 30,910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 366,000<span></span>
</td>
<td class="nump">$ 181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event- Underwriting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Shares issued in offerings, net of cost</a></td>
<td class="nump">$ 134,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued in offerings, net of cost, shares</a></td>
<td class="nump">15,151,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,424,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 8.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_txmd_AdditionalPeriodForPurchaseShare', window );">Number of days of the option to purchase shares</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options Granted</a></td>
<td class="nump">2,272,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=txmd_SubsequentEvent1Member', window );">Subsequent Event - Exercises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Shares issued for exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 758,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares issued for exercise of options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">281,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Shares issued in exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,285,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Shares issued in exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_txmd_AdditionalPeriodForPurchaseShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to additonal period for purchase of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">txmd_AdditionalPeriodForPurchaseShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>txmd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28,29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 02<br> -Paragraph 29, 30, 31<br> -Article 5<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued during the period that is attributable to transactions involving issuance of stock not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=txmd_SubsequentEvent1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=txmd_SubsequentEvent1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M<R]W;W)K8F]O:RYX;6PN<F5L<\7:S6Z;0!B%X5NQN(# ?#^3Q(JSRB;;IC>
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M@@?5\VCFU,RC:=L>U!WC!R\(I2Z4'N5WWR('7QY&^8O9_ M02P,$%     @
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MKG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2D 83 <V4R43P H)DIAR
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M101'^RO.2,-NK(+QM1G_!%!+ P04    " !.A%I(ABNO3_0$   *%   #P
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M[V8CRF"K;9:-]+DPGQ1I<]\+^;"#]>5_4$L#!!0    ( $Z$6D@X%[)TH (
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ML*.^='!O1R^M,$=E/]I?;)9(G[5?\K(XXR/YC=FQ:KFWI4*>V/I@/5 JB)Q
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M1Z=:>AC:TWQ(O_RG8/,'4$L#!!0    ( $Z$6DA?'DF:00(  "<(   8
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M1+4YG&/0D6PX'\N7_P;%7U!+ P04    " !.A%I(0171Y1P$  !!$0  &
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MN>Q^UI?OUL<@>X?KNFR'_\GZW'9U-9K,DJKX39^'X_!YH6\T>K.P 7H#O!J
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M@GG\IPF[V%,%IHM7QY(:1^W2EJ[5]78^Y?%,/N!5.? .?G#3"6W)"9T_V7@
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M-AY B^C M\_N[BGI_?M9$PFM"^'.QR9=J90X')8'LK[2ZA]02P,$%     @
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MX;V+=;Q2,;$X+ ]D?:7E?U!+ P04    " !.A%I(EF-;&J0!  "Q P  &0
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M2&BL#V]=K..5BHG%87D@ZRLM/P%02P,$%     @ 3H1:2 ''/(:B 0  L0,
M !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULA5/;;J,P$/T5RQ]0$T*:
M5420FE95^[!2U8?=9P<&L&HSU#:A^_?K"]"DBMH7/#.<<^:,+_F(^LVT )9\
M*-F9/6VM[7>,F;(%Q<T-]M"Y/S5JQ:U+=<-,KX%7@:0D2Y/DEBDN.EKDH?:B
MBQP'*T4'+YJ802FN_QU XKBG*SH77D736E]@1<X67B44=$9@1S34>WJWVATR
MCPB /P)&<Q83[_V(^.:3YVI/$V\!))36*W"WG. >I/1"KO'[I/G9TA//XUG]
M,4SKW!^Y@7N4?T5E6V<VH:2"F@_2ON+X!-,(&R]8HC3A2\K!6%0SA1+%/^(J
MNK".\4^63+3KA'0BI OA5R"PV"C8?."6%[G&D9B>^[-;[1Q<>Q&G3)PWX\8.
MFCH,7N2G8K7=Y.SDA2XPD7B8, N".?6K+5)ZC9X&>OHS?7U)7T>'Z\GA[<\"
MV:5 %@6R[T:,F,.,V7YIPL[V5(%NPM4QI,2ALW%+E^IR.^_2<":?\"+O>0._
MN6Y$9\@1K3O9<  UH@77/KG94-*Z][,D$FKKPZV+=;Q2,;'8SP]D>:7%?U!+
M P04    " !.A%I(8@ZJ!J0!  "Q P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-2YX;6R%4\MNVS 0_!6"'Q#*LE.[ABP@3E"TAP!!#NV9EE82$9*KD)25
M_'WYD!4[,)*+N+N:F9WEHQC1O-@.P)$W);7=T<ZY?LN8K3I0W-Y@#]K_:= H
M[GQJ6F9[ [R.)"59GF4_F.)"T[*(M2=3%C@X*30\&6('I;AYWX/$<4<7]%1X
M%FWG0H&5!9MYM5"@K4!-##0[>K?8[E<!$0%_!8SV+";!^P'Q)21_ZAW-@@60
M4+F@P/URA'N0,@CYQJ^3YD?+0#R/3^J_XK3>_8%;N$?Y3]2N\V8S2FIH^"#=
M,XZ_81KA-@A6*&W\DFJP#M6)0HGB;VD5.JYC^I.O)]IU0CX1\IFPR:+QU"C:
M?.".EX7!D=B>A[-;;#W<!!&O3+PWZ\>.FB8.7A;'<K'>%.P8A"XPB;B?,#."
M>?6K+7)ZC9Y'>OX]?7E)7R:'R\GAS^\%5I<"JR2P^FK$A-E/F$WVJ0D[VU,%
MIHU7QY(*!^W2EL[5^7;>Y?%,/N!ET?,6'KEIA;;D@,Z?;#R !M&!;Y_=W%+2
M^?<S)Q(:%\*UCTVZ4BEQV)\>R/Q*R_]02P,$%     @ 3H1:2&#6_;ZC 0
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M8 _:_VG0*.Y\:EIF>P.\CB0E69YEWYCB0M.RB+5G4Q8X."DT/!MB!Z6X>3^
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MD="Z$-[[V*0KE1*'P_) UE=:_0=02P,$%     @ 3H1:2%(E@ ^E 0  L0,
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M9.,!M(@.O'WVL*.D]^]G322T+H1['YMTI5+B<%@>R/I*JW]02P,$%     @
M3H1:2 (,AVJR 0  %@0  !D   !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
MA539;IPP%/T5RQ\0LPQ).F*0,JFJ]J%2E(?VV0,7L.*%VF9(_[Y>@,Q$J/."
M%\YVN3;EI/2;Z0$L>A=<F@/NK1WVA)BZ!T'-G1I NC>MTH):M]0=,8,&V@22
MX"1+DGLB*).X*L/>BZY*-5K.)+QH9$8AJ/Y[!*ZF T[QLO'*NM[Z#5*59.4U
M3( T3$FDH3W@IW1_+#PB 'XQF,S%'/GL)Z7>_.)'<\")CP <:NL5J!O.\ R<
M>R%G_&?6_+#TQ,OYHOXM5.O2GZB!9\5_L\;V+FR"40,M';E]5=-WF$L("6O%
M37BB>C16B86"D:#O<60RC%-\4^0S;9N0S81L)3PF(7@T"C&_4DNK4JL)F8'Z
MWJ5[!]=>Q"DCE\VXLH.F#H57Y;G*BL>2G+W0%282CQ&3K@CBU#<M,KQ%SZ+%
M;7I^3<]CPCRZ/^2W!7;7 KLHL)M+_+)58L0<9\Q]<MNDV#0I9H'T/R8+YO.G
M(!>-$Z"[<#X-JM4H;>S;NKM>@:<L-/X#7I4#[> GU1V3!IV4=<<G=+E5RH*S
M3^X*C'IW2=<%A];ZZ8.;ZWANX\*J8;F%ZZ^@^@=02P,$%     @ 3H1:2*5X
M172E 0  L0,  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULA5/;CILP
M$/T5RQ^P)H1DJX@@;;:JVH=*JWUHGQT8P%K;0VT3MG]?7X!-JDC[@F>&<YGQ
MI9S0O-D>P)%W);4]TMZYX<"8K7M0W#[@ -K_:=$H[GQJ.F8' [R))"59GF5[
MIKC0M"IC[<54)8Y."@TOAMA1*6[^GD#B=*0;NA1>1=>[4&!5R59>(Q1H*U 3
M ^V1/FT.IR(@(N"7@,E>Q23T?D9\"\F/YDBST )(J%U0X'ZYP#-(&82\\9]9
M\\,R$*_C1?U;G-9W?^86GE'^%HWK?;,9)0VT?)3N%:?O,(^P"X(U2AN_I!ZM
M0[50*%'\/:U"QW5*?XILIMTGY#,A7PE?(H$EH]CF5^YX51J<B!UX.+O-P<--
M$/'*Q/=F_=A1T\3!J_)2Y?MMR2Y!Z :3B*>$V:P(YM7O6N3T'CU/%I_3M[?T
M;>IPF]P?]Y\+%+<"11(HYA&+>R,FS&G![/XS85=[JL!T\>I84N.H7=K2M;K>
MSJ<\GLD'O"H'WL%/;CJA+3FC\R<;#Z!%=.#MLX<=);U_/VLBH74A?/2Q25<J
M)0Z'Y8&LK[3Z!U!+ P04    " !.A%I(TI58%<X!  #@!   &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,2YX;6R-5,MNHS 4_17+'U 3"-")"%+3T:A=C%1U
MT5D[<'FH-F9L$SI_7S^ )A5*9H-]S7E=L)V-0KZK!D"C#\XZM<>-UOV.$%4T
MP*FZ$SUTYDTE)*?:E+(FJI= 2T?BC(1!D!!.VP[GF5M[D7DF!LW:#EXD4@/G
M5/X[ !/C'F_PO/#:UHVV"R3/R,(K6PZ=:D6')%1[_+#9'5*+<("W%D9U-D<V
M^U&(=UL\EWL<V C H-!6@9KA!(_ F!4RQG\GS2]+2SR?S^J_7+<F_9$J>!3L
M3UOJQH0-,"JAH@/3KV)\@JF%V H6@BGW1,6@M. S!2-./_S8=FX<_9LTFFCK
MA' BA OA/G#!O9&+^9-JFF=2C$CUU/Z[S<[ I14QRLAD4Z9MIRE=XWEVRL,D
MR<C)"EU@//'@,9L%08SZJD6(U^BAM[A-CR[ID4\830G3VP+;2X&M%]A. O=K
M+7K,8<;\N&T2KYK$7B -KIC,F/_XDLFJ23()A%=,9DQTVR1=-4DG@>T5DQD3
M?S,A9UN0@ZS=25.H$$.G_0Y<5I?#_!"Z+?P%S[.>UO";RKKM%#H*;0Z"VZ^5
M$!J,?7 78]28ZV8I&%3:3E,SE_X$^D*+?KY/EDLM_P102P,$%     @ 3H1:
M2#%!/=BR 0  %@0  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULA53;
M;ILP&'X5RP]0$T(:%A&DIM.T74RJ>K%=._ #5GU@M@G=V\\'H$F%EAM\^DZ_
M?IMB5/K-=  6O0LNS1%WUO8'0DS5@:#F0?4@W4FCM*#6+75+3*^!UH$D.$F3
MY)$(RB0NB[#WHLM"#98S"2\:F4$(JO^>@*OQB#=XWGAE;6?]!BD+LO!J)D :
MIB32T!SQT^9PVGE$ /QB,)JK.?+9STJ]^<6/^H@3'P$X5-8K4#=<X!DX]T+.
M^,^D^6'IB=?S6?U;J-:E/U,#SXK_9K7M7-@$HQH:.G#[JL;O,)40$E:*F_!%
MU6"L$C,%(T'?X\AD&,=XDN43;9V03H1T(>1)"!Z-0LROU-*RT&I$IJ>^=YN#
M@VLOXI21RV9<V4%3A\++XE*F^\>"7+S0#2823Q&S61#$J:]:I'B-GD:+^_3M
M+7T;$VZC>Y[=%\AN!;(HD$TE[M=*C)C3C,GOF^Q637:3P)?_F$R8//ED0JX:
M)T"WX7X:5*E!VMBW97=Y D]I:/P'O"QZVL)/JELF#3HKZZY/Z'*CE 5GGSSL
M,.K<(UT6'!KKIWLWU_'>QH55_?P*EU]!^0]02P,$%     @ 3H1:2&<1U\ND
M 0  L0,  !D   !X;"]W;W)K<VAE971S+W-H965T,S,N>&ULC5/;;J,P$/T5
MRQ]0$Z"[5420FE95]V&EJ@^[SPX,8-5FJ&U"]^_7%R!)%:E]P3/#.6?.^%),
MJ-],!V#)AY*]V='.VF'+F*DZ4-S<X "]^].@5MRZ5+?,#!IX'4A*LC1)?C#%
M14_+(M1>=%G@:*7HX443,RK%];\]2)QV=$.7PJMH.^L+K"S8RJN%@MX([(F&
M9D?O-]M][A$!\$? 9,YBXKT?$-]\\JO>T<1;  F5]0K<+4=X "F]D&O\/FN>
M6GKB>;RH/X5IG?L#-_" \J^H;>?,)I34T/!1VE><GF$>X=8+5BA-^))J-!;5
M0J%$\8^XBCZL4_R39S/M.B&=">E*N$N"\=@HV'SDEI>%QHF8@?NSVVP=7'L1
MITR<-^/&#IHZ#%X6QS*]VQ3LZ(4N,)&XCY@3@CGUJRU2>HV>QA9?T[-+>A8=
M9K/#;PCDEP)Y%,AG@>S:B!&S7S#YIR;L;$\5Z#9<'4,J''L;MW2MKK?S/@UG
M<H*7Q<!;^,UU*WI##FC=R88#:! MN/;)S2TEG7L_:R*AL3[\Z6(=KU1,+ [+
M UE?:?D?4$L#!!0    ( $Z$6DAPN%?!I@$  +$#   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,T+GAM;(53VVZC,!#]%<L?4!-"TFY$D)JNJO9AI:H/W6<'
M!K!J,]0VH?OW]05HLHK4%SPSG,N,+_F(^MVT )9\*MF9/6VM[7>,F;(%Q<T-
M]M"Y/S5JQ:U+=<-,KX%7@:0D2Y-DRQ07'2WR4'O118Z#E:*#%TW,H!37_PX@
M<=S3%9T+KZ)IK2^P(F<+KQ(*.B.P(QKJ/;U?[0Z91P3 FX#1G,7$]WY$?/?)
M<[6GB6\!))36*W"WG. !I/1"SOACTORV],3S>%9_#-.Z[H_<P /*OZ*RK6LV
MH:2"F@_2ON+X!-,(&R]8HC3A2\K!6%0SA1+%/^,JNK".\<\FFVC7">E$2!?"
M71(:CT:AS=_<\B+7.!+3<W]VJYV#:R_BE(GKS;BQ@Z8.@Q?YJ4CO-CD[>:$+
M3"0>(F:U()A3OVJ1TFOT-%K\3%]?TM>QPW5T_[7]62"[%,BB0#:-N+TV8L0<
M9LSM?R;L;$\5Z"9<'4-*'#H;MW2I+K?S/@UG\@TO\IXW\(?K1G2&'-&ZDPT'
M4"-:</;)S8:2UKV?)9%06Q_>NEC'*Q43B_W\0)976GP!4$L#!!0    ( $Z$
M6DAO<BM1FP(  .\)   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;(V6
MV8Z;,!B%7P7Q (-M%D-$D#I9U%Y4&LU%>^TD3H(&<&H[R?3MZXU,4AE"D,+V
MG?,?VV!37AG_$$=*9?#9-IV8AT<I3[,H$MLC;8EX82?:J3M[QELBU2D_1.+$
M*=D94=M$"( L:DG=A55IKKWQJF1GV=0=?>.!.+<MX7]?:<.N\Q"&_87W^G"4
M^D)4E=%-MZM;VHF:=0&G^WGX#<[6,-6((7[5]"KNC@,=?L/8AS[YL9N'0&>@
M#=U*;4'4[D(7M&FTDZK\QYE^U=3"^^/>?6V:J^)OB* +UORN=_*HTH(PV-$]
M.3?RG5V_4]<&DW#+&F'^@^U92-;VDC!HR:?=UYW97^V=+'8ROP Y ;H)$!@5
MQ$X03Q4D3I!\">"H('6"=*H@<X+L/T%D.\MT]9)(4I6<70-Q(OH!A#.%<VVB
MG /5OT(-G?'D9O"J\E*A/"^CBS9Z8)!A7GNF&&86CBG ,+/L&3C,K'H&#3/K
MGHEO3*3:ZVTT>FQT8AN-G$'R6*0S#+9A+8,+E.(1;&6QK,AS#(>QM<4@Q''Q
M/'3L#1V[T.E(:,>D0/V>UTF\=1)7)_/5L<*E96#RO$;JK9&Z&M@WRI99]DS^
MO$CF+9(Y@PD]CKT&V!C$ (ST.'8#&^< Q\,]MNHYG((</0^4>P/E+I#W27-#
M8QD(0*%JC02R'%;)LPEY"F^>PN5!(QUD&:AFF"(?>8\LEF0Q1A.>7 B\><QE
M'6C"S "AWP(Z"^]+G[D)T4(PM=LPN>A)G""]38CEG[$@<K'2"1;^^0/&SB(;
M>>EN$)Y0QS]_P,193'AQH7]Z@.F4J$,31'2W#I[(@?XD_%!W(M@PJ994L_+M
M&9-4F8 7M?8>U=?7[:2A>ZD/L3KF]GO$GDAVZC^O;M]XU3]02P,$%     @
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MK3YX_Y/Y'F(CN.&UM+]@<Y"*-R=* !KZ[;Y5:[^]^V<"/6V<@#P!#80H>4C
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M;!B FC;DQ-0KG[Y37T)B! ^<2?L%AY-4O)\I >C)AVN[P;:36XE"3ULG8$_
M"P'%-PF1)T2?"- ELW5](XJ4A> 3D",QAXVV&BZ,B%8&NABI]\EJ"KM397$N
M(Q07\&R$KC#88IX<!G^-J&:5!0)U@-44^#J%FWS$CI_<YT?7_-CQ(^^?7&<<
M+"9S53A,FB*49E_#*@?+LQAOXOMQXM4XL8^3KOFD+H[#X'R3WT!5#H62)(K_
M8W.3U32)3[-:M?=)O ^.L_R^3[KJDWJ?_,8A.$RZ"5$2W3@$!T,HQPA%G_+
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M0IO#[,Y<)X2F1B=^R"+0FSMF21CMM T+$TO_V_E$B^ERB2PW6?T74$L#!!0
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M=\MLI-3"&($'FB8[\UMQJG1BHVV1F_+H+UI?T7(__3><?EZJ?U!+ P04
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M-\>VWU7=?FV_AMB#MCJ[CSO7+TSK_P!02P,$%     @ 3H1:2%O]A5_N @
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M*(EV$+0!XY $]!)H0L)A)DP\.02:R.790?(91M&E4>36"SFC$-X.D%T&R%R
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M<\.Y8MI:>J>SV^GCV#AHV4:9V]RD[0XH;J#X?CAOC8>^^C]02P,$%     @
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MS;HQUZ ]Y_U^8G<6WO1.K.? +E=K,S'X;(9<;-8OFT1FZ^BE=_0& P/F8<3
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M !L[ -GPL0,@*%YY%":C6P ;>T#FX8(N;I;Y2'4@M<H\>@#0/0!<V2;*(S-
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MD=-#+[;&W7)[KT)C%1Z,/)S[Q*E9;?X"4$L#!!0    ( $Z$6DCC:^C+?P(
M '8)   9    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;)56VX[:,!#]E2@?
M0.+$N:$0"5)5[4.EU3ZTSP8,1)O$U#9D^_?U+5G8&N*^8'MRYIP9CP>[' A]
M8R>,N??>M3U;^2?.S\L@8+L3[A!;D#/NQ9<#H1WB8DF/ 3M3C/;*J6N#* S3
MH$--[U>ELKW0JB07WC8]?J$>NW0=HG\VN"7#R@?^:'AMCB<N#4%5!I/?ONEP
MSQK2>Q0?5OX:+&N02XA"_&SPP&[FG@Q^2\B;7'S?K_Q0QH!;O..2 HGABFO<
MMI))*/\VI!^:TO%V/K)_5>F*\+>(X9JTOYH]/XEH0]_;XP.ZM/R5#-^PR2&1
MA#O2,O7K[2Z,DVYT\;T.O>NQZ=4XZ"]I:MSL#I%QB"8'\-PA-@[QAP-4F>K(
M5%Y?$$=52<G@L3.2U09+ :>21#![(ADF]DEQ4K5357FMDC K@ZLDNL-$"K/1
M&# A L%NE8A\FWNDW*/' K5&9 X*\;V"-JYCDT0^3P#O": F@(:@N ^R5YA"
MIZ$QZ2).'H-J#8H6>3P?2F(-)=&A@-"V7QJS&3$.&Y9:15)#8"V*$1DQ#IED
M5I',$, G(AH#83$ODEM%<DT0%T]$# 8^V=+Z7\S#0 IK((4BB,-DG@"$UE.L
MS(['& !K$ #,GY[:@&#LHA/9=:+Y U0;$(Q3!YW8KA//GZ':@)P.$;#W/X"F
M>BY;DMBKE_Q']>Q="5*7ZFD03!SZ$M@;$V0NU3.MF3C\R0![;X+<I7IC!\-/
M.L'-==9A>E37//-VY-)S?=5,UNDIL8[D=?C)OI%/#'5-?M!4Y1D=\0]$CTW/
MO"WAXK)5=^*!$(Y%7.$B\;V3> 1-BQ8?N)QF8D[ULT O.#F/KYSIJ57]!5!+
M P04    " !.A%I(,3?WJ88"  #?"0  &0   'AL+W=O<FMS:&5E=',O<VAE
M970U-"YX;6R-EM^.HC 4QE^%\  #+2!JD$0QF]V+329SL7M=M0H9H&Q;=?;M
MMW\9G:V5&Z'U=[Y^YWAL6UP)?6<UQCSXZ-J>K<*:\V$916Q?XPZQ%S+@7GQS
M)+1#7 SI*6(#Q>B@@KHV@G$\BSK4]&%9J+E76A;DS-NFQZ\T8.>N0_3O!K?D
MN@I!:"?>FE/-Y414%M$8=V@ZW+.&] '%QU6X!LLM2"6BB%\-OK*;]T":WQ'R
M+@<_#JLPEAYPB_=<2B#QN. *MZU4$BO_,:*?:\K VW>K_DVE*^SO$,,5:7\W
M!UX+MW$8'/ 1G5O^1J[?L<DADX)[TC+U&>S/C)/.AH1!AS[TL^G5\ZJ_R1<F
MS!T 30 < V#F#4A,0#(&@-P;D)J ]$M I%-1A=@BCLJ"DFO !B3; RP%3J6(
M4 Y$]DP45FE25=JRN)09R(KH(H7N&*B8C6; 2$1"W;D$#%WA4(7#QPM4FDC
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MVQH'+3YR^9J+=ZKO'WK R6"O4^.=KOP'4$L#!!0    ( $Z$6DB,C/!0G0,
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ML-/[_%QV/\SEJ\8YR#[AUI3M\#_8GMO.5&-(&%3Y;W<MZN%Z<;\(@6%T &
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M4\AMUU^FZKK1KT7T35<?S5N>\573_']02P,$%     @ 3H1:2!(":KXO @
M:P8  !D   !X;"]W;W)K<VAE971S+W-H965T-C$N>&ULC57+;J,P%/T5Q ?4
M@(T3(H+4/$8SBY&J+F;63N($5(RI[83.WX]?D*0BM)OXP3GGGGMMW^0=%V^R
MI%0%'ZQNY#(LE6H7 ,A]21F13[REC?YRY((1I9?B!&0K*#E8$JM!$D48,%(U
M89';O1=1Y/RLZJJA+R*09\:(^+>B->^681SV&Z_5J51F Q0Y&'B'BM%&5KP)
M!#TNP^=XL<4&80%_*MK)FWE@O.\X?S.+7X=E&!D+M*9[912('BYT3>O:".G
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MFUNA[TLXA,%#79R[(V5_KIW^#U!+ P04    " !.A%I(R=).[LD"   *"P
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M3+.R.Q=#IU8.CTZ+"MR10[<N'? 45]7S.2R.H]YP&)*M*J9.O)?LGM/POTK
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M"3T3 2'Q'XX@:O ^#UJX@E_G"O;-[GM-R[91,7MLH#,HQ\;>"%#(,T90S=$
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M3H;^:SG )A!@M8MY,%D,$9E'&,2!?13M:&XABZY@=J\:S!Y8YPP&TK["T ]
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M-]H92JV:;:=8L=IH 1/2?Q0XS@.>;3^KO:B1BE.ZO(J7K$S)A:C#>Z&K=H!
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MRQE3L;R[1MO+1C"NYC9=E@("RM!3 <(&QY&DZ11*1^I)M_\SB @YE5[D^&/
M&Z%+)JK?Z1_HK@U$3Z!*,.P:JV,8ZQT)MW1,W'S(*+\?3!\16S.%6U]@1"6G
M:LI> 75 # \INB=A:ZE9#8D;8H]FHDN!]!611.0/&72+R9L9:]AP0:OQ #;R
MKSZP68,517=V'O.>[SRF+1S0&03KX\H.+JCEB!ERM?J3>216T:9GR)$9?U"9
MD>PJ>SJ'.M^GZRG6)+8'MHFGFL9L\U\]1[9E^[!Q]#3ESB]MB%>'PQ&FD11Q
M_K+=.V]YS3T[0SI)I3;/UWU;'D =Z!4VG9W,QH'_:KJ8!_/9@$N>#@;!;+3X
MTFB'>JG4IG&'$\+IA1.;#[OO<_ZIZ@>5)YS,6HJCE"Y;@:M.\%&;K%]MQ"5]
M@[G/@R:VDN_#9/)QHV*3S X:X%V82$ Z%Q8[OKR@9+^\R"6($5/C /-$,)$7
MT7Y;CS2&6>&9Z+!DW>PA-#6-)#O0UK2R2^T9=V]]'T]>8\L@3&(X$J;$2Q\.
MELRE@)&6GN293(O(YTRW.6$6L<&M8\R_B3Q3 ,"&[68=A^5LJ5Y/054T1-5!
M,!C-@_YLU-K[-[!Y(?!DO[\(!K,)1?6X!2<8A$Y<M$9.O!H, ?T7<[_^!DIA
M'*1%Y#E>N:;[W=1 M#R/ZJ]V0LIO@503+2T,L'?.?-C:1=J% =;^'TV'N!]O
M/PB,IZ-@-NS_EA" &V);=#=0%+W.>EL<=&5!R597,<\4&5/:<D67X<*]'LWA
M/:=\!XEK:R-^F'9.FL>3:Q]3YP!(KR["GS%7_TE4Y_J H:FMRV$=:X O=RN'
M4]!#;>P;'Z*HI\!=&+)Y%?@>F++CI'%RB-4N22_"VCTU84#%^+<G1RP*4TT\
M-N5CODW@U<!G?^&L?FJ^1Z6&M- >]ZZJ>(Q94A%)K4B7Z9HA5YT58,@%H!TH
M(G"\)G#\!G"<G$>6^M4NI*@ /Q@+FRFTJMG9HG+<EADAA7C$U-3LN<1' &#M
M1?$V(C\<&3?3=7K'V%46*!6:G&U0T*,UYRR)J8:2IFXCVKI+[_4(ET@![T(2
MK#S#F]P5.P@E0"<LS*-VA#6P(GA6"S0T"MW(@06B3.!'BHA6M":42[.?#1RJ
M>**U>[!V,E4K [4&+2JY6^!D!UMM,C"'1]DZ)1*/5:E/LH$[5Z&9R&>=3MU8
M%'-UR,H>UDE3Q<E)@;:OH^+*9)@ZPQ'U>&(; UOS)+M'21QPPBS"\G,<FUZG
MX @L%A K)3%LS)L6WVC0=L^E[6JK-<3+])LT7AZ3ET\>:IK2%@JT)8I"P?<P
M<=Q0O%IVV:XBIRR $Q-/M-F&Q;?368>J&OB;3=NE,BYCC'12#261JM*,HB9I
MSS,69RIN@O2*"YXX)Q3F]IH!^444Z/FGQM:H<?VX"5M#I!:LEBMZ4421\ TV
M+\"MI;(Q9@4N6MMW%2M$;1(K6R7X$T4Z;;2$ER2+<R<'5#KSWD048_ASDCXV
M*SF>AEE"I>X_P$E2,-A>^D'S-4XAT,IKD?YNBLZ2T'KZX2KH<GX.I_W ;QD7
M.2-K?9PE))$W[%[;IDC0-"Q@3:70/:YHX<24D\G*(G!%0D'BH^$_;$C3 LB)
M5E@V>Z 0U:6&'VL!98Q$XIZ?.1<SCYZ8Z5!]#%B=+JS6HS77K:!JV*P)4F\/
M?%6I[3KL@_B$/70G_F :H&(U'H^P6/!T- QFXZ'W2;WL ZRU.Z1RVZ L+8:S
M8#&88G_@X6*$W8.]$?PSG@6SR11[8(!0%HPF"VR%NAA.@^%XX#L%FV';[75+
M)*H "W$/86A8P*]7K?AE17#Y0+S?K @N!PZOM+' KU@.MZ4 KF\*O\"9'?K-
MTMFFY.2*G LM!H!CK*:3%)G!;W$?86='AU%V-'K<BQI\W11.UI<;0,;]#)S[
M#?00"7HIQ-.9DFM3\ISD:6S+"[,5C#LK>6)89$Y&4 I[YW*T1*#:Z]IZ;18M
MC>7+(QTB=^(7G+JWUDX>FXJW+MO!9[#<+2L'8A<D9DU=;6TU6X^^MUX)K9R1
M4 *B682  #L:UX[+!5U=Q@?$];I+GQK/7L6Q;L%.Y7E%L-[3)2:X@SD"G[F
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M^O#,4#NRW*8$D!=A1GMU (RA3#/H*0>Y6@%_C KOAWY]#!2#&?H%"(XHSVA
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M;XSJ=>,%9M8='>_6[E"BQIPD(E?4+:._ZR$-(*:1R<$TVJ@M8S%H@"V3*>F
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M8[HF\2=17O2KNC>8K/%^E^33UF"_KH\V$'D_*1&*N'I\@%&'"0\JZ9/R_6#
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MS]FE/D&8';,]H4:)$^<6YX5;+F2)GN.+D'"4C'EH6.=!A]*$8CQG"R0.OU2
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MF"]VN_V?_A=02P$"% ,4    " !.A%I(FRN4Z!,"  "9)@  $P
M    @ $     6T-O;G1E;G1?5'EP97-=+GAM;%!+ 0(4 Q0    ( $Z$6DA(
M=07NQ0   "L"   +              "  40"  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( $Z$6DB/XWO2*0(  +TF   :              "  3(#  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( $Z$6DBNC/DG60,
M $(/   0              "  9,%  !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ 3H1:2"&Q'VL^ 0  :0,  !$              ( !&@D  &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ 3H1:2)E<G",0!@  G"<  !,
M         ( !APH  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !.
MA%I(SCB5]48"  !Z"@  #0              @ '($   >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( $Z$6DB&*Z]/] 0   H4   /              "  3D3
M  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !.A%I(.!>R=* "  #L"0
M&               @ %:&   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ 3H1:2$XG=*_& P  -1   !@              ( !,!L  'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( $Z$6DA?'DF:00(
M "<(   8              "  2P?  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    " !.A%I(0171Y1P$  !!$0  &               @ &C
M(0  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 3H1:2,69
M)>CQ!   VA@  !@              ( !]24  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( $Z$6DCHC\><K04  %0;   8
M  "  1PK  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " !.
MA%I("!!0C*$!  "Q P  &               @ '_,   >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ 3H1:2*;:38JC 0  L0,  !@
M         ( !UC(  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( $Z$6DB^S(_+I $  +$#   8              "  :\T  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    " !.A%I(.>,$6J,!  "Q P
M&0              @ &)-@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( $Z$6DB)_ 7[I0$  +$#   9              "  6,X  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ 3H1:2)9C6QJD
M 0  L0,  !D              ( !/SH  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    " !.A%I(LX?PK*,!  "Q P  &0
M@ $:/   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( $Z$
M6D@!QSR&H@$  +$#   9              "  ?0]  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ 3H1:2&(.J@:D 0  L0,  !D
M         ( !S3\  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    " !.A%I(8-;]OJ,!  "P P  &0              @ &H00  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( $Z$6DC+\N/5HP$  +$#
M   9              "  8)#  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ 3H1:2, 6PQNC 0  L0,  !D              ( !7$4
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !.A%I(.*^M
MI:0!  "Q P  &0              @ $V1P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( $Z$6DB1LAA+HP$  +$#   9
M  "  1%)  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M3H1:2$]##6ZD 0  L0,  !D              ( !ZTH  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    " !.A%I(5RDU :0!  "Q P  &0
M            @ '&3   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( $Z$6DCKWDM!M (  ,(+   9              "  :%.  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ 3H1:2!]!W6ZC 0
ML0,  !D              ( !C%$  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    " !.A%I(4B6 #Z4!  "Q P  &0              @ %F
M4P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( $Z$6DCD
M)L0-I@$  +$#   9              "  4)5  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ 3H1:2,NBZR^E 0  L0,  !D
M     ( !'U<  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M" !.A%I( #C7+Z4!  "Q P  &0              @ '[6   >&PO=V]R:W-H
M965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( $Z$6D@"#(=JL@$  !8$   9
M              "  ==:  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L!
M A0#%     @ 3H1:2*5X172E 0  L0,  !D              ( !P%P  'AL
M+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " !.A%I(TI58%<X!
M  #@!   &0              @ &<7@  >&PO=V]R:W-H965T<R]S:&5E=#,Q
M+GAM;%!+ 0(4 Q0    ( $Z$6D@Q03W8L@$  !8$   9              "
M :%@  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 3H1:
M2&<1U\ND 0  L0,  !D              ( !BF(  'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    " !.A%I(<+A7P:8!  "Q P  &0
M        @ %E9   >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( $Z$6DAO<BM1FP(  .\)   9              "  4)F  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ 3H1:2,&N)F9- @  2@<
M !D              ( !%&D  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    " !.A%I(^XQRU^@!   Z!0  &0              @ &8:P
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( $Z$6DA#$ZN[
M*0(  ,,&   9              "  ;=M  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ 3H1:2+T.7=/C 0  OP0  !D
M ( !%W   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " !.
MA%I(9:*?&"4"  #?!@  &0              @ $Q<@  >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( $Z$6D@2+O_OW0$  -4$   9
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M970T-2YX;6Q02P$"% ,4    " !.A%I(+2PNH0H"  !G!@  &0
M    @ &%@0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M $Z$6D@<4]9-S@,  &T2   9              "  <:#  !X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ 3H1:2%O]A5_N @  ,0P  !D
M             ( !RX<  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    " !.A%I(2X^_9'<$  "Z%P  &0              @ 'PB@  >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( $Z$6DBKMF, NP(
M   *   9              "  9Z/  !X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ 3H1:2&8WX^R/ P  YP\  !D              ( !
MD)(  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " !.A%I(
M(:_^#-,"  "X"@  &0              @ %6E@  >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( $Z$6DCC:^C+?P(  '8)   9
M      "  6"9  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ 3H1:2#$W]ZF& @  WPD  !D              ( !%IP  'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " !.A%I(C(SP4)T#   !$
M&0              @ '3G@  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( $Z$6DB. #:=BP$  #\#   9              "  :>B  !X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ 3H1:2.$7]8DR
M @  :@<  !D              ( !::0  'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    " !.A%I(4X&#[BX"   -!P  &0
M@ '2I@  >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( $Z$
M6D@YE3N%  (   ,&   9              "  3>I  !X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ 3H1:2(5S(_K@ P  =A(  !D
M         ( !;JL  'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M    " !.A%I($@)JOB\"  !K!@  &0              @ &%KP  >&PO=V]R
M:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( $Z$6DB'+VH=S $  '@$
M   9              "  >NQ  !X;"]W;W)K<VAE971S+W-H965T-C(N>&UL
M4$L! A0#%     @ 3H1:2,3ZRC2? P  XPX  !D              ( ![K,
M 'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " !.A%I(R=).
M[LD"   *"P  &0              @ '$MP  >&PO=V]R:W-H965T<R]S:&5E
M=#8T+GAM;%!+ 0(4 Q0    ( $Z$6DA4_O/18XD  !+V 0 4
M  "  <2Z  !X;"]S:&%R9613=')I;F=S+GAM;%!+!08     20!) /$3  !9
%1 $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.1.900</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>169</ContextCount>
  <ElementCount>305</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - THE COMPANY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Company</Role>
      <ShortName>THE COMPANY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/Inventory</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssets</Role>
      <ShortName>OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - FIXED ASSETS, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNet</Role>
      <ShortName>FIXED ASSETS, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - PREPAID EXPENSE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpense</Role>
      <ShortName>PREPAID EXPENSE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilities</Role>
      <ShortName>OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://therapeuticsmd.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - RELATED PARTIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedParties</Role>
      <ShortName>RELATED PARTIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - BUSINESS CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrations</Role>
      <ShortName>BUSINESS CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</Role>
      <ShortName>OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - FIXED ASSETS, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetTables</Role>
      <ShortName>FIXED ASSETS, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - PREPAID EXPENSE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpenseTables</Role>
      <ShortName>PREPAID EXPENSE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/PrepaidExpense</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialData</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/InventoryDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/InventoryTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentAssetsDetails</Role>
      <ShortName>OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentAssetsTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - FIXED ASSETS, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetDetailsNarrative</Role>
      <ShortName>FIXED ASSETS, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNetTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - FIXED ASSETS, NET (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/FixedAssetsNetDetails</Role>
      <ShortName>FIXED ASSETS, NET (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/FixedAssetsNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - PREPAID EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/PrepaidExpenseDetails</Role>
      <ShortName>PREPAID EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/PrepaidExpenseTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - INTANGIBLE ASSETS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetailsNarrative</Role>
      <ShortName>INTANGIBLE ASSETS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - INTANGIBLE ASSETS (Details )</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details )</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - INTANGIBLE ASSETS (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IntangibleAssetsDetails1</Role>
      <ShortName>INTANGIBLE ASSETS (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IntangibleAssetsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesDetails</Role>
      <ShortName>OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/OtherCurrentLiabilitiesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - NOTES PAYABLE (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://therapeuticsmd.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>NOTES PAYABLE (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/NotesPayable</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative3</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - STOCKHOLDERS' EQUITY (Details Narrative 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetailsNarrative4</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details Narrative 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - STOCKHOLDERS' EQUITY (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails1</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - STOCKHOLDERS' EQUITY (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails2</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - STOCKHOLDERS' EQUITY (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/StockholdersEquityDetails3</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/StockholdersEquityTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - INCOME TAXES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>INCOME TAXES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - INCOME TAXES (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/IncomeTaxesDetails1</Role>
      <ShortName>INCOME TAXES (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/IncomeTaxesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>00000059 - Disclosure - RELATED PARTIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/RelatedPartiesDetailsNarrative</Role>
      <ShortName>RELATED PARTIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/RelatedParties</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>00000060 - Disclosure - BUSINESS CONCENTRATIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/BusinessConcentrationsDetailsNarrative</Role>
      <ShortName>BUSINESS CONCENTRATIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/BusinessConcentrations</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>00000061 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>00000062 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>00000063 - Disclosure - SELECTED QUARTERLY FINANCIAL DATA (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataDetails</Role>
      <ShortName>SELECTED QUARTERLY FINANCIAL DATA (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SelectedQuarterlyFinancialDataTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="txmd-20151231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>00000064 - Disclosure - SUBSEQUENT EVENTS (Details Narative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://therapeuticsmd.com/role/SubsequentEventsDetailsNarative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://therapeuticsmd.com/role/SubsequentEvents</ParentRole>
      <Position>64</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>txmd-20151231.xml</File>
    <File>txmd-20151231.xsd</File>
    <File>txmd-20151231_cal.xml</File>
    <File>txmd-20151231_def.xml</File>
    <File>txmd-20151231_lab.xml</File>
    <File>txmd-20151231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001387131-16-004361-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001387131-16-004361-xbrl.zip
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M6AUGX9J@&$MB5\,).X2S6="?ZFJF81\2SF9Y>)B/O@,XKR.,@$G3^DXFFQ*
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M LU@&ZH'F/L;/>_>E,RR8)1^NCI3KJ/1^1F57#^31\_WZ*XFTYAYKLZ4.$&
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ML<54R.;;*\83&D"0*AC3H\RF]*Q[ CB\IXNDD0)$^N(#E43C!*5Y 2E]-8A
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M=Z G_QXN9EQCB#$5J$-D\)VXJ+FBP+6K' +LVW!'6- !'C8XS'#8+J5+2,(
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M8#1*9EB3EN4?,JY5PR=:#)PG8%0'9_+&=RZ/L/A@B<G>4?&3JS,H.3[$238
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M3SE;;N*>>/."%8G7P=7 6+BX]CWD.'/F(&/1&KS[CV"-]%9-R)@BC%7-K]X
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M3%+BM;2.!I<PZ\JR;2PR><#U2%7"Y<".A>1,<E:T=W*)/5B/'Y$\-L+=TCU
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MCU P+<R!#A(.]LF'9D_O [4Z\<6]<!ZB+&"O%#ML'0P0B7WT_I"S4L7+E4>
MX-?L3%6Q+QQ@-I$-A1**Q\/8&&>$[H(3<<'DP0RCT=D[V>;I^DZ(U#F/J5Y)
M?A.=4&S#0L_43&R<;#-UYZ&_#[V'9ZI55D(P] P8,D(3[N+S&$Q P91>$H7
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M ,$&(.S-I70(Q&(#$'9"+#8 X6 HQ 8@V  $&X!P&.2*@]D !!N 8 ,0GAV
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MA?Q%?"7&:LH/Y\F742XS_*]<^O_*L3^)<5_$/P$;\?GQ[]?OO])JDI^ RPP
M($'RMY^N/G_XZ>^U2J_^U[_L9DMSLA..WG]\ ?W9!7QAI/P<A?>TA,\9 N#+
MB/>\"N0NQY,@F@I!J,3#S4%Q 01;]7:CT>@9"+29;91"ZRG'):<Q3FLB!O#Q
M)L*OOF1ID@(MPO7 \V\8?+56LUWK==LS\-O"Q@KT?!FF?CIEAD*[^(<(AN^F
M<!;>:.0'/K"0!8A4;9\UJH_OL]>LUFKM9D<2VRKSS9TXL'%_Y ^ ULX')!/
M7KY&((3YXKF*AKXSX'HIOS>4NM<'.?:I*8:! +DS/I,9O6^=,U X6Y/TIWFE
MI"YUDA^PX@9J)9\^G7_[M_/E@W-]]>OGJP]7%^>@H9Q?7'SY_OGFZO.OSM<O
M'Z\NKBYGU95"ON&DH'!N>N^\_O/Y^WW)W&OG,M!.@9N"ECH)E"0;4OX&D<T,
M.#:QBJ?L<PF,5YP6Y5@/J( 4)Q1X!WK;>/OK;FA \REQC01N_4&0#06)Z-Y
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MYV7$G-J%?$[W<IT$'I8R.T_(]^W.G\ZL*D]AFK*+,YU T4Q"8H0N4\8AO 5
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MK=*_%_W4>2_SFD[6OW4Q4P@;D8>XK1F^RUHPET8(;SFF6FK9F* H4V6EROM
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M\U6"8.8R]4_R6E782VBCZ('%5TG,C- Y29.7,O5\*N:<9(5>[<6KM&08JF^
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MIL/47A"4A7U5K!0)"N-9O7#*510C3CO@O0*%3SSZP#W&,+1?K8;T/1G0QX+
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M3^?0FVZ]UW";O=Z^'?I>JDIJ^_6MJ=Z;FZD4M6 Z9QAE_4#L%L6?OXX<QQN
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M5M._M)C+2EHY*/_ZERPYN_6\R=OK/'@BOU&^8O] 0-\; .@[(/#?__[?_^7
M?_ZJWJ+64%]IU%FWZSEUKL'MO3=:/R$G@L&^B='??OH C)XTFVH-_I=&K.74
MSQJUG_YN?<765_RRON(<U==%VEFDUQ;J7*/3!/(B"+[V\?4+Y_CYR\VETS!,
MA(U?G*O/_[K\?//EV[]G#KF_YG'O;>!U[FR0\<"ZX;CN[/=V)Z'4+U!HK6<+
MK>T^BU>7%VIOK[R0K;!V;,AC*ZP=&8AW7&%M+W/:R\I_=:HO4O[K@Q_ZR1TW
M(L!6>LNA?S@5B5ZM-M%+%")JMVMNK=W9ULZ.KWK4%L^JV\%J&H_PF!.N&/7"
MQ:&^>0_:H+,<YAM!T2U1VK,K!W;=7O>1RA=;VLHI'T.MU7(;C]4DV!N&L/6"
M.ILL(J=BMCDJ;.>B[VD5F,KM6LVG:!VVKMAA'GNM57>;G>Z^G?@>"D6%^C-%
M#EBMU%M^^&R0W'RY.?\X8U,^@8I$CPC^&R]$U.Y5W5IKS8+CMOC4(1XUJ.C=
MNEM;M[K\7I><>K9/)7?A+7/!S;KKK@=W8I@%XLM(OW7!_L(;7/H.77?69V5]
M5M9G97U6>XX\UF=U9""V/BOKLSHL/XCU61W.65F?E?59[9VSQ/JL]N(8K,_*
M^JQ.T7EA?58G>>S69V5]5B?NR+ ^JY,Y:NNS6NJS6M4/-9]NEGKAK0^/G%.-
MPY?/.GN9C+/.;,;9S?GG7Z_>?;QTSJ^O+V^N7>?SY0T!YBGI9YO-&WX) ?O&
M]-LY[$*CFI2C""L=4EFC.$J2O*8UYSA2'F\VSKC(-WP'-^V?'M?#Q(*7(IU]
M0S5N\35FZ)J?"9<4G6F%H](JFZNY$S>>N"U+JJWE4*Q5#]2C>*BBNG9.U)J[
M\1XZN_<&;=^%>/#8LD57UJ_$3NDZBIV_X#?.A>*4A6_/B6WN'$;'?1KGQBUV
M;MQB.P?&<8,=BZ&:R&YQ?0M _TV@UB.&9S-\!FX%[U8XW\38\ZF@CTD(Q6>Y
M (7S>AHGE3>G=LL]4]U34$4I<DX(?FO=+P>RG4->NSV*O5F[/8J]6?M1',5>
MNHB5+Z3&SA!I%&EVGQ] \^7KY;=SG#3))B9P+AD8\EL0G4;I ]89G'C8IG7Y
M^1Q=8-1L).!3D+M1<WNM1V(?; S;7AS5ZZ;;[#WBQWBYC3TB_ML3*@OHZKC-
MUB.>=4M,+S?C2YQ9K5'I/&+0/?FX4'W#/W/[[\6]"*()59PV>M?$DXBJ+S^(
M?@*[LI+HHGEZ-;?3?.0&L K!QH_A]1;.X9'K]Y3!OWK<HJ6%S1]&,-\B<.67
MP[]XM#I\20UF]>M-W;[GJEG!712/L=D UG7W)E-G&&>WV)ES2-7@I2[]2#3V
M*>-\I]IR.ZWZ7NSEE,_A=;/G=IN/"._V'MX4^-NMEMNK/I+_:,E@\_E+NSR"
MH]=9_['29>F\]K&I4#0026)9QN*;L]-T:^W-<FS+,JP*=5"'88EB/\[!JK*[
M#AW^'(5GG@VC.MPH!7L4>[B=0UZ[/8J]6?M1',7^JZMK#?LI"U)J;9S&WE",
MO?AW[NIZ[Z?>V \3#)2"G\>/VW-MF847+[/0<3OU1R*K;&&-(SIQ6T_E)(_=
M$OK!22+/4?3]<"A&?JCBE%;3]_>[G,[6_=E/D'1NHO2Q4H*V:,K+%4WIM&MN
MH_&(B]M6R#F&PWY=:[;=:G?-"^PESGK-#%-[Q$^GYW:MY=8?R_,X#7H^%"'E
M.8#;O\I53Q#17KS\TLR8+S>P+2NT2?OFJ905VML."!9;%F"++2MTHJ=ARPK9
MLD*G G1;5NAYMYPM*[37^I/U_-NC.)RUVZ/8F[4?Q5'LM9O(EA6:&?]P*J'8
MLD('<U2OZVZS]T@7,EM6:)<G5.^YS=:>U*@YQ*/:25FAIBTKM/(-;\L*[502
MM66%]N(8;%FA?=#';$[L7AQ&8',Q#^3VM66%7@CGFXV>6^L^$@5@><_F[^$:
MZ%O5S?:#MO?P8C( \'>Z5AS=]3G4'BEDO#?WYD'JK+:LT NB:KO3<GM=6Y!O
MU^=@5:@].@Q+%/MQ#E:5W;^@*EMHZ,#C%NQ1[.%V#GGM]BCV9NU'<11'K\#:
MTD/[6Y&DVG ;[4?,-Z=1D>1$3MR6'CK)8[>$?G"RR7., ;;TT/.%'UMZ:#EK
MVWVIDD:S[M;K:S*UXRQ5<NR'_;I6:[CM9G7[9VU+#VV-GH&6W5;7TO,!"2G'
M5GK(7--_LB3U1]/G+>OE*A.5+JY45%Q@-Z)G?Q..=&<(6E5Z!U^L%Y?G9 DF
M\2=I["'*G 4^O#(6Z5TT=&"8&%]W!"QO3%4OLD2,LL )_)' :'N:[ ?]%DQI
M"?6J,Q5>#/N$90[N'#^A$=0+?@A/!F*09EZ $0X3D/^F:BV5BG-.0?RS)7):
M+@T2ZYH#-%PLN!)'&CF<X)=G]>%*>%#GP4N*RW1J35ZB [!X9-RG '1N0EI-
MK<.35ISW68Q3X="\# 'R_7!^S[0\5.UI\[&@@</(\<<3SX\IZR$6@^@VA-,?
MFHN>\VI5YO6&%ZZ']3+HS =8:TMJV_\%7X6T&.2'5/T"@!]F8P%/)\X$CA7/
M6:(A8$0 B@X^!FOP%J'Y@W#NO"%L(XM3(4(@GR2#4Y6XY<+9#H(,QWV[2Q 5
MSVD#]=I6QIAE0"A=#/^W,F<*U_<#?8DJ-RZYNK;66*;IGXV\L1],WSK7TW$_
M"LR;Y5UG?@\+7U_KOGJ13\XZAU&K.UGJ!W[.T(%Q>:ED34@<@-7.(!KW_9 (
M 2^ 6[A;@&" K2*[$W@/#?V([H9A-DAS_JIO%$S0CAY"H(K^%.XC>@^_^UZY
MKL QQGXR] <\O.+(?GKGB!\3/^9I:3@@):"Y1KWB_(8T=R^642P/$8MD E<7
M[F0 ]Q;<&4C%P)R3G/O#=^?Q+7R$/;K.>88;"GSX^"[V_O0#U[GP0F\(?U]F
M>/NYSE42>P*^_Z<WP2/])'[X@\AUOF5)@J]=1QG,?#Z*82FT5?[B_T:Q\$KX
MNJ6%_: %1.@B,9BTD" *W?R_LVJU^8]O+I&%PK8H/AO%0CCW'IP1R$@Y16!U
M@EM10AF*,.!1$(O]!/ 1, 7E!! -/9BY7.@:X<J9(-"!ER\'1+99^H*OO(4$
MQL0!,\Z0F*2PQM,H++V#2>6#FR0JUU+5+JE* _(%*0OI:48C !0")!\S<J9B
M<!?"N+<P KR$/T@:HM6\+/[7>S,(M2I@#@OQUL&<M3CI,HBL!9X7L0>LL?!"
M73Q #1$FK,.]:M3=9A-$_E?UAMOL5ID#O:I5W7J[3KSX4=W0E8JA5!$;KN*<
M_CTHG!7G4BOL7MDJU!PA ,09P3MR-D1S#.<(@N@A6:YA;,/DLLSXPO65:::_
M_23+%JY9;KEQ:-66=U$&\M^ &,XE7]NX#%W<T<3)??$&'VDISIR:"R>P/Q5H
M]\KUN[L",JV7*/I3K6VM*-,32O)L>OS#J<[4K+JM[B,NS!,L]7,@OBX@L\Y>
M..WVT>'X"!5M@W+VAESV/:5IBP2SR\1P2S"'0C#V?I'DTK/D8LG%WB\K$TQ]
MET=F"6:?"&8CK>5*K(E__4N6G-UZWN3ME8Z9.:>0F?=^,@BB)(O%#6S\71 -
M?O_[?_^7 __YJWKE>G GAED@OHQF7SX/A[]&T?#!#X(;W(@>PAG BN&/;V+T
MMY\^Q-$8;;EGU1K\+XWH<ZU^UJC]]/?-F5=O[H0T\%(0$EE1<<UH$T[OR"I\
M2SVG!JK-E$?==ES',YH?%:S*:(0.13K[!OK&T1,S%XZT*/I%!SR]W86Q>9&)
MV;;P.PQ[["Y;^#U2\?GXFAL=/+;8%GXG>AJVA9]MX7<J0+<M_':J.ML6?@=<
MR,4>Q1YNYY#7;H]B;]9^%$>Q5T9FV\+O:.):; N_@SFJUTVWV7ND8KYMX;?+
M$ZIWW&;KD;@)2TPO-^.+M/!KV!9^*]_PS]R^;>'W/%RU+?SVXAAL"[]]T,=L
M_XF].(S ]CTXD-O7MO![(9SO5%MNIV5[KNSZ'%XW>VZW^8CP;N_A38&_W6JY
MO:K-J]GU.>PTM>GH=5;;PN\E;\Y.TZVU-\NQ+<NP*M1!'88EBOTX!ZO*[CIT
MV#;L._ H!7L4>[B=0UZ[/8J]6?M1',7^JZMK#6O;\YF8L@?+,%IBM#INI_Y(
M9-5I=.TZD1-?7:FVQWY$QVX)_> DD><H^K8]W_-%'=N>;SEKVWT[KTZ[YC8:
MC[BX3Z.=U[$?]NM:L^U6NVM>8+8]WP$=<<UMUUIN_;$\C].@YT,14IX#N,,O
MWX3C;J#3U$MWS2H#ERTK='#ZRUZ4%6KN%@RVK-#:V&++"IWH:=BR0K:LT*D
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MI]//42H.2ZVJ&M="XQ?G^N;+Q?_]QY>/[R^_7><_]'YQ+O_G^]7-OT]-T]+
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M0WE4_>UI>Z(3LUS3<LVG<<W&EKBF3I30"DT>9$9*(HQ%S(\EQRGA>D!"H5:
M2;V;D05)94(][$X$$R"1+)%%F$"#3=$E 33H#_P)TR8^3-2)Q4927@O*<M$
M2!'TRQ$:Z\S@M78I>)Y8P/8 702Y_:7^J-UUSC7H-I:G\JOX#6\T@ON)3@AE
M1[BH\)K45A;6_&.\:]#TPVZ @LUQA"8&OI'Z C8?2F^?6CIF/LC!*-*2S'-L
M4U FG-?>&].N,VO2(:R3MB12*J2-QS2^E+X.[T;A;42W,UQSLFK0W' J@@(-
MM7!@7/DSGP2 FJ%1,)[FU*!_!(2.AV<3+P; ^:1PZ2%S Z1^&GL\B;3PU>!.
MC-'X-,5?PVR$#ME8K9A<M!&&&:C':?&!EX4#CH*=1 E@F5J6AW>WS/PVRPW"
M005"%PV:"%PM_OY[&#V<@6J&':C"9(1GFR31P)<$"T>.MJ=?G/_?WM7VMHTK
MZ^\7N/]!*+I %V!4O5OJO@#9-%WT8K?M;=/NW4\+Q:83X<A25I+3IK_^<DCJ
MQ8X=^4T6;<_BG#T^CBR2,^3,D)QYGA?73RJHY<RMVGB>RWZ*0.?%\,?2%=?;
MOJH5YK,G4^@Q>X\\_>$V2Z32L*7"G3W\+T<ZB\,R3RUAK3U2<<K["TFS49E=
M7BTCOK.6)^5P+F02U^;\"8O.S:OC8AGT+;P[L'1W\%,C(*R7R,)S]8&YY%Q]
MX+3$A$_B>3RWW '/_,\H#+X$WZ)W830J4X+.\EO0(^^H.%ZW?.('_LQ)^OQO
M -)+_J2>+>4A95Y+=HMS_YF@58Z#0()40$Q/E),^MSV#N*R[,U'K\J"5=U ^
M*@\?&GW=+/X3,ZE,I! NC=_L-+*X:\O26."TX4\EC!??R]^&][2Y)9%.DY8,
MYJ*)(OS/?.Y8/<6.^CIRZ5:!.3(!VTQ'\KYGP=SDL4HC98*[4Z;XZLX._)5
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MW:I$@,(#2#H[/(!"N100.0T1"E%)B%!XZ"I$A,)=5Z8B0N$.6]P)Y)U- FM
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M!["FF.=Q+9NXAG+*.OYC@\_)O0P-,!3H/Q1PB>79Q+9;BDO0:O5OM0:Z@Y'
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M1LP(_UR@0,\)"A9HL>N'L'R43:GX8]+3^>9/QS@U=E3Y_SK!PMAT813Z:%@
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MPUQ=:?S(Y"LKN!-O=?M)EV](,"-<,;F0\#\5O%NO/BPN[)UH<]O65+%(19H
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M'VV+>"GR9=XO24=-[C"5>>5FY0/IXAGZ@;O,@9RDHZZ;-]FA4V$$G'9Y3^G
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M"AOMY! D(^<E@4N&(WX5Z,WG.*#I4QHREY/M9Z+*J/_U??+X34!#\#+?P3\
M1=\UG O[TU\OZ+T7G<5YJ+SLHZ1P@1F#:H 4Q<^3XT.ODS3; !419*AFF07-
M\C3TF1?C-0(^QV&>+6X^&V>;'AZW5[\LU&_?]C(P3 ZH(5K*=[HJGK+< ^="
MMB2VJ <Y72G(OBJ0* M 6M1^K J)TV>:^F'& ((+%*<T#1\]R)7Z^'+I\1K\
M^IV2CMCI;6:CPJU;S4I*-. QJB=?0JF(C^"&DZ#?;U:T0*[A$*M#X&QMJU2L
M7M"V?IV\L[4J]?N)]_O>TMSDX9)&S;6QOJ_UM.Y*=O:HNRG5J2'$ 88>[>3:
MP4!.FO3[QL6/212LO/C&\Q\,B%!1.<."7L4:!3()CO[7ZM7M^9*0<$JG +@J
M\BP,H$I+5D2Y+D_93.IN-C KNYD7U'0X0&%63IHK!#79D*.MW9NL5DG,MT1]
MU2.Z=(XK1:C5[%2%:!--#IT^S>3P&-"5.U1<0)D%00@+("^Z]L)@'I]XZS#W
M(B-H>GB<7ARR4;]U]<?$@ 98-EI*N>TU#P$F$L:D9$,&N07-O3"F077EJ"?L
MIB9V&V\S*=P.M*DHT<#*J)Z$)]\O5H4HF71*EZ$?8BM0(PI*>%&9;W]#T\?0
MI_/%C1%1O5SN2WSTFB 7^M"RH &;G9Y2D1G*EMOH7-8\]I,5O?6>9T7^D*3J
M0Z0^8K>X,BG<AI.*$A&*#.K)]0R F#!J4I/O-U;W?^AR2=.09L9S:165LWV:
M7L5ZBR:33-[_9KVZ'5\3[O/8V1C-NPS])/**;'-FWA?3TW,XCNSUJ=Z)[^G(
M<4#&2D=UK.^(5&SD?WJK]1^J7 87:0S;E)"_R^C?"WBSZI'VW&S7T+HM%V]0
MMUTD7D$X.<9LM),+PE>TA!,?;V**D-HYNT\IKV>"&U@]N9Q:Z@G!9<KHU)!B
M!5A/7F<78O@2.ZLBJ<PC5_]LU/<[@?)^9M=ES^\4<4/-:F'0EAD/*@=JK(@I
M)$7,W=[-2Y;3%42I<-;/,Q4)T= X?15*5^1#28 &0#9%.C[G800;-T%+;O]T
M_.[==S\M]KV.+U4SY%UT*9RMT]6JU>OR]L^3][5>IYZ>9H[@GC*OD$)E%D@F
M/LN@"ER81/!34/C[KQY4'N<90-"E< 8"M6HU"-H_XP"!4B=M82A8%WO+)8,$
MCSE7><-EASOJ><,E\"Z%ZY[77?!N_XRJY\V7MQL]/\^R8H<IFCUO%]D44K)A
M</Y246])I7YJ'/BP45'['-&NZROI GOM+9AA3M!1N@OD&57=!/"49#@08=2M
M=[][3,[*_$UT^XB4KKTP.'N&%W I1"2OH*CX2<&@'.>BRK)YDS% @-,=R&##
M6ML3:^[)X3E:9=T#1'G"7%A&F1D/?)G;?.A@YN?A8UDW%16./WH1W$F_>: T
MOX#/A$ELB ?JR5UBM$_I)B)UM&CPUZ-@%VTE.>'TI&+8\^.0B5\ C-G8$,OW
M>;Q,TI50]0YV<WZN7 Y8\;E;;@TP8[/JLF":'$M#-9768"4KF<7U#JW!/<7-
M7J'%@MZ'H'F<P\,R':OU9*[N^)J4K"[ZJF@F!TR/8EU\E)#8T/(7WJ>#Q0FO
M[A/!0Q?/_T5?M,9)=&Z!H5&SC8P.$2)HJ#738*,D)IR:,/(IT%'Y,3@G4YC5
M_MD5%E1*51!H_H:BYQ4*:2<+H)FREZ]I&B9LK@M.V?K;8$N'SG6_*]7L J!%
MA H)*LVTD!#$; G!MC^,? ITS)@B 2AS'GGW"KLZO[M"@U*M"@6M'U'TODHC
MZ=BWHB% -$5?EYOT\S#SO>@7MO76.P,]J2L$]"E;@4%'AP(7/<K)I14Y.1'T
M!!@F=0YBL?(SC:+_BI.G^(9Z61+3@)]3="-U%O1NEY,]:K>7E1IB%""RT5"S
MS/0(L!W_"GRD8A3G3.ET@/J21$6<>^G+>1C15%6&2D/G%D :-=O Z1 A HQ:
M,RU0:G+"Z2?<K0HGN*#K)(4DJ9O<RPL]2'3DCO>N1J4[6U@E+2+D&!54 ^@W
M\.!+24X$/2G%3(<D#N03-G?>)ZD^ZM&A<HL;I8IMN+1($*%$I9?&NW!24M%.
M!XCKXBX*_?,H\;H!> V-6S HU&M#H4& " BR5AH8"$+"*?=T]E(ZL$U)@I]H
M%'Q\N4PV257=J60 G[.SER%FU&<O-DR3PV:HIKKX::.8Q!'ACW5FY(%)X?7)
MFG(F7,AL[!,*0N64')[7BU61%ALFQXL:"P,Z2QL#Q^30&Z3F$-PUN*<,\(JH
M@8@IGK._J=;,!EK7@5ZMNMU@KT2( DE]VFF#OF5PIXS]<I;I40.A)CO,-"BG
M08RDJAHO-1E"M'1UZ\,*#P3N'"E;W&-C&SQ^6_-J>1[&7NR'; 0D66C(<!G&
MZO3VV@!C6A?7+/@FQ]X(9>5[X24K29:D9B85-_ESQ8\D1T_D(/; L$ODM%R7
M4L%6?:X6!1H0*=62CKEN;LYN;S!!H<I-M4&$1.L>&!IU97QT")'!1*V=[L1+
M\/R  S8G7O:@L4W\Y+0Z9$.95D%(]G<T7=Y01NIA]A..;BWO76<+ZM/PT;N+
MX+)-"4 =E(TL3GV#A?(M%V&@1P,;"R4UE^<SDM8\1R2F?''B15'RQ-.]ETE*
M@J2XRY=%1+R*A9'\V[^_/_K^_3M^X^#?OO\=^_?OCIBH;$WAR@&-=AJ<WJ;4
M&ESH2=(7UAZ:MFN3N"VK)BO7+J:V^1T-U!1*R8732A(<&&C?M*DNVK0F5XVM
M5IS3W9(RFJ*_'J5D0X,O>UVE>MI 2/QR(>1Q#AP(M,':A*CJQ<]T2,F3W(LN
M;-?(&F#<@A"4P+A.DS5-\Y=KIB^_0//W(N0W]_33E9G%K3/J5[[MA?3TB-Q/
MKY)2D=GPF08EK/@2"@>V&GZS9\>NI'3Z:IA>U=;C83(9&MSH=5-/4ZCVZ?,X
M9QJ&; L@U&)8/WOVHP(.XGY,DN IC/3+01M6QT6PK8WI5,+NY4,#MP'*RJOS
MBA6?SVHO_BY99P]8GS?)IUN4RTKK5^(;6C3 ZE&P"Z:2G%!!CP-%IW0-9RI9
M.33Z4*0G=_L@HEGI]I.(:EHT*.I14#H9H^QWR H)!!\.&%G"9UK8V,!E4IA8
M[N!Z,2(V<0E?/&':P@GUC;9-@0@]#C#VOK'/,?7V1>C=097)D%?LX=EK#TD4
MT#2#C6+^TK/3LF=WB9BA1C4Q9<N+9FH:J+#T"OU\]G%^,;^=G]V0V>4IN;F]
M.OFOGZXN3L\6-[\A9W_\/+_]!1U4[0[N30P3P='B"%]/C1%RPP[S&XQ((@75
MJ>&U]P(GAG:'OEWB*8Y[U0JK#GK;E&A 9%1/>[B[%M0XP,,C7_)@,$745-3.
M(Y-ZE:7HI$R*!D!F_<R':=&&#0>4JNJM9?%6[3:T0^5V0Z]4L;V/;Y&@@8I:
M+VT%W520X4"&M7^9VK78>96)'4KO_LW:H;0/8=$Y%+B/%.9PT">>^>+/BM#8
M#Z5KCE8<KI^][E&]^P"VAAR- ^K74?4H=LG!<]):/.28W%!*+I.<DO??X0#<
MX-@!EFC!L/C  40$!L< F@QLS\]9D.S/KM.J%#[H^,6+M&LC):7C8S.=JIT3
MLRX9&N3H=5.<DY6+I0Q(F4-:>REY! [R;^^^?O?N_1_(^W='[][Q_T\R<1_6
M$\_._H,&?R!Q4OTU%*];@)=+]G-A=KMIM+P0; *?3.9ZPE0IV9TEFS1H,*=1
M3#4?)K$!;=_^=@,W@-*'WQKA]_[WOS_Z_L._'[W[[CTG?__;WQV]^_[W1^_>
M?Z\!),9T\%D0\+MV7G3MA<$\/O'6(5N6-MI4%WVQ8'0:UK(VI!7BZN5" W-K
M5:705\U(>&9"&!-?\.* X(+F7AC3X,Q+8S9*LIGO%ZN"/^7 -M2A'^K6?S:,
M+B%H;T@3@OU<:"!HK:HB^EH1DD!0XL">O-*U7A)/O<>PVUO@BHUH]5/'1K+6
MMH)R!ARXZ3LS'7G4BNN4>\SI-BZ\66JK1E\C(L=7<GC1.*MN)YXGZ6EY-U&^
M -ES-#E,AM.EW1CS6JN\(0+0S+9CM)8F7O.]51SP;0<-KKWT*N6500*^G;NF
M*2^&915QT#-/%\CI,T@?V]%QHH'H('5[(D!'C2WY&[9'"9(H\M*,K&DJMM]O
M,:)5U&F;U7$!JX:2F:9#I\X /2J['$C1J%&S%X52J <O[,2KO@-:HV*8&FYM
MQ?N@)JA1PZREHBW$1)00+[ST146MN:8&FJ:LJ"4+:LCU%Q;5X0[S&<G U9\5
MYT0G*4/6?19L:,!HKZOI".90EGM20=_>M9Z18R(LVJSR#.08L6>YOFMC#NGB
M3C++N++34D\*+OV:3D.*%U3&U9P24)B6<@.*P]NQ3 JKGA4<ZK+P Y2T0AFZ
MA=L\]I,5K<OX]N3K::G=%L,PJMRN?Z$D10,KLWYRE0N@)IN:R]BJ*]]X$<W*
M!'M]M2>)RNDIK%K%UA%LFP0-6-1Z=4%2$F"J@'*29/G5$DJX9#=)I%\3=:C<
M3EI*%=OS5(L$#2S4>LFS4<;+H-X#'<D8(0YL_)@F67:=)DMMCE"+PB4F%*HU
M\=#X&=>1N:Q8%PR<@JPY"0X87*UIZL'EAK)(3V]Y-SV]TZN4?6JW+E/JB-&X
MDCX-I0N5%7U5*PG+E>X;&D50-8S&3,%H%@>S8!7&(1@#J;NE>;IYUI+9Z;)E
MD$&MU8P5)QH(#E)7NL0"*Z0C<B^8CWC.C]?BQP'/!<TH:]\'9MXI6ZY%":_&
M:49E#X_;+%D+]=L)L@8&--"ST5)>;0L>#K5@PX4#9Z=TG5(_]/A#/FPHK> -
MWG_P_ZEI R.'X])Q?:IWJL?IR-'@JU]'^3;ZAD,XLP8/#HA)2P;;I<7$"S6K
M!1JN=;U./4U5N>[:#!E>1##K@FU$^LQM4DZ"&5E5)6HV9$AQ(RFH7\]'C @)
M8*!HB^VN4$WKO+B.U6Y018AFKC)IIRZK$XK@])O2V[Q%LA/DRETF<=(>!":S
M5=3.(:1760*13(H+1EK]ND#Z%&8^V_YY,4V*K 04HC V/ &4\7(<PHIYG%/6
M8*8WF-3DKM]C,BG=?9M)18L&3CT**JK"\Y]+*.% 47/97[^W&M]#?%Y;<=?(
MXO0>CX7RK6L[!GHWJ/I>H"JF]Y#B9EHF6>@JOY)2$A$?J'  K$(]#V/<]425
M=,2.'[<P*-QYSD)!B0U(1BVU/@K7+JT[;YM1I">?=-UD0)*.%AN6>O24*CDG
M7DSN"R_UXOP%DU.2UX!F1!GH74*J5^TFIK3$N,(!?6J:'BGH;O)P@&L3USAG
MO2>JY!7,NC*<D<391[I,4BKH;KUGFIT]LQUMD@9L D]?YCE=\<<:&"=KPX@W
M3,_:?H]?=)]+M]>FD_/Q]O(Y7(-L_X;*KC_+R!T76@W3',1B&J+,SM+7?*0Q
MU:?\:*G=#PVMRC*L)5)LBPFSFO+=L^0QS.#D"0H/X(/4)<U[SQ Z-$Z7#BKU
M6LN%)@$N[Z52K0L/1H/HE*"J9U5=7_OH9:$/&[ P*MBHZ#DWL.9V":"!)C6A
M9<F*)JXW3%_ES%=?.CPB=\ M$C($/Y*CB!XKQ[4-*DR.P.*A8+#'"QKQAP-^
M/]/P_@%&TR-;@M[3RV)U1].K)3>V<9O)#I5CA;D$ZW8&-S$\3A(::&^E?A?Q
ME3#B"6DDYN+@;H%?WGB3KKJA'1/U5:I;*,2E:;XND=NBD2H%VP4CFQ1H,*=4
M2RXZ7]]DXV18KK%5:EV$,>4[\3XC&X23H$-25(F0F@H?2KJJ&9 "I(33&N&R
MUV8?6<GU@].&9TN2, E8RZ6Y:;-GT+/;"Q_I?1C#*HGY\PAJ$D[4 3N]8HZR
M4ZPT[NV>ZMHY%K?*K!&%&4Z+E*EYS=N"EYVYI$_\%[VGM>)U7L_9UAS),?0Q
M(G+1]MI*7KOUN$<8LT7BDH(,<3M9K!DS).E=&D.%#2/Q*3$C *C&( N$=CBQ
M0U2M[DB,'HXKY;]=K?DAT]DS3?TPTV[C1\A!@.!^,VW=K5((=ESW:FZ&.)SF
MT)(#T)T((:B!+2S8 ;*-@A! V\)0:T=]D.#N5WT4N@_'??.,KQ$.H>1#@&'9
M#%MWS)FP(U32M'=%T<3CDY="<AYN()9;SN%(;#$B@*+"$&OW>1!@E%4=A<;#
M<8\+FN5IZ.=E(>49LR#@Y6Q&#&*#+ 38M3/7UK5J!6%'N)7VP]8$:2VM?$NR
MB,.#\,@[ G^O, 3HMS38VIL?+/[MU-_% , U"<R"OQ7BKE]VFVA>SN16WGEL
M;W"2K""ED:?6+N!AKRS,Z0U-'T.?BG9<4#^YC[D4TRN^^_^LVR=5W31B^T'6
M_7X3S8!U9*AR:!]SF:0I]'"&[<]BU6FLD#Y"#K:!I31SZ$AI"3DHZ*LTEY*)
MROU'<Z):8KQ4:V.P:;\\@!\;C+6[9VOF@X*M:2^M@FLF7/C6.,V?5P%'W_L/
M)?;@+\-'VH+R1YJOO51ZPW87 EV@<W>& URWES8Y?G=F0A^@O0R2..LEQ7$J
M1,!#/^:7<O?HHP9>I'&;SF/R-FJ]QMRCP9C+]NT$:5-GL?%^FT'+;JN?\4RJ
MUY3&AK _K/0U]PRNF$2=A7JU//&RA_,H>>HK26=FF219V*"\,FU808_&QUHH
MJ4\E3I8$F CG0O>8"IL80#M^#3>@P<>7SVS'/X_K&HTS/P\?^=OV/1 <(\CQ
M3=F1AG96 0.EH 'Q:-6E1SYF-S^1\XNKGV_(^>+J$[FZ/EO,;N>7/Y+9R>W\
MR_QV?G:# ]RMQ2P$OMB./Z*M%=-MLAOX[^=3D^W2=]Q8V@W]CKZ#9I#MT;CN
M,&Q\BN0)2:N/\7Q2?EN4_17^[</LL^2S3Y&5V:=U"5ZO_AR2^\O-:N2:1FZ3
M3%4O7H7MYN]H,*E0RE0"'@<,VG42YS%;T-^'=Q&=91FU+&$I,TU7Q%)G@+Z,
M99<##9RLU)2<58,)5L1AS48\SH<#=74UFO,D/4V*NWQ91#/?3XI8BSDSB]MW
M[?N5;S]JKZ='@S8+)<TEA=[ Q/A(TQ<&N[<D*$6P>4_(P(&[]IB">IZG8<85
MO$[I*BQ65F-1R3>=SS.8H7=["B8T6+35M,_Y!8R3!"4K#@!6Q4C:&02Z<(B&
MV&F<R:AP*\*DI$0#*J-Z<E0)\JA$5H:/+RNC,SZ6-$V96<S >^V5QAZ>*;V7
M4GV3YVHQH &8C9;]'DMPX4R;J,H7PT;7KH1TBW**ZM$*556%HQMD:/"DU^U@
MZD3/8S^ES(F>4O'?1OBE/.+N?Z'>6H#C:J(##>L4&+7D1@/&P2I+P>P']K\@
MA[D5%.-;4EY(*@J]NS#"%""33:[V0POJT_#14&/*CG5:P.J-,4-5YD-8&-=6
M9VD^+@DAREM28@4CO)X3LZ^%VB5?#\^T\%.H;\9=@P$_X&1EY9="!(4Q#VO2
MF1J6'R<%6XW&N3$8;,<Z\>RL-:9G7I;X\&-/J[/ZI3]?4*(*#VN,VIS=C<"C
MQ(P D1J#+##9X3P05*JU5N,2-QZKA<*U]S)J'5CSX5@$=LRP6P&63$[W*(\T
MO4LR.F[YUU98N_9;"S*LT*LB2PO*5A#:FX\6?--"3V.&&7H=)OS04RLLIP64
M8;]4D&&%7G-I<;'9L(]:FK3X$<S%>K/LEX@-9OS0-"MN7BPVHC6HL0KATRWA
MJA&! +%&XRQ J^3''''L4UJ-6718M4\0UC3-$ $X4[]5*+7G1O>\TC"]57?&
M+'-'40-8O.>]@[L,1D$( &UAJ 6P#5+0..'1JO?=99A??CF[07F7@6T2JUNY
M_M^+$!YUM,J)M>!SFJ1H:T8K4[&/"5N<R59A*761"6;+6$1'Y9(E;,RQ"2!_
MN6:*P^/C< 5V#22V36$0,"D0>PTS(E++C1Z:?9I+&&5*/7BBQ-<R?.;W^3&'
M1#=%S6#*L%[5=]FFW5BIC3!OIMH\V'!HJ6\7?0NZ+.* O%D+&+\%%&:4;;W"
M_(4$=)UD(9*46OLURM:+'*RKS^U6G0>QG=+K;;F="BL!A[*=.J]20+?=3AD%
M(0"TA:$6P#9(P;Z=ZE>];SMU/K^<79Z@W$ZEB4]ID)TS)$ A(R@#<K5LU!+1
M+9_Z^1S?^;(SHW/QR\R$!IBVFBJN@'$^ JU%,B^BS9=#@;'U[ X2A]NT=L@K
M)!9\4V'2^HV17B:4F!SR@D@;DVC?QFF:5Q9NJRPS7($UL$P%/9WR.M1UZ5$"
M3J.D/=9PO0S2-.TBC&G&G'M*@U ;3-+33P4SI=HZC+6(40),I:$677=>_"N)
MX*5<F$@Y"PY<+6@9'V"FV.#*0.\25[UJ-W&E)<86Z>E35 [QE/2 JH. V&62
MTYZ42SWY5 !3*:W#5Y,6,[P4>AK1%0,]KL1*^[WXUIMYK%&6[:(K!Q$VU.O=
M$S9<EX+(W4OC,C:VT"$WF1=O[8;Y-<UD8G )TG[%6Z5RM=2X0-BKIWP+3/Q,
MW@0EX5N(50,.IZIBK#GVXD=%;JMQBZK$-[F7YGV-KJW'#3\>D3MZ'\8Q#& V
M%PFQ&)L78]'GIE[JQJ5Q8->L#JOL%.MUQ*L">U%52'@>+Y-TQ2MM]!5YMN5V
M6H=GF$FMPCQVK&BVR</TE4KW?+Z^OCC[='9Y.[L@I_.;DXNKF\^+LQMR=4[J
M8Q,ROSR_6GR:W<ZO+M&4&\@IO.0&+T!HC_*;)&X3)63EVDD1F]_1X$BAE,J#
ML6U)*!Y_"4L&+(" 2K:WWC/LM R8Z% YSI]1J=A)EVF2( *'2J\^?  /R8$)
M!T;*\D";Y(@XJ'<\\YRN>C,&[/F=;F&'FM7:P=HRH\'B4(V-4][-R4]GIY\O
MSF"^N[RZ/!9SGB(_8.MY3_/&5?4*D7BVZ#Q):ULZYO=2.WN=JE_E^NDI/>GD
M<++3;]"C?:X@4KZ<V0VU]1%/!Y"NPGI\5)18+H1::>GRJ;P=U29,[[VXK*1X
MDL19$H6!V"[$P35K0MA-B,J,Y8#PHOKIF+Y9<D>RG=8_W&5SM"HF[D+PY*YR
M']9(MT\;LH](2SJO>->4#P&4^@MD\PETSQAMU6!0Q3E*LB*EM_0Y_QCIL_]V
M_YF#&7R&1MK9.%1\XW4,2;UAW=%Y^],9.;GZ=#V[_ 7'R"K+S[!%US4SV;=X
M"<G X+2<<Z_BK5K.6FHT".Q545,Y",X7*@YTCOLFO(_#9>C#W3/)OCYW;,OL
M-" ^R*!6/-R*$PT<!ZDKAP8^?9HM?H%@P,W\Q\OY^?QD=GE+9B<G5Y\O^?WK
MZZN+^0F:ZP)U6<R-)^\M$6W@<!L,[56]'1C5DJ.!7K^.VK*F9,."SA<JS.KS
M@&:6B6%F]'8F>LQ Z_-L4$'B\O9J@63Y5K_W -=<RI+HX3\H+%GA_( M7GDU
M(E&5P-JY;2W5[:-].VF"]CM_6XE$@^_=V*$M&\C%'I&&X"-2BC[BL091"4N(
MQ^R9Y=K%O9$"$X?S%T?,JDLOCZC)T:"V7T<IYL6VU0MR\GFQ.(-5YLW-V2V2
MA:6V^D:/![;@<WPCQLZ,SLT8,Q,:Q-EJJK@IP_F8VP-.[O-J7G1>3FNE_7IT
MF @4"+5<KP[AQX];^_7L^?Q/9Z?(7"9?091O3[77*+U>TX;5+2SMC6G#L9\/
M$0RME94]*&<E):^\:MR=$]4D!;25MS@LLN9REB9@;T*=+]#/,CFZANDI 6MQ
M=CV;GY*S/UV?7=Z<X7!M/R9)\!1&$1LBW8J!UGOS@3)<.KM1YC6]WB !DP-T
M&ZV[<*UD< >XD7( >V>]R?W!30M.Q^GFMJ9TLM#[V-!@U5Y7.?!Y.[O\<?[Q
MX@S5:I$O%AHUV:W]J VC\T".E2%2/,?(A09ZUJJJZ^DW.#&[0[V55B'%/DX<
MB.P/,9K9#@"3PT*.%_/9Q_D%HOIWI_0NMW:%.F*WIS@FA=N',RI*-) RJB<?
MI=SEF+U9VY@^#Z:EG@Y(1D^E(44*I3Z/='EU>W9#KF>_S-@:;:)[YKQ@WD,2
M!33-(!B9OQAO"&NI'5_YMWC(RD)7*0FJP?(;(IC(+,_3\*[(H2(-R1-R[:48
MSPID<Z'VCKTK&,#O-'MOJ%EFN&J8T3B0H1I+"+Z].OFOGZXN3L\6-PS!?_P\
MOT62]U+?HQV0L&?@F.3VLFW"GI8<#<[Z=514H($[S8P%\_)'85=_4,O$,C'.
M>L)8>GK,2.L/7)U<?3HCM[,_8=F<+6@$5>_8U)^_W*9>G$%]KR3N.]WL9W-;
M:]#.B';-03,/&IA9*BH7'^1LA/.1)B,ZUZ:ST-[3#9*  9F6?G  .WJ\VGO)
MQ=G%[/;LE.T?%WBB6(LP^S6;Q<%GUN=I[H6QQ6LD/3Q.@6BC?@MZ)@8\8+/0
M4H(7\/##S187.K=X KT:YRF_ZPE*V_M#.U:GU2X'&-.J"FC!AP:- Y3M@O+C
MYYOYY=G-#3FYNCPYN[Q=\,)L2'P?O((2YN+&?QPP*^'^'8W](6>< V6XQ>8(
M\]H@'2  $5J':RU5!]O(X!ZU)07S=MK*^'XW.TP(.E#WN-XA$@X+UGWNF&W3
M/\UOH9[8#9E=GH)7AJO"9Y=X[@G_L6 K;)I&+W41B$:%4&NW/%B*2PR/-+$)
MXH$BT*!XG-Y=&-=2&J5U&G(P.VAC _0Y9EMF-& V.F([SL. ;N\QS]G%V0EL
M_O_XF>W^SQ87OU25&Z&6\>QV1MY\OIQ]/ITSFK<XD'I3W&7T[P6;<,X>+4JI
MZ<G=%M,V*]VNGJVF18.X'@4EC-7D1-"C<WY=@WJ/N/7T4X+*?(2M(T8+J_Y*
M,Q]OSO[X&9+PSJ R Y*%8JN$&*^:\V(1/S*P.(X;]2K?B1=IZ=$ RT))^7):
MR*;2=<1VU<FR74H1"<J\[ 'V6^P_D-[QZ$4P9"SA9L?K^G4>:W.ZSYCT,F++
M*!NBM*I / X(+JA/F>YW;)#<IEZPN?TI:H9EF]]G490\P0O/YTEZFA1W^;*(
M*BIAM?9P:Y>?<'L2N?O&:1]5[DX^&D>]!Z.D*IP@EU2D9".1QU-KL;S>="6X
M)L<Q[NK257;>7D\^21$Q"Y^NHT6#TQX%=27JT#SBIRT>88<H>W8494 L$&?+
MBP:! Q662G^$SS0H;QCC@&3W=NIY&(<YO0@?:6!<(5CP37F/6&N&Z1:QQ(0&
M=K::RAZP<ZT=">A6:R],8=A<I:=AMDXR+[I:7B3Q/3=)J&HYRXX2Y12:6QC;
M0NL(.7@ /%YY"=.U* @1@(AC+@,5PL^9BE^\J*"-XO7S.,O38D7[-E^6O"XQ
M/,B<)FBM&-&@=(BVTM3.> EG;C_QT>#' <TZG]]V&Z,CG^1FA=4V1DV+!F8]
M"NHO[F#9Q]P\>"G]Z&50YG8%9:+$.QWK\O&..4\/9#X95LEF7S=*DM.SGO&F
MMDZ!AHM! ]?QNDLG1R#IF(LB35DX4 UWO^U\HI+2]8U["T^H($.#*KUNVHH-
MB&*!"_I(XX(NJ)_<LZV8]8FC!9_;:+FE&>T0> \3&HS9:BI?*N-\I,&( W8W
M]!Y6D@NZ3M+Z<1C+>+0EK]/)=8@YK>G4AA$-#(=H*TV9@I?4S$B ^!"NU^(!
MXY^\.&#R[^%I DLD6C*[7><-,:B]M+/AQ /&(>K*"SC!S _M*G;Q* 4.7,Z"
M1\J&259:91E$[.5R^LJ>G0FMI_;,+&BP9Z>G].C>A@L3U!8THZP=(:'DE*T7
MHH2? Y5EDWNR*RPXW2X#K4UI+P1[V=! SUY7>3$H.+G/:_#B0.&9E\9L8&37
M-.6[:SN'U\OE$GV6)C21U\."!G5V>G815W$1QD8X'PZL2?=^3U(:A#G\2Y=P
M9^*8]%ZVK+KQ.O:&' VV^G64;[$V.'A^+><@P,*]6\++_FH*!^# X.>,7BW/
MLCQ<>3G--$W3)7*)-+6"37"U*=#@2:E6%T*,"(!3D^$ Q74:)BESEF$2+*@?
M>5G&G]'E >K@;T7&K\F>TLQ/0QZUUB;W#!7C-L]JG)'M?*MA,M" <Z3B\EJN
MS8L$OY?TJ?'@<YK$[)\^;9PYVZWJAHMQB=^Q1C;Q.U0&&OR.5%R!7\82O9!Y
MEA60\M)XC[XE% >N;_P'&A01FU=F3,D@C HX)[RA?I'RVN]GSWY4!#0X9T"!
M\\ B%T>+R^ZZN3>BN(</.8T^[JVA6I'*G7\%S?C:FVE2!+3\$*R"UDD.)]]>
MQ 9D]4F2U=\D(5MD%RGQO<@OHGK1S2G9V(UI3J(DR\B:K;DS^#9ADMA@+,M4
M^\EJQ3BR1D%A;*.ZSL<OGXZ]!=WMQVH?^S0CT,XH];@R\R(<+58*F\9 +0 ;
M-A5/&@]#9[^ :?!I:Y@:H7W<"#%JJ;()I2*PX0L9Q$.4**R]4#+Z,A"V:T#C
M+@#A Z2UJB8@+OD%($P [(PS,< N67^7$\(P?VE@G]!;]AIE\)5:7C3 '*BP
M<45;O@U,Q;D8-H1VKT&Q45B]XCEXZ6DM::I5Z$!3=0M22S$(T3Q4=Q.PP\U%
M.(S.-UDV;O1)E_V*'$K@K2#_ZQ]\&UD>6P_"_&X^,<5@V&7CJ$;)+N2C&SX[
M-,HTKFAY$,36- UIN.:/YOZA\?"DU>BQY'7^1JBM.=(KH7V,:( \1%O[K5^T
MD80#G.KWPOIJ*_8P3?^^V[ W")L<: !HI:;5 X3 M\/:B_GS*N!P>O^A!!/\
MI;%P^ME+4[9'7211=)ZD3UX:&'W=8&X7\!II$N!L(.OD@!NGK\GG/0D1!)ZD
M>60(W#OB-E<$K[T7B(G,0._2D@QN18NC^BPK5OQ\WCS[[ESZ!(C=59,H$+VM
M:&R(WY$]IA'A;7A) ==/PYBPA0'Y&'G^K\>,,H&2DY^2@%F\&4!8U@@]+<4G
M'7$?=_A8V]='I@F;[+*!U!&577QA\@&X5[-V. [YX3=)UHARM51-UKS+WFRR
M63G_CAZ 0P5//>C&-43?0!LF%?7@&F6*,6+/?MG9.F_7(^1LN:2@&JTKGBR\
MG%_'CGVV"Q<O)0P;&V-$3C,JQANO'@_#Y2$<":.-,(V!W'LF*1-#TI8<;*/A
ME"YIFE*VG7NN#S2&QB-'2YMF#(PR60W_0:(0(G^,_B;0!Z4\CGYQIL7O[.PP
MPJG9]AM>'N-6Z%Z&&<KL;-,^V*!Z3V[-.3D@1ZEK>@9Q)CV#*$1@\[KBK.M3
M&(>K8K5@JGM1N</)SI/T:DWA.EQ\?T'9\FRH#]Y*]C0>>0?-H?;/6PB>?'#L
MPQIC%AB73E9"/$FY?+(N/X!M!)D?.ALV8@;)FF:$C#!7/2(&"$(X H9K;T+\
MW^L7&HO8*X(0,@:R8K7RTA<2;N3B@/ZUR((K<R*JS.,XV.34:5-$^QG=YN3:
M&M+.R>WC0@-7:U45-67X<R.5SR7')$^8$\8!P$8>YXD1<"I"Y[DH2D6EQ),6
M%1H :56S (S(+"FW7B7<<."G/2RXC0-]E\0SG=O2J*_W6!T&-%BST=("=E$2
MWQ,VEZYP9FLWJG65EFJ:0T4X49VUCJ*:TFHE%1H\:54S%5#S\110@Q?USD_G
M)_,87N8.9BNXRJZQ54/K^JE$K;K=IQ$E0C2H,6DGO6E  [;1C=@*G=%R/Q2%
MJW![_&@"BY?%ZHZF5TM1W.#:@]O5W1(_)D)G 4.CHG5P4$DU.0YZ5>N"0-#R
M2Q2BZ,1:D.\)! N:%VDL2KU<+3_'F1?!9I--GG5QE^LT"0I?#8U![,X ,\*H
M&D8#>'& :[C"<ID3D "%$9@(0%Y1"8$U3RV%_0\A9E_YC0\T6EZ$2WJUM(5?
M+XN[3$0[Y3?IA69Z'-"R4U*N6LRXV-2UK.XX[AY!V.KEP%CI#?'MYB.'62>G
MV4#[J9$#7YA\U.S5+%/ M_D9LOD.J3Y$H&-)XU.\K*!4^)3\F7]PZSL3.]K;
M;M=V%V%,YSE=Z<I6[DZ\TWWTCANEM?O>D6PTXW#'!DD[_5V-.O@0X5]Z'4//
M&%S8D>P#&G3ZX,5.!+^6X68,CH#LXTW9-Z#/"&T--%J-K$V)MT8Q.!P#JR[@
M=4GSGFNG:M))7K-7**M\R;Y!YQ24CS2]2S)Z8<"F04?=0_9($KQK=:#$0,;6
M?%"60[>HT1%/ ANEPDK@M"C1^#.C>O)C\X*FVN0B \_">_KDY30-O:@7.VW:
M2:"C4E>)G"8A/N HM).B;]X3694T.#!3Y4[SUW_,&1%J4K=O<^J5;3_.*=.A
MP8M!.?EYSC(1O?=HT='"H&]!\-</3IN9YQ79+@1JW;JM?'MU.[L@\\LO9Y>W
M5XM?]A3QEDMMFG+Y3=3.XMS]*M<A;CWIY./.3K\N*#@#*3G(#%%ALS+795X=
M')M38AID$^0924HJ4HMJFLF1TJ-8%R(EV>8(?T^>H_R.^IDUP[P]E-F97QEL
M4.UFK#DGQ](H=74(2YOOY 4;$9A2CKC#5"8-:T:9B<%YHJU1<2GA5DD].>2L
M553/=57*XTXP979E)PESF1'<\NGW7 I:UXY*JV[7+TF$DV/"1CN=U_%K^OVB
MX0N-@R0]I>LD"]6I'QI"USA0*]H%09L*%0*4JNFZ_Y$3L^E&4..894X+"D<+
M"QI!9=1K+X5#AYZPA9'%:?C"0OE6&,- /SFN!BBIGF]2ZM/PD5]L/DX%-UDS
M]A?RAE=U?/_A[401C_;<R59M=G=Q+-BPQ4>&J*P.FUS=_G2V(">?%XNSRULR
MN[DYN[V9J-N87V.8$@5*U%'!S>^..\+BS$JIG1P0W!"1,TQW4[1/>/R8)IGN
M$**/"<4C*RT#K!Y8X1QH'+25FO(!U^8QE2-R#Y0X<#;S_6)5\-FB.1C8OR/*
M*^C%0;/XNM9X75;#SL0[35G9<:.TLE9V)-O->/A>C(>8WH/")G^[8[ND%):-
M>%A"U_(G6])HU-<<ZICH\<V=5MJJUR_G\S^=G5JL6[;?YG[RXF+I^7F1P@X<
M@BS:B\/V;*ZWP#9&=#?$)I[)9\F!BNHVRZLFJXL06A53[@:4K3!EPSS5:4"_
M0;K3 #TG%G\U2NO='PHXVSH/*2W0L!OU)EFAIWIFN5Z<7<_FI^3L3]=GES=G
M$W5(<PTCO_NE7/ 9.?!-_I;Z2@LTM(\JZ5^7^IS191'!)3U-6]BQNMR:##&F
MB4(;OLD7#R.4[<)0$!"@P(Z^K#^-W989!P)5!MEA,)LJ^7T<"A7JJC*:<WK,
MN<F&'57FD\% 4Y2QGPT)'+61QCZ>0X"@*=K(?R,G7IJ^P/9)W U"C[E&B*>Y
MF!C>-%I!2'#98Z@E4C52L,4%1UM@B@ VR='CNA$2'#3#H,&K)J9IYL"UY[32
M52HG1/-#\9T+NO)"N,#9BK'SHC3OAS>)61H25-J8; E7DZA#6 M8Z-_%]L\T
MO'_@CR$_TM2[AP=)2AGMYY%%82,<^)_' 5WJ6T'<E6865$^O]]X1'BO.[:V^
M[8QN7RT:)PO-&-C2 /FR<B4.]T9MJ-D[:CW<0-\%P+'%7D?J[V3_ISD_&ZJR
MO!H>+\;9F=H61M:G:R-D3.YWMU0<^X):&5.Q]Z9VS&Y]Z!"#VI[3AA.?OQR@
M]=9>TF''L9$RJMM4?/B.& =IC=V)&/9EXFFFYJ:LR@P??>QC(1+)_MS:>,M-
M>J^\R6?+'1K1!?U9EH<K'OKT%.?L9)FD_&WJ%^JE/Z ?%@KS+^ES?OM$HT?Z
M*8GSAQ%'3U9"D0R- 0U@>QC0+_$0AH>]&=T!PE#XNT,$_B]LQ-X^)3MIJEH6
M7IAWS!V/[E+0@8*ZK;T"R[\_6"RSSP_/INJ1AAS/39.W1#2(.F1,-_17H/K?
M#Q75YZQ==]9(0AAN3#<-W@[2(.F $=U07P'H[P\6T(QV=VW$A2$'=,/@+0'-
M: \9T!OU94!_>+>G4X*9[Z<%#4X89>A[T2T4[.PKM=7/XRS^;ZM^'>SO8Y@<
M0$.T5&1B 1OQ2SZ2 R.FXEFEAC=>Y*6]!4UTQ(YO'!L4[MP?5E!.CB<K]71
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MX=@LXL)IH&ZZ<LNM"VA9,KL<;<,,:D41K3C18'V0NLKGJX[O@*E]*E0&2W"
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M^\TF7MPX:*ONWTZY'-.-]O;/N'I9J9L4DA1/ [V(:M1P-UE<3'Q(HFI?(QP
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M-'\>WSXEOU O5<Y\@X4<7O\K=!\-@2/  %P 9B()EXF^\Q]22G?0_;68@P2
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M$CS \6P1(/8*8QQ_S^R3T+*=8&SYS/A\E)Y\ZHUJC+]&V=)J%0 )YK77:Q<
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M1X@(B\+C1$*NT<P-_FNNV1GR;2%LMICT_OG#9-0?S.9_Z0Q^O!TN3+KTBWQ
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M1[/4ZK^O>E;C+Z'"1/-WIO"H>'O*3,PHI?3$%.X,'^E9A-?>V)TJ5=#%#.,
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MFQ*(<R-:I00]QPL:L^Y*!H,JQ%$\?=H4@BM%DY9=V2&S#KKEXT$!/HIC2AO
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M"'K4H'I9>SZS804+G:@/^HIR !ZX^& QG\NMYK^!K.:SK=Q4A<WUFK""A.1
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M,C,Q7V-A;"YX;6Q02P$"% ,4    " !.A%I(CP3Y_N(J  #?, , %0
M        @ &='P$ ='AM9"TR,#$U,3(S,5]D968N>&UL4$L! A0#%     @
M3H1:2%QO@B/,:0  P@@& !4              ( !LDH! '1X;60M,C Q-3$R
M,S%?;&%B+GAM;%!+ 0(4 Q0    ( $Z$6DCO[JK /D,  //I!  5
M      "  ;&T 0!T>&UD+3(P,34Q,C,Q7W!R92YX;6Q02P4&      8 !@"*
) 0  (O@!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
